CA2643962A1 - Antibiotic compounds - Google Patents
Antibiotic compounds Download PDFInfo
- Publication number
- CA2643962A1 CA2643962A1 CA002643962A CA2643962A CA2643962A1 CA 2643962 A1 CA2643962 A1 CA 2643962A1 CA 002643962 A CA002643962 A CA 002643962A CA 2643962 A CA2643962 A CA 2643962A CA 2643962 A1 CA2643962 A1 CA 2643962A1
- Authority
- CA
- Canada
- Prior art keywords
- pyran
- tetrahydro
- methoxy
- phenyl
- difluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title claims description 221
- 230000003115 biocidal effect Effects 0.000 title abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 48
- 229920002554 vinyl polymer Polymers 0.000 claims description 66
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 63
- 150000003839 salts Chemical class 0.000 claims description 31
- 208000015181 infectious disease Diseases 0.000 claims description 26
- VUHCPMIDSUGHNO-UHFFFAOYSA-N 6-methoxy-1,5-naphthyridin-4-amine Chemical compound N1=CC=C(N)C2=NC(OC)=CC=C21 VUHCPMIDSUGHNO-UHFFFAOYSA-N 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- -1 carbamoyloxyalkyl Chemical group 0.000 abstract description 17
- 239000001257 hydrogen Substances 0.000 abstract description 16
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 16
- 125000000217 alkyl group Chemical group 0.000 abstract description 8
- 239000003242 anti bacterial agent Substances 0.000 abstract description 8
- 229940088710 antibiotic agent Drugs 0.000 abstract description 8
- 150000002431 hydrogen Chemical group 0.000 abstract description 8
- 229910052736 halogen Inorganic materials 0.000 abstract description 6
- 150000002367 halogens Chemical group 0.000 abstract description 6
- 125000003545 alkoxy group Chemical group 0.000 abstract description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract description 4
- 125000005197 alkyl carbonyloxy alkyl group Chemical group 0.000 abstract description 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract description 2
- 125000003118 aryl group Chemical group 0.000 abstract description 2
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 abstract description 2
- 125000005242 carbamoyl alkyl group Chemical group 0.000 abstract description 2
- 125000006355 carbonyl methylene group Chemical group [H]C([H])([*:2])C([*:1])=O 0.000 abstract description 2
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract description 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract description 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 abstract description 2
- 125000004438 haloalkoxy group Chemical group 0.000 abstract description 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 2
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 abstract description 2
- 229910052720 vanadium Inorganic materials 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 description 123
- 239000007787 solid Substances 0.000 description 109
- 239000000243 solution Substances 0.000 description 104
- 238000000034 method Methods 0.000 description 95
- 239000010410 layer Substances 0.000 description 91
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 89
- 239000006260 foam Substances 0.000 description 69
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 62
- 239000011541 reaction mixture Substances 0.000 description 59
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 57
- 235000011114 ammonium hydroxide Nutrition 0.000 description 57
- 238000004587 chromatography analysis Methods 0.000 description 53
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 49
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 39
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 39
- 239000003480 eluent Substances 0.000 description 37
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 239000012267 brine Substances 0.000 description 31
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 31
- 238000006243 chemical reaction Methods 0.000 description 30
- 101150041968 CDC13 gene Proteins 0.000 description 28
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 28
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 27
- 239000003921 oil Substances 0.000 description 25
- 238000002360 preparation method Methods 0.000 description 24
- 239000000706 filtrate Substances 0.000 description 23
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 20
- 230000002829 reductive effect Effects 0.000 description 20
- PNYDVKRZZLUMCJ-OWOJBTEDSA-N (e)-3-(2,5-difluorophenyl)prop-2-enal Chemical compound FC1=CC=C(F)C(\C=C\C=O)=C1 PNYDVKRZZLUMCJ-OWOJBTEDSA-N 0.000 description 19
- 150000001299 aldehydes Chemical class 0.000 description 18
- 150000001412 amines Chemical class 0.000 description 18
- 239000002253 acid Substances 0.000 description 16
- 150000001408 amides Chemical class 0.000 description 16
- 238000004440 column chromatography Methods 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 14
- 239000012071 phase Substances 0.000 description 14
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 13
- 239000007832 Na2SO4 Substances 0.000 description 13
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 13
- 239000000284 extract Substances 0.000 description 13
- 229910052938 sodium sulfate Inorganic materials 0.000 description 13
- 235000011152 sodium sulphate Nutrition 0.000 description 13
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 12
- 238000001816 cooling Methods 0.000 description 12
- 150000002009 diols Chemical class 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 12
- SZHYPQDQYNLZJP-UHFFFAOYSA-N 3-oxo-4h-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid Chemical compound S1CC(=O)NC2=NC(C(=O)O)=CC=C21 SZHYPQDQYNLZJP-UHFFFAOYSA-N 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 11
- 239000003039 volatile agent Substances 0.000 description 11
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
- 235000017557 sodium bicarbonate Nutrition 0.000 description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 8
- 150000001336 alkenes Chemical class 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 8
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 7
- 239000012298 atmosphere Substances 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 7
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 241000193996 Streptococcus pyogenes Species 0.000 description 6
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 6
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000001665 trituration Methods 0.000 description 6
- 238000010792 warming Methods 0.000 description 6
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 5
- HOPFINDBXLGBEL-UHFFFAOYSA-N 3-methoxyquinoline-5-carbaldehyde Chemical compound C1=CC=C(C=O)C2=CC(OC)=CN=C21 HOPFINDBXLGBEL-UHFFFAOYSA-N 0.000 description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 5
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 5
- 238000010511 deprotection reaction Methods 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 150000005054 naphthyridines Chemical class 0.000 description 5
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 5
- PPZNNZQHBXZAPS-UHFFFAOYSA-N (6-methoxy-1,5-naphthyridin-4-yl) trifluoromethanesulfonate Chemical compound N1=CC=C(OS(=O)(=O)C(F)(F)F)C2=NC(OC)=CC=C21 PPZNNZQHBXZAPS-UHFFFAOYSA-N 0.000 description 4
- YUCBLVFHJWOYDN-PDNPBWJSSA-N 1,4-bis[(r)-[(2s,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methoxy]phthalazine Chemical compound C1=C(OC)C=C2C([C@@H](OC=3C4=CC=CC=C4C(O[C@@H]([C@H]4N5CC[C@H]([C@H](C5)CC)C4)C=4C5=CC(OC)=CC=C5N=CC=4)=NN=3)[C@@H]3C[C@@H]4CCN3C[C@@H]4CC)=CC=NC2=C1 YUCBLVFHJWOYDN-PDNPBWJSSA-N 0.000 description 4
- YUCBLVFHJWOYDN-HVLQGHBFSA-N 1,4-bis[(s)-[(2r,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methoxy]phthalazine Chemical compound C1=C(OC)C=C2C([C@H](OC=3C4=CC=CC=C4C(O[C@H]([C@@H]4N5CC[C@H]([C@H](C5)CC)C4)C=4C5=CC(OC)=CC=C5N=CC=4)=NN=3)[C@H]3C[C@@H]4CCN3C[C@@H]4CC)=CC=NC2=C1 YUCBLVFHJWOYDN-HVLQGHBFSA-N 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 150000003457 sulfones Chemical class 0.000 description 4
- XAWHCSKPALFWBI-DAFODLJHSA-N (e)-3-(2,5-difluorophenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC(F)=CC=C1F XAWHCSKPALFWBI-DAFODLJHSA-N 0.000 description 3
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 3
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
- LEJRFUDTXRWNFQ-UHFFFAOYSA-N 3-fluoro-6-methoxyquinoline Chemical compound N1=CC(F)=CC2=CC(OC)=CC=C21 LEJRFUDTXRWNFQ-UHFFFAOYSA-N 0.000 description 3
- UDMNXSDHUDGMTR-UHFFFAOYSA-N 3-fluoro-6-methoxyquinoline-5-carbaldehyde Chemical compound N1=CC(F)=CC2=C(C=O)C(OC)=CC=C21 UDMNXSDHUDGMTR-UHFFFAOYSA-N 0.000 description 3
- BFQJQBBLBSGLTQ-UHFFFAOYSA-N 3-methoxyquinoxaline-5-carbaldehyde Chemical compound C1=CC=C(C=O)C2=NC(OC)=CN=C21 BFQJQBBLBSGLTQ-UHFFFAOYSA-N 0.000 description 3
- VEPGNAIYGRUSIA-UHFFFAOYSA-N 3-oxo-4h-pyrido[3,2-b][1,4]thiazine-6-carbaldehyde Chemical compound S1CC(=O)NC2=NC(C=O)=CC=C21 VEPGNAIYGRUSIA-UHFFFAOYSA-N 0.000 description 3
- JSHPICHDBDUEFJ-UHFFFAOYSA-N 6-methoxy-1,5-naphthyridine-4-carbaldehyde Chemical compound N1=CC=C(C=O)C2=NC(OC)=CC=C21 JSHPICHDBDUEFJ-UHFFFAOYSA-N 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 102100032373 Coiled-coil domain-containing protein 85B Human genes 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- 241000606768 Haemophilus influenzae Species 0.000 description 3
- 101000868814 Homo sapiens Coiled-coil domain-containing protein 85B Proteins 0.000 description 3
- 241000193998 Streptococcus pneumoniae Species 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 108010059993 Vancomycin Proteins 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- DGODWNOPHMXOTR-UHFFFAOYSA-N dipotassium;dioxido(dioxo)osmium;dihydrate Chemical compound O.O.[K+].[K+].[O-][Os]([O-])(=O)=O DGODWNOPHMXOTR-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 3
- 125000001207 fluorophenyl group Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 3
- GRCYJTGPLQQLOX-HIFRSBDPSA-N tert-butyl n-[(3r,6s)-6-[(1-phenyltetrazol-5-yl)sulfonylmethyl]oxan-3-yl]carbamate Chemical compound O1C[C@H](NC(=O)OC(C)(C)C)CC[C@H]1CS(=O)(=O)C1=NN=NN1C1=CC=CC=C1 GRCYJTGPLQQLOX-HIFRSBDPSA-N 0.000 description 3
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 3
- 229960003165 vancomycin Drugs 0.000 description 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 3
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 3
- XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 2
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical compound CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 2
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
- QLWRJVBMSPHFMO-UHFFFAOYSA-N 3-fluoro-6-methoxy-1,5-naphthyridine-4-carbaldehyde Chemical compound N1=CC(F)=C(C=O)C2=NC(OC)=CC=C21 QLWRJVBMSPHFMO-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- YNVIAXULFXXTLV-UHFFFAOYSA-N 5-bromo-3-methoxyquinoline Chemical compound C1=CC=C(Br)C2=CC(OC)=CN=C21 YNVIAXULFXXTLV-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 2
- 241000589291 Acinetobacter Species 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241001647372 Chlamydia pneumoniae Species 0.000 description 2
- 241000606153 Chlamydia trachomatis Species 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- 241000194031 Enterococcus faecium Species 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 241000588655 Moraxella catarrhalis Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 241001312524 Streptococcus viridans Species 0.000 description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
- VKIJXFIYBAYHOE-VOTSOKGWSA-N [(e)-2-phenylethenyl]boronic acid Chemical compound OB(O)\C=C\C1=CC=CC=C1 VKIJXFIYBAYHOE-VOTSOKGWSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229940038705 chlamydia trachomatis Drugs 0.000 description 2
- MLIREBYILWEBDM-UHFFFAOYSA-N cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 2
- 150000005676 cyclic carbonates Chemical class 0.000 description 2
- WACQKHWOTAEEFS-UHFFFAOYSA-N cyclohexane;ethyl acetate Chemical compound CCOC(C)=O.C1CCCCC1 WACQKHWOTAEEFS-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229940047650 haemophilus influenzae Drugs 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 229940041033 macrolides Drugs 0.000 description 2
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000011368 organic material Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- LKBZAGUOZDYGKG-BDAKNGLRSA-N tert-butyl n-[(3r,6s)-6-(hydroxymethyl)oxan-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H]1CC[C@@H](CO)OC1 LKBZAGUOZDYGKG-BDAKNGLRSA-N 0.000 description 2
- GRCYJTGPLQQLOX-DZGCQCFKSA-N tert-butyl n-[(3s,6r)-6-[(1-phenyltetrazol-5-yl)sulfonylmethyl]oxan-3-yl]carbamate Chemical compound O1C[C@@H](NC(=O)OC(C)(C)C)CC[C@@H]1CS(=O)(=O)C1=NN=NN1C1=CC=CC=C1 GRCYJTGPLQQLOX-DZGCQCFKSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 2
- GGKJSDIZPPMNGO-UHFFFAOYSA-N (2-cyanoquinolin-8-yl) trifluoromethanesulfonate Chemical compound C1=C(C#N)N=C2C(OS(=O)(=O)C(F)(F)F)=CC=CC2=C1 GGKJSDIZPPMNGO-UHFFFAOYSA-N 0.000 description 1
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- NROSRTMHTJHLLE-SFYZADRCSA-N (2s,5r)-5-[(2-methylpropan-2-yl)oxycarbonylamino]oxane-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N[C@@H]1CC[C@@H](C(O)=O)OC1 NROSRTMHTJHLLE-SFYZADRCSA-N 0.000 description 1
- APRXGTHUKVIKKD-SKDRFNHKSA-N (2s,5r)-5-amino-n-(6-methoxy-1,5-naphthyridin-4-yl)oxane-2-carboxamide Chemical compound C12=NC(OC)=CC=C2N=CC=C1NC(=O)[C@@H]1CC[C@@H](N)CO1 APRXGTHUKVIKKD-SKDRFNHKSA-N 0.000 description 1
- NOZCEBQQKKTOIV-OWOJBTEDSA-N (e)-3-(2,5-difluorophenyl)prop-2-en-1-ol Chemical compound OC\C=C\C1=CC(F)=CC=C1F NOZCEBQQKKTOIV-OWOJBTEDSA-N 0.000 description 1
- IOUDZAFBPDDAMK-AATRIKPKSA-N (e)-3-(2-fluorophenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1F IOUDZAFBPDDAMK-AATRIKPKSA-N 0.000 description 1
- DWPBUTPTXDAJJX-DUXPYHPUSA-N (e)-3-(3-fluorophenyl)prop-2-enal Chemical compound FC1=CC=CC(\C=C\C=O)=C1 DWPBUTPTXDAJJX-DUXPYHPUSA-N 0.000 description 1
- RTSIUKMGSDOSTI-SNAWJCMRSA-N (e)-3-(3-fluorophenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=CC(F)=C1 RTSIUKMGSDOSTI-SNAWJCMRSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- PWMWNFMRSKOCEY-UHFFFAOYSA-N 1-Phenyl-1,2-ethanediol Chemical compound OCC(O)C1=CC=CC=C1 PWMWNFMRSKOCEY-UHFFFAOYSA-N 0.000 description 1
- GGZHVNZHFYCSEV-UHFFFAOYSA-N 1-Phenyl-5-mercaptotetrazole Chemical compound SC1=NN=NN1C1=CC=CC=C1 GGZHVNZHFYCSEV-UHFFFAOYSA-N 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- HMBHAQMOBKLWRX-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-3-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)COC2=C1 HMBHAQMOBKLWRX-UHFFFAOYSA-N 0.000 description 1
- VVVOJODFBWBNBI-UHFFFAOYSA-N 2,5-difluorobenzaldehyde Chemical compound FC1=CC=C(F)C(C=O)=C1 VVVOJODFBWBNBI-UHFFFAOYSA-N 0.000 description 1
- KQZYTBQVPPVWRX-UJKRDPEBSA-N 2-[(2r,3r,6r)-3-[[(e)-3-(2,5-difluorophenyl)prop-2-enoyl]amino]-6-[2-(3-methoxyquinolin-5-yl)ethyl]oxan-2-yl]acetic acid Chemical compound N([C@@H]1CC[C@H](O[C@@H]1CC(O)=O)CCC1=CC=CC2=NC=C(C=C21)OC)C(=O)\C=C\C1=CC(F)=CC=C1F KQZYTBQVPPVWRX-UJKRDPEBSA-N 0.000 description 1
- YANFBCZMBOJMGL-BSLALVQMSA-N 2-[(2r,3r,6r)-6-[2-(3-methoxyquinolin-5-yl)ethyl]-3-[(3-oxo-4h-pyrido[3,2-b][1,4]thiazine-6-carbonyl)amino]oxan-2-yl]acetic acid Chemical compound S1CC(=O)NC2=NC(C(=O)N[C@@H]3CC[C@H](O[C@@H]3CC(O)=O)CCC3=CC=CC4=NC=C(C=C43)OC)=CC=C21 YANFBCZMBOJMGL-BSLALVQMSA-N 0.000 description 1
- RPRFQQQHIBASPC-UHFFFAOYSA-N 2-chloro-8-methylquinoxaline Chemical compound C1=C(Cl)N=C2C(C)=CC=CC2=N1 RPRFQQQHIBASPC-UHFFFAOYSA-N 0.000 description 1
- NXYFPLVZSNIKPI-UHFFFAOYSA-N 2-cyano-n-(2-methyl-6-nitrophenyl)acetamide Chemical compound CC1=CC=CC([N+]([O-])=O)=C1NC(=O)CC#N NXYFPLVZSNIKPI-UHFFFAOYSA-N 0.000 description 1
- JTBLDDQXNQKMJS-UHFFFAOYSA-N 2-fluoro-6-methoxy-1,5-naphthyridine-4-carbaldehyde Chemical compound FC1=NC2=CC=C(N=C2C(=C1)C=O)OC JTBLDDQXNQKMJS-UHFFFAOYSA-N 0.000 description 1
- KBSMXRAGKAYNAB-UHFFFAOYSA-N 2-methoxy-8-(2-phenylethenyl)-1,5-naphthyridine Chemical compound C12=NC(OC)=CC=C2N=CC=C1C=CC1=CC=CC=C1 KBSMXRAGKAYNAB-UHFFFAOYSA-N 0.000 description 1
- RYWFTXZEPPKNCQ-UHFFFAOYSA-N 2-methoxy-8-methylquinoxaline Chemical compound C1=CC=C(C)C2=NC(OC)=CN=C21 RYWFTXZEPPKNCQ-UHFFFAOYSA-N 0.000 description 1
- FCMRHMPITHLLLA-UHFFFAOYSA-N 2-methyl-6-nitroaniline Chemical compound CC1=CC=CC([N+]([O-])=O)=C1N FCMRHMPITHLLLA-UHFFFAOYSA-N 0.000 description 1
- IBADFXOMCWHDMS-UHFFFAOYSA-N 3,5-dibromoquinoline Chemical compound C1=CC=C(Br)C2=CC(Br)=CN=C21 IBADFXOMCWHDMS-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZGIKWINFUGEQEO-UHFFFAOYSA-N 3-bromoquinoline Chemical compound C1=CC=CC2=CC(Br)=CN=C21 ZGIKWINFUGEQEO-UHFFFAOYSA-N 0.000 description 1
- WZOYHMMSKGEABR-UHFFFAOYSA-N 3-fluoro-6-methoxyquinoline-4-carbaldehyde Chemical compound N1=CC(F)=C(C=O)C2=CC(OC)=CC=C21 WZOYHMMSKGEABR-UHFFFAOYSA-N 0.000 description 1
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
- HIWPTYUKGHNQCU-UHFFFAOYSA-N 4-bromo-6-fluoroquinoline Chemical compound N1=CC=C(Br)C2=CC(F)=CC=C21 HIWPTYUKGHNQCU-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- BNNMDMGPZUOOOE-UHFFFAOYSA-N 4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1 BNNMDMGPZUOOOE-UHFFFAOYSA-N 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- HFZLPVADKSFIOB-UHFFFAOYSA-N 5-bromo-3-fluoro-6-methoxyquinoline Chemical compound N1=CC(F)=CC2=C(Br)C(OC)=CC=C21 HFZLPVADKSFIOB-UHFFFAOYSA-N 0.000 description 1
- PCDIPDSIWAQVDA-QZTJIDSGSA-N 6-[[[(3r,6s)-6-[2-(6-fluoro-3-methoxyquinolin-4-yl)ethyl]oxan-3-yl]amino]methyl]-4h-pyrido[3,2-b][1,4]thiazin-3-one Chemical compound S1CC(=O)NC2=NC(CN[C@@H]3CC[C@@H](OC3)CCC3=C4C=C(F)C=CC4=NC=C3OC)=CC=C21 PCDIPDSIWAQVDA-QZTJIDSGSA-N 0.000 description 1
- YMLJFUQNRSDOJK-UHFFFAOYSA-N 6-fluoroquinoline-4-carbaldehyde Chemical compound N1=CC=C(C=O)C2=CC(F)=CC=C21 YMLJFUQNRSDOJK-UHFFFAOYSA-N 0.000 description 1
- PDGKZDPIWAKVLH-UHFFFAOYSA-N 6-methoxyquinoline-4-carbaldehyde Chemical compound N1=CC=C(C=O)C2=CC(OC)=CC=C21 PDGKZDPIWAKVLH-UHFFFAOYSA-N 0.000 description 1
- JZHJYBWJAAFRNA-BQYQJAHWSA-N 7-fluoro-2-methoxy-8-[(e)-2-phenylethenyl]-1,5-naphthyridine Chemical compound C12=NC(OC)=CC=C2N=CC(F)=C1\C=C\C1=CC=CC=C1 JZHJYBWJAAFRNA-BQYQJAHWSA-N 0.000 description 1
- SNUZUAUVNMCODC-UHFFFAOYSA-N 7-fluoro-3-oxo-4h-1,4-benzothiazine-6-carbaldehyde Chemical compound S1CC(=O)NC2=C1C=C(F)C(C=O)=C2 SNUZUAUVNMCODC-UHFFFAOYSA-N 0.000 description 1
- UJFYEKCUKWTOOU-CQLNOVPUSA-N 7-fluoro-6-[[[(3r,6s)-6-[(1s)-1-hydroxy-2-(6-methoxyquinolin-4-yl)ethyl]oxan-3-yl]amino]methyl]-4h-1,4-benzothiazin-3-one Chemical compound N1C(=O)CSC(C=C2F)=C1C=C2CN[C@@H](CO1)CC[C@H]1[C@@H](O)CC1=CC=NC2=CC=C(OC)C=C21 UJFYEKCUKWTOOU-CQLNOVPUSA-N 0.000 description 1
- KCRMGBHUBHYMHU-UHFFFAOYSA-N 8-(dibromomethyl)-2-methoxyquinoxaline Chemical compound C1=CC=C(C(Br)Br)C2=NC(OC)=CN=C21 KCRMGBHUBHYMHU-UHFFFAOYSA-N 0.000 description 1
- KBDDFKYRMCBPOT-UHFFFAOYSA-N 8-bromo-7-fluoro-2-methoxy-1,5-naphthyridine Chemical compound N1=CC(F)=C(Br)C2=NC(OC)=CC=C21 KBDDFKYRMCBPOT-UHFFFAOYSA-N 0.000 description 1
- NZKPWVAKHWJDAX-UHFFFAOYSA-N 8-methyl-1h-quinoxalin-2-one Chemical compound C1=C(O)N=C2C(C)=CC=CC2=N1 NZKPWVAKHWJDAX-UHFFFAOYSA-N 0.000 description 1
- 241000606750 Actinobacillus Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241001148536 Bacteroides sp. Species 0.000 description 1
- 241001518086 Bartonella henselae Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000180135 Borrelia recurrentis Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- DUPSKZUZAFJKLT-ASQKFFOYSA-N C(C)(C)(C)OC(N[C@H]1[C@H](O[C@@H](CC1)CS(=O)(=O)C1=NN=NN1C1=CC=CC=C1)CC(CO)O)=O Chemical compound C(C)(C)(C)OC(N[C@H]1[C@H](O[C@@H](CC1)CS(=O)(=O)C1=NN=NN1C1=CC=CC=C1)CC(CO)O)=O DUPSKZUZAFJKLT-ASQKFFOYSA-N 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- LIHMGQSDHIFJOO-GPVBVBQSSA-N Cl.Cl.Cl.COC=1N=C2C(=CC=NC2=CC1)CC[C@@H]1CC[C@H]([C@H](O1)CC(=O)O)NCC=1C=CC=2SCC(NC2N1)=O Chemical compound Cl.Cl.Cl.COC=1N=C2C(=CC=NC2=CC1)CC[C@@H]1CC[C@H]([C@H](O1)CC(=O)O)NCC=1C=CC=2SCC(NC2N1)=O LIHMGQSDHIFJOO-GPVBVBQSSA-N 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241001518260 Corynebacterium minutissimum Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000520130 Enterococcus durans Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- LVUYRJMVDYDNBC-QVIGOSPQSA-N FC1=C(C=C(C=C1)F)/C=C/C(=O)N[C@H]1[C@H](O[C@@H](CC1)CC(C1=C2C=C(C=NC2=CC=C1)OC)O)CO Chemical compound FC1=C(C=C(C=C1)F)/C=C/C(=O)N[C@H]1[C@H](O[C@@H](CC1)CC(C1=C2C=C(C=NC2=CC=C1)OC)O)CO LVUYRJMVDYDNBC-QVIGOSPQSA-N 0.000 description 1
- DVNUXLQMJWKHCF-XHGXXWPFSA-N FC1=C(C=C(C=C1)F)/C=C/C(=O)N[C@H]1[C@H](O[C@@H](CC1)CC(O)C1=C(C=NC2=CC=C(C=C12)OC)F)CO Chemical compound FC1=C(C=C(C=C1)F)/C=C/C(=O)N[C@H]1[C@H](O[C@@H](CC1)CC(O)C1=C(C=NC2=CC=C(C=C12)OC)F)CO DVNUXLQMJWKHCF-XHGXXWPFSA-N 0.000 description 1
- IDGYIFNYEPVMNA-VNPIZTODSA-N FC1=C(C=CC=C1)/C=C/C(=O)N[C@H]1CO[C@@H](CC1)[C@H](CC1=CC=NC2=CC=C(C=C12)OC)O Chemical compound FC1=C(C=CC=C1)/C=C/C(=O)N[C@H]1CO[C@@H](CC1)[C@H](CC1=CC=NC2=CC=C(C=C12)OC)O IDGYIFNYEPVMNA-VNPIZTODSA-N 0.000 description 1
- GROYHVJQIXIBGS-LWIALYQHSA-N FC=1C=C(C=CC1)/C=C/C(=O)N[C@H]1CO[C@@H](CC1)[C@H](CC1=CC=NC2=CC=C(C=C12)OC)O Chemical compound FC=1C=C(C=CC1)/C=C/C(=O)N[C@H]1CO[C@@H](CC1)[C@H](CC1=CC=NC2=CC=C(C=C12)OC)O GROYHVJQIXIBGS-LWIALYQHSA-N 0.000 description 1
- YVTRPLMYBULCOZ-LSMJVOJFSA-N FC=1C=NC2=CC=C(C=C2C1C(C[C@@H]1CC[C@H]([C@H](O1)CO)NC(=O)C=1C=CC=2SCC(NC2N1)=O)O)OC Chemical compound FC=1C=NC2=CC=C(C=C2C1C(C[C@@H]1CC[C@H]([C@H](O1)CO)NC(=O)C=1C=CC=2SCC(NC2N1)=O)O)OC YVTRPLMYBULCOZ-LSMJVOJFSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Natural products OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 201000000628 Gas Gangrene Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 229910013470 LiC1 Inorganic materials 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000010315 Mastoiditis Diseases 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241000513886 Mycobacterium avium complex (MAC) Species 0.000 description 1
- 241000187482 Mycobacterium avium subsp. paratuberculosis Species 0.000 description 1
- 241000187478 Mycobacterium chelonae Species 0.000 description 1
- 241000186364 Mycobacterium intracellulare Species 0.000 description 1
- 241000186363 Mycobacterium kansasii Species 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 241000191992 Peptostreptococcus Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004146 Propane-1,2-diol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010037075 Protozoal infections Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037294 Puerperal pyrexia Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 241000223105 Trypanosoma brucei Species 0.000 description 1
- 239000012963 UV stabilizer Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000202921 Ureaplasma urealyticum Species 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 241000606834 [Haemophilus] ducreyi Species 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 239000012378 ammonium molybdate tetrahydrate Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000006256 asymmetric dihydroxylation reaction Methods 0.000 description 1
- FIXLYHHVMHXSCP-UHFFFAOYSA-H azane;dihydroxy(dioxo)molybdenum;trioxomolybdenum;tetrahydrate Chemical compound N.N.N.N.N.N.O.O.O.O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O[Mo](O)(=O)=O.O[Mo](O)(=O)=O.O[Mo](O)(=O)=O FIXLYHHVMHXSCP-UHFFFAOYSA-H 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 229940092524 bartonella henselae Drugs 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 229940075419 choline hydroxide Drugs 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- NPOMSUOUAZCMBL-UHFFFAOYSA-N dichloromethane;ethoxyethane Chemical compound ClCCl.CCOCC NPOMSUOUAZCMBL-UHFFFAOYSA-N 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
- CLINBLOBAIWBEQ-ZZXKWVIFSA-N ethyl (e)-3-(2,5-difluorophenyl)prop-2-enoate Chemical compound CCOC(=O)\C=C\C1=CC(F)=CC=C1F CLINBLOBAIWBEQ-ZZXKWVIFSA-N 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- MXDNEPDJMODRAI-VIFPVBQESA-N methyl (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]hex-5-enoate Chemical compound C=CCC[C@@H](C(=O)OC)NC(=O)OC(C)(C)C MXDNEPDJMODRAI-VIFPVBQESA-N 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229940013390 mycoplasma pneumoniae Drugs 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- SEECOMGXLQNHDX-JTJUYXQDSA-N n-[(2r,3r,6s)-2-(2-hydroxyethyl)-6-[(e)-2-(6-methoxy-1,5-naphthyridin-4-yl)ethenyl]oxan-3-yl]-3-oxo-4h-pyrido[3,2-b][1,4]thiazine-6-carboxamide Chemical compound S1CC(=O)NC2=NC(C(=O)N[C@@H]3CC[C@H](O[C@@H]3CCO)/C=C/C3=CC=NC4=CC=C(N=C43)OC)=CC=C21 SEECOMGXLQNHDX-JTJUYXQDSA-N 0.000 description 1
- XHYDUGOLDWKDHD-KVHVUPLMSA-N n-[(2s,3r,6s)-6-[2-hydroxy-2-(3-methoxyquinolin-5-yl)ethyl]-2-(hydroxymethyl)oxan-3-yl]-3-oxo-4h-pyrido[3,2-b][1,4]thiazine-6-carboxamide Chemical compound S1CC(=O)NC2=NC(C(=O)N[C@@H]3CC[C@H](O[C@@H]3CO)CC(O)C3=CC=CC4=NC=C(C=C43)OC)=CC=C21 XHYDUGOLDWKDHD-KVHVUPLMSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 239000004533 oil dispersion Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- GUWZGMWHDAJAOC-UHFFFAOYSA-N oxoplatinum;hydrate Chemical compound O.[Pt]=O GUWZGMWHDAJAOC-UHFFFAOYSA-N 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- 229960002218 sodium chlorite Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- KXCAEQNNTZANTK-UHFFFAOYSA-N stannane Chemical compound [SnH4] KXCAEQNNTZANTK-UHFFFAOYSA-N 0.000 description 1
- 229910000080 stannane Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- JJXOIFHXNBFRNV-UHFFFAOYSA-N tert-butyl (2-methylpropan-2-yl)oxycarbonyl carbonate Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C.CC(C)(C)OC(=O)OC(=O)OC(C)(C)C JJXOIFHXNBFRNV-UHFFFAOYSA-N 0.000 description 1
- AVJJIUDUTJDPQD-VIFPVBQESA-N tert-butyl n-[(2s)-1-hydroxyhex-5-en-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H](CO)CCC=C AVJJIUDUTJDPQD-VIFPVBQESA-N 0.000 description 1
- RWOHBVPVOZWRMG-BDAKNGLRSA-N tert-butyl n-[(3r,6s)-6-formyloxan-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H]1CC[C@@H](C=O)OC1 RWOHBVPVOZWRMG-BDAKNGLRSA-N 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 150000003527 tetrahydropyrans Chemical class 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- NDLIRBZKZSDGSO-UHFFFAOYSA-N tosyl azide Chemical compound CC1=CC=C(S(=O)(=O)[N-][N+]#N)C=C1 NDLIRBZKZSDGSO-UHFFFAOYSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 1
- MHNHYTDAOYJUEZ-UHFFFAOYSA-N triphenylphosphane Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 MHNHYTDAOYJUEZ-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
The invention relates to selected antibiotics of formula (Al) wherein R1 represents alkyl, alkoxy, haloalkoxy, halogen or cyano; one or two of U, V, W and X represent(s) N, the remaining represent CH, or, in case of U, V and/or W, may also represent CRa and, in the case of X, may also represent CRb, Ra representing halogen and Rb representing halogen or alkoxy; A3 represents NHCO, CH2CH2, CH=CH, COCH2, CH(OH)CH2, CH2CH(OH), CH(OH)CH(OH) or OCH2; A4 represents CH2, CO, CH2CH=CH, COCH=CH or CH2CONH; R2 represents hydrogen, alkyl, hydroxyalkyl, alkylcarbonyloxyalkyl, carbamoyloxyalkyl, carboxyalkyl or carbamoylalkyl; R3 and R4 each independently represent hydrogen, hydroxy or alkylcarbonyloxy; or R3 and R4 together represent a bridged dimethylmethylenedioxy chain attached to the carbons bearing R3 and R4; R5 represents hydrogen, alkyl or hydroxyalkyl; and the dotted line represents a single bond or, when R3 and R4 represent hydrogen, also a double bond; and D represents alkyl, aryl or heteroaryl. An example of such an antibiotic is (E)-2-{(2R,3R,6R)-3-[3-(2,5-difluoro-phenyl)- allylamino]-6-[2-(6-methoxy-[l,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-ethanol.
Description
ANTIBIOTIC COMPOUNDS
The present invention concerns novel antibiotics, pharmaceutical antibacterial compositions containing them and the use thereof in the manufacture of a medicament for the treatment of infections (e.g. bacterial infections). These compounds are useful antimicrobial agents effective against a variety of human and veterinary pathogens including among others Gram positive and Gram negative aerobic and anaerobic bacteria and mycobacteria.
The intensive use of antibiotics has exerted a selective evolutionary pressure on micro-organisms to produce genetically based resistance mechanisms. Modern medicine and socio-economic behaviour exacerbates the problem of resistance development by creating slow growth situations for pathogenic microbes, e.g. in artificial joints, and by supporting long-term host reservoirs, e.g. in immuno-compromised patients.
In hospital settings, an increasing number of strains of Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus spp., and Pseudomonas aeruginosa, major sources of infections, are becoming multi-drug resistant and therefore difficult if not impossible to treat:
- S. aureus is resistant to B-lactam and quinolone antibiotics and now even to vancomycin;
- S. pneumoniae is becoming resistant to penicillin and quinolone antibiotics and even to new macrolides;
- Enteroccocci are quinolone and vancomycin resistant and B-lactam antibiotics are inefficacious against these strains;
- Enterobacteriacea are cephalosporin and quinolone resistant;
- P. aeruginosa are 13-lactam and quinolone resistant.
Further new emerging organisms like Acinetobacter spp. or C. difficile, which have been selected during therapy with the currently used antibiotics, are becoming a real problem in hospital settings.
In addition, microorganisms that are causing persistent infections are increasingly being recognized as causative agents or cofactors of severe chronic diseases like peptic ulcers or heart diseases.
The present invention concerns novel antibiotics, pharmaceutical antibacterial compositions containing them and the use thereof in the manufacture of a medicament for the treatment of infections (e.g. bacterial infections). These compounds are useful antimicrobial agents effective against a variety of human and veterinary pathogens including among others Gram positive and Gram negative aerobic and anaerobic bacteria and mycobacteria.
The intensive use of antibiotics has exerted a selective evolutionary pressure on micro-organisms to produce genetically based resistance mechanisms. Modern medicine and socio-economic behaviour exacerbates the problem of resistance development by creating slow growth situations for pathogenic microbes, e.g. in artificial joints, and by supporting long-term host reservoirs, e.g. in immuno-compromised patients.
In hospital settings, an increasing number of strains of Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus spp., and Pseudomonas aeruginosa, major sources of infections, are becoming multi-drug resistant and therefore difficult if not impossible to treat:
- S. aureus is resistant to B-lactam and quinolone antibiotics and now even to vancomycin;
- S. pneumoniae is becoming resistant to penicillin and quinolone antibiotics and even to new macrolides;
- Enteroccocci are quinolone and vancomycin resistant and B-lactam antibiotics are inefficacious against these strains;
- Enterobacteriacea are cephalosporin and quinolone resistant;
- P. aeruginosa are 13-lactam and quinolone resistant.
Further new emerging organisms like Acinetobacter spp. or C. difficile, which have been selected during therapy with the currently used antibiotics, are becoming a real problem in hospital settings.
In addition, microorganisms that are causing persistent infections are increasingly being recognized as causative agents or cofactors of severe chronic diseases like peptic ulcers or heart diseases.
A new type of quinoline or naphthyridine derivatives having antibacterial activity and therefore useful for treating infections in mammals, particularly in humans, has been reported in the last few years.
WO 99/37635, WO 00/21948, WO 00/21952, WO 00/43383, WO 03/101138, WO 01/025227, WO 02/040474 and WO 2004/011454 disclose quinoline, naphthyridine and quinazoline derivatives containing a 4-methylpiperidinyl spacer.
WO 00/78748, WO 02/50040 and WO 02/050061 disclose quinoline and naphthyridine derivatives containing a piperazinyl spacer.
WO 01/07432, WO 01/07433, WO 02/08224, WO 02/056882, WO 03/064421, 3 1, WO 2004/02490 and WO 2004/058144 disclose quinoline, quinoxaline and naphthyridine derivatives containing a 4-aminopiperidinyl spacer.
WO 04/035569 and WO 2006/014580 disclose quinoline and naphthyridine derivatives containing a 3-aminomethylpiperidinyl spacer.
WO 2004/002992, WO 03/087098, WO 2004/014361 and WO 2004/035569 disclose quinoline, quinoxaline and naphthyridine derivatives containing a 4-aminocyclohexyl spacer.
In addition, PCT application No. PCT/EP2005/010154 (published as WO
2006/032466) describes certain bicyclic derivatives as useful antimicrobial agents that are effective against a variety of multi-drug resistant bacteria. Said bicyclic derivatives have the formula (Al) Ri V U
W\ M-D
X (Ai) wherein R' represents alkyl, alkoxy, haloalkoxy, halogen or cyano;
one or two of U, V, W and X represent(s) N, the remaining represent CH, or, in the case of U, V and/or W, may also represent CRa and, in the case of X, may also represent CRb;
Ra represents halogen;
WO 99/37635, WO 00/21948, WO 00/21952, WO 00/43383, WO 03/101138, WO 01/025227, WO 02/040474 and WO 2004/011454 disclose quinoline, naphthyridine and quinazoline derivatives containing a 4-methylpiperidinyl spacer.
WO 00/78748, WO 02/50040 and WO 02/050061 disclose quinoline and naphthyridine derivatives containing a piperazinyl spacer.
WO 01/07432, WO 01/07433, WO 02/08224, WO 02/056882, WO 03/064421, 3 1, WO 2004/02490 and WO 2004/058144 disclose quinoline, quinoxaline and naphthyridine derivatives containing a 4-aminopiperidinyl spacer.
WO 04/035569 and WO 2006/014580 disclose quinoline and naphthyridine derivatives containing a 3-aminomethylpiperidinyl spacer.
WO 2004/002992, WO 03/087098, WO 2004/014361 and WO 2004/035569 disclose quinoline, quinoxaline and naphthyridine derivatives containing a 4-aminocyclohexyl spacer.
In addition, PCT application No. PCT/EP2005/010154 (published as WO
2006/032466) describes certain bicyclic derivatives as useful antimicrobial agents that are effective against a variety of multi-drug resistant bacteria. Said bicyclic derivatives have the formula (Al) Ri V U
W\ M-D
X (Ai) wherein R' represents alkyl, alkoxy, haloalkoxy, halogen or cyano;
one or two of U, V, W and X represent(s) N, the remaining represent CH, or, in the case of U, V and/or W, may also represent CRa and, in the case of X, may also represent CRb;
Ra represents halogen;
Rb represents halogen or alkoxy;
D represents alkyl, aryl or heteroaryl;
M is notably the group M2:
M2 = --A3 I _ N - A4 ~-wherein A3 represents NHCO, CH2CH2, CH=CH, COCH2, CH(OH)CH2, CH2CH(OH), CH(OH)CH(OH) or OCH2;
A4 represents CH2, CO, CH2CH=CH, COCH=CH or CH2CONH;
R2 represents hydrogen, alkyl, hydroxyalkyl, alkylcarbonyloxyalkyl, carbamoyloxyalkyl, carboxyalkyl or carbamoylalkyl;
R3 and R4 each independently represent hydrogen, hydroxy or alkylcarbonyloxy;
or R3 and R4 together represent a bridged dimethylmethylenedioxy chain attached to the carbons bearing R3 and R4;
R5 represents hydrogen, alkyl or hydroxyalkyl; and the dotted line represents a single bond or, when R3 and R4 represent hydrogen, also a double bond.
This invention relates to selected compounds of formula (Al) as described above and salts thereof.
Thus, the compounds of this invention are selected from the following:
- (E)-2-{(2R,3R,6R)-(3-[3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-ethanol;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-acryloylamino]-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-3-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carbonyl)-amino]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-3-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-ylmethyl)-amino]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1S)-l-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- (1R)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl} -1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- (1S)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl} -1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- 2-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1R,2R)-1,2-dihydroxy-2-(3-methoxy-quinoxalin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- 2-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(S)-l-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2R)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2S)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2R)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
D represents alkyl, aryl or heteroaryl;
M is notably the group M2:
M2 = --A3 I _ N - A4 ~-wherein A3 represents NHCO, CH2CH2, CH=CH, COCH2, CH(OH)CH2, CH2CH(OH), CH(OH)CH(OH) or OCH2;
A4 represents CH2, CO, CH2CH=CH, COCH=CH or CH2CONH;
R2 represents hydrogen, alkyl, hydroxyalkyl, alkylcarbonyloxyalkyl, carbamoyloxyalkyl, carboxyalkyl or carbamoylalkyl;
R3 and R4 each independently represent hydrogen, hydroxy or alkylcarbonyloxy;
or R3 and R4 together represent a bridged dimethylmethylenedioxy chain attached to the carbons bearing R3 and R4;
R5 represents hydrogen, alkyl or hydroxyalkyl; and the dotted line represents a single bond or, when R3 and R4 represent hydrogen, also a double bond.
This invention relates to selected compounds of formula (Al) as described above and salts thereof.
Thus, the compounds of this invention are selected from the following:
- (E)-2-{(2R,3R,6R)-(3-[3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-ethanol;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-acryloylamino]-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-3-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carbonyl)-amino]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-3-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-ylmethyl)-amino]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1S)-l-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- (1R)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl} -1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- (1S)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl} -1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- 2-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1R,2R)-1,2-dihydroxy-2-(3-methoxy-quinoxalin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- 2-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(S)-l-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2R)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2S)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2R)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S, 3R, 6S)-6-[(2S)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl] -2-hydroxymethyl-tetrahydro-pyran-3 -yl }-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2S,5R,6R)-(5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-(2-hydroxy-ethyl))-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide;
- (2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[ 1,5 ]naphthyridin-4-yl)-amide;
- (1S)-l-{(2S,5R)-5-[(E)-3-(3-fluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-methoxy-quinolin-4-yl)-ethanol;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl] -2-hydroxymethyl-tetrahydro-pyran-3 -yl }-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2S,5R,6R)-(5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-(2-hydroxy-ethyl))-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide;
- (2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[ 1,5 ]naphthyridin-4-yl)-amide;
- (1S)-l-{(2S,5R)-5-[(E)-3-(3-fluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-methoxy-quinolin-4-yl)-ethanol;
- 7-fluoro-6-({(3R,6S)-6-[(1S)-l-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-benzo[1,4]thiazin-3-one;
- 3-(2-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-l-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(3-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-l-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-l-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(3-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-l-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 8-((1R,2R)-2-{(2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-1,2-dihydroxy-ethyl)-quinoline-2-carbonitrile;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{3R,6S)-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-5-yl)-vinyl] -tetrahydro-pyran-3 -yl }-amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3R,6S)-6-[2-(6-fluoro-3-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-amine;
- 6-({(3R,6S)-6-[2-(6-fluoro-3-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-pyrido [3,2-b] [ 1,4]thiazin-3 -one;
- (1R,2R)-l-{(2R,5S)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-fluoro-quinolin-4-yl)-ethane-1,2-diol;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-(E)-6-[2-(6-fluoro-quinolin-4-yl)-vinyl]-tetrahydro-pyran-3-yl}-amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-amine;
- 6-({3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-pyrido [3,2-b] [ 1,4]thiazin-3-one;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2R, 3R, 6S)-2-(2-hydroxy-ethyl)-6-[(E)-2-(6-methoxy-[ 1,5 ]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-3-yl}-amide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2R,3R,6S)-{3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
- [(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-(6-methoxy-[1,5]naphthyridin-4-ylcarbamoyl)-tetrahydro-pyran-2-yl] -acetic acid;
and salts thereof.
The invention relates in particular to compounds selected from the following:
- (E)-2-{(2R,3R,6R)-(3-[3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-ethanol;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-acryloylamino]-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-3-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carbonyl)-amino]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-3-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-ylmethyl)-amino]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1S)-l-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- (1R)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl} -1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- (1S)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl} -1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- 2-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1R,2R)-1,2-dihydroxy-2-(3-methoxy-quinoxalin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- 2-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl] -tetrahydro-pyran-2-yl }-acetamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(S)-l-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2R)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2S)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S, 3R, 6S)-6-[(2R)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S, 3R, 6S)-6-[(2S)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl] -2-hydroxymethyl-tetrahydro-pyran-3 -yl }-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2S,5R,6R)-(5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-(2-hydroxy-ethyl))-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide;
- (2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[ 1,5 ]naphthyridin-4-yl)-amide;
- (1S)-l-{(2S,5R)-5-[(E)-3-(3-fluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-methoxy-quinolin-4-yl)-ethanol;
- 7-fluoro-6-({(3R,6S)-6-[(1S)-l-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3 -ylamino }-methyl)-4H-benzo [ 1,4]thiazin-3 -one;
- 3-(2-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-l-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(3-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-l-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 8-((1R,2R)-2-{(2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-1,2-dihydroxy-ethyl)-quinoline-2-carbonitrile;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{3R,6S)-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-5-yl)-vinyl] -tetrahydro-pyran-3 -yl} -amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3R,6S)-6-[2-(6-fluoro-3-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-amine;
- 6-({(3R,6S)-6-[2-(6-fluoro-3-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-pyrido [3,2-b] [ 1,4]thiazin-3 -one;
- (1R,2R)-l-{(2R,5S)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-fluoro-quinolin-4-yl)-ethane-1,2-diol;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-(E)-6-[2-(6-fluoro-quinolin-4-yl)-vinyl]-tetrahydro-pyran-3-yl}-amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-amine;
- 6-({3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-pyrido [3,2-b] [ 1,4]thiazin-3 -one;
and to salts thereof.
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{3R,6S)-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-5-yl)-vinyl] -tetrahydro-pyran-3 -yl }-amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3R,6S)-6-[2-(6-fluoro-3-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-amine;
- 6-({(3R,6S)-6-[2-(6-fluoro-3-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-pyrido [3,2-b] [ 1,4]thiazin-3 -one;
- (1R,2R)-l-{(2R,5S)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-fluoro-quinolin-4-yl)-ethane-1,2-diol;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-(E)-6-[2-(6-fluoro-quinolin-4-yl)-vinyl]-tetrahydro-pyran-3-yl}-amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-amine;
- 6-({3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-pyrido [3,2-b] [ 1,4]thiazin-3-one;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2R, 3R, 6S)-2-(2-hydroxy-ethyl)-6-[(E)-2-(6-methoxy-[ 1,5 ]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-3-yl}-amide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2R,3R,6S)-{3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
- [(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-(6-methoxy-[1,5]naphthyridin-4-ylcarbamoyl)-tetrahydro-pyran-2-yl] -acetic acid;
and salts thereof.
The invention relates in particular to compounds selected from the following:
- (E)-2-{(2R,3R,6R)-(3-[3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-ethanol;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-acryloylamino]-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-3-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carbonyl)-amino]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-3-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-ylmethyl)-amino]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1S)-l-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- (1R)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl} -1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- (1S)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl} -1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- 2-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1R,2R)-1,2-dihydroxy-2-(3-methoxy-quinoxalin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- 2-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl] -tetrahydro-pyran-2-yl }-acetamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(S)-l-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2R)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2S)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S, 3R, 6S)-6-[(2R)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S, 3R, 6S)-6-[(2S)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl] -2-hydroxymethyl-tetrahydro-pyran-3 -yl }-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2S,5R,6R)-(5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-(2-hydroxy-ethyl))-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide;
- (2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[ 1,5 ]naphthyridin-4-yl)-amide;
- (1S)-l-{(2S,5R)-5-[(E)-3-(3-fluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-methoxy-quinolin-4-yl)-ethanol;
- 7-fluoro-6-({(3R,6S)-6-[(1S)-l-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3 -ylamino }-methyl)-4H-benzo [ 1,4]thiazin-3 -one;
- 3-(2-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-l-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(3-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-l-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 8-((1R,2R)-2-{(2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-1,2-dihydroxy-ethyl)-quinoline-2-carbonitrile;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{3R,6S)-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-5-yl)-vinyl] -tetrahydro-pyran-3 -yl} -amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3R,6S)-6-[2-(6-fluoro-3-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-amine;
- 6-({(3R,6S)-6-[2-(6-fluoro-3-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-pyrido [3,2-b] [ 1,4]thiazin-3 -one;
- (1R,2R)-l-{(2R,5S)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-fluoro-quinolin-4-yl)-ethane-1,2-diol;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-(E)-6-[2-(6-fluoro-quinolin-4-yl)-vinyl]-tetrahydro-pyran-3-yl}-amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-amine;
- 6-({3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-pyrido [3,2-b] [ 1,4]thiazin-3 -one;
and to salts thereof.
The following invention compounds are preferred:
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2R,3R,6S)-{3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
as well as their salts.
According to a first embodiment, the compounds of this invention will be selected from the following:
- (E)-2-{(2R,3R,6R)-(3-[3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-ethanol;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-acryloylamino]-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1S)-l-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- (1R)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl}-1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- (1S)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl} -1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- 2-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1R,2R)-1,2-dihydroxy-2-(3-methoxy-quinoxalin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- 2-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl] -tetrahydro-pyran-2-yl }-acetamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2R,3R,6S)-{3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
as well as their salts.
According to a first embodiment, the compounds of this invention will be selected from the following:
- (E)-2-{(2R,3R,6R)-(3-[3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-ethanol;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-acryloylamino]-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1S)-l-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- (1R)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl}-1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- (1S)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl} -1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- 2-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1R,2R)-1,2-dihydroxy-2-(3-methoxy-quinoxalin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- 2-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl] -tetrahydro-pyran-2-yl }-acetamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(S)-l-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl] -2-hydroxymethyl-tetrahydro-pyran-3 -yl }-(E)-acrylamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2S,5R,6R)-(5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-(2-hydroxy-ethyl))-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide;
- (2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[ 1,5 ]naphthyridin-4-yl)-amide;
- (1S)-l-{(2S,5R)-5-[(E)-3-(3-fluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-methoxy-quinolin-4-yl)-ethanol;
- 3-(2-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-l-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(3-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-l-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 8-((1R,2R)-2-{(2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-1,2-dihydroxy-ethyl)-quinoline-2-carbonitrile;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{3R,6S)-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-5-yl)-vinyl] -tetrahydro-pyran-3 -yl} -amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3R,6S)-6-[2-(6-fluoro-3-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-amine;
- (1R,2R)-l-{(2R,5S)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-fluoro-quinolin-4-yl)-ethane- 1,2-diol;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-(E)-6-[2-(6-fluoro-quinolin-4-yl)-vinyl]-tetrahydro-pyran-3-yl}-amine;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl] -2-hydroxymethyl-tetrahydro-pyran-3 -yl }-(E)-acrylamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2S,5R,6R)-(5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-(2-hydroxy-ethyl))-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide;
- (2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[ 1,5 ]naphthyridin-4-yl)-amide;
- (1S)-l-{(2S,5R)-5-[(E)-3-(3-fluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-methoxy-quinolin-4-yl)-ethanol;
- 3-(2-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-l-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(3-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-l-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 8-((1R,2R)-2-{(2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-1,2-dihydroxy-ethyl)-quinoline-2-carbonitrile;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{3R,6S)-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-5-yl)-vinyl] -tetrahydro-pyran-3 -yl} -amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3R,6S)-6-[2-(6-fluoro-3-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-amine;
- (1R,2R)-l-{(2R,5S)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-fluoro-quinolin-4-yl)-ethane- 1,2-diol;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-(E)-6-[2-(6-fluoro-quinolin-4-yl)-vinyl]-tetrahydro-pyran-3-yl}-amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-amine;
- 6-({3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-pyrido [3,2-b] [ 1,4]thiazin-3-one;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2R,3R,6S)-{3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
or will be salts of these compounds.
According to said first embodiment, the compounds of this invention will in particular be selected from the following:
- (E)-2-{(2R,3R,6R)-(3-[3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-ethanol;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-acryloylamino]-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1S)-l-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- (1R)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl} -1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- (1S)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl}-1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- 2-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1R,2R)-1,2-dihydroxy-2-(3-methoxy-quinoxalin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- 6-({3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-pyrido [3,2-b] [ 1,4]thiazin-3-one;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2R,3R,6S)-{3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
or will be salts of these compounds.
According to said first embodiment, the compounds of this invention will in particular be selected from the following:
- (E)-2-{(2R,3R,6R)-(3-[3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-ethanol;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-acryloylamino]-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1S)-l-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- (1R)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl} -1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- (1S)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl}-1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- 2-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1R,2R)-1,2-dihydroxy-2-(3-methoxy-quinoxalin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- 2-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(S)-l-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl] -2-hydroxymethyl-tetrahydro-pyran-3 -yl }-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2S,5R,6R)-(5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-(2-hydroxy-ethyl))-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide;
- (2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[ 1,5 ]naphthyridin-4-yl)-amide;
- (1S)-l-{(2S,5R)-5-[(E)-3-(3-fluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-methoxy-quinolin-4-yl)-ethanol;
- 3-(2-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-l-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(3-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-l-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 8-((1R,2R)-2-{(2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-1,2-dihydroxy-ethyl)-quinoline-2-carbonitrile;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{3R,6S)-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-5-yl)-vinyl] -tetrahydro-pyran-3 -yl} -amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3R,6S)-6-[2-(6-fluoro-3-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-amine;
- (1R,2R)-l-{(2R,5S)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-fluoro-quinolin-4-yl)-ethane-1,2-diol;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(S)-l-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl] -2-hydroxymethyl-tetrahydro-pyran-3 -yl }-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2S,5R,6R)-(5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-(2-hydroxy-ethyl))-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide;
- (2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[ 1,5 ]naphthyridin-4-yl)-amide;
- (1S)-l-{(2S,5R)-5-[(E)-3-(3-fluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-methoxy-quinolin-4-yl)-ethanol;
- 3-(2-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-l-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(3-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-l-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 8-((1R,2R)-2-{(2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-1,2-dihydroxy-ethyl)-quinoline-2-carbonitrile;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{3R,6S)-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-5-yl)-vinyl] -tetrahydro-pyran-3 -yl} -amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3R,6S)-6-[2-(6-fluoro-3-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-amine;
- (1R,2R)-l-{(2R,5S)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-fluoro-quinolin-4-yl)-ethane-1,2-diol;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-(E)-6-[2-(6-fluoro-quinolin-4-yl)-vinyl]-tetrahydro-pyran-3-yl}-amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-amine;
or will be salts of these compounds.
According to said first embodiment, the compounds of this invention can also be selected from the following:
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{3R,6S)-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-5-yl)-vinyl] -tetrahydro-pyran-3 -yl} -amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-(E)-6-[2-(6-fluoro-quinolin-4-yl)-vinyl]-tetrahydro-pyran-3-yl}-amine;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2R,3R,6S)-{3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
or be salts of these compounds.
According to one variant of this first embodiment, the compounds of this invention will be selected from the following:
- (E)-2-{(2R,3R,6R)-(3-[3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-ethanol;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-acryloylamino]-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1S)-l-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-amine;
or will be salts of these compounds.
According to said first embodiment, the compounds of this invention can also be selected from the following:
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{3R,6S)-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-5-yl)-vinyl] -tetrahydro-pyran-3 -yl} -amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-(E)-6-[2-(6-fluoro-quinolin-4-yl)-vinyl]-tetrahydro-pyran-3-yl}-amine;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2R,3R,6S)-{3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
or be salts of these compounds.
According to one variant of this first embodiment, the compounds of this invention will be selected from the following:
- (E)-2-{(2R,3R,6R)-(3-[3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-ethanol;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-acryloylamino]-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1S)-l-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- (1R)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl} -1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- (1S)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl} -1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- 2-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1R,2R)-1,2-dihydroxy-2-(3-methoxy-quinoxalin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl] -tetrahydro-pyran-2-yl}-acetic acid;
- 2-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(S)-l-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl] -2-hydroxymethyl-tetrahydro-pyran-3 -yl }-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2S,5R,6R)-(5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-(2-hydroxy-ethyl))-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide;
- (2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[ 1,5 ]naphthyridin-4-yl)-amide;
- 8-((1R,2R)-2-{(2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-1,2-dihydroxy-ethyl)-quinoline-2-carbonitrile;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{3R,6S)-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-5-yl)-vinyl] -tetrahydro-pyran-3 -yl} -amine;
- (1S)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl} -1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- 2-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1R,2R)-1,2-dihydroxy-2-(3-methoxy-quinoxalin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl] -tetrahydro-pyran-2-yl}-acetic acid;
- 2-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(S)-l-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl] -2-hydroxymethyl-tetrahydro-pyran-3 -yl }-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2S,5R,6R)-(5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-(2-hydroxy-ethyl))-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide;
- (2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[ 1,5 ]naphthyridin-4-yl)-amide;
- 8-((1R,2R)-2-{(2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-1,2-dihydroxy-ethyl)-quinoline-2-carbonitrile;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{3R,6S)-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-5-yl)-vinyl] -tetrahydro-pyran-3 -yl} -amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3R,6S)-6-[2-(6-fluoro-3-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-amine;
- (1R,2R)-l-{(2R,5S)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-fluoro-quinolin-4-yl)-ethane-1,2-diol;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-(E)-6-[2-(6-fluoro-quinolin-4-yl)-vinyl]-tetrahydro-pyran-3-yl}-amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-amine;
or will be salts of these compounds.
According to said variant of this first embodiment, the compounds of this invention will in particular be selected from the following:
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{3R,6S)-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-5-yl)-vinyl] -tetrahydro-pyran-3 -yl }-amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-(E)-6-[2-(6-fluoro-quinolin-4-yl)-vinyl]-tetrahydro-pyran-3-yl}-amine;
or will be salts of these compounds.
According to another variant of this first embodiment, the compounds of this invention will be selected from the following:
- (1S)-l-{(2S,5R)-5-[(E)-3-(3-fluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-methoxy-quinolin-4-yl)-ethanol;
- 3-(2-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-l-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(3-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-l-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
or will be salts of these compounds.
- (1R,2R)-l-{(2R,5S)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-fluoro-quinolin-4-yl)-ethane-1,2-diol;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-(E)-6-[2-(6-fluoro-quinolin-4-yl)-vinyl]-tetrahydro-pyran-3-yl}-amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-amine;
or will be salts of these compounds.
According to said variant of this first embodiment, the compounds of this invention will in particular be selected from the following:
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{3R,6S)-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-5-yl)-vinyl] -tetrahydro-pyran-3 -yl }-amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-(E)-6-[2-(6-fluoro-quinolin-4-yl)-vinyl]-tetrahydro-pyran-3-yl}-amine;
or will be salts of these compounds.
According to another variant of this first embodiment, the compounds of this invention will be selected from the following:
- (1S)-l-{(2S,5R)-5-[(E)-3-(3-fluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-methoxy-quinolin-4-yl)-ethanol;
- 3-(2-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-l-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(3-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-l-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
or will be salts of these compounds.
According to a second embodiment, the compounds of this invention will be selected from the following:
- {(2R,3R,6R)-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-3-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carbonyl)-amino]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-3-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-ylmethyl)-amino]-tetrahydro-pyran-2-yl}-acetic acid;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2R)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2S)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S, 3R, 6S)-6-[(2R)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S, 3R, 6S)-6-[(2S)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 7-fluoro-6-({(3R,6S)-6-[(1S)-l-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3 -ylamino }-methyl)-4H-benzo [ 1,4]thiazin-3 -one;
- 6-({(3R,6S)-6-[2-(6-fluoro-3-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-pyrido [3,2-b] [ 1,4]thiazin-3 -one;
- 6-({3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-pyrido [3,2-b] [ 1,4]thiazin-3-one;
or will be salts of these compounds.
The compounds of this invention are suitable for the use as chemotherapeutic active compounds in human and veterinary medicine and as substances for preserving inorganic and organic materials in particular all types of organic materials for example polymers, lubricants, paints, fibres, leather, paper and wood.
These compounds according to the invention are particularly active against bacteria and bacteria-like organisms. They are therefore particularly suitable in human and veterinary medicine for the prophylaxis and chemotherapy of local and systemic infections caused by these pathogens as well as disorders related to bacterial infections comprising pneumonia, otitis media, sinusitis, bronchitis, tonsillitis, and mastoiditis related to infection by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Enterococcus faecalis, E. faecium, E. casselif avus, S. epidermidis, S. haemolyticus, or Peptostreptococcus spp.; pharyngitis, rheumatic fever, and glomerulonephritis related to infection by Streptococcus pyogenes, Groups C and G streptococci, Corynebacterium diphtheriae, or Actinobacillus haemolyticum; respiratory tract infections related to infection by Mycoplasma pneumoniae, Legionella pneumophila, Streptococcus pneumoniae, Haemophilus influenzae, or Chlamydia pneumoniae; blood and tissue infections, including endocarditis and osteomyelitis, caused by S. aureus, S. haemolyticus, E.
faecalis, E. faecium, E. durans, including strains resistant to known antibacterials such as, but not limited to, beta-lactams, vancomycin, aminoglycosides, quinolones, chloramphenicol, tetracyclines and macrolides; uncomplicated skin and soft tissue infections and abscesses, and puerperal fever related to infection by Staphylococcus aureus, coagulase-negative staphylococci (i.e., S.
epidermidis, S. haemolyticus, etc.), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcal groups C-F (minute colony streptococci), viridans streptococci, Corynebacterium minutissimum, Clostridium spp., or Bartonella henselae;
uncomplicated acute urinary tract infections related to infection by Staphylococcus aureus, coagulase-negative staphylococcal species, or Enterococcus spp.; urethritis and cervicitis;
sexually transmitted diseases related to infection by Chlamydia trachomatis, Haemophilus ducreyi, Treponema pallidum, Ureaplasma urealyticum, or Neiserria gonorrheae;
toxin diseases related to infection by S. aureus (food poisoning and toxic shock syndrome), or Groups A, B, and C streptococci; ulcers related to infection by Helicobacter pylori; systemic febrile syndromes related to infection by Borrelia recurrentis; Lyme disease related to infection by Borrelia burgdorferi; conjunctivitis, keratitis, and dacrocystitis related to infection by Chlamydia trachomatis, Neisseria gonorrhoeae, S. aureus, S.
pneumoniae, S.
pyogenes, H. influenzae, or Listeria spp.; disseminated Mycobacterium avium complex (MAC) disease related to infection by Mycobacterium avium, or Mycobacterium intracellulare; infections caused by Mycobacterium tuberculosis, M. leprae, M.
paratuberculosis, M. kansasii, or M. chelonei; gastroenteritis related to infection by Campylobacter jejuni; intestinal protozoa related to infection by Cryptosporidium spp.;
odontogenic infection related to infection by viridans streptococci;
persistent cough related to infection by Bordetella pertussis; gas gangrene related to infection by Clostridium perfringens or Bacteroides spp.; and atherosclerosis or cardiovascular disease related to infection by Helicobacter pylori or Chlamydia pneumoniae.
The compounds according to this invention are further useful for the preparation of a medicament for the treatment of infections that are mediated by bacteria such as E. coli, Klebsiella pneumoniae and other Enterobacteriaceae, Acinetobacter spp., Stenothrophomonas maltophilia, Neisseria meningitidis, Bacillus cereus, Bacillus anthracis, Corynebacterium spp., Propionibacterium acnes and bacteroide spp.
The compounds according to this invention are further useful to treat protozoal infections caused by Plasmodium malaria, Plasmodium falciparum, Toxoplasma gondii, Pneumocystis carinii, Trypanosoma brucei and Leishmania spp.
The present list of pathogens is to be interpreted merely as examples and in no way as limiting.
As well as in humans, bacterial infections can also be treated in other species like pigs, ruminants, horses, dogs, cats and poultry.
The present invention also relates to pharmacologically acceptable salts, or solvates and hydrates, respectively, and to compositions and formulations of the compounds mentioned above.
Examples of pharmacologically acceptable salts of sufficiently basic compounds of this invention are selected from the group consisting of salts of physiologically acceptable mineral acids like hydrochloric, hydrobromic, sulfuric and phosphoric acid; or salts of organic acids like methanesulfonic, p-toluenesulfonic, lactic, acetic, trifluoroacetic, citric, succinic, fumaric, maleic and salicylic acid. Further, a sufficiently acidic compound of this invention may form alkali or earth alkaline metal salts, for example sodium, potassium, lithium, calcium or magnesium salts; ammonium salts; or organic base salts, for example methylamine, dimethylamine, trimethylamine, triethylamine, ethylenediamine, ethanolamine, choline hydroxide, meglumin, piperidine, morpholine, tris-(2-hydroxyethyl)amine, lysine or arginine salts. The compounds of this invention may be solvated, especially hydrated.
The hydratation can occur during the process of production or as a consequence of the hygroscopic nature of the initially water free compounds of this invention.
- {(2R,3R,6R)-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-3-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carbonyl)-amino]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-3-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-ylmethyl)-amino]-tetrahydro-pyran-2-yl}-acetic acid;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2R)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2S)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S, 3R, 6S)-6-[(2R)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S, 3R, 6S)-6-[(2S)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 7-fluoro-6-({(3R,6S)-6-[(1S)-l-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3 -ylamino }-methyl)-4H-benzo [ 1,4]thiazin-3 -one;
- 6-({(3R,6S)-6-[2-(6-fluoro-3-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-pyrido [3,2-b] [ 1,4]thiazin-3 -one;
- 6-({3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-pyrido [3,2-b] [ 1,4]thiazin-3-one;
or will be salts of these compounds.
The compounds of this invention are suitable for the use as chemotherapeutic active compounds in human and veterinary medicine and as substances for preserving inorganic and organic materials in particular all types of organic materials for example polymers, lubricants, paints, fibres, leather, paper and wood.
These compounds according to the invention are particularly active against bacteria and bacteria-like organisms. They are therefore particularly suitable in human and veterinary medicine for the prophylaxis and chemotherapy of local and systemic infections caused by these pathogens as well as disorders related to bacterial infections comprising pneumonia, otitis media, sinusitis, bronchitis, tonsillitis, and mastoiditis related to infection by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Enterococcus faecalis, E. faecium, E. casselif avus, S. epidermidis, S. haemolyticus, or Peptostreptococcus spp.; pharyngitis, rheumatic fever, and glomerulonephritis related to infection by Streptococcus pyogenes, Groups C and G streptococci, Corynebacterium diphtheriae, or Actinobacillus haemolyticum; respiratory tract infections related to infection by Mycoplasma pneumoniae, Legionella pneumophila, Streptococcus pneumoniae, Haemophilus influenzae, or Chlamydia pneumoniae; blood and tissue infections, including endocarditis and osteomyelitis, caused by S. aureus, S. haemolyticus, E.
faecalis, E. faecium, E. durans, including strains resistant to known antibacterials such as, but not limited to, beta-lactams, vancomycin, aminoglycosides, quinolones, chloramphenicol, tetracyclines and macrolides; uncomplicated skin and soft tissue infections and abscesses, and puerperal fever related to infection by Staphylococcus aureus, coagulase-negative staphylococci (i.e., S.
epidermidis, S. haemolyticus, etc.), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcal groups C-F (minute colony streptococci), viridans streptococci, Corynebacterium minutissimum, Clostridium spp., or Bartonella henselae;
uncomplicated acute urinary tract infections related to infection by Staphylococcus aureus, coagulase-negative staphylococcal species, or Enterococcus spp.; urethritis and cervicitis;
sexually transmitted diseases related to infection by Chlamydia trachomatis, Haemophilus ducreyi, Treponema pallidum, Ureaplasma urealyticum, or Neiserria gonorrheae;
toxin diseases related to infection by S. aureus (food poisoning and toxic shock syndrome), or Groups A, B, and C streptococci; ulcers related to infection by Helicobacter pylori; systemic febrile syndromes related to infection by Borrelia recurrentis; Lyme disease related to infection by Borrelia burgdorferi; conjunctivitis, keratitis, and dacrocystitis related to infection by Chlamydia trachomatis, Neisseria gonorrhoeae, S. aureus, S.
pneumoniae, S.
pyogenes, H. influenzae, or Listeria spp.; disseminated Mycobacterium avium complex (MAC) disease related to infection by Mycobacterium avium, or Mycobacterium intracellulare; infections caused by Mycobacterium tuberculosis, M. leprae, M.
paratuberculosis, M. kansasii, or M. chelonei; gastroenteritis related to infection by Campylobacter jejuni; intestinal protozoa related to infection by Cryptosporidium spp.;
odontogenic infection related to infection by viridans streptococci;
persistent cough related to infection by Bordetella pertussis; gas gangrene related to infection by Clostridium perfringens or Bacteroides spp.; and atherosclerosis or cardiovascular disease related to infection by Helicobacter pylori or Chlamydia pneumoniae.
The compounds according to this invention are further useful for the preparation of a medicament for the treatment of infections that are mediated by bacteria such as E. coli, Klebsiella pneumoniae and other Enterobacteriaceae, Acinetobacter spp., Stenothrophomonas maltophilia, Neisseria meningitidis, Bacillus cereus, Bacillus anthracis, Corynebacterium spp., Propionibacterium acnes and bacteroide spp.
The compounds according to this invention are further useful to treat protozoal infections caused by Plasmodium malaria, Plasmodium falciparum, Toxoplasma gondii, Pneumocystis carinii, Trypanosoma brucei and Leishmania spp.
The present list of pathogens is to be interpreted merely as examples and in no way as limiting.
As well as in humans, bacterial infections can also be treated in other species like pigs, ruminants, horses, dogs, cats and poultry.
The present invention also relates to pharmacologically acceptable salts, or solvates and hydrates, respectively, and to compositions and formulations of the compounds mentioned above.
Examples of pharmacologically acceptable salts of sufficiently basic compounds of this invention are selected from the group consisting of salts of physiologically acceptable mineral acids like hydrochloric, hydrobromic, sulfuric and phosphoric acid; or salts of organic acids like methanesulfonic, p-toluenesulfonic, lactic, acetic, trifluoroacetic, citric, succinic, fumaric, maleic and salicylic acid. Further, a sufficiently acidic compound of this invention may form alkali or earth alkaline metal salts, for example sodium, potassium, lithium, calcium or magnesium salts; ammonium salts; or organic base salts, for example methylamine, dimethylamine, trimethylamine, triethylamine, ethylenediamine, ethanolamine, choline hydroxide, meglumin, piperidine, morpholine, tris-(2-hydroxyethyl)amine, lysine or arginine salts. The compounds of this invention may be solvated, especially hydrated.
The hydratation can occur during the process of production or as a consequence of the hygroscopic nature of the initially water free compounds of this invention.
The pharmaceutical composition according to the present invention contains at least one compound of one of the above compound lists (or a pharmaceutically acceptable salt thereof) as the active agent and optionally carriers and/or diluents and/or adjuvants, and may also contain additional known antibiotics.
As mentioned above, therapeutically useful agents that contain compounds according to this invention, their solvates, salts or formulations are also comprised in the scope of the present invention. In general, the compounds according to this invention will be administered by using the known and acceptable modes known in the art, either alone or in combination with any other therapeutic agent. Such therapeutically useful agents can be administered by one of the following routes: oral, e.g. as tablets, dragee, coated tablets, pills, semisolids, soft or hard capsules, for example soft and hard gelatine capsules, aqueous or oily solutions, emulsions, suspensions or syrups, parenteral including intravenous, intramuscular and subcutaneous injection, e.g. as an injectable solution or suspension, rectal as suppositories, by inhalation or insufflation, e.g. as a powder formulation, as microcrystal or as a spray (e.g. liquid aerosol), transdermal, for example via an transdermal delivery system (TDS) such as a plaster containing the active ingredient, topical or intranasal. The substance of the present invention can also be used to impregnate or coated devices that are foreseen for implantation like catheters or artificial joints. The pharmaceutically useful agents may also contain additives for conservation, stabilisation, e.g. UV stabilizers, emulsifiers, sweetener, aromatisers, salts to change the osmotic pressure, buffers, coating additives and antioxidants.
Another aspect of the invention concerns a method for the treatment of disease comprising the administration to the patient of a pharmaceutically active amount of a compound according to this invention (or a pharmaceutically acceptable salt thereof).
Moreover, the compounds according to this invention may also be used for cleaning purposes, e.g. to remove pathogenic microbes and bacteria from surgical instruments or to make a room or an area aseptic. For such purposes, the compounds according to this invention could be contained in a solution or in a spray formulation.
As mentioned above, therapeutically useful agents that contain compounds according to this invention, their solvates, salts or formulations are also comprised in the scope of the present invention. In general, the compounds according to this invention will be administered by using the known and acceptable modes known in the art, either alone or in combination with any other therapeutic agent. Such therapeutically useful agents can be administered by one of the following routes: oral, e.g. as tablets, dragee, coated tablets, pills, semisolids, soft or hard capsules, for example soft and hard gelatine capsules, aqueous or oily solutions, emulsions, suspensions or syrups, parenteral including intravenous, intramuscular and subcutaneous injection, e.g. as an injectable solution or suspension, rectal as suppositories, by inhalation or insufflation, e.g. as a powder formulation, as microcrystal or as a spray (e.g. liquid aerosol), transdermal, for example via an transdermal delivery system (TDS) such as a plaster containing the active ingredient, topical or intranasal. The substance of the present invention can also be used to impregnate or coated devices that are foreseen for implantation like catheters or artificial joints. The pharmaceutically useful agents may also contain additives for conservation, stabilisation, e.g. UV stabilizers, emulsifiers, sweetener, aromatisers, salts to change the osmotic pressure, buffers, coating additives and antioxidants.
Another aspect of the invention concerns a method for the treatment of disease comprising the administration to the patient of a pharmaceutically active amount of a compound according to this invention (or a pharmaceutically acceptable salt thereof).
Moreover, the compounds according to this invention may also be used for cleaning purposes, e.g. to remove pathogenic microbes and bacteria from surgical instruments or to make a room or an area aseptic. For such purposes, the compounds according to this invention could be contained in a solution or in a spray formulation.
PREPARATION OF THE COMPOUNDS OF THIS INVENTION
Abbreviations:
The following abbreviations are used:
AcOH acetic acid AD-mix a 1,4-bis(dihydroquinine)phthalazine, K3Fe(CN)6, K2C03 and K20s04.2H20 AD-mix 1,4-bis(dihydroquinidine)phthalazine, K3Fe(CN)6, K2C03 and K20s04.2H20 AIBN 2,2'-azoisobutyronitrile aq. aqueous BINAP 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl Boc2O di-tert-butyl dicarbonate dba dibenzylideneacetone DCC dicyclohexyl carbodiimide 1,2-DCE 1,2-dichloroethane DCM dichloromethane (DHQ)2PHAL 1,4-bis(dihydroquinine)phthalazine (DHQD)2PHAL 1,4-bis(dihydroquinidine)phthalazine DIAD diisopropyl azodicarboxylate DIBAH diisobutylaluminium hydride DIPA diisopropylamine DIPEA N,N-diisopropylethylamine DMAP 4-dimethylaminopyridine 1,2-DME 1,2-dimethoxyethane DMF N,N-dimethylformamide DMSO dimethylsulfoxide DMPU 1,3-dimethyl-3,4,5,6-tetrahydro-2(lH)-pyrimidone EA ethyl acetate ESI electron spray ionisation ether or Et20 diethyl ether EtOH ethanol h hour(s) HATU O-(7-azabenzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate Hept heptane Hex hexane HV high vacuum conditions KHMDS potassium hexamethyldisilazide MeOH methanol min minute(s) MCPBA meta-chloroperbenzoic acid MeCN acetonitrile MeOH methanol MS mass spectroscopy NB S N-bromosuccinimide NHS N-hydroxysuccinimide n-BuLi n-butyl lithium org. organic Pd/C palladium on carbon PPh3 triphenylphosphine PTSA para-toluene sulfonic acid quant. quantitative rac racemic Rf retention factor sat. saturated Si0z silica gel rt room temperature TBAF tetrabutylammonium fluoride TEA triethylamine TFA trifluoroacetic acid THF tetrahydrofuran TsC1 para-toluene sulfonyl chloride wt% weight percent Preparation methods:
The compounds of this invention can be prepared according to the procedures described in the examples hereafter which illustrate the preparation of the pharmacologically active compounds of the invention but do not limit the scope thereof.
Whenever the invention compounds are obtained in the form of mixtures of enantiomers, the enantiomers can be separated using methods known to one skilled in the art (e.g. by formation and separation of diastereomeric salts or by chromatography on a chiral stationary phase).
Whenever the invention compounds are obtained in the form of mixtures of diasteromers they may be separated by an appropriate combination of silica gel chromatography, high performance liquid chromatography (HPLC) and crystallization techniques.
EXAMPLES
All temperatures are stated in C. All analytical and preparative HPLC
investigations on non-chiral phases are performed using RP-C18 based columns. Analytical HPLC
investigations are performed on two different instruments with cycle-times of -2.5 min and -3.5 min respectively.
Preparation A: 3-methoxy-quinoline-5-carbaldehyde:
A.i. 3,5-dibromoquinoline:
To concentrated H2SO4 (130 ml) was added dropwise at 0 C, over 80 min, 3-bromoquinoline (50 g) at a rate allowing the internal temperature to be maintained between 0 and 10 C. After the addition was complete, NBS (48 g) was added portionwise and the reaction mixture was stirred at rt overnight. The reaction mixture was poured onto ice (2 1) and the resulting solid was dissolved in DCM (600 ml). The aq. layer was further extracted with DCM
(600 ml) and the combined extracts were washed with 1MNaOH (300 mL) and concentrated in vacuo. The residue was dispersed in Si02 and the resulting dispersal was loaded on the top of a column and eluted with a DCM-Hex (1-1, 3 1) then DCM (3 1) and finally DCM-ether (1-1, 2 1). The title compound was recovered from the last fraction after evaporation to yield 40 g of a white solid.
iH NMR (CDC13) 8: 8.94 (d, J = 2.2 Hz, 1H); 8.73 (d, J = 2.2 Hz, 1H); 8.08 (d, J = 8.5 Hz, 1 H); 7.88 (d, J = 7.5 Hz, 1 H); 7.62 (dd, J = 7.5, 8.5 Hz, 1 H).
A.H. 5-bromo-3-methoxyquinoline:
To a mixture of sodium methoxide (14.5 g) in DMPU (350 ml) heated at 125 C, was added in one portion intermediate A.i (34.5 g). The reaction was then heated at the same temperature for 1 h. The reaction mixture was then cooled to rt and poured onto ice (300 g). After the ice melt, the solid was filtered off and dried under vacuum. The filtrate was extracted with ether (4 x 150 ml). The combined extracts were washed with brine and dried over Na2SO4. After filtration, the solvent was evaporated and the residue was purified over Si02 (Hex-EA 4-1) to afford a material that was pooled with the solid. The material was dissolved in DCM and dried over Na2SO4. After filtration and evaporation, the solid was further dried under HV to afford the title compound (24.5 g) as a beige solid.
iH NMR (CDC13) 8: 8.68 (d, J =2.8 Hz, 1H); 8.03 (d, J = 8.3 Hz, 1H); 7.80 (d, J = 7.5 Hz, 1H); 7.72 (d, J = 2.8 Hz, 1H); 7.42 (dd, J = 7.5, 8.3 Hz, 1H); 4.02 (s, 3H).
MS (ESI, m/z): 239.7 [M+H+].
A.iii. 3-methoxy-quinoline-5-carbaldehyde:
To a solution of intermediate A.ii (10 g) in THF (250 ml) cooled to -78 C, was added n-BuLi (22 ml). After 15 min, a solution of DMF (10 ml) in ether (20 ml) was quickly added. The solution was stirred 15 min and EtOH (5 ml), followed by 1M NaHSO4 (40 ml), was added.
After warming to rt, the organic layer was diluted with EA (100 ml). The two layers were separated and the aq. layer was extracted once with EA (100 ml). The combined org. layers were washed with brine and concentrated to dryness. The residue was chromatographed over Si0z (EA-Hex 1-2 then 1-1) to afford the title compound (4.75 g) as a yellowish solid.
Abbreviations:
The following abbreviations are used:
AcOH acetic acid AD-mix a 1,4-bis(dihydroquinine)phthalazine, K3Fe(CN)6, K2C03 and K20s04.2H20 AD-mix 1,4-bis(dihydroquinidine)phthalazine, K3Fe(CN)6, K2C03 and K20s04.2H20 AIBN 2,2'-azoisobutyronitrile aq. aqueous BINAP 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl Boc2O di-tert-butyl dicarbonate dba dibenzylideneacetone DCC dicyclohexyl carbodiimide 1,2-DCE 1,2-dichloroethane DCM dichloromethane (DHQ)2PHAL 1,4-bis(dihydroquinine)phthalazine (DHQD)2PHAL 1,4-bis(dihydroquinidine)phthalazine DIAD diisopropyl azodicarboxylate DIBAH diisobutylaluminium hydride DIPA diisopropylamine DIPEA N,N-diisopropylethylamine DMAP 4-dimethylaminopyridine 1,2-DME 1,2-dimethoxyethane DMF N,N-dimethylformamide DMSO dimethylsulfoxide DMPU 1,3-dimethyl-3,4,5,6-tetrahydro-2(lH)-pyrimidone EA ethyl acetate ESI electron spray ionisation ether or Et20 diethyl ether EtOH ethanol h hour(s) HATU O-(7-azabenzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate Hept heptane Hex hexane HV high vacuum conditions KHMDS potassium hexamethyldisilazide MeOH methanol min minute(s) MCPBA meta-chloroperbenzoic acid MeCN acetonitrile MeOH methanol MS mass spectroscopy NB S N-bromosuccinimide NHS N-hydroxysuccinimide n-BuLi n-butyl lithium org. organic Pd/C palladium on carbon PPh3 triphenylphosphine PTSA para-toluene sulfonic acid quant. quantitative rac racemic Rf retention factor sat. saturated Si0z silica gel rt room temperature TBAF tetrabutylammonium fluoride TEA triethylamine TFA trifluoroacetic acid THF tetrahydrofuran TsC1 para-toluene sulfonyl chloride wt% weight percent Preparation methods:
The compounds of this invention can be prepared according to the procedures described in the examples hereafter which illustrate the preparation of the pharmacologically active compounds of the invention but do not limit the scope thereof.
Whenever the invention compounds are obtained in the form of mixtures of enantiomers, the enantiomers can be separated using methods known to one skilled in the art (e.g. by formation and separation of diastereomeric salts or by chromatography on a chiral stationary phase).
Whenever the invention compounds are obtained in the form of mixtures of diasteromers they may be separated by an appropriate combination of silica gel chromatography, high performance liquid chromatography (HPLC) and crystallization techniques.
EXAMPLES
All temperatures are stated in C. All analytical and preparative HPLC
investigations on non-chiral phases are performed using RP-C18 based columns. Analytical HPLC
investigations are performed on two different instruments with cycle-times of -2.5 min and -3.5 min respectively.
Preparation A: 3-methoxy-quinoline-5-carbaldehyde:
A.i. 3,5-dibromoquinoline:
To concentrated H2SO4 (130 ml) was added dropwise at 0 C, over 80 min, 3-bromoquinoline (50 g) at a rate allowing the internal temperature to be maintained between 0 and 10 C. After the addition was complete, NBS (48 g) was added portionwise and the reaction mixture was stirred at rt overnight. The reaction mixture was poured onto ice (2 1) and the resulting solid was dissolved in DCM (600 ml). The aq. layer was further extracted with DCM
(600 ml) and the combined extracts were washed with 1MNaOH (300 mL) and concentrated in vacuo. The residue was dispersed in Si02 and the resulting dispersal was loaded on the top of a column and eluted with a DCM-Hex (1-1, 3 1) then DCM (3 1) and finally DCM-ether (1-1, 2 1). The title compound was recovered from the last fraction after evaporation to yield 40 g of a white solid.
iH NMR (CDC13) 8: 8.94 (d, J = 2.2 Hz, 1H); 8.73 (d, J = 2.2 Hz, 1H); 8.08 (d, J = 8.5 Hz, 1 H); 7.88 (d, J = 7.5 Hz, 1 H); 7.62 (dd, J = 7.5, 8.5 Hz, 1 H).
A.H. 5-bromo-3-methoxyquinoline:
To a mixture of sodium methoxide (14.5 g) in DMPU (350 ml) heated at 125 C, was added in one portion intermediate A.i (34.5 g). The reaction was then heated at the same temperature for 1 h. The reaction mixture was then cooled to rt and poured onto ice (300 g). After the ice melt, the solid was filtered off and dried under vacuum. The filtrate was extracted with ether (4 x 150 ml). The combined extracts were washed with brine and dried over Na2SO4. After filtration, the solvent was evaporated and the residue was purified over Si02 (Hex-EA 4-1) to afford a material that was pooled with the solid. The material was dissolved in DCM and dried over Na2SO4. After filtration and evaporation, the solid was further dried under HV to afford the title compound (24.5 g) as a beige solid.
iH NMR (CDC13) 8: 8.68 (d, J =2.8 Hz, 1H); 8.03 (d, J = 8.3 Hz, 1H); 7.80 (d, J = 7.5 Hz, 1H); 7.72 (d, J = 2.8 Hz, 1H); 7.42 (dd, J = 7.5, 8.3 Hz, 1H); 4.02 (s, 3H).
MS (ESI, m/z): 239.7 [M+H+].
A.iii. 3-methoxy-quinoline-5-carbaldehyde:
To a solution of intermediate A.ii (10 g) in THF (250 ml) cooled to -78 C, was added n-BuLi (22 ml). After 15 min, a solution of DMF (10 ml) in ether (20 ml) was quickly added. The solution was stirred 15 min and EtOH (5 ml), followed by 1M NaHSO4 (40 ml), was added.
After warming to rt, the organic layer was diluted with EA (100 ml). The two layers were separated and the aq. layer was extracted once with EA (100 ml). The combined org. layers were washed with brine and concentrated to dryness. The residue was chromatographed over Si0z (EA-Hex 1-2 then 1-1) to afford the title compound (4.75 g) as a yellowish solid.
iH NMR (CDC13) 8: 10.32 (s, 1H); 9.02 (d, J = 2.9 Hz, 1H); 8.75 (d, J = 2.9 Hz, 1H); 8.31 (d, J = 8.3 Hz, 1H); 8.02 (d, J = 7.1 Hz, 1H); 7.72 (dd, J = 7.1, 8.3 Hz, 1H);
4.02 (s, 3H).
MS (ESI, m/z): 187.9 [M+H+].
Preparation B: 6-methoxy-[1,5]naphthyridine-4-carbaldehyde:
B.i. 2-methoxy-8-styryl-[1,5]naphthyridine:
Trifluoromethanesulfonic acid 6-methoxy-[1,5]naphthyridin-4-yl ester (1.5 g, 4.86 mmol), trans-phenylvinyl boronic acid (0.8 g, 5.35 mmol) and K2C03 (0.9 g, 6.32 mmol) were introduced in a two-neck flask. The atmosphere was flushed with nitrogen.
Dioxane (20 ml) and water (5 ml) were added. The mixture was stirred at rt for 5 min and (P(Ph)3)4Pd (0.28 g, 0.24 mmol) was added. The mixture was heated at reflux for 5 h. After cooling, the reaction mixture was diluted with EA (10 ml) and water (50 ml). The aqueous layer was extracted with EA (2 x 100 ml). The combined extracts were concentrated to dryness. The residue was chromatographed over Si0z (Hex-EA 1-1) to afford the title alkene (1.26 g, 4.8 mmol) as an oil that crystallized on standing.
iH NMR (d6-DMSO) 8: 8.77 (d, J = 4.7 Hz, 1H); 8.28 (d, J = 9.0 Hz, 1H); 8.19 (d, J = 16.7 Hz, 1 H); 8.01 (d, J = 4.7 Hz, 1 H); 7.91 (d, J = 16.7 Hz, 1 H); 7.74 (m, 2H);
7.40-7.34 (m, 3H); 7.30 (d, J = 9.0 Hz, 1H); 4.12 (s, 3H).
B.H. 1-(6-methoxy-[1,5]naphthyridin-4 yl)-2 phenyl-ethane-1,2-diol:
To a mixture of intermediate B.i (1.26 g, 4.8 mmol) in 2-methyl-2-propanol (24 ml) and water (24 ml) were added methanesulfonamide (0.52 g) and AD mix (3 (7 g). The mixture was stirred at rt for 12 h. Sodium bisulfite (7.5 g) was added carefully and stirring was continued 20 min. The two layers were decanted and the aqueous layer was extracted with EA
(2 x 100 ml). The combined organic layers were dried over NazSO4, filtered and concentrated to dryness. The residue was triturated in Hex-EA (1-3, 30 ml) and the resulting solid was filtered off and dried in vacuo to afford the title diol (1.3 g) as a white solid.
MS (ESI, m/z): 297.1 [M+H+].
B.iii. 6-methoxy-[1, 5]naphthyridine-4-carbaldehyde:
To a solution of intermediate B.ii (1.3 g, 4.4 mmol) in acetone (15 ml) was added a solution of Na104 (2.35 g, 10.96 mmol) in water (5 ml). The reaction mixture was stirred at rt for 30 min. The reaction mixture was diluted with THF (100 ml) and the solids were filtered off.
4.02 (s, 3H).
MS (ESI, m/z): 187.9 [M+H+].
Preparation B: 6-methoxy-[1,5]naphthyridine-4-carbaldehyde:
B.i. 2-methoxy-8-styryl-[1,5]naphthyridine:
Trifluoromethanesulfonic acid 6-methoxy-[1,5]naphthyridin-4-yl ester (1.5 g, 4.86 mmol), trans-phenylvinyl boronic acid (0.8 g, 5.35 mmol) and K2C03 (0.9 g, 6.32 mmol) were introduced in a two-neck flask. The atmosphere was flushed with nitrogen.
Dioxane (20 ml) and water (5 ml) were added. The mixture was stirred at rt for 5 min and (P(Ph)3)4Pd (0.28 g, 0.24 mmol) was added. The mixture was heated at reflux for 5 h. After cooling, the reaction mixture was diluted with EA (10 ml) and water (50 ml). The aqueous layer was extracted with EA (2 x 100 ml). The combined extracts were concentrated to dryness. The residue was chromatographed over Si0z (Hex-EA 1-1) to afford the title alkene (1.26 g, 4.8 mmol) as an oil that crystallized on standing.
iH NMR (d6-DMSO) 8: 8.77 (d, J = 4.7 Hz, 1H); 8.28 (d, J = 9.0 Hz, 1H); 8.19 (d, J = 16.7 Hz, 1 H); 8.01 (d, J = 4.7 Hz, 1 H); 7.91 (d, J = 16.7 Hz, 1 H); 7.74 (m, 2H);
7.40-7.34 (m, 3H); 7.30 (d, J = 9.0 Hz, 1H); 4.12 (s, 3H).
B.H. 1-(6-methoxy-[1,5]naphthyridin-4 yl)-2 phenyl-ethane-1,2-diol:
To a mixture of intermediate B.i (1.26 g, 4.8 mmol) in 2-methyl-2-propanol (24 ml) and water (24 ml) were added methanesulfonamide (0.52 g) and AD mix (3 (7 g). The mixture was stirred at rt for 12 h. Sodium bisulfite (7.5 g) was added carefully and stirring was continued 20 min. The two layers were decanted and the aqueous layer was extracted with EA
(2 x 100 ml). The combined organic layers were dried over NazSO4, filtered and concentrated to dryness. The residue was triturated in Hex-EA (1-3, 30 ml) and the resulting solid was filtered off and dried in vacuo to afford the title diol (1.3 g) as a white solid.
MS (ESI, m/z): 297.1 [M+H+].
B.iii. 6-methoxy-[1, 5]naphthyridine-4-carbaldehyde:
To a solution of intermediate B.ii (1.3 g, 4.4 mmol) in acetone (15 ml) was added a solution of Na104 (2.35 g, 10.96 mmol) in water (5 ml). The reaction mixture was stirred at rt for 30 min. The reaction mixture was diluted with THF (100 ml) and the solids were filtered off.
The filtrate was concentrated to dryness and the residue was resuspended in water (100 ml), ether (10 ml) and Hex (100 ml). The slurry was stirred at rt for 15 min and filtered. The solids were washed with water and Hex. After drying, the title aldehyde (0.42 g) was recovered as a white solid.
iH NMR (d6-DMSO) 8: 11.25 (s, 1H); 9.02 (d, J = 4.4 Hz, 1H); 8.42 (d, J = 9.1 Hz, 1H);
7.92 (d, J = 4.4 Hz, 1H); 7.40 (d, J = 9.1 Hz, 1H); 4.11 (s, 3H).
Preparation C: (E)-3-(2,5-difluoro-phenyl)-propenal:
C.i. (E)-3-(2,5-difluoro-phenyl)-acrylic acid ethyl ester:
To an iced chilled suspension of NaH (1.13 g, 60% in oil dispersion, 28.2 mmol) in THF
(32 ml) was added triethylphosphonoacetate (5.6 ml, 28.2 mmol). The reaction mixture was stirred at rt for 20 min. 2,5-difluoro-benzaldehyde (3.34 g, 23.5 mol) was added dropwise.
After 30 min, 10% aq. NaHSO4 (100 ml) was added and the mixture was diluted with EA
(150 ml). The two phases were separated and the aq. layer was extracted twice (2 x 100 ml).
The combined org. layers were washed with brine (100 ml), dried over Na2SO4, filtered and concentrated to dryness. The residue was chromatographed over Si02 (Hex-EA 19-1) to afford the title unsaturated ester (5.0 g, 100%) as colourless oil.
iH NMR (CDC13): 7.76 (dd, J= 1, 16.1 Hz, 1H); 7.26-7.21 (m, 1H); 7.13-7.03 (m, 2H);
6.52 (d, J = 16.1Hz, 1H); 4.29 (q, J = 7.1 Hz, 2H); 1.36 (t, J = 7.1 Hz, 3H).
C.ii. (E)-3-(2,5-difluoro phenyl) prop-2-en-l-ol:
To a solution of intermediate C.i (5.0 g, 23.5 mmol) in ether (100 ml), cooled to 0 C, was added a DIBAH (1M in Hex, 60 ml, 60 mmol). The mixture was stirred at the same temperature for 40 min. Water (6 ml) was added and the mixture was stirred 30 min. The solid was filtered off and thoroughly washed with ether. The filtrate was concentrated to dryness to afford the title alcohol (4.0 g, 98% yield) as colorless oil.
iH NMR (CDC13): 7.15 (ddd, J= 3.1, 5.9, 9.0 Hz, 1H); 7.00 (td, J= 4.6, 9.0 Hz, 1H);
6.95-6.87 (m, 1H); 6.75 (dd J= 1.3, 16.1 Hz, 1H); 6.45 (td, J = 5.3, 16.1 Hz, 1H); 4.38 (br d, J= 5.3 Hz, 2H); 1.63 (s, 1 H).
C.iii. (E)-3-(2,5-difluoro phenyl) propenal:
To a solution of intermediate C.ii (1.70 g, 10 mmol) in DCM (20 ml) was added at rt, a solution of Dess-Martin periodinane (15 wt% in DCM, 20 ml). The mixture was stirred at rt for 3 h. After concentration to dryness, the residue was chromatographed over Si02 (Hex-EA
9-1) to afford the title aldehyde (1.06 g, 63% yield) as a white solid.
iH NMR (d6-DMSO): 9.74 (d, J = 7.6Hz, 1H); 7.88-7.81 (m, 1H); 7.79 (overlapped dd, J = 1.4, 16.0 Hz, 1H); 7.46-7.37 (m, 2H); 6.67 (dd, J = 7.6, 16.0 Hz, 1 H).
Preparation D: 3-methoxy-quinoxaline-5-carbaldehyde:
D.i. 2-cyano-N-(2-methyl-6-nitro-phenyl)-acetamide:
To a solution of 2-methyl-6-nitroaniline (25 g, 164.3 mmol) in benzene (200 ml) were added cyanoacetic acid (14.5 g, 170.46 mmol) and PC15 (35 g, 168 mmol). The reaction mixture was heated at 60 C for 7 h. After cooling to rt, the reaction mixture was filtered and the solid was washed with benzene and water. The solid was dried under reduced pressure to afford the title acetamide (24 g, 109 mmol) as a yellow solid.
iH NMR (d6-DMSO) 8: 10.2 (s, 1H); 7.78 (d, J = 8.3 Hz, 1H); 7.65 (d, J = 8.3 Hz, 1H);
7.43 (t, J= 8.3 Hz, 1H); 3.95 (s, 2H); 2.30 (s, 3H).
D.H. 3-hydroxy-5-methyl-l-oxy-quinoxaline-2-carbonitrile:
To a solution mixture of intermediate D.i (24 g, 109.5 mmol) in 1M aq. NaOH
(100 ml) was added pyridine (100 ml). The reaction mixture was stirred at rt for 4 h. The pH was adjusted to 6 by addition of 1M aq. HC1. The solid was filtered off and washed with water. The solid was triturated with EtOH. After drying under HV, the title nitrile (17.7 g, 87.9 mmol) was obtained as a yellow solid.
MS (ESI, m/z): 202.1 [M+H]+.
D.iii. 8-methyl-quinoxalin-2-ol:
To a solution of intermediate D.ii (17.7 g, 87.9 mmol) in water (300 ml) and EtOH (24 ml) was added sodium dithionite (35.4 g, 203.9 mmol). The reaction mixture was heated at 60 C
for 1 h. The reaction mixture was filtered till warm, and the pH of the filtrate was adjusted to 2 by adding 1M aq. HC1. The pH of the solution was subsequently made basic by adding solid NaOH (10 g). EA (150 ml) was added. The aq. layer was extracted twice more with EA
(2 x 150 ml). The combined organic extracts were dried over NazSO4, filtered and concentrated to dryness. The residue was dried under HV to afford the title intermediate (11.1 g, 69 mmol) as a yellow solid.
iH NMR (d6-DMSO) 8: 11.25 (s, 1H); 9.02 (d, J = 4.4 Hz, 1H); 8.42 (d, J = 9.1 Hz, 1H);
7.92 (d, J = 4.4 Hz, 1H); 7.40 (d, J = 9.1 Hz, 1H); 4.11 (s, 3H).
Preparation C: (E)-3-(2,5-difluoro-phenyl)-propenal:
C.i. (E)-3-(2,5-difluoro-phenyl)-acrylic acid ethyl ester:
To an iced chilled suspension of NaH (1.13 g, 60% in oil dispersion, 28.2 mmol) in THF
(32 ml) was added triethylphosphonoacetate (5.6 ml, 28.2 mmol). The reaction mixture was stirred at rt for 20 min. 2,5-difluoro-benzaldehyde (3.34 g, 23.5 mol) was added dropwise.
After 30 min, 10% aq. NaHSO4 (100 ml) was added and the mixture was diluted with EA
(150 ml). The two phases were separated and the aq. layer was extracted twice (2 x 100 ml).
The combined org. layers were washed with brine (100 ml), dried over Na2SO4, filtered and concentrated to dryness. The residue was chromatographed over Si02 (Hex-EA 19-1) to afford the title unsaturated ester (5.0 g, 100%) as colourless oil.
iH NMR (CDC13): 7.76 (dd, J= 1, 16.1 Hz, 1H); 7.26-7.21 (m, 1H); 7.13-7.03 (m, 2H);
6.52 (d, J = 16.1Hz, 1H); 4.29 (q, J = 7.1 Hz, 2H); 1.36 (t, J = 7.1 Hz, 3H).
C.ii. (E)-3-(2,5-difluoro phenyl) prop-2-en-l-ol:
To a solution of intermediate C.i (5.0 g, 23.5 mmol) in ether (100 ml), cooled to 0 C, was added a DIBAH (1M in Hex, 60 ml, 60 mmol). The mixture was stirred at the same temperature for 40 min. Water (6 ml) was added and the mixture was stirred 30 min. The solid was filtered off and thoroughly washed with ether. The filtrate was concentrated to dryness to afford the title alcohol (4.0 g, 98% yield) as colorless oil.
iH NMR (CDC13): 7.15 (ddd, J= 3.1, 5.9, 9.0 Hz, 1H); 7.00 (td, J= 4.6, 9.0 Hz, 1H);
6.95-6.87 (m, 1H); 6.75 (dd J= 1.3, 16.1 Hz, 1H); 6.45 (td, J = 5.3, 16.1 Hz, 1H); 4.38 (br d, J= 5.3 Hz, 2H); 1.63 (s, 1 H).
C.iii. (E)-3-(2,5-difluoro phenyl) propenal:
To a solution of intermediate C.ii (1.70 g, 10 mmol) in DCM (20 ml) was added at rt, a solution of Dess-Martin periodinane (15 wt% in DCM, 20 ml). The mixture was stirred at rt for 3 h. After concentration to dryness, the residue was chromatographed over Si02 (Hex-EA
9-1) to afford the title aldehyde (1.06 g, 63% yield) as a white solid.
iH NMR (d6-DMSO): 9.74 (d, J = 7.6Hz, 1H); 7.88-7.81 (m, 1H); 7.79 (overlapped dd, J = 1.4, 16.0 Hz, 1H); 7.46-7.37 (m, 2H); 6.67 (dd, J = 7.6, 16.0 Hz, 1 H).
Preparation D: 3-methoxy-quinoxaline-5-carbaldehyde:
D.i. 2-cyano-N-(2-methyl-6-nitro-phenyl)-acetamide:
To a solution of 2-methyl-6-nitroaniline (25 g, 164.3 mmol) in benzene (200 ml) were added cyanoacetic acid (14.5 g, 170.46 mmol) and PC15 (35 g, 168 mmol). The reaction mixture was heated at 60 C for 7 h. After cooling to rt, the reaction mixture was filtered and the solid was washed with benzene and water. The solid was dried under reduced pressure to afford the title acetamide (24 g, 109 mmol) as a yellow solid.
iH NMR (d6-DMSO) 8: 10.2 (s, 1H); 7.78 (d, J = 8.3 Hz, 1H); 7.65 (d, J = 8.3 Hz, 1H);
7.43 (t, J= 8.3 Hz, 1H); 3.95 (s, 2H); 2.30 (s, 3H).
D.H. 3-hydroxy-5-methyl-l-oxy-quinoxaline-2-carbonitrile:
To a solution mixture of intermediate D.i (24 g, 109.5 mmol) in 1M aq. NaOH
(100 ml) was added pyridine (100 ml). The reaction mixture was stirred at rt for 4 h. The pH was adjusted to 6 by addition of 1M aq. HC1. The solid was filtered off and washed with water. The solid was triturated with EtOH. After drying under HV, the title nitrile (17.7 g, 87.9 mmol) was obtained as a yellow solid.
MS (ESI, m/z): 202.1 [M+H]+.
D.iii. 8-methyl-quinoxalin-2-ol:
To a solution of intermediate D.ii (17.7 g, 87.9 mmol) in water (300 ml) and EtOH (24 ml) was added sodium dithionite (35.4 g, 203.9 mmol). The reaction mixture was heated at 60 C
for 1 h. The reaction mixture was filtered till warm, and the pH of the filtrate was adjusted to 2 by adding 1M aq. HC1. The pH of the solution was subsequently made basic by adding solid NaOH (10 g). EA (150 ml) was added. The aq. layer was extracted twice more with EA
(2 x 150 ml). The combined organic extracts were dried over NazSO4, filtered and concentrated to dryness. The residue was dried under HV to afford the title intermediate (11.1 g, 69 mmol) as a yellow solid.
iH NMR (d6-DMSO) 8: 11.75 (br s, 1H); 8.17 (s, 1H); 7.62 (d, J= 8.4 Hz, 1H);
7.40 (d, J = 8.4 Hz, 1H); 7.21 (t, J = 8.4 Hz, 1H); 2.42 (s, 3H).
MS (ESI, m/z): 161.1 [M+H]+.
D.iv. 2-chloro-8-methyl-quinoxaline:
A solution of intermediate D.iii (1 l.l g, 69.5 mmol) in phosphorus oxychloride (80 ml) was heated at 110 C during 2 h. After cooling to rt, the reaction mixture was poured onto ice (200 g). The aqueous layer was extracted with EA (2 x 200 ml). The combined extracts were washed with brine (100 ml), dried over NazSO4, filtered and concentrated to dryness. The residue was chromatographed over silica gel (Hex-EA 1-1) to afford the title intermediate (12.5 g, 69.5 mmol) as a red solid.
iH NMR (d6-DMSO) 8: 8.99 (s, 1H); 7.97 (m, 1H); 7.80 (m, 2H); 2.68 (s, 3H).
MS (ESI, m/z): 179.2 [M+H]+.
D.v. 2-methoxy-8-methyl-quinoxaline:
To a solution of intermediate D.iv (12.5 g, 69.5 mmol) in DMF (80 ml) was added sodium methoxide (9 g, 166 mmol). The reaction mixture was heated at 45 C for 4 h.
After cooling to rt, the reaction mixture was partitioned between water (10 ml) and EA (200 ml). The organic layer was washed once with water (100 ml), dried over NazSO4, filtered and concentrated to dryness. The residue was chromatographed over silica gel (Hex-EA 1-4) to afford the title intermediate (10.2 g, 58.55 mmol) as a yellow solid.
'H NMR (CDC13) 8: 8.48 (s, 1H); 7.88 (d, J = 7.9 Hz, 1H); 7.55 (d, J = 7.9 Hz, 1H); 7.47 (t, J = 7.9 Hz, 1H); 4.12 (s, 3H); 2.69 (s, 3H).
MS (ESI, m/z): 175.4 [M+H]+.
D.vi. 8-dibromomethyl-2-methoxy-quinoxaline:
To a solution of intermediate D.v (10.2 g) in CC14 (560 ml) were added AIBN
(0.96 g) and NBS (25.9 g, 145.5 mmol). The reaction mixture was heated at 80 C for 3 h.
After cooling to rt, the reaction mixture was washed with water (200 ml) and the organic layer was dried over NazSO4, filtered and concentrated in vacuo. The residue was triturated with MeOH to give, after drying under HV, the title dibromide (14.4 g, 43.3 mmol) as a slightly beige solid.
iH NMR (d6-DMSO) 8: 8.69 (s, 1H); 8.25 (dd, J = 1.3, 7.5 Hz, 1H); 8.07 (dd, J
= 1.3, 8.3 Hz, 1H); 8.02 (s, 1H); 7.74 (dd, J = 7.5, 8.3 Hz, 1H); 4.14 (s, 3H).
MS (ESI, m/z): 332.8 [M+H]+.
7.40 (d, J = 8.4 Hz, 1H); 7.21 (t, J = 8.4 Hz, 1H); 2.42 (s, 3H).
MS (ESI, m/z): 161.1 [M+H]+.
D.iv. 2-chloro-8-methyl-quinoxaline:
A solution of intermediate D.iii (1 l.l g, 69.5 mmol) in phosphorus oxychloride (80 ml) was heated at 110 C during 2 h. After cooling to rt, the reaction mixture was poured onto ice (200 g). The aqueous layer was extracted with EA (2 x 200 ml). The combined extracts were washed with brine (100 ml), dried over NazSO4, filtered and concentrated to dryness. The residue was chromatographed over silica gel (Hex-EA 1-1) to afford the title intermediate (12.5 g, 69.5 mmol) as a red solid.
iH NMR (d6-DMSO) 8: 8.99 (s, 1H); 7.97 (m, 1H); 7.80 (m, 2H); 2.68 (s, 3H).
MS (ESI, m/z): 179.2 [M+H]+.
D.v. 2-methoxy-8-methyl-quinoxaline:
To a solution of intermediate D.iv (12.5 g, 69.5 mmol) in DMF (80 ml) was added sodium methoxide (9 g, 166 mmol). The reaction mixture was heated at 45 C for 4 h.
After cooling to rt, the reaction mixture was partitioned between water (10 ml) and EA (200 ml). The organic layer was washed once with water (100 ml), dried over NazSO4, filtered and concentrated to dryness. The residue was chromatographed over silica gel (Hex-EA 1-4) to afford the title intermediate (10.2 g, 58.55 mmol) as a yellow solid.
'H NMR (CDC13) 8: 8.48 (s, 1H); 7.88 (d, J = 7.9 Hz, 1H); 7.55 (d, J = 7.9 Hz, 1H); 7.47 (t, J = 7.9 Hz, 1H); 4.12 (s, 3H); 2.69 (s, 3H).
MS (ESI, m/z): 175.4 [M+H]+.
D.vi. 8-dibromomethyl-2-methoxy-quinoxaline:
To a solution of intermediate D.v (10.2 g) in CC14 (560 ml) were added AIBN
(0.96 g) and NBS (25.9 g, 145.5 mmol). The reaction mixture was heated at 80 C for 3 h.
After cooling to rt, the reaction mixture was washed with water (200 ml) and the organic layer was dried over NazSO4, filtered and concentrated in vacuo. The residue was triturated with MeOH to give, after drying under HV, the title dibromide (14.4 g, 43.3 mmol) as a slightly beige solid.
iH NMR (d6-DMSO) 8: 8.69 (s, 1H); 8.25 (dd, J = 1.3, 7.5 Hz, 1H); 8.07 (dd, J
= 1.3, 8.3 Hz, 1H); 8.02 (s, 1H); 7.74 (dd, J = 7.5, 8.3 Hz, 1H); 4.14 (s, 3H).
MS (ESI, m/z): 332.8 [M+H]+.
D.vii. 3-methoxy-quinoxaline-5-carbaldehyde:
To a solution of intermediate D.vi (10.7 g, 32.2 mmol) in EtOH (330 ml) was added, at rt, a solution of silver nitrate (15 g) in water (70 ml). The reaction was stirred at rt for 1 h. The reaction mixture was diluted with MeCN (200 ml) and the solids were filtered off and the filtrate was concentrated in vacuo. The residue was filtered over a silica gel pad (eluent: EA) to afford the title aldehyde (6.2 g, 32.2 mmol) as a slightly yellow solid.
iH NMR (d6-DMSO) 8: 11.15 (s, 1H); 8.74 (s, 1H); 8.36 (dd, J = 1.3, 8.1 Hz, 1H); 8.21 (dd, J = 1.3, 7.9 Hz, 1H); 7.80 (dd, J = 7.9, 8.1 Hz, 1H); 4.14 (s, 3H).
MS (ESI, m/z): 189.2 [M+H]+.
Preparation E: 3-fluoro-6-methoxy-[1,5] naphthyridine-4-carbaldehyde:
E.i. trans-7-fluoro-2-methoxy-8-styryl-[1,5]naphthyridine:
8-bromo-7-fluoro-2-methoxy-[1,5]naphthyridine (prepared as in WO 2004/058144;
7 g, 27.2 mmol), trans-phenylvinyl boronic acid (4.23 g, 1.05 eq) and K2C03 (4.9 g) were introduced in a two-necked flask. The atmosphere was flushed with nitrogen and dioxane (40 ml) and water (10 ml) were added. The mixture was stirred at rt for 5 min and Pd(PPh3)4 (1.56 g, 5 mol%) was added. The mixture was heated at reflux overnight. After cooling, the solvent was evaporated in vacuo and the residue was extracted with EA (2 x 150 ml). The combined extracts were washed with brine, dried over NazSO4, filtered and concentrated to dryness. The residue was chromatographed (Hept-EA 2-1) to afford the title compound (7.2 g, 94% yield) as a white solid.
MS (ESI, m/z): 281.0 [M+H]+.
E.H. 1-(3 fluoro-6-methoxy-[1,5]naphthyridin-4 yl)-2 phenyl-ethane-l,2-diol:
The title diol (7.6 g, 94% yield) was obtained as a white foam, starting from intermediate E.i (7.2 g, 8.9 mmol) and using the procedure of Example 2, step 2.iv. The compound was purified by chromatography using EA as an eluent.
iH NMR (CDC13) 8: 8.42 (d, J = 0.7 Hz, 1H); 8.28 (d, J = 9.1 Hz, 1H); 7.24-7.15 (m, 4H);
7.08 (m, 2H); 6.70 (br s, 1H); 5.28 (br s, 1H); 5.10 (d, J= 7.9 Hz, 1H); 4.11 (s, 3H);
3.85 (br s, 1H).
To a solution of intermediate D.vi (10.7 g, 32.2 mmol) in EtOH (330 ml) was added, at rt, a solution of silver nitrate (15 g) in water (70 ml). The reaction was stirred at rt for 1 h. The reaction mixture was diluted with MeCN (200 ml) and the solids were filtered off and the filtrate was concentrated in vacuo. The residue was filtered over a silica gel pad (eluent: EA) to afford the title aldehyde (6.2 g, 32.2 mmol) as a slightly yellow solid.
iH NMR (d6-DMSO) 8: 11.15 (s, 1H); 8.74 (s, 1H); 8.36 (dd, J = 1.3, 8.1 Hz, 1H); 8.21 (dd, J = 1.3, 7.9 Hz, 1H); 7.80 (dd, J = 7.9, 8.1 Hz, 1H); 4.14 (s, 3H).
MS (ESI, m/z): 189.2 [M+H]+.
Preparation E: 3-fluoro-6-methoxy-[1,5] naphthyridine-4-carbaldehyde:
E.i. trans-7-fluoro-2-methoxy-8-styryl-[1,5]naphthyridine:
8-bromo-7-fluoro-2-methoxy-[1,5]naphthyridine (prepared as in WO 2004/058144;
7 g, 27.2 mmol), trans-phenylvinyl boronic acid (4.23 g, 1.05 eq) and K2C03 (4.9 g) were introduced in a two-necked flask. The atmosphere was flushed with nitrogen and dioxane (40 ml) and water (10 ml) were added. The mixture was stirred at rt for 5 min and Pd(PPh3)4 (1.56 g, 5 mol%) was added. The mixture was heated at reflux overnight. After cooling, the solvent was evaporated in vacuo and the residue was extracted with EA (2 x 150 ml). The combined extracts were washed with brine, dried over NazSO4, filtered and concentrated to dryness. The residue was chromatographed (Hept-EA 2-1) to afford the title compound (7.2 g, 94% yield) as a white solid.
MS (ESI, m/z): 281.0 [M+H]+.
E.H. 1-(3 fluoro-6-methoxy-[1,5]naphthyridin-4 yl)-2 phenyl-ethane-l,2-diol:
The title diol (7.6 g, 94% yield) was obtained as a white foam, starting from intermediate E.i (7.2 g, 8.9 mmol) and using the procedure of Example 2, step 2.iv. The compound was purified by chromatography using EA as an eluent.
iH NMR (CDC13) 8: 8.42 (d, J = 0.7 Hz, 1H); 8.28 (d, J = 9.1 Hz, 1H); 7.24-7.15 (m, 4H);
7.08 (m, 2H); 6.70 (br s, 1H); 5.28 (br s, 1H); 5.10 (d, J= 7.9 Hz, 1H); 4.11 (s, 3H);
3.85 (br s, 1H).
E.iii. 3 fluoro-6-methoxy-[1,5]naphthyridine-4-carbaldehyde:
To a solution of intermediate E.ii (7.6 g, 23.95 mmol) in acetone (150 ml) was added a solution of Na104 (12.8 g) in water (30 ml). The mixture was stirred at rt for 1 h. The solvent was removed in vacuo and the residue was diluted with water (500 ml). The resulting solid was filtered off, thoroughly washed with water, collected and dried under HV
to afford the title aldehyde (4.0 g) as a light beige solid.
iH NMR (d6-DMSO) 8: 11.08 (s, 1H); 9.01 (d, J= 1.3 Hz, 1H); 8.41 (d, J= 9.1 Hz, 1H);
7.37 (d, J= 9.1 Hz, 1H); 4.09 (s, 3H).
MS (ESI, m/z): 206.9 [M+H]+.
Preparation F: 3-fluoro-6-methoxy-quinoline-5-carbaldehyde:
F.i. 5-bromo-3-fluoro-6-methoxy-quinoline:
To a solution of 3-fluoro-6-methoxy-quinoline (0.89 g) in MeCN (9 ml), cooled to 0 C, was added NBS (1 g). The mixture was stirred 2 h at this temperature. The reaction mixture was allowed to warm up to rt and proceeded overnight. 10% aq. NaHSO3 (20 ml) was added. The mixture was further diluted with water (100 ml) and the resulting solid was filtered off, washed with water and dried in vacuo to afford the title compound (1.03 g, 80%
yield) as a white solid.
iH NMR (d6-DMSO) 8: 8.85 (d, J= 2.7 Hz, 1H); 8.18 (dd, J= 2.7, 10.2 Hz, 1H);
8.14 (d, J = 9.0 Hz, 1H); 7.77 (d, J = 9.0 Hz, 1H); 4.04 (s, 3H).
MS (ESI, m/z): 255.7 [M-H+].
F.H. 3-fluoro-6-methoxy-quinoline-5-carbaldehyde:
This aldehyde (0.68 g, 3.31 mmol) was obtained as a white solid, starting from intermediate F.i (1.0 g, 3.9 mmol) and using the procedures described in Preparation E, steps E.i, E.ii and E.iii.
iH NMR (d6-DMSO) 8: 10.69 (s, 1H); 9.16 (dd, J= 2.9, 11.7 Hz, 1H); 8.88 (d, J=
2.9 Hz, 1 H); 8.3 8 (d, J = 9.0 Hz, 1 H); 7.83 (d, J = 9.0 Hz, 1 H); 4.12 (s, 3H).
To a solution of intermediate E.ii (7.6 g, 23.95 mmol) in acetone (150 ml) was added a solution of Na104 (12.8 g) in water (30 ml). The mixture was stirred at rt for 1 h. The solvent was removed in vacuo and the residue was diluted with water (500 ml). The resulting solid was filtered off, thoroughly washed with water, collected and dried under HV
to afford the title aldehyde (4.0 g) as a light beige solid.
iH NMR (d6-DMSO) 8: 11.08 (s, 1H); 9.01 (d, J= 1.3 Hz, 1H); 8.41 (d, J= 9.1 Hz, 1H);
7.37 (d, J= 9.1 Hz, 1H); 4.09 (s, 3H).
MS (ESI, m/z): 206.9 [M+H]+.
Preparation F: 3-fluoro-6-methoxy-quinoline-5-carbaldehyde:
F.i. 5-bromo-3-fluoro-6-methoxy-quinoline:
To a solution of 3-fluoro-6-methoxy-quinoline (0.89 g) in MeCN (9 ml), cooled to 0 C, was added NBS (1 g). The mixture was stirred 2 h at this temperature. The reaction mixture was allowed to warm up to rt and proceeded overnight. 10% aq. NaHSO3 (20 ml) was added. The mixture was further diluted with water (100 ml) and the resulting solid was filtered off, washed with water and dried in vacuo to afford the title compound (1.03 g, 80%
yield) as a white solid.
iH NMR (d6-DMSO) 8: 8.85 (d, J= 2.7 Hz, 1H); 8.18 (dd, J= 2.7, 10.2 Hz, 1H);
8.14 (d, J = 9.0 Hz, 1H); 7.77 (d, J = 9.0 Hz, 1H); 4.04 (s, 3H).
MS (ESI, m/z): 255.7 [M-H+].
F.H. 3-fluoro-6-methoxy-quinoline-5-carbaldehyde:
This aldehyde (0.68 g, 3.31 mmol) was obtained as a white solid, starting from intermediate F.i (1.0 g, 3.9 mmol) and using the procedures described in Preparation E, steps E.i, E.ii and E.iii.
iH NMR (d6-DMSO) 8: 10.69 (s, 1H); 9.16 (dd, J= 2.9, 11.7 Hz, 1H); 8.88 (d, J=
2.9 Hz, 1 H); 8.3 8 (d, J = 9.0 Hz, 1 H); 7.83 (d, J = 9.0 Hz, 1 H); 4.12 (s, 3H).
Preparation G: (3R,6S)-[6-(1-phenyl-lH-tetrazole-5-sulfonylmethyl)-tetrahydro-pyran-3-yl]-carbamic acid tert-butyl ester:
G.i. toluene-4-sulfonic acid (2S, 5R)-5-tert-butoxycarbonylamino-tetrahydro pyran-2 ylmethyl ester:
To an ice-chilled solution of (3R,6S)-(6-hydroxymethyl-tetrahydro-pyran-3-yl)-carbamic acid tert-butyl ester (obtained as described in Eur. J. Org. Chem. (2003); 25 g, 108 mmol) in DCM
(650 ml) were added TEA (30 ml), DMAP (1.8 g) and TsC1(22.6 g). The reaction was stirred at rt for 4 h. Saturated NaHCO3 (100 ml) was added. The volatiles were removed under reduced pressure and the residue was taken up in EA (400 ml). The org. layer was washed with saturated CuS04 (2 x 150 ml), water (3 x 150 ml) and brine (100 ml). The org. layer was dried over NazSO4, filtered and concentrated to dryness to afford after drying a white solid (41.8 g) that was carried on without further purification.
G.ii. (3R,6S)-(6-iodomethyl-tetrahydro pyran-3 yl)-carbamic acid tert-butyl ester:
To a solution of intermediate G.i (18 g, 46.7 mmol) in acetone (200 ml) was added Nal (20 g).
The reaction mixture was heated at reflux 24 h. After cooling to rt, water (200 ml) was added and the volatiles were removed in vacuo. The residue was filtered, thoroughly washed with water and Hex and dried under HV to afford the iodide (12.2 g, 76% yield) as a beige solid.
MS (ESI, m/z): 342.2 [M+H+].
G.iii. (3R,6S)-[6-(1 phenyl-IH-tetrazol-5 ylsulfanylmethyl)-tetrahydro pyran-3 ylJ-carbamic acid tert-butyl ester:
To a solution of 1-phenyl-lH-tetrazole-5-thiol (7 g, 39 mmol) in EtOH (100 ml) was added KOH (3.0 g). The reaction mixture was refluxed for 1 h and intermediate G.ii (11.6 g, 34 mmol) was added. The mixture was refluxed overnight. Water (150 ml) was added and the volatiles were removed under reduced pressure. The solid was filtered off, thoroughly washed with water and dried under HV to afford the sulphide (13.3 g, quant.) as a white solid.
MS (ESI, m/z): 392.5 [M+H+].
G.i. toluene-4-sulfonic acid (2S, 5R)-5-tert-butoxycarbonylamino-tetrahydro pyran-2 ylmethyl ester:
To an ice-chilled solution of (3R,6S)-(6-hydroxymethyl-tetrahydro-pyran-3-yl)-carbamic acid tert-butyl ester (obtained as described in Eur. J. Org. Chem. (2003); 25 g, 108 mmol) in DCM
(650 ml) were added TEA (30 ml), DMAP (1.8 g) and TsC1(22.6 g). The reaction was stirred at rt for 4 h. Saturated NaHCO3 (100 ml) was added. The volatiles were removed under reduced pressure and the residue was taken up in EA (400 ml). The org. layer was washed with saturated CuS04 (2 x 150 ml), water (3 x 150 ml) and brine (100 ml). The org. layer was dried over NazSO4, filtered and concentrated to dryness to afford after drying a white solid (41.8 g) that was carried on without further purification.
G.ii. (3R,6S)-(6-iodomethyl-tetrahydro pyran-3 yl)-carbamic acid tert-butyl ester:
To a solution of intermediate G.i (18 g, 46.7 mmol) in acetone (200 ml) was added Nal (20 g).
The reaction mixture was heated at reflux 24 h. After cooling to rt, water (200 ml) was added and the volatiles were removed in vacuo. The residue was filtered, thoroughly washed with water and Hex and dried under HV to afford the iodide (12.2 g, 76% yield) as a beige solid.
MS (ESI, m/z): 342.2 [M+H+].
G.iii. (3R,6S)-[6-(1 phenyl-IH-tetrazol-5 ylsulfanylmethyl)-tetrahydro pyran-3 ylJ-carbamic acid tert-butyl ester:
To a solution of 1-phenyl-lH-tetrazole-5-thiol (7 g, 39 mmol) in EtOH (100 ml) was added KOH (3.0 g). The reaction mixture was refluxed for 1 h and intermediate G.ii (11.6 g, 34 mmol) was added. The mixture was refluxed overnight. Water (150 ml) was added and the volatiles were removed under reduced pressure. The solid was filtered off, thoroughly washed with water and dried under HV to afford the sulphide (13.3 g, quant.) as a white solid.
MS (ESI, m/z): 392.5 [M+H+].
G.iv. (3R,6S)-[6-(1 phenyl-IH-tetrazole-5-sulfonylmethyl)-tetrahydro pyran-3 ylJ-carbamic acid tert-butyl ester:
To a solution of intermediate G.iii (13.3 g, 34 mmol) in EtOH (150 ml) and THF
(150 ml) were added ammonium molybdate tetrahydrate (11 g, 8.9 mmol) and then 30% H202 (50 ml).
The mixture was heated at 60 C overnight. The reaction mixture was cooled to rt, diluted with water (200 ml) and the volatiles were removed under reduced pressure. The residue was partitioned between EA (300 ml) and water (100 ml) and the aq. layer was extracted with EA
(2 x 300 ml). The combined extracts were concentrated to dryness. The residue was resuspended in ether. The solids were filtered off, washed with water and Hex to afford the title sulfone (11.8 g, 81 % yield) as a white solid.
iH NMR (CDC13) 8: 7.69-7.60 (m, 5H); 4.23 (m, 1H); 3.95-3.80 (m, 2H); 3.68-3.52 (m, 2H);
2.86 (t, J= 10.7 Hz, 1H); 2.11 (m, 1H); 1.79 (m, 1H); 1.60-45 (m, 2H); 1.43 (s, 9H); 1.37 (m, 1 H).
MS (ESI, m/z): 424.5 [M+H+].
Preparation H: 6-fluoro-quinoline-4-carbaldehyde:
Starting from 4-bromo-6-fluoro-quinoline (see WO 2004/014361 for a preparation; 6 g, 26.5 mmol), the title aldehyde (4.3 g, 24.5 mmol) was prepared as a beige solid using the procedures described in Preparation E, steps E.i, E.ii and E.iii.
iH NMR (d6-DMSO) 8: 10.50 (s, 1H); 9.23 (d, J = 4.2 Hz, 1H); 8.68 (dd, J =
2.9, 10.8 Hz, 1H); 8.25 (dd, J = 5.8, 9.3 Hz, 1H); 8.11 (d, J = 4.2 Hz, 1H); 7.83 (ddd, J =
2.9, 9.3, 10.8 Hz, 1 H).
Preparation I: (3S,6R)-[6-(1-phenyl-lH-tetrazole-5-sulfonylmethyl)-tetrahydro-pyran-3-yl]-carbamic acid tert-butyl ester:
I.i. (S)-(1-hydroxymethyl pent-4-enyl)-carbamic acid tert-butyl ester:
To a suspension of LiBH4 (1.15 g, 53 mmol) in THF (300 ml) at rt was added a solution of (S)-2-tert-butoxycarbonylamino-hex-5-enoic acid methyl ester (12.9 g, 53 mmol, prepared according to J. Org. Chem. (1995), 60, 2210) in THF (100 ml). The mixture was stirred at rt for 4 h, poured into water and extracted with EA. The organic layer was washed with brine, dried over MgSO4 and concentrated to give the title alcohol (11.4 g, 99%
yield) as a colourless oil.
iH NMR (CDC13) 8: 5.75-5.65 (m, 1H), 5.00-4.90 (m, 2H), 4.5 (br, 1H, OH), 3.70-3.45 (m, 3H), 2.10-2.00 (m, 2H), 1.60-1.35 (m, 2H), 1.38 (s, 9H).
I.H. (1 S, 3RS, 4RS)-(1-hydroxymethyl-3-oxiranyl propyl)-carbamic acid tert-butyl ester:
Intermediate I.i (11.4 g, 53 mmol) was dissolved in 1,2-DCE (300 ml) and water (250 ml) and 1Mphosphate buffer pH 8(150 ml) was added. MCPBA (14.3 g, 1. 1 eq, 70%) was added and the mixture vigorously stirred overnight. The two phases were separated and the aqueous phase was extracted once more with DCM. The combined organic layers were washed with a sat. NaHCO3 solution, dried over MgSO4, filtered and concentrated to dryness.
The residue was purified by chromatography over Si02 (Hex:EA 1:1 then EA) to give the title epoxide (7.74 g, 63% yield, mixture of diastereomers) as a colourless oil.
iH NMR (CDC13) 8: 4.90-4.85 (m, 1H), 3.75-3.50 (m, 3H), 3.00-2.90 (m, 1H), 2.80-2.51 (m, 1H), 2.6 (br, 1H, OH), 2.55-2.50 (m, 1H), 1.80-1.40 (m, 4H), 1.42 (s, 9H).
I.iii. (3S, 6R)-(6-hydroxymethyl-tetrahydro pyran-3 yl)-carbamic acid tert-butyl ester:
A solution of intermediate I.ii (2.3 g, 10 mmol) in DCM (50 ml) was treated with D,L-10-camphor sulfonic acid (0.1 eq). The reaction was slightly exothermic.
The mixture was stirred at rt for 3 h, concentrated and purified by chromatography over Si0z (EA) to give the title tetrahydropyran derivative (0.874 g, 37% yield) as a colourless solid.
'H NMR (CDC13) 8: 4.28 (br, 1H), 4.20-10 (m, 1H), 3.70-3.30 (m, 5H), 3.04 (t, 1H, J=10.6 Hz), 2.20-2.00 (m, 2H, 1.75-1.20 (m, 11H).
Liv. (3R,6S)-[6-(1 phenyl-IH-tetrazole-5-sulfonylmethyl)-tetrahydro pyran-3 ylJ-carbamic acid tert-butyl ester:
This sulfone (5.9 g, 13.9 mmol) was obtained as a white solid starting from intermediate I.iii (8.2 g, 35.4 mmol) and using the procedures described in Preparation G.
To a solution of intermediate G.iii (13.3 g, 34 mmol) in EtOH (150 ml) and THF
(150 ml) were added ammonium molybdate tetrahydrate (11 g, 8.9 mmol) and then 30% H202 (50 ml).
The mixture was heated at 60 C overnight. The reaction mixture was cooled to rt, diluted with water (200 ml) and the volatiles were removed under reduced pressure. The residue was partitioned between EA (300 ml) and water (100 ml) and the aq. layer was extracted with EA
(2 x 300 ml). The combined extracts were concentrated to dryness. The residue was resuspended in ether. The solids were filtered off, washed with water and Hex to afford the title sulfone (11.8 g, 81 % yield) as a white solid.
iH NMR (CDC13) 8: 7.69-7.60 (m, 5H); 4.23 (m, 1H); 3.95-3.80 (m, 2H); 3.68-3.52 (m, 2H);
2.86 (t, J= 10.7 Hz, 1H); 2.11 (m, 1H); 1.79 (m, 1H); 1.60-45 (m, 2H); 1.43 (s, 9H); 1.37 (m, 1 H).
MS (ESI, m/z): 424.5 [M+H+].
Preparation H: 6-fluoro-quinoline-4-carbaldehyde:
Starting from 4-bromo-6-fluoro-quinoline (see WO 2004/014361 for a preparation; 6 g, 26.5 mmol), the title aldehyde (4.3 g, 24.5 mmol) was prepared as a beige solid using the procedures described in Preparation E, steps E.i, E.ii and E.iii.
iH NMR (d6-DMSO) 8: 10.50 (s, 1H); 9.23 (d, J = 4.2 Hz, 1H); 8.68 (dd, J =
2.9, 10.8 Hz, 1H); 8.25 (dd, J = 5.8, 9.3 Hz, 1H); 8.11 (d, J = 4.2 Hz, 1H); 7.83 (ddd, J =
2.9, 9.3, 10.8 Hz, 1 H).
Preparation I: (3S,6R)-[6-(1-phenyl-lH-tetrazole-5-sulfonylmethyl)-tetrahydro-pyran-3-yl]-carbamic acid tert-butyl ester:
I.i. (S)-(1-hydroxymethyl pent-4-enyl)-carbamic acid tert-butyl ester:
To a suspension of LiBH4 (1.15 g, 53 mmol) in THF (300 ml) at rt was added a solution of (S)-2-tert-butoxycarbonylamino-hex-5-enoic acid methyl ester (12.9 g, 53 mmol, prepared according to J. Org. Chem. (1995), 60, 2210) in THF (100 ml). The mixture was stirred at rt for 4 h, poured into water and extracted with EA. The organic layer was washed with brine, dried over MgSO4 and concentrated to give the title alcohol (11.4 g, 99%
yield) as a colourless oil.
iH NMR (CDC13) 8: 5.75-5.65 (m, 1H), 5.00-4.90 (m, 2H), 4.5 (br, 1H, OH), 3.70-3.45 (m, 3H), 2.10-2.00 (m, 2H), 1.60-1.35 (m, 2H), 1.38 (s, 9H).
I.H. (1 S, 3RS, 4RS)-(1-hydroxymethyl-3-oxiranyl propyl)-carbamic acid tert-butyl ester:
Intermediate I.i (11.4 g, 53 mmol) was dissolved in 1,2-DCE (300 ml) and water (250 ml) and 1Mphosphate buffer pH 8(150 ml) was added. MCPBA (14.3 g, 1. 1 eq, 70%) was added and the mixture vigorously stirred overnight. The two phases were separated and the aqueous phase was extracted once more with DCM. The combined organic layers were washed with a sat. NaHCO3 solution, dried over MgSO4, filtered and concentrated to dryness.
The residue was purified by chromatography over Si02 (Hex:EA 1:1 then EA) to give the title epoxide (7.74 g, 63% yield, mixture of diastereomers) as a colourless oil.
iH NMR (CDC13) 8: 4.90-4.85 (m, 1H), 3.75-3.50 (m, 3H), 3.00-2.90 (m, 1H), 2.80-2.51 (m, 1H), 2.6 (br, 1H, OH), 2.55-2.50 (m, 1H), 1.80-1.40 (m, 4H), 1.42 (s, 9H).
I.iii. (3S, 6R)-(6-hydroxymethyl-tetrahydro pyran-3 yl)-carbamic acid tert-butyl ester:
A solution of intermediate I.ii (2.3 g, 10 mmol) in DCM (50 ml) was treated with D,L-10-camphor sulfonic acid (0.1 eq). The reaction was slightly exothermic.
The mixture was stirred at rt for 3 h, concentrated and purified by chromatography over Si0z (EA) to give the title tetrahydropyran derivative (0.874 g, 37% yield) as a colourless solid.
'H NMR (CDC13) 8: 4.28 (br, 1H), 4.20-10 (m, 1H), 3.70-3.30 (m, 5H), 3.04 (t, 1H, J=10.6 Hz), 2.20-2.00 (m, 2H, 1.75-1.20 (m, 11H).
Liv. (3R,6S)-[6-(1 phenyl-IH-tetrazole-5-sulfonylmethyl)-tetrahydro pyran-3 ylJ-carbamic acid tert-butyl ester:
This sulfone (5.9 g, 13.9 mmol) was obtained as a white solid starting from intermediate I.iii (8.2 g, 35.4 mmol) and using the procedures described in Preparation G.
Example 1: (E)-2-{(2R,3R,6R)-(3-[3-(2,5-ditluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5] naphthyridin-4-yl)-ethyl] -tetrahydro-pyran-2-yl}-ethanol:
i.i. [(2R, 3R, 6S)-6-(tert-butyl-dimethyl-silanyloxymethyl)-2-((2RS)-2, 3-dihydroxy propyl)-3, 6-dihydro-2H-pyran-3 ylJ-carbamic acid tert-butyl ester:
To a mixture of (2R,3R,6S)-[2-allyl-6-(tert-butyl-dimethyl-silanyloxymethyl)-3,6-dihydro-2H-pyran-3-yl]-carbamic acid tert-butyl ester (obtained as described in Eur.
J. Org. Chem.
(2003), 2418-2427; 60.7 g, 158.2 mmol) in 2-methyl-2-propanol (750 ml) and water (750 ml) were added potassium ferricyanide (182.4 g, 553.8 mmol), potassium carbonate (65.8 g, 476.0 mmol), (DHQ)2PHAL (1.12 g, 1.4 mmol) and potassium osmate dihydrate (0.118 g).
The reaction mixture was mechanically stirred at rt for 24 h. Sodium bisulfite (316 g) was added slowly. The two layers were decanted and the aq. layer was extracted once more with EA (500 ml). The combined org. extracts were washed with brine, dried over MgS04, filtered and concentrated to dryness. The residue was filtered through a pad of Si0z (Hex-EA 1-4) to afford the title diol as a yellow oil (61.0 g, 146.0 mmol). The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 418.0 [M+H+].
I.H. [(2R,3R,6S)-2-((4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-6-hydroxymethyl-tetrahydro pyran-3 ylJ-carbamic acid tert-butyl ester:
To a mixture of intermediate l.i (61 g, 146.0 mmol) in THF (710 ml) were added PTSA
(1.38 g, 7.3 mmol) and 2,2-dimethoxypropane (54.0 ml, 439.1 mmol). The reaction mixture was stirred at rt for 90 min. TBAF (1M in THF, 230 ml) was added. The reaction proceeded for 90 min. The reaction mixture was concentrated to dryness and the residue was chromatographed over Si0z (Hex-EA 1-4) to afford the title compound as a thick oil (44.7 g, 130.1 mmol). The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 344.2 [M+H+].
l.iii. [(2R,3R,6S)-2-((4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-6-hydroxymethyl-tetrahydro pyran-3 ylJ-carbamic acid tert-butyl ester:
To a solution of intermediate l.ii (19.7 g, 57.3 mmol) in EA (230 ml) was added platinum oxide (0.7 g). The resulting suspension was stirred under hydrogen for 5 h.
The catalyst was removed by filtration through celite and the filtrate evaporated under reduced pressure. The residue was purified by column chromatography over Si02 (EA-Hex 4-1 to 1-0) to afford the title compound as a white solid (19.43 g). The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 346.1 [M+H+].
l.iv. [(2R, 3R, 6S)-2-((4R)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-6-(1 phenyl-JH-tetrazol-5 ylsulfanylmethyl)-tetrahydro pyran-3 ylJ-carbamic acid tert-butyl ester:
To an ice-chilled solution of intermediate l.iii (19.4 g, 56.1 mmol) in THF
(500 ml) were added PPh3 (29 g), phenyltetrazole thiol (14 g) and DIAD (16.7 ml) dropwise.
The resulting solution was stirred at rt overnight. The reaction mixture was concentrated to dryness and the residue purified by column chromatography over Si0z (EA-Hex 1-3 to 1-0) to afford the title sulfide as a colorless solid (28.85g, 99% yield). The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 506.0 [M+H+]
l.v. [(2R,3R,6S)-2-((4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-6-(1 phenyl-JH-tetrazole-5-sulfonylmethyl)-tetrahydro pyran-3 ylJ-carbamic acid tert-butyl ester:
To a solution of intermediate l.iv (28.4 g) in EtOH (240 ml) and THF (240 ml) were added ammonium molybdate heptahydrate (17.73 g) and 50% aq. H202 (82.5 ml). The mixture was heated at 60 C overnight. After cooling to rt, the reaction mixture was diluted with water (250 ml) and the volatiles were removed under reduced pressure. EA (150 ml) was added to the aq. residue and the phases were separated. The aq. layer was extracted three times with EA. The combined org. layers were dried over MgS04, filtered and evaporated under reduced pressure. The residue was purified by column chromatography over Si0z (DCM-MeOH 19-1 to 9-1) to afford first the desired sulfone as a colourless thick oil (4.9 g), then [(2R,3R,6S)-2-((2RS)-2,3-dihydroxy-propyl)-6-(1-phenyl-lH-tetrazole-5-sulfonylmethyl)-tetrahydro-pyran-3-yl]-carbamic acid tert-butyl ester as a white foam (9.4 g).
The latter was taken up in THF (90 ml), and was treated with PTSA (0.187 g) and 2,2-dimethoxypropane (6.95 ml). The reaction mixture was stirred at rt for 2.5 h. Water (8 ml) and aq. NaHCO3 were added before concentration to dryness. The residue was partitioned between water and EA
and the phases were separated. The org. layer was washed with brine, dried over MgS04, filtered and evaporated under reduced pressure. The residue was further dried under HV to afford more of the title sulfone (9.94 g).
MS (ESI, m/z): 538.0 [M+H+].
i.i. [(2R, 3R, 6S)-6-(tert-butyl-dimethyl-silanyloxymethyl)-2-((2RS)-2, 3-dihydroxy propyl)-3, 6-dihydro-2H-pyran-3 ylJ-carbamic acid tert-butyl ester:
To a mixture of (2R,3R,6S)-[2-allyl-6-(tert-butyl-dimethyl-silanyloxymethyl)-3,6-dihydro-2H-pyran-3-yl]-carbamic acid tert-butyl ester (obtained as described in Eur.
J. Org. Chem.
(2003), 2418-2427; 60.7 g, 158.2 mmol) in 2-methyl-2-propanol (750 ml) and water (750 ml) were added potassium ferricyanide (182.4 g, 553.8 mmol), potassium carbonate (65.8 g, 476.0 mmol), (DHQ)2PHAL (1.12 g, 1.4 mmol) and potassium osmate dihydrate (0.118 g).
The reaction mixture was mechanically stirred at rt for 24 h. Sodium bisulfite (316 g) was added slowly. The two layers were decanted and the aq. layer was extracted once more with EA (500 ml). The combined org. extracts were washed with brine, dried over MgS04, filtered and concentrated to dryness. The residue was filtered through a pad of Si0z (Hex-EA 1-4) to afford the title diol as a yellow oil (61.0 g, 146.0 mmol). The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 418.0 [M+H+].
I.H. [(2R,3R,6S)-2-((4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-6-hydroxymethyl-tetrahydro pyran-3 ylJ-carbamic acid tert-butyl ester:
To a mixture of intermediate l.i (61 g, 146.0 mmol) in THF (710 ml) were added PTSA
(1.38 g, 7.3 mmol) and 2,2-dimethoxypropane (54.0 ml, 439.1 mmol). The reaction mixture was stirred at rt for 90 min. TBAF (1M in THF, 230 ml) was added. The reaction proceeded for 90 min. The reaction mixture was concentrated to dryness and the residue was chromatographed over Si0z (Hex-EA 1-4) to afford the title compound as a thick oil (44.7 g, 130.1 mmol). The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 344.2 [M+H+].
l.iii. [(2R,3R,6S)-2-((4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-6-hydroxymethyl-tetrahydro pyran-3 ylJ-carbamic acid tert-butyl ester:
To a solution of intermediate l.ii (19.7 g, 57.3 mmol) in EA (230 ml) was added platinum oxide (0.7 g). The resulting suspension was stirred under hydrogen for 5 h.
The catalyst was removed by filtration through celite and the filtrate evaporated under reduced pressure. The residue was purified by column chromatography over Si02 (EA-Hex 4-1 to 1-0) to afford the title compound as a white solid (19.43 g). The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 346.1 [M+H+].
l.iv. [(2R, 3R, 6S)-2-((4R)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-6-(1 phenyl-JH-tetrazol-5 ylsulfanylmethyl)-tetrahydro pyran-3 ylJ-carbamic acid tert-butyl ester:
To an ice-chilled solution of intermediate l.iii (19.4 g, 56.1 mmol) in THF
(500 ml) were added PPh3 (29 g), phenyltetrazole thiol (14 g) and DIAD (16.7 ml) dropwise.
The resulting solution was stirred at rt overnight. The reaction mixture was concentrated to dryness and the residue purified by column chromatography over Si0z (EA-Hex 1-3 to 1-0) to afford the title sulfide as a colorless solid (28.85g, 99% yield). The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 506.0 [M+H+]
l.v. [(2R,3R,6S)-2-((4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-6-(1 phenyl-JH-tetrazole-5-sulfonylmethyl)-tetrahydro pyran-3 ylJ-carbamic acid tert-butyl ester:
To a solution of intermediate l.iv (28.4 g) in EtOH (240 ml) and THF (240 ml) were added ammonium molybdate heptahydrate (17.73 g) and 50% aq. H202 (82.5 ml). The mixture was heated at 60 C overnight. After cooling to rt, the reaction mixture was diluted with water (250 ml) and the volatiles were removed under reduced pressure. EA (150 ml) was added to the aq. residue and the phases were separated. The aq. layer was extracted three times with EA. The combined org. layers were dried over MgS04, filtered and evaporated under reduced pressure. The residue was purified by column chromatography over Si0z (DCM-MeOH 19-1 to 9-1) to afford first the desired sulfone as a colourless thick oil (4.9 g), then [(2R,3R,6S)-2-((2RS)-2,3-dihydroxy-propyl)-6-(1-phenyl-lH-tetrazole-5-sulfonylmethyl)-tetrahydro-pyran-3-yl]-carbamic acid tert-butyl ester as a white foam (9.4 g).
The latter was taken up in THF (90 ml), and was treated with PTSA (0.187 g) and 2,2-dimethoxypropane (6.95 ml). The reaction mixture was stirred at rt for 2.5 h. Water (8 ml) and aq. NaHCO3 were added before concentration to dryness. The residue was partitioned between water and EA
and the phases were separated. The org. layer was washed with brine, dried over MgS04, filtered and evaporated under reduced pressure. The residue was further dried under HV to afford more of the title sulfone (9.94 g).
MS (ESI, m/z): 538.0 [M+H+].
l.vi. {(2R,3R,6S)-2-((4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-6-trans-[2-(6-methoxy-[1,5]naphthyridin-4 yl)-vinylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
To a solution of 6-methoxy-[1,5]naphthyridine-4-carbaldehyde (see preparation B; 1.7 g, 9.03 mmol) and intermediate l.v (4 g, 7.45 mmol) in 1,2-DME (40 ml) cooled to -78 C, was added dropwise, over 10 min, KHMDS (0.5M in toluene, 24 ml). The mixture was stirred 30 min at this temperature. The reaction was then allowed to warm up to rt over 30 min, whereupon water (50 ml) was added. The two layers were decanted, the aq. layer was extracted twice with EA (2 x 150 ml). The combined org. layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was chromatographed over Si02 (Hex-EA 1-1 then 1-4) to afford the title alkene (2.8 g, 62% yield) as a colourless foam.
MS (ESI, m/z): 500.4 [M+H+]
l.vii.a. {(2R,3R,6S)-2-(2-hydroxy-ethyl)-6-trans-[2-(6-methoxy-[1,5]naphthyridin-4 yl)-vinylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
and 1.vii.b. {(2R, 3R, 6R)-2-(2-hydroxy-ethyl)-6-[2-(6-methoxy-[1, 5]naphthyridin-4 yl)-ethylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
A solution of intermediate l.vi (2.8 g, 5.6 mmol) in a THF-AcOH-water mixture (1-3-1, 50 ml) was heated at 60 C for 6 h. The reaction mixture was concentrated to dryness, and the residue was partitioned between EA and saturated NaHCO3. The pH was adjusted to 7 by adding solid NaHCO3. The aq. layer was extracted once with EA and the combined org.
layers were washed with brine, dried over NazSO4, filtered and concentrated to dryness. The residue was taken up in acetone (100 ml) and a warm solution of Na104 (3 g) in water (10 ml) was added. The mixture was stirred 1 h. The reaction mixture was filtered through a pad of celite and the solvent was removed in vacuo. The residue was extracted twice with EA. The combined org. layers were dried over NazSO4, filtered and concentrated in vacuo. The residue was taken up in MeOH (30 ml) and NaBH4 (0.7 g) was added. The reaction proceeded for 15 min. 10% aq. NaHSO4 (100 ml) was added. The volatiles were removed in vacuo and the aq. residue was extracted three times with EA (3 x 100 ml). The combined org.
layers were washed with brine, dried over NazSO4, filtered and concentrated to dryness.
The residue was chromatographed over Si0z (DCM-MeOH 19-1) to afford a colourless foam (1.76 g) which was characterized as a mixture of the two title compounds.
To a solution of 6-methoxy-[1,5]naphthyridine-4-carbaldehyde (see preparation B; 1.7 g, 9.03 mmol) and intermediate l.v (4 g, 7.45 mmol) in 1,2-DME (40 ml) cooled to -78 C, was added dropwise, over 10 min, KHMDS (0.5M in toluene, 24 ml). The mixture was stirred 30 min at this temperature. The reaction was then allowed to warm up to rt over 30 min, whereupon water (50 ml) was added. The two layers were decanted, the aq. layer was extracted twice with EA (2 x 150 ml). The combined org. layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was chromatographed over Si02 (Hex-EA 1-1 then 1-4) to afford the title alkene (2.8 g, 62% yield) as a colourless foam.
MS (ESI, m/z): 500.4 [M+H+]
l.vii.a. {(2R,3R,6S)-2-(2-hydroxy-ethyl)-6-trans-[2-(6-methoxy-[1,5]naphthyridin-4 yl)-vinylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
and 1.vii.b. {(2R, 3R, 6R)-2-(2-hydroxy-ethyl)-6-[2-(6-methoxy-[1, 5]naphthyridin-4 yl)-ethylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
A solution of intermediate l.vi (2.8 g, 5.6 mmol) in a THF-AcOH-water mixture (1-3-1, 50 ml) was heated at 60 C for 6 h. The reaction mixture was concentrated to dryness, and the residue was partitioned between EA and saturated NaHCO3. The pH was adjusted to 7 by adding solid NaHCO3. The aq. layer was extracted once with EA and the combined org.
layers were washed with brine, dried over NazSO4, filtered and concentrated to dryness. The residue was taken up in acetone (100 ml) and a warm solution of Na104 (3 g) in water (10 ml) was added. The mixture was stirred 1 h. The reaction mixture was filtered through a pad of celite and the solvent was removed in vacuo. The residue was extracted twice with EA. The combined org. layers were dried over NazSO4, filtered and concentrated in vacuo. The residue was taken up in MeOH (30 ml) and NaBH4 (0.7 g) was added. The reaction proceeded for 15 min. 10% aq. NaHSO4 (100 ml) was added. The volatiles were removed in vacuo and the aq. residue was extracted three times with EA (3 x 100 ml). The combined org.
layers were washed with brine, dried over NazSO4, filtered and concentrated to dryness.
The residue was chromatographed over Si0z (DCM-MeOH 19-1) to afford a colourless foam (1.76 g) which was characterized as a mixture of the two title compounds.
MS (ESI, m/z): 430.1 [M+H+].
1.viii.a. {(2R, 3R, 6R)-2-(2-hydroxy-ethyl)-6-[2-(6-methoxy-[1, 5]naphthyridin-4 yl)-ethylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
and l.viii.b. [(2R,3R,6S)-6-[(IR,2R)-1,2-dihydroxy-2-(6-methoxy-[],5Jnaphthyridin-4 yl)-ethylJ-2-(2-hydroxy-ethyl)-tetrahydro pyran-3 ylJ-carbamic acid tert-butyl ester:
To a solution of intermediate l.vii (1.76 g, mixture of compounds), was added potassium ferricyanide (4.04 g), K2C03 (1.7 g) methanesulfonamide (0.47 g), (DHDQ)2PHAL
(0.035 g) and potassium osmate dihydrate (0.005 g). The mixture was stirred 40 h at rt.
Sodium bisulfite (6 g) was added. The two layers were decanted and the aq. layer was extracted twice with EA
(2 x 150 ml). The combined org. layers were washed with brine, dried over NazSO4, filtered and concentrated to dryness. The residue was chromatographed over Si0z (DCM-MeOH
19-1) to afford first the title alkane l.viii.a (1.34 g, 3.1 mmol) as a colourless foam.
MS (ESI, m/z): 432.0 [M+H+].
Elution was pursued with DCM-MeOH 6-1 to give the title diol l.viii.b (0.4 g, 0.86 mmol) as a colourless foam.
MS (ESI, m/z): 464.3 [M+H+].
l.ix. (2R,3R,6R)-2-{3-amino-6-[2-(6-methoxy-[1,5]naphthyridin-4 yl)-ethylJ-tetrahydro-pyran-2 yl}-ethanol:
A solution of intermediate l.viii.a (1.34 g, 3.1 mmol) in TFA (10 ml) was stirred at rt for 15 min. After evaporation to dryness, the residue was dissolved in water (50 ml), washed once with EA (50 ml). The pH of the aq. layer was adjusted to 12 adding 3M aq. NaOH
and the aq.
layer was extracted four times with DCM-MeOH 9-1 mixture (4 x 100 ml). The combined org. layers were washed with brine, dried over NazSO4, filtered and concentrated to dryness.
After further drying under HV, the residue was purified by chromatography over Si0z (DCM-MeOH 6-1 containing 1% aq. NH4OH) to give the title amine (0.65 g, 63%
yield) as a colourless foam.
MS (ESI, m/z): 332.3 [M+H+].
1.viii.a. {(2R, 3R, 6R)-2-(2-hydroxy-ethyl)-6-[2-(6-methoxy-[1, 5]naphthyridin-4 yl)-ethylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
and l.viii.b. [(2R,3R,6S)-6-[(IR,2R)-1,2-dihydroxy-2-(6-methoxy-[],5Jnaphthyridin-4 yl)-ethylJ-2-(2-hydroxy-ethyl)-tetrahydro pyran-3 ylJ-carbamic acid tert-butyl ester:
To a solution of intermediate l.vii (1.76 g, mixture of compounds), was added potassium ferricyanide (4.04 g), K2C03 (1.7 g) methanesulfonamide (0.47 g), (DHDQ)2PHAL
(0.035 g) and potassium osmate dihydrate (0.005 g). The mixture was stirred 40 h at rt.
Sodium bisulfite (6 g) was added. The two layers were decanted and the aq. layer was extracted twice with EA
(2 x 150 ml). The combined org. layers were washed with brine, dried over NazSO4, filtered and concentrated to dryness. The residue was chromatographed over Si0z (DCM-MeOH
19-1) to afford first the title alkane l.viii.a (1.34 g, 3.1 mmol) as a colourless foam.
MS (ESI, m/z): 432.0 [M+H+].
Elution was pursued with DCM-MeOH 6-1 to give the title diol l.viii.b (0.4 g, 0.86 mmol) as a colourless foam.
MS (ESI, m/z): 464.3 [M+H+].
l.ix. (2R,3R,6R)-2-{3-amino-6-[2-(6-methoxy-[1,5]naphthyridin-4 yl)-ethylJ-tetrahydro-pyran-2 yl}-ethanol:
A solution of intermediate l.viii.a (1.34 g, 3.1 mmol) in TFA (10 ml) was stirred at rt for 15 min. After evaporation to dryness, the residue was dissolved in water (50 ml), washed once with EA (50 ml). The pH of the aq. layer was adjusted to 12 adding 3M aq. NaOH
and the aq.
layer was extracted four times with DCM-MeOH 9-1 mixture (4 x 100 ml). The combined org. layers were washed with brine, dried over NazSO4, filtered and concentrated to dryness.
After further drying under HV, the residue was purified by chromatography over Si0z (DCM-MeOH 6-1 containing 1% aq. NH4OH) to give the title amine (0.65 g, 63%
yield) as a colourless foam.
MS (ESI, m/z): 332.3 [M+H+].
l.x. (E)-2-{(2R,3R,6R)-3-[3-(2,5-difluoro phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4 yl)-ethylJ-tetrahydro pyran-2 yl}-ethanol:
To a solution of intermediate l.ix (0.1 g, 0.3 mmol) in 1,2-DCE (4.5 ml) and MeOH (1.5 ml) were added (E)-3-(2,5-difluoro-phenyl)-propenal (see Preparation C, 0.055 g, 1.1 eq.) and 3A
molecular sieves (1 g). The mixture was heated at 50 C overnight. After cooling to rt, NaBH4 (0.1 g) was added. The reaction proceeded for 2 h before filtration through a pad of hydromatrix (treated with saturated aq. NaHCO3). The filtrate was concentrated to dryness.
The residue was chromatographed over Si02 (DCM-MeOH 19-1 containing 0.5% aq.
NH4OH) (0.09 g, 61% yield) was obtained as a colourless oil.
MS (ESI, m/z): 484.1 [M+H+].
Example 2: {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-acryloylamino]-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid:
2.i. {(2R,3R,6S)-2-((4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-6-[(E)-2-(3-methoxy-quinolin-S yl)-vinylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
A Julia coupling was performed as described in Example 1, step l.vi, starting from intermediate l.v (1.99 g, 3.7 mmol) and 3-methoxy-quinoline-5-carbaldehyde (see Preparation A; 0.67 g) to afford the title compound as a white foam (1.07 g, 2.14 mmol). The compound was purified by column chromatography over Si0z (EA-Hex 1-1). The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 499.2 [M+H+].
2.ii. {(2R,3R,6R)-2-((4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-6-[2-(3-methoxy-quinolin-S yl)-ethylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
To a solution of intermediate 2.i (1.07 g, 2.14 mmol) in EA (35 ml) was added 10% Pd/C
(0.23 g). The resulting suspension was stirred under hydrogen for 1 h. The catalyst was removed by filtration. The filtrate was evaporated under reduced pressure and further dried under HV to afford the title compound as a white foam (1.03 g, 2.05 mmol). The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 501.1 [M+H+].
To a solution of intermediate l.ix (0.1 g, 0.3 mmol) in 1,2-DCE (4.5 ml) and MeOH (1.5 ml) were added (E)-3-(2,5-difluoro-phenyl)-propenal (see Preparation C, 0.055 g, 1.1 eq.) and 3A
molecular sieves (1 g). The mixture was heated at 50 C overnight. After cooling to rt, NaBH4 (0.1 g) was added. The reaction proceeded for 2 h before filtration through a pad of hydromatrix (treated with saturated aq. NaHCO3). The filtrate was concentrated to dryness.
The residue was chromatographed over Si02 (DCM-MeOH 19-1 containing 0.5% aq.
NH4OH) (0.09 g, 61% yield) was obtained as a colourless oil.
MS (ESI, m/z): 484.1 [M+H+].
Example 2: {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-acryloylamino]-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid:
2.i. {(2R,3R,6S)-2-((4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-6-[(E)-2-(3-methoxy-quinolin-S yl)-vinylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
A Julia coupling was performed as described in Example 1, step l.vi, starting from intermediate l.v (1.99 g, 3.7 mmol) and 3-methoxy-quinoline-5-carbaldehyde (see Preparation A; 0.67 g) to afford the title compound as a white foam (1.07 g, 2.14 mmol). The compound was purified by column chromatography over Si0z (EA-Hex 1-1). The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 499.2 [M+H+].
2.ii. {(2R,3R,6R)-2-((4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-6-[2-(3-methoxy-quinolin-S yl)-ethylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
To a solution of intermediate 2.i (1.07 g, 2.14 mmol) in EA (35 ml) was added 10% Pd/C
(0.23 g). The resulting suspension was stirred under hydrogen for 1 h. The catalyst was removed by filtration. The filtrate was evaporated under reduced pressure and further dried under HV to afford the title compound as a white foam (1.03 g, 2.05 mmol). The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 501.1 [M+H+].
2.iii. 3-(2RS)-{(2R,3R,6R)-3-amino-6-[2-(3-methoxy-quinolin-S yl)-ethyl]-tetrahydro pyran-2 yl} propane-l,2-diol:
A solution of intermediate 2.ii (1.03 g) in TFA (21 ml) was stirred for 10 min. Water (7 ml) was added. The resulting mixture was stirred for 1 h and concentrated to dryness. The residue was basified with 1M aq. NaOH. DCM-MeOH 9-1 was added and the phases were separated.
The aq. layer was extracted six times with DCM-MeOH 9-1 and the combined extracts were dried over MgSO4, filtered and evaporated under reduced pressure. The title compound (0.69 g, 1.91 mmol) was obtained as a white foam. This was obtained as a 2-1 mixture of epimers.
'H NMR (CDC13) main signals 8: 8.65 (d, J = 2.8 Hz, 1H); 7.89 (d, J = 8.4 Hz, 1H); 7.56 (m, 1H); 7.45 (m, 1H); 7.31 (m, 1H); 4.03 (m, 1H); 3.94 (s, 3H); 3.79 (m, 1H);
3.63 (m, 2H);
3.47 (m, 1H); 3.14 (m, 2H); 2.95 (m, 1H); 2.25-2.05 (m, 5H); 2.03-1.87 (m, 3H);
1.85-1.67 (m, 3H); 1.59 (m, 1H); 1.23 (m, 1H).
MS (ESI, m/z): 361.1 [M+H+].
2.iv. (E)-3-(2, 5-dif luoro phenyl)-N-{(2R, 3R, 6R)-2-((2RS)-2, 3-dihydroxy propyl)-6-[2-(3-methoxy-quinolin-S yl)-ethyl]-tetrahydro pyran-3 yl}-acrylamide:
To a solution of intermediate 2.iii (0.360 g, 1 mmol) and 3-(2,5-difluoro-phenyl)-acrylic acid (0.203 g, 1.1 mmol) in DMF (15 ml) were added DIPEA (0.514 ml, 3 mmol) and HATU
(0.456 g, 1.2 mmol). The reaction mixture was stirred at rt for 90 min and concentrated to dryness. The residue was dissolved in DCM-MeOH 9-1 (50 ml) and washed with saturated NaHCO3 (20 ml). The aq. layer was extracted twice with DCM-MeOH 9-1 (2 x 20 ml) and the combined org. layers were dried over MgS04, filtered and evaporated under reduced pressure. The residue was purified by column chromatography over Si0z (DCM-MeOH 19-1 containing 1% aq. NH4OH to DCM-MeOH 9-1 containing 1% aq. NH4OH) to afford the title amide (0.331 g, 62% yield) as orange solid.
iH NMR (d6-DMSO) main signals 8: 8.69 (d, J = 2.7 Hz, 1H); 8.30 (d, J = 8.6 Hz, 1H);
7.87-7.79 (m, 2H); 7.56-7.50 (m, 4H); 7.40-7.27 (m, 2H); 7.02 (dd, J = 5.1, 15.9 Hz, 1H);
4.58 (m, 2H); 4.23 (m, 1H); 4.06 (overlapped m, 2H); 4.02 (overlapped s, 3H);
3.86-3.76 (m, 2H); 3.45-3.24 (overlapped m, 2H); 3.09-2.99 (m, 1H); 2.16 (m, 1H); 2.00 (m, 3H); 1.67 (m, 2H); 1.37 (m, 1H); 1.21 (m, 1H).
MS (ESI, m/z): 527.0 [M+H+].
A solution of intermediate 2.ii (1.03 g) in TFA (21 ml) was stirred for 10 min. Water (7 ml) was added. The resulting mixture was stirred for 1 h and concentrated to dryness. The residue was basified with 1M aq. NaOH. DCM-MeOH 9-1 was added and the phases were separated.
The aq. layer was extracted six times with DCM-MeOH 9-1 and the combined extracts were dried over MgSO4, filtered and evaporated under reduced pressure. The title compound (0.69 g, 1.91 mmol) was obtained as a white foam. This was obtained as a 2-1 mixture of epimers.
'H NMR (CDC13) main signals 8: 8.65 (d, J = 2.8 Hz, 1H); 7.89 (d, J = 8.4 Hz, 1H); 7.56 (m, 1H); 7.45 (m, 1H); 7.31 (m, 1H); 4.03 (m, 1H); 3.94 (s, 3H); 3.79 (m, 1H);
3.63 (m, 2H);
3.47 (m, 1H); 3.14 (m, 2H); 2.95 (m, 1H); 2.25-2.05 (m, 5H); 2.03-1.87 (m, 3H);
1.85-1.67 (m, 3H); 1.59 (m, 1H); 1.23 (m, 1H).
MS (ESI, m/z): 361.1 [M+H+].
2.iv. (E)-3-(2, 5-dif luoro phenyl)-N-{(2R, 3R, 6R)-2-((2RS)-2, 3-dihydroxy propyl)-6-[2-(3-methoxy-quinolin-S yl)-ethyl]-tetrahydro pyran-3 yl}-acrylamide:
To a solution of intermediate 2.iii (0.360 g, 1 mmol) and 3-(2,5-difluoro-phenyl)-acrylic acid (0.203 g, 1.1 mmol) in DMF (15 ml) were added DIPEA (0.514 ml, 3 mmol) and HATU
(0.456 g, 1.2 mmol). The reaction mixture was stirred at rt for 90 min and concentrated to dryness. The residue was dissolved in DCM-MeOH 9-1 (50 ml) and washed with saturated NaHCO3 (20 ml). The aq. layer was extracted twice with DCM-MeOH 9-1 (2 x 20 ml) and the combined org. layers were dried over MgS04, filtered and evaporated under reduced pressure. The residue was purified by column chromatography over Si0z (DCM-MeOH 19-1 containing 1% aq. NH4OH to DCM-MeOH 9-1 containing 1% aq. NH4OH) to afford the title amide (0.331 g, 62% yield) as orange solid.
iH NMR (d6-DMSO) main signals 8: 8.69 (d, J = 2.7 Hz, 1H); 8.30 (d, J = 8.6 Hz, 1H);
7.87-7.79 (m, 2H); 7.56-7.50 (m, 4H); 7.40-7.27 (m, 2H); 7.02 (dd, J = 5.1, 15.9 Hz, 1H);
4.58 (m, 2H); 4.23 (m, 1H); 4.06 (overlapped m, 2H); 4.02 (overlapped s, 3H);
3.86-3.76 (m, 2H); 3.45-3.24 (overlapped m, 2H); 3.09-2.99 (m, 1H); 2.16 (m, 1H); 2.00 (m, 3H); 1.67 (m, 2H); 1.37 (m, 1H); 1.21 (m, 1H).
MS (ESI, m/z): 527.0 [M+H+].
2.v. (E)-3-(2, 5-difluoro phenyl)-1-{(2RS, 5R)-2-hydroxy-5-[2-(3-methoxy-quinolin-S yl)-ethylJ-hexahydro pyrano[3,2-b]pyrrol-1 yl} propenone:
To a solution of intermediate 2.iv (0.153 g) in acetone (1.7 ml) was added at rt a solution of Na104 (0.156 g) in water (0.5 ml). The reaction mixture was stirred for 30 min and concentrated to dryness. The residue was purified over Si02 (EA-Hex 2-1) to afford a colourless gum (0.118 g, 82% yield).
MS (ESI, m/z): 495.1 [M+H+].
2.vi. {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro phenyl)-acryloylaminoJ-6-[2-(3-methoxy-quinolin-S yl)-ethylJ-tetrahydro pyran-2 yl}-acetic acid:
To a solution of intermediate 2.v (0.114 g, 0.23 mmol) in 2-methyl-2-propanol (5 ml) and 2-methyl-2-butene (1.2 ml) was added dropwise a solution of sodium chlorite (0.193 g) and sodium dihydrogen phosphate (0.193 g) in water (2 ml). The resulting solution was stirred at rt overnight and the volatiles were removed under HV. The residue was diluted with water and Hex. The phases were separated and the org. layer was extracted once with Hex. The aq.
layer was acidified to pH 3 and extracted three times with EA. The combined extracts were washed with cold water and evaporated under reduced pressure. The colourless gum thus obtained was triturated in ether, filtered and dried under reduced pressure to give the title compound as a white solid (0.069 g, 58% yield).
iH NMR (d6-DMSO) 8: 12.32 (br. s, 1H); 8.82 (m, 1H); 8.58 (m, 1H); 8.05 (m, 2H); 7.51 (m, 4H); 7.37 (m, 2H); 7.03 (m, 1H); 4.36 (m, 1H); 4.02 (overlapped s, 3H); 4.01 (overlapped m, 1H); 3.86 (m, 1H); 3.39 (m, 1H); 3.10 (m, 1H); 2.44 (overlapped m, 2H); 2.25 (m, 1H);
1.92 (m, 2H); 1.65 (m, 2H); 1.37 (m, 1 H).
MS (ESI, m/z): 511.0 [M+H+].
Example 3: {(2R,3R,6R)-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-3-[(3-oxo-3,4-dihydro-2H-pyrido [3,2-b] [1,4]thiazine-6-carbonyl)-amino]-tetrahydro-pyran-2-yl}-acetic acid:
3.i. 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2R,3R,6R)-2-((2RS)-2,3-dihydroxy propyl)-6-[2-(3-methoxy-quinolin-5yl)-ethylJ-tetrahydro pyran-3 yl}-amide:
Starting from intermediate 2.iii (0.270 g, 0.75 mmol) and 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid (0.174 g, 1.1 eq), the title compound (0.187 g, 0.32 mmol) was obtained as a pale brown-orange foam using the procedure of Example 2, step 2.iv. The compound was obtained as a 2-1 mixture of epimers.
iH NMR (d6-DMSO) main signals 8: 11.29 (s, 1H); 8.69 (dd, J= 1.7, 2.7 Hz, 1H);
8.36 (d, J= 9.3Hz, 1H); 8.01 (d, J= 7.9 Hz, 1H); 7.88-7.79 (m, 2H); 7.66 (dd, J= 1.3, 7.9 Hz, 1H);
7.51 (m, 1H); 4.64 (d, J = 5.2 Hz, 2H); 4.5 8(m, 1H); 4.25 (m, 1H); 4.08 (overlapped m, 1H);
4.03 (overlapped s, 3H); 3.95 (m, 1H); 3.77 (m, 1H); 3.69 (d, J= 5.1 Hz, 2H);
3.39-3.25 (overlapped m, 4H); 3.07 (m, 1H); 2.28 (m, 1H); 1.98 (m, 2H); 1.83-1.58 (m, 3H);
1.27 (m, 1H); 1.20 (m, 1H).
3.ii. 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid [(2R, 3R, 6R)-6-[2-(3-methoxy-quinolin-S yl)-ethyl]-2-(2-oxo-ethyl)-tetrahydro pyran-3 ylJ-amide:
Starting from intermediate 3.i (0.148 g, 0.27 mmol), and using the procedure of Example 2, step 2.v, the title aldehyde (0.078 g, 56% yield) was obtained as a colourless foam.
MS (ESI, m/z): 521.1 [M+H+].
3.iii. {(2R,3R,6R)-6-[2-(3-methoxy-quinolin-S yl)-ethyl]-3-[(3-oxo-3,4-dihydro-2H pyrido[3,2-b][1,4] thiazine-6-carbonyl)-aminoJ-tetrahydro pyran-2 yl}-acetic acid:
Starting from intermediate 3.ii (0.073 g, 0.14 mmol), the title acid (0.032 g, 42% yield) was obtained as an off-white solid using the procedure described in Example 2, step 2.vi. The compound was purified by trituration in ether.
'H NMR (d6-DMSO) 8: 11.29 (s, 1H); 8.76 (m, 1H); 8.55 (m, 1H); 8.12-7.87 (m, 3H);
7.67-7.47 (m, 3H); 4.45 (m, 1H); 4.14 (overlapped m, 1H); 4.04 (overlapped s, 3H);
3.96 (overlapped m, 1H); 3.76 (m, 1H); 3.46-3.25 (m, 2H); 3.04 (m, 1H); 2.53-2.20 (m, 4H);
2.01 (m, 2H); 1.69 (m, 2H); 1.30 (m, 1H).
MS (ESI, m/z): 537.0 [M+H+].
To a solution of intermediate 2.iv (0.153 g) in acetone (1.7 ml) was added at rt a solution of Na104 (0.156 g) in water (0.5 ml). The reaction mixture was stirred for 30 min and concentrated to dryness. The residue was purified over Si02 (EA-Hex 2-1) to afford a colourless gum (0.118 g, 82% yield).
MS (ESI, m/z): 495.1 [M+H+].
2.vi. {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro phenyl)-acryloylaminoJ-6-[2-(3-methoxy-quinolin-S yl)-ethylJ-tetrahydro pyran-2 yl}-acetic acid:
To a solution of intermediate 2.v (0.114 g, 0.23 mmol) in 2-methyl-2-propanol (5 ml) and 2-methyl-2-butene (1.2 ml) was added dropwise a solution of sodium chlorite (0.193 g) and sodium dihydrogen phosphate (0.193 g) in water (2 ml). The resulting solution was stirred at rt overnight and the volatiles were removed under HV. The residue was diluted with water and Hex. The phases were separated and the org. layer was extracted once with Hex. The aq.
layer was acidified to pH 3 and extracted three times with EA. The combined extracts were washed with cold water and evaporated under reduced pressure. The colourless gum thus obtained was triturated in ether, filtered and dried under reduced pressure to give the title compound as a white solid (0.069 g, 58% yield).
iH NMR (d6-DMSO) 8: 12.32 (br. s, 1H); 8.82 (m, 1H); 8.58 (m, 1H); 8.05 (m, 2H); 7.51 (m, 4H); 7.37 (m, 2H); 7.03 (m, 1H); 4.36 (m, 1H); 4.02 (overlapped s, 3H); 4.01 (overlapped m, 1H); 3.86 (m, 1H); 3.39 (m, 1H); 3.10 (m, 1H); 2.44 (overlapped m, 2H); 2.25 (m, 1H);
1.92 (m, 2H); 1.65 (m, 2H); 1.37 (m, 1 H).
MS (ESI, m/z): 511.0 [M+H+].
Example 3: {(2R,3R,6R)-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-3-[(3-oxo-3,4-dihydro-2H-pyrido [3,2-b] [1,4]thiazine-6-carbonyl)-amino]-tetrahydro-pyran-2-yl}-acetic acid:
3.i. 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2R,3R,6R)-2-((2RS)-2,3-dihydroxy propyl)-6-[2-(3-methoxy-quinolin-5yl)-ethylJ-tetrahydro pyran-3 yl}-amide:
Starting from intermediate 2.iii (0.270 g, 0.75 mmol) and 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid (0.174 g, 1.1 eq), the title compound (0.187 g, 0.32 mmol) was obtained as a pale brown-orange foam using the procedure of Example 2, step 2.iv. The compound was obtained as a 2-1 mixture of epimers.
iH NMR (d6-DMSO) main signals 8: 11.29 (s, 1H); 8.69 (dd, J= 1.7, 2.7 Hz, 1H);
8.36 (d, J= 9.3Hz, 1H); 8.01 (d, J= 7.9 Hz, 1H); 7.88-7.79 (m, 2H); 7.66 (dd, J= 1.3, 7.9 Hz, 1H);
7.51 (m, 1H); 4.64 (d, J = 5.2 Hz, 2H); 4.5 8(m, 1H); 4.25 (m, 1H); 4.08 (overlapped m, 1H);
4.03 (overlapped s, 3H); 3.95 (m, 1H); 3.77 (m, 1H); 3.69 (d, J= 5.1 Hz, 2H);
3.39-3.25 (overlapped m, 4H); 3.07 (m, 1H); 2.28 (m, 1H); 1.98 (m, 2H); 1.83-1.58 (m, 3H);
1.27 (m, 1H); 1.20 (m, 1H).
3.ii. 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid [(2R, 3R, 6R)-6-[2-(3-methoxy-quinolin-S yl)-ethyl]-2-(2-oxo-ethyl)-tetrahydro pyran-3 ylJ-amide:
Starting from intermediate 3.i (0.148 g, 0.27 mmol), and using the procedure of Example 2, step 2.v, the title aldehyde (0.078 g, 56% yield) was obtained as a colourless foam.
MS (ESI, m/z): 521.1 [M+H+].
3.iii. {(2R,3R,6R)-6-[2-(3-methoxy-quinolin-S yl)-ethyl]-3-[(3-oxo-3,4-dihydro-2H pyrido[3,2-b][1,4] thiazine-6-carbonyl)-aminoJ-tetrahydro pyran-2 yl}-acetic acid:
Starting from intermediate 3.ii (0.073 g, 0.14 mmol), the title acid (0.032 g, 42% yield) was obtained as an off-white solid using the procedure described in Example 2, step 2.vi. The compound was purified by trituration in ether.
'H NMR (d6-DMSO) 8: 11.29 (s, 1H); 8.76 (m, 1H); 8.55 (m, 1H); 8.12-7.87 (m, 3H);
7.67-7.47 (m, 3H); 4.45 (m, 1H); 4.14 (overlapped m, 1H); 4.04 (overlapped s, 3H);
3.96 (overlapped m, 1H); 3.76 (m, 1H); 3.46-3.25 (m, 2H); 3.04 (m, 1H); 2.53-2.20 (m, 4H);
2.01 (m, 2H); 1.69 (m, 2H); 1.30 (m, 1H).
MS (ESI, m/z): 537.0 [M+H+].
Example 4: {(2R,3R,6R)-6-[2-(6-methoxy-[1,5] naphthyridin-4-yl)-ethyl]-3-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b] [1,4]thiazin-6-ylmethyl)-amino]-tetrahydro-pyran-2-yl}-acetic acid trihydrochloride:
4.i. (2RS)-3-{(2R,3R,6R)-3-amino-6-[2-(6-methoxy-[],5Jnaphthyridin-4 yl)-ethylJ-tetrahydro pyran-2 yl} propane-l,2-diol:
The title compound (1.30 g, 94% yield) was obtained as a white solid starting from intermediate 1.vi (1.98 g, 3.98 mmol) using the procedures of Example 2, steps 2.ii and 2.iii.
MS (ESI, m/z): 362.1 [M+H+].
4.ii. 6-({(2R, 3R, 6R)-2-((2RS)-2, 3-dihydroxy propyl)-6-[2-(6-methoxy-[1, 5]naphthyridin-4 yl)-ethylJ-tetrahydro pyran-3 ylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one:
Starting from intermediate 4.i (0.644 g, 1.78 mmol) and 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carbaldehyde (0.380 g, 1.1 eq.), the title compound (0.583 g, 60% yield) was obtained as a white foam using the procedure of Example 1, step l.x.
iH NMR (d6-DMSO) 8: 10.93 (s, 1H); 8.69 (dd, J = 1. 1, 4.4 Hz, 1H); 8.27 (d, J
= 9.0 Hz, 1H);
7.78 (dd, J= 1.3, 7.9 Hz, 1H); 7.56 (t, J= 4.4 Hz, 1H); 7.28 (d, J= 9.0 Hz, 1H); 7.12 (d, J = 7.9 Hz, 1H); 4.65-4.46 (m, 2H); 4.20-4.05 (overlapped m, 1H); 4.05 (overlapped s, 3H);
3.70 (overlapped s, 2H); 3.70-3.56 (overlapped m, 2H); 3.56 (overlapped s, 2H);
3.41-3.19 (overlapped m, 3H); 3.17-3.07 (m, 1H); 2.74 (m, 1H); 2.09 (m, 1H);
1.92-1.70 (m, 5H); 1.51 (m, 1H); 1.3 7(m, 1H); 1.25 (m, 1 H) .
MS (ESI, m/z): 540.0 [M+H+].
4.iii. {(2R,3R,6R)-2-((2RS)-2,3-dihydroxy propyl)-6-[2-(6-methoxy-[],5Jnaphthyridin-4 yl)-ethylJ-tetrahydro pyran-3 yl}-(3-oxo-3,4-dihydro-2M pyrido[3,2-b][1,4]thiazin-6 ylmethyl)-carbamic acid tert-butyl ester:
To a solution of intermediate 4.ii (0.5 g, 0.92 mmol) in dioxane (4.5 ml) and water (0.6 ml) was added 1M aq. NaOH (1 ml). The solution was cooled to 0 C and Boc2O (0.303 g) was added. After stirring overnight, 1M aq. NaOH (0.5 ml) and Boc2O (0.3 g) were added. After 4 h, 1M aq. NaOH (1 ml) and Boc2O (0.3 g) were added again and the reaction mixture was stirred for 16 h. EA was added and the phases were separated. The aq. layer was extracted twice with EA and the combined org. layers were washed with brine, dried over MgS04, filtered and evaporated under reduced pressure. The residue was purified by column chromatography over Si02 (DCM-MeOH 19-1 containing 1% aq. NH4OH then DCM-MeOH
9-1 containing 1% aq. NH4OH) to afford the title compound as a pale yellow foam (0.449 g, 76% yield).
iH NMR (CDC13) main signals 8: 9.27 (br. s, 1H); 8.64 (dd, J = 1.3, 4.5 Hz, 1H); 8.19 (dd, J = 1.2, 9.0 Hz, 1H); 7.56 (m, 1H); 7.36 (m, 1H); 7.10 (dd, J = 1.8, 9.0 Hz, 1H); 6.84 (br. d, J = 5.4 Hz, 1H); 4.66-4.53 (m, 2H); 4.39-4.09 (m, 2H); 4.04 (overlapped s, 3H);
4.00 (overlapped m, 1H); 3.73-3.51 (m, 3H); 3.47 (d, J = 5.4 Hz, 2H); 3.23-3.09 (m, 2H);
2.12-1.13 (m, 19H).
MS (ESI, m/z): 640.0 [M+H+].
4.iv. [(2R,3R,6R)-6-[2-(6-methoxy-[I,5]naphthyridin-4 yl)-ethylJ-2-(2-oxo-ethyl)-tetrahydro-pyran-3 ylJ-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6 ylmethyl)-carbamic acid tert-butyl ester:
Starting from intermediate 4.iii (0.444 g, 0.69 mmol), and using the procedure of Example 2, step 2.v, the title aldehyde (0.372 g, 88% yield) was obtained as a colourless thick oil. The compound was purified by column chromatography over Si0z using DCM-MeOH 19-1 as an eluent.
iH NMR (CDC13) 8: 9.77 (br. s, 1H); 8.65 (d, J = 4.5 Hz, 1H); 8.37 (br. s, 1H); 8.19 (d, J = 9.0 Hz, 1H); 7.57 (d, J = 8.0 Hz, 1H); 7.36 (d, J = 4.5 Hz, 1H); 7.10 (d, J = 9.0 Hz, 1H);
6.84 (d, J = 7.7 Hz, 1H); 4.83 (m, 1H); 4.20-4.13 (m, 2H); 4.06 (s, 3H); 3.60 (m, 1H); 3.48 (d, J= 2.3 Hz, 2H); 3.23 (m, 1H); 3.07 (m, 1H); 2.90 (m, 1H); 2.5 9(m, 1H); 1.90 (m, 2H);
1.75 (m, 3H); 1.34 (m, 11H).
MS (ESI, m/z): 608.0 [M+H+].
4.v. {(2R,3R,6R)-3-[tert-butoxycarbonyl-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-ylmethyl)-aminoJ-6-[2-(6-methoxy-[I,5]naphthyridin-4 yl)-ethylJ-tetrahydro pyran-2 yl}-acetic acid:
Starting from intermediate 4.iv (0.365 g, 0.6 mmol), the title acid (0.258 g, 69% yield) was obtained as a yellow solid using the procedure of Example 2, step 2.vi. The compound was purified by trituration in ether.
iH NMR (d6-DMSO) 8: 12.28 (s, 1H); 10.92 (s, 1H); 8.68 (d, J = 4.4 Hz, 1H);
8.26 (d, J = 9.0 Hz, 1H); 7.76 (d, J = 8.0 Hz, 1H); 7.56 (d, J = 4.4 Hz, 1H); 7.27 (d, J = 9.0 Hz, 1H);
6.82 (d, J = 8.0 Hz, 1H); 4.50 (m, 2H); 4.19 (m, 2H); 4.05 (s, 3H); 3.64 (m, 1H); 3.56 (d, J= 3.4 Hz, 2H); 3.22 (m, 1H); 3.07 (m, 1H); 2.79 (m, 1H); 2.3 7(m, 1H); 1.93 (m, 1H);
1.87-1.73 (m, 4H); 1.46-1.37 (m, 6H); 1.26 (m, 4H).
MS (ESI, m/z): 624.0 [M+H+].
4.vi. {(2R, 3R, 6R)-6-[2-(6-methoxy-[1,5]naphthyridin-4 yl)-ethylJ-3-[(3-oxo-3,4-dihydro-2H pyrido[3,2-b][1,4] thiazin-6 ylmethyl)-aminoJ-tetrahydro pyran-2 yl}-acetic acid trihydrochloride:
To a suspension of intermediate 4.v (0.256 g, 0.41 mmol) in dioxane (1 ml) was added anhydrous HC1 in dioxane (5N, 0.86 ml). The resulting solution was stirred at rt for 3 h. The mixture was concentrated to dryness. The residual solid was diluted with ether and evaporated under reduced pressure. The solid thus obtained was triturated in ether and filtered. After drying under HV, the trihydrochloride salt was collected as a white solid (0.260 g).
iH NMR (d6-DMSO) 8: 11.16 (s, 1H); 9.53 (br. s, 1H); 9.18 (br. s, 1H); 8.95 (d, J= 5.1 Hz, 1H); 8.56 (d, J = 9.0 Hz, 1H); 7.92 (m, 2H); 7.53 (d, J = 9.2 Hz, 1H); 7.30 (d, J = 7.9 Hz, 1H);
4.65 (m, 1H); 4.28 (br. s, 2H); 4.11 (s, 3H); 3.82 (m, 1H); 3.64 (overlapped s, 2H);
3.60 (overlapped m, 1H); 3.26 (m, 2H); 2.86-2.66 (m, 2H); 2.09 (m, 1H); 1.96 (m, 4H);
1.34 (m, 1H).
MS (ESI, m/z): 524.7 [M+H+].
Example 5: {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid dihydrochloride:
5.i. (2RS)-3-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro phenyl)-allylaminoJ-6-[2-(6-methoxy-[1,5]naphthyridin-4 yl)-ethylJ-tetrahydro pyran-2 yl} propane-l,2-diol:
Starting from intermediate 4.i (0.470 g, 1.3 mmol) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.240 g; 1.1 eq.), the title compound (0.450 g, 67% yield) was obtained as a white foam according to the procedure of Example 1, step l.x.
iH NMR (d6-DMSO) 8: 8.69 (dd, J = 1. 1, 4.4 Hz, 1H); 8.27 (d, J = 9.0 Hz, 1H);
7.58-7.48 (m, 2H); 7.31-7.22 (m, 2H); 7.18-7.10 (m, 1 H); 6.62 (t, J= 16.1 Hz, 1 H); 6.52 (m, 1 H); 4.73 (br.
s, 1H); 4.55-4.44 (m, 2H); 4.17 (m, 1H); 4.05 (s, 3H); 3.69-3.58 (m, 2H); 3.38 (overlapped m, 2H); 3.28 (overlapped m, 2H); 3.12 (m, 1H); 2.77 (m, 1H); 1.99-1.72 (m, 6H);
1.54-1.23 (m, 3H).
MS (ESI, m/z): 514.0 [M+H+].
4.i. (2RS)-3-{(2R,3R,6R)-3-amino-6-[2-(6-methoxy-[],5Jnaphthyridin-4 yl)-ethylJ-tetrahydro pyran-2 yl} propane-l,2-diol:
The title compound (1.30 g, 94% yield) was obtained as a white solid starting from intermediate 1.vi (1.98 g, 3.98 mmol) using the procedures of Example 2, steps 2.ii and 2.iii.
MS (ESI, m/z): 362.1 [M+H+].
4.ii. 6-({(2R, 3R, 6R)-2-((2RS)-2, 3-dihydroxy propyl)-6-[2-(6-methoxy-[1, 5]naphthyridin-4 yl)-ethylJ-tetrahydro pyran-3 ylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one:
Starting from intermediate 4.i (0.644 g, 1.78 mmol) and 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carbaldehyde (0.380 g, 1.1 eq.), the title compound (0.583 g, 60% yield) was obtained as a white foam using the procedure of Example 1, step l.x.
iH NMR (d6-DMSO) 8: 10.93 (s, 1H); 8.69 (dd, J = 1. 1, 4.4 Hz, 1H); 8.27 (d, J
= 9.0 Hz, 1H);
7.78 (dd, J= 1.3, 7.9 Hz, 1H); 7.56 (t, J= 4.4 Hz, 1H); 7.28 (d, J= 9.0 Hz, 1H); 7.12 (d, J = 7.9 Hz, 1H); 4.65-4.46 (m, 2H); 4.20-4.05 (overlapped m, 1H); 4.05 (overlapped s, 3H);
3.70 (overlapped s, 2H); 3.70-3.56 (overlapped m, 2H); 3.56 (overlapped s, 2H);
3.41-3.19 (overlapped m, 3H); 3.17-3.07 (m, 1H); 2.74 (m, 1H); 2.09 (m, 1H);
1.92-1.70 (m, 5H); 1.51 (m, 1H); 1.3 7(m, 1H); 1.25 (m, 1 H) .
MS (ESI, m/z): 540.0 [M+H+].
4.iii. {(2R,3R,6R)-2-((2RS)-2,3-dihydroxy propyl)-6-[2-(6-methoxy-[],5Jnaphthyridin-4 yl)-ethylJ-tetrahydro pyran-3 yl}-(3-oxo-3,4-dihydro-2M pyrido[3,2-b][1,4]thiazin-6 ylmethyl)-carbamic acid tert-butyl ester:
To a solution of intermediate 4.ii (0.5 g, 0.92 mmol) in dioxane (4.5 ml) and water (0.6 ml) was added 1M aq. NaOH (1 ml). The solution was cooled to 0 C and Boc2O (0.303 g) was added. After stirring overnight, 1M aq. NaOH (0.5 ml) and Boc2O (0.3 g) were added. After 4 h, 1M aq. NaOH (1 ml) and Boc2O (0.3 g) were added again and the reaction mixture was stirred for 16 h. EA was added and the phases were separated. The aq. layer was extracted twice with EA and the combined org. layers were washed with brine, dried over MgS04, filtered and evaporated under reduced pressure. The residue was purified by column chromatography over Si02 (DCM-MeOH 19-1 containing 1% aq. NH4OH then DCM-MeOH
9-1 containing 1% aq. NH4OH) to afford the title compound as a pale yellow foam (0.449 g, 76% yield).
iH NMR (CDC13) main signals 8: 9.27 (br. s, 1H); 8.64 (dd, J = 1.3, 4.5 Hz, 1H); 8.19 (dd, J = 1.2, 9.0 Hz, 1H); 7.56 (m, 1H); 7.36 (m, 1H); 7.10 (dd, J = 1.8, 9.0 Hz, 1H); 6.84 (br. d, J = 5.4 Hz, 1H); 4.66-4.53 (m, 2H); 4.39-4.09 (m, 2H); 4.04 (overlapped s, 3H);
4.00 (overlapped m, 1H); 3.73-3.51 (m, 3H); 3.47 (d, J = 5.4 Hz, 2H); 3.23-3.09 (m, 2H);
2.12-1.13 (m, 19H).
MS (ESI, m/z): 640.0 [M+H+].
4.iv. [(2R,3R,6R)-6-[2-(6-methoxy-[I,5]naphthyridin-4 yl)-ethylJ-2-(2-oxo-ethyl)-tetrahydro-pyran-3 ylJ-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6 ylmethyl)-carbamic acid tert-butyl ester:
Starting from intermediate 4.iii (0.444 g, 0.69 mmol), and using the procedure of Example 2, step 2.v, the title aldehyde (0.372 g, 88% yield) was obtained as a colourless thick oil. The compound was purified by column chromatography over Si0z using DCM-MeOH 19-1 as an eluent.
iH NMR (CDC13) 8: 9.77 (br. s, 1H); 8.65 (d, J = 4.5 Hz, 1H); 8.37 (br. s, 1H); 8.19 (d, J = 9.0 Hz, 1H); 7.57 (d, J = 8.0 Hz, 1H); 7.36 (d, J = 4.5 Hz, 1H); 7.10 (d, J = 9.0 Hz, 1H);
6.84 (d, J = 7.7 Hz, 1H); 4.83 (m, 1H); 4.20-4.13 (m, 2H); 4.06 (s, 3H); 3.60 (m, 1H); 3.48 (d, J= 2.3 Hz, 2H); 3.23 (m, 1H); 3.07 (m, 1H); 2.90 (m, 1H); 2.5 9(m, 1H); 1.90 (m, 2H);
1.75 (m, 3H); 1.34 (m, 11H).
MS (ESI, m/z): 608.0 [M+H+].
4.v. {(2R,3R,6R)-3-[tert-butoxycarbonyl-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-ylmethyl)-aminoJ-6-[2-(6-methoxy-[I,5]naphthyridin-4 yl)-ethylJ-tetrahydro pyran-2 yl}-acetic acid:
Starting from intermediate 4.iv (0.365 g, 0.6 mmol), the title acid (0.258 g, 69% yield) was obtained as a yellow solid using the procedure of Example 2, step 2.vi. The compound was purified by trituration in ether.
iH NMR (d6-DMSO) 8: 12.28 (s, 1H); 10.92 (s, 1H); 8.68 (d, J = 4.4 Hz, 1H);
8.26 (d, J = 9.0 Hz, 1H); 7.76 (d, J = 8.0 Hz, 1H); 7.56 (d, J = 4.4 Hz, 1H); 7.27 (d, J = 9.0 Hz, 1H);
6.82 (d, J = 8.0 Hz, 1H); 4.50 (m, 2H); 4.19 (m, 2H); 4.05 (s, 3H); 3.64 (m, 1H); 3.56 (d, J= 3.4 Hz, 2H); 3.22 (m, 1H); 3.07 (m, 1H); 2.79 (m, 1H); 2.3 7(m, 1H); 1.93 (m, 1H);
1.87-1.73 (m, 4H); 1.46-1.37 (m, 6H); 1.26 (m, 4H).
MS (ESI, m/z): 624.0 [M+H+].
4.vi. {(2R, 3R, 6R)-6-[2-(6-methoxy-[1,5]naphthyridin-4 yl)-ethylJ-3-[(3-oxo-3,4-dihydro-2H pyrido[3,2-b][1,4] thiazin-6 ylmethyl)-aminoJ-tetrahydro pyran-2 yl}-acetic acid trihydrochloride:
To a suspension of intermediate 4.v (0.256 g, 0.41 mmol) in dioxane (1 ml) was added anhydrous HC1 in dioxane (5N, 0.86 ml). The resulting solution was stirred at rt for 3 h. The mixture was concentrated to dryness. The residual solid was diluted with ether and evaporated under reduced pressure. The solid thus obtained was triturated in ether and filtered. After drying under HV, the trihydrochloride salt was collected as a white solid (0.260 g).
iH NMR (d6-DMSO) 8: 11.16 (s, 1H); 9.53 (br. s, 1H); 9.18 (br. s, 1H); 8.95 (d, J= 5.1 Hz, 1H); 8.56 (d, J = 9.0 Hz, 1H); 7.92 (m, 2H); 7.53 (d, J = 9.2 Hz, 1H); 7.30 (d, J = 7.9 Hz, 1H);
4.65 (m, 1H); 4.28 (br. s, 2H); 4.11 (s, 3H); 3.82 (m, 1H); 3.64 (overlapped s, 2H);
3.60 (overlapped m, 1H); 3.26 (m, 2H); 2.86-2.66 (m, 2H); 2.09 (m, 1H); 1.96 (m, 4H);
1.34 (m, 1H).
MS (ESI, m/z): 524.7 [M+H+].
Example 5: {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid dihydrochloride:
5.i. (2RS)-3-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro phenyl)-allylaminoJ-6-[2-(6-methoxy-[1,5]naphthyridin-4 yl)-ethylJ-tetrahydro pyran-2 yl} propane-l,2-diol:
Starting from intermediate 4.i (0.470 g, 1.3 mmol) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.240 g; 1.1 eq.), the title compound (0.450 g, 67% yield) was obtained as a white foam according to the procedure of Example 1, step l.x.
iH NMR (d6-DMSO) 8: 8.69 (dd, J = 1. 1, 4.4 Hz, 1H); 8.27 (d, J = 9.0 Hz, 1H);
7.58-7.48 (m, 2H); 7.31-7.22 (m, 2H); 7.18-7.10 (m, 1 H); 6.62 (t, J= 16.1 Hz, 1 H); 6.52 (m, 1 H); 4.73 (br.
s, 1H); 4.55-4.44 (m, 2H); 4.17 (m, 1H); 4.05 (s, 3H); 3.69-3.58 (m, 2H); 3.38 (overlapped m, 2H); 3.28 (overlapped m, 2H); 3.12 (m, 1H); 2.77 (m, 1H); 1.99-1.72 (m, 6H);
1.54-1.23 (m, 3H).
MS (ESI, m/z): 514.0 [M+H+].
5.ii. [(E)-3-(2, 5-difluoro phenyl)-allylJ-{(2R, 3R, 6R)-2-((2RS)-2, 3-dihydroxy propyl)-6-[2-(6-methoxy-[1,5]naphthyridin-4 yl)-ethylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
Starting from intermediate 5.i (0.73 g, 1.42 mmol), the title compound (0.65 g, 74% yield) was obtained as a white foam using the procedure of Example 4, step 4.iii. The compound was purified by column chromatography over Si0z (DCM-MeOH 19-1 then 9-1). This was obtained as a 2-1 mixture of epimers.
iH NMR (CDC13) main signals 8: 8.66 (d, J = 3.7 Hz, 1H); 8.30 (dd, J = 6.3, 9.0 Hz, 1H);
7.42 (m, 1H); 7.14 (overlapped d, J = 9.1 Hz, 1H); 7.09 (overlapped m, 1H);
7.01-6.93 (m, 1H); 6.90-6.84 (m, 1H); 6.52 (d, J = 16.0 Hz, 1H); 6.24 (m, 1H); 4.35-4.20 (m, 3H); 4.06 (s, 3H); 3.96-3.89 (m, 1H); 3.83 (dd, J = 5.2, 16.9 Hz, 1H); 3.66 (m, 2H); 3.50 (m, 1H);
3.26-3.14 (m, 3H); 2.27-2.20 (br. m, 2H); 2.10-1.84 (m, 6H); 1.47 (overlapped s, 9H);
1.46 (overlapped m, 1H).
MS (ESI, m/z): 614.1 [M+H+].
5.iii. [(E)-3-(2,5-dfluoro phenyl)-allylJ-[(2R,3R,6R)-6-[2-(6-methoxy-[1,5]naphthyridin-4 yl)-ethylJ-2-(2-oxo-ethyl)-tetrahydro pyran-3 ylJ-carbamic acid tert-butyl ester:
Starting from intermediate 5.ii (0.645 g, 1.05 mmol), the title aldehyde (0.557 g, 91% yield) was obtained as a white foam, using the procedure of Example 2, step 2.v. The residue was purified by column chromatography over Si0z (DCM-MeOH 97-3 to 19-1).
'H NMR (CDC13) 8: 9.75 (m, 1H); 8.65 (d, J = 4.6 Hz, 1H); 8.29 (d, J = 9.1 Hz, 1H); 7.43 (d, J = 4.6 Hz, 1H); 7.14 (overlapped d, J = 9.1 Hz, 1H); 7.08 (overlapped m, 1H);
7.02-6.95 (m, 1H); 6.92-6.85 (m, 1H); 6.52 (d, J = 16.1 Hz, 1H); 6.22 (td, J = 5.2, 15.8 Hz, 1H); 4.79 (m, 1H); 4.24 (m, 1H); 4.08 (s, 3H); 3.76 (dd, J= 4.5, 16.8Hz, 1H); 3.66-3.58 (m, 1H);
3.31-3.21 (m, 1H); 3.14-3.04 (m, 1H); 2.89-2.80 (m, 1H); 2.54 (dd, J= 4.7, 15.3 Hz, 1H);
1.93-1.89 (m, 4H); 1.86-1.79 (m, 1H); 1.48 (overlapped s, 9H); 1.47 (overlapped m, 2H).
MS (ESI, m/z): 582.0 [M+H+]
5.iv. {(2R,3R,6R)-3-{tert-butoxycarbonyl-[(E)-3-(2,5-difluoro phenyl)-allylJ-amino}-6-[2-(6-methoxy-[1, 5]naphthyridin-4 yl)-ethylJ-tetrahydro pyran-2 yl}-acetic acid:
Starting from intermediate 5.iii (0.557 g, 0.96 mmol), the title acid (0.58 g, 99% yield) was obtained as a colourless foam using the procedure of Example 2, step 2.vi. The compound was purified by trituration in ether.
Starting from intermediate 5.i (0.73 g, 1.42 mmol), the title compound (0.65 g, 74% yield) was obtained as a white foam using the procedure of Example 4, step 4.iii. The compound was purified by column chromatography over Si0z (DCM-MeOH 19-1 then 9-1). This was obtained as a 2-1 mixture of epimers.
iH NMR (CDC13) main signals 8: 8.66 (d, J = 3.7 Hz, 1H); 8.30 (dd, J = 6.3, 9.0 Hz, 1H);
7.42 (m, 1H); 7.14 (overlapped d, J = 9.1 Hz, 1H); 7.09 (overlapped m, 1H);
7.01-6.93 (m, 1H); 6.90-6.84 (m, 1H); 6.52 (d, J = 16.0 Hz, 1H); 6.24 (m, 1H); 4.35-4.20 (m, 3H); 4.06 (s, 3H); 3.96-3.89 (m, 1H); 3.83 (dd, J = 5.2, 16.9 Hz, 1H); 3.66 (m, 2H); 3.50 (m, 1H);
3.26-3.14 (m, 3H); 2.27-2.20 (br. m, 2H); 2.10-1.84 (m, 6H); 1.47 (overlapped s, 9H);
1.46 (overlapped m, 1H).
MS (ESI, m/z): 614.1 [M+H+].
5.iii. [(E)-3-(2,5-dfluoro phenyl)-allylJ-[(2R,3R,6R)-6-[2-(6-methoxy-[1,5]naphthyridin-4 yl)-ethylJ-2-(2-oxo-ethyl)-tetrahydro pyran-3 ylJ-carbamic acid tert-butyl ester:
Starting from intermediate 5.ii (0.645 g, 1.05 mmol), the title aldehyde (0.557 g, 91% yield) was obtained as a white foam, using the procedure of Example 2, step 2.v. The residue was purified by column chromatography over Si0z (DCM-MeOH 97-3 to 19-1).
'H NMR (CDC13) 8: 9.75 (m, 1H); 8.65 (d, J = 4.6 Hz, 1H); 8.29 (d, J = 9.1 Hz, 1H); 7.43 (d, J = 4.6 Hz, 1H); 7.14 (overlapped d, J = 9.1 Hz, 1H); 7.08 (overlapped m, 1H);
7.02-6.95 (m, 1H); 6.92-6.85 (m, 1H); 6.52 (d, J = 16.1 Hz, 1H); 6.22 (td, J = 5.2, 15.8 Hz, 1H); 4.79 (m, 1H); 4.24 (m, 1H); 4.08 (s, 3H); 3.76 (dd, J= 4.5, 16.8Hz, 1H); 3.66-3.58 (m, 1H);
3.31-3.21 (m, 1H); 3.14-3.04 (m, 1H); 2.89-2.80 (m, 1H); 2.54 (dd, J= 4.7, 15.3 Hz, 1H);
1.93-1.89 (m, 4H); 1.86-1.79 (m, 1H); 1.48 (overlapped s, 9H); 1.47 (overlapped m, 2H).
MS (ESI, m/z): 582.0 [M+H+]
5.iv. {(2R,3R,6R)-3-{tert-butoxycarbonyl-[(E)-3-(2,5-difluoro phenyl)-allylJ-amino}-6-[2-(6-methoxy-[1, 5]naphthyridin-4 yl)-ethylJ-tetrahydro pyran-2 yl}-acetic acid:
Starting from intermediate 5.iii (0.557 g, 0.96 mmol), the title acid (0.58 g, 99% yield) was obtained as a colourless foam using the procedure of Example 2, step 2.vi. The compound was purified by trituration in ether.
iH NMR (CDC13) 8: 8.52 (d, J = 4.6 Hz, 1H); 8.36 (d, J = 9.1 Hz, 1H); 7.27 (overlapped m, 1H); 7.12-6.86 (m, 4H); 6.53 (d, J = 15.8 Hz, 1H); 6.27 (m, 1H); 4.60 (m, 1H);
4.30-4.07 (m, 2H); 3.99 (s, 3H); 3.85-3.70 (m, 2H); 3.02 (m, 2H); 2.79 (m, 1H); 2.49 (dd, J
= 3.7, 14.2 Hz, 1H); 1.94-1.90 (m, 3H); 1.84-1.77 (m, 3H); 1.52-1.40 (overlapped m, 3H); 1.27 (s, 9H).
MS (ESI, m/z): 598.1 [M+H+].
5.v. {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro phenyl)-allylaminoJ-6-[2-(6-methoxy-[1,5]naphthyridin-4 yl)-ethylJ-tetrahydro pyran-2 yl}-acetic acid dihydrochloride:
Starting from intermediate 5.iv (0.100 g, 0.167 mml), the title compound (0.074 g, 78% yield) was obtained as a white solid, using the procedure of Example 4, step 4.vi.
'H NMR (D20) 8: 8.80 (d, J = 9.2 Hz, 1H); 8.36 (d, J = 9.2 Hz, 1H); 8.03 (d, J
= 6.0 Hz, 1H);
7.51 (d, J = 9.3 Hz, 1H); 7.31 (m, 1H); 7.15 (m, 2H); 6.97 (d, J = 16.3 Hz, 1H); 6.35 (m, 1H);
4.79 (overlapped s, 1H); 4.61 (m, 1H); 4.14 (s, 3H); 4.06-3.84 (m, 3H); 3.58 (m, 1H);
3.45 (m, 2H); 2.90-2.79 (m, 1H); 2.59 (dd, J = 3.6, 15.0 Hz, 1H); 2.25-2.00 (m, 3H);
1.96-1.79 (m, 3H); 1.54-1.40 (m, 1H).
MS (ESI, m/z): 498.0 [M+H+].
Example 6: {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1S)-1-hydroxy-2-(6-methoxy-[1,5] naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid dihydrochloride:
6.i. [(2R,3R,6S)-6-[(IR,2R)-1,2-dihydroxy-2-(6-methoxy-[],5Jnaphthyridin-4 yl)-ethylJ-2-((4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-tetrahydro pyran-3 ylJ-carbamic acid tert-butyl ester:
To a suspension of intermediate 1.vi (1.274 g, 2.55 mmol) and methane sulfonamide (0.291 g, 3.06 mmol) in 2-methyl-2-propanol (13 ml), water (13 ml) and EA (4 ml) was added AD-mix (3 (4.5 g). The reaction mixture was stirred at rt for 24 h. Sodium metabisulfite (10 g) and EA (50 ml) were added. The two layers were decanted and the aq. layer was extracted twice with EA. The combined org. layers were dried over NazSO4, filtered and concentrated in vacuo. The residue was chromatographed over Si0z (DCM-MeOH 9-1) to afford the desired diol as a white foam (1.2 g). The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 534.0 [M+H+].
4.30-4.07 (m, 2H); 3.99 (s, 3H); 3.85-3.70 (m, 2H); 3.02 (m, 2H); 2.79 (m, 1H); 2.49 (dd, J
= 3.7, 14.2 Hz, 1H); 1.94-1.90 (m, 3H); 1.84-1.77 (m, 3H); 1.52-1.40 (overlapped m, 3H); 1.27 (s, 9H).
MS (ESI, m/z): 598.1 [M+H+].
5.v. {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro phenyl)-allylaminoJ-6-[2-(6-methoxy-[1,5]naphthyridin-4 yl)-ethylJ-tetrahydro pyran-2 yl}-acetic acid dihydrochloride:
Starting from intermediate 5.iv (0.100 g, 0.167 mml), the title compound (0.074 g, 78% yield) was obtained as a white solid, using the procedure of Example 4, step 4.vi.
'H NMR (D20) 8: 8.80 (d, J = 9.2 Hz, 1H); 8.36 (d, J = 9.2 Hz, 1H); 8.03 (d, J
= 6.0 Hz, 1H);
7.51 (d, J = 9.3 Hz, 1H); 7.31 (m, 1H); 7.15 (m, 2H); 6.97 (d, J = 16.3 Hz, 1H); 6.35 (m, 1H);
4.79 (overlapped s, 1H); 4.61 (m, 1H); 4.14 (s, 3H); 4.06-3.84 (m, 3H); 3.58 (m, 1H);
3.45 (m, 2H); 2.90-2.79 (m, 1H); 2.59 (dd, J = 3.6, 15.0 Hz, 1H); 2.25-2.00 (m, 3H);
1.96-1.79 (m, 3H); 1.54-1.40 (m, 1H).
MS (ESI, m/z): 498.0 [M+H+].
Example 6: {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1S)-1-hydroxy-2-(6-methoxy-[1,5] naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid dihydrochloride:
6.i. [(2R,3R,6S)-6-[(IR,2R)-1,2-dihydroxy-2-(6-methoxy-[],5Jnaphthyridin-4 yl)-ethylJ-2-((4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-tetrahydro pyran-3 ylJ-carbamic acid tert-butyl ester:
To a suspension of intermediate 1.vi (1.274 g, 2.55 mmol) and methane sulfonamide (0.291 g, 3.06 mmol) in 2-methyl-2-propanol (13 ml), water (13 ml) and EA (4 ml) was added AD-mix (3 (4.5 g). The reaction mixture was stirred at rt for 24 h. Sodium metabisulfite (10 g) and EA (50 ml) were added. The two layers were decanted and the aq. layer was extracted twice with EA. The combined org. layers were dried over NazSO4, filtered and concentrated in vacuo. The residue was chromatographed over Si0z (DCM-MeOH 9-1) to afford the desired diol as a white foam (1.2 g). The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 534.0 [M+H+].
6.ii. {(2R,3R,6S)-2-((4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-6-[(4R,5R)-5-(6-methoxy-[1,5]naphthyridin-4 yl)-2-oxo-[1,3]dioxolan-4 ylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
To an ice-chilled solution of intermediate 6.i (1.22 g, 2.30 mmol) in DCM (12 ml) were added pyridine (1.12 ml, 13.80 mmol) and triphosgene (0.341 g, 1.15 mmol). The reaction was stirred 30 min at 0 C and then 1 h at rt. The reaction mixture was diluted with saturated NaHCO3 and the two layers were decanted. The org. layer was dried over Na2SO4, filtered, and concentrated to dryness. The residue was chromatographed over Si02 (DCM-MeOH
19-1) to afford the title cyclic carbonate (1.18 g, 92% yield) as a a white foam. The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 560.0 [M+H+].
6.iii. {(2R,3R,6S)-2-((4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-6-[(IS)-1-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4 yl)-ethylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
To a solution of intermediate 6.ii (1.178 g, 2.11 mmol) in EA (80 ml) was added 20%
Pd(OH)2 on carbon (moisturized, 0.443 g) and the suspension was stirred under hydrogen atmosphere for 2 h. The catalyst was filtered off and the filtrate concentrated to dryness. The residue was purified by column chromatography over Si0z (DCM-MeOH 9-1) to afford the title compound (0.973 g, 89% yield) as a white foam.
MS (ESI, m/z): 518.0 [M+H+].
6.iv. (2RS)-3-{(2R,3R,6S)-3-amino-6-[(IS)-1-hydroxy-2-(6-methoxy-[],5Jnaphthyridin-4 yl)-ethylJ-tetrahydro pyran-2 yl} propane-l,2-diol:
Starting from intermediate 6.iii (0.97 g, 1.87 mmol), and using the procedure of Example 2, step 2.iii, the title amine (0.57 g, 80% yield) was obtained as a brown foam.
The compound was obtained as a 2-1 mixture of epimers.
iH NMR (d6-DMSO) main signals 8: 8.69 (d, J = 4.4 Hz, 1H); 8.27 (d, J = 9.0 Hz, 1H);
7.59 (d, J = 4.5 Hz, 1H); 7.27 (d, J = 9.0 Hz, 1H); 4.57-4.42 (m, 2H); 4.06 (overlapped s, 3H);
4.05-3.89 (overlapped m, 2H); 3.68 (m, 1H); 3.59-3.45 (m, 2H); 3.28 (m, 3H);
2.93-2.82 (m, 2H); 1.87-1.69 (m, 1H); 1.62-1.57 (m, 3H); 1.54-1.27 (m, 4H).
MS (ESI, m/z): 378.2 [M+H+].
To an ice-chilled solution of intermediate 6.i (1.22 g, 2.30 mmol) in DCM (12 ml) were added pyridine (1.12 ml, 13.80 mmol) and triphosgene (0.341 g, 1.15 mmol). The reaction was stirred 30 min at 0 C and then 1 h at rt. The reaction mixture was diluted with saturated NaHCO3 and the two layers were decanted. The org. layer was dried over Na2SO4, filtered, and concentrated to dryness. The residue was chromatographed over Si02 (DCM-MeOH
19-1) to afford the title cyclic carbonate (1.18 g, 92% yield) as a a white foam. The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 560.0 [M+H+].
6.iii. {(2R,3R,6S)-2-((4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-6-[(IS)-1-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4 yl)-ethylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
To a solution of intermediate 6.ii (1.178 g, 2.11 mmol) in EA (80 ml) was added 20%
Pd(OH)2 on carbon (moisturized, 0.443 g) and the suspension was stirred under hydrogen atmosphere for 2 h. The catalyst was filtered off and the filtrate concentrated to dryness. The residue was purified by column chromatography over Si0z (DCM-MeOH 9-1) to afford the title compound (0.973 g, 89% yield) as a white foam.
MS (ESI, m/z): 518.0 [M+H+].
6.iv. (2RS)-3-{(2R,3R,6S)-3-amino-6-[(IS)-1-hydroxy-2-(6-methoxy-[],5Jnaphthyridin-4 yl)-ethylJ-tetrahydro pyran-2 yl} propane-l,2-diol:
Starting from intermediate 6.iii (0.97 g, 1.87 mmol), and using the procedure of Example 2, step 2.iii, the title amine (0.57 g, 80% yield) was obtained as a brown foam.
The compound was obtained as a 2-1 mixture of epimers.
iH NMR (d6-DMSO) main signals 8: 8.69 (d, J = 4.4 Hz, 1H); 8.27 (d, J = 9.0 Hz, 1H);
7.59 (d, J = 4.5 Hz, 1H); 7.27 (d, J = 9.0 Hz, 1H); 4.57-4.42 (m, 2H); 4.06 (overlapped s, 3H);
4.05-3.89 (overlapped m, 2H); 3.68 (m, 1H); 3.59-3.45 (m, 2H); 3.28 (m, 3H);
2.93-2.82 (m, 2H); 1.87-1.69 (m, 1H); 1.62-1.57 (m, 3H); 1.54-1.27 (m, 4H).
MS (ESI, m/z): 378.2 [M+H+].
6.v. (2RS)-3-{(2R, 3R, 6S)-3-[(E)-3-(2, 5-d fluoro phenyl)-allylaminoJ-6-[(1 S)-1-hydroxy-2-(6-methoxy-[],5Jnaphthyridin-4 yl)-ethylJ-tetrahydro pyran-2 yl} propane-l,2-diol:
Starting from intermediate 6.iv (0.570g, 1.51mmo1) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.279 g, 1. 1 eq), the title compound (0.420g. 52% yield) was obtained as a white solid according to the procedure described in Example 1, step l.x.
iH NMR (d6-DMSO) main signals 8: 8.69 (d, J = 4.4 Hz, 1H); 8.27 (d, J = 9.0 Hz, 1H);
7.59 (d, J= 4.5 Hz, 1H); 7.52 (m, 2H); 7.32-7.23 (m, 2H); 7.22-7.10 (m, 1H);
6.62 (overlapped t, J = 16.3 Hz, 1H); 6.53 (overlapped m, 1H); 4.58 (m, 1H);
4.48 (d, J = 6.5 Hz, 1H); 4.26-4.09 (m, 1H); 4.04 (s, 3H); 3.91 (m, 1H); 3.72 (m, 1H);
3.53 (m, 2H);
3.40-3.29 (m, 4H); 2.92 (m, 1H); 2.76 (m, 1H); 1.96 (m, 1H); 1.82-1.68 (m, 4H);
1.62-1.37 (m, 3H).
Rf = 0.38 (DCM-MeOH 9-1 containing 1% aq. NH4OH).
MS (ESI, m/z): 529.8.
6.vi. [(E)-3-(2,5-difluoro phenyl)-allylJ-{(2R,3R,6S)-2-((2RS)-2,3-dihydroxy propyl)-6-[(1S)-1-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4 yl)-ethylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
Starting from intermediate 6.v (0.363 g, 0.69 mmol), and using the procedure of Example 4, step 4.iii, the title N-protected amine (0.279 g, 64% yield) was obtained as a white foam. The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 629.9 [M+H+].
6.vii. {(2R,3R,6S)-3-{tert-butoxycarbonyl-[(E)-3-(2,5-difluoro phenyl)-allylJ-amino}-6-[(IS)-1-hydroxy-2-(6-methoxy-[],5Jnaphthyridin-4 yl)-ethylJ-tetrahydro pyran-2 yl}-acetic acid:
Starting from intermediate 6.vi (0.275 g, 0.43 mmol), the title acid (0.257 g, 99% yield) was obtained as a colourless foam using the procedure described in Example 2, steps 2.v and vi.
MS (ESI, m/z): 614.0 [M+].
Starting from intermediate 6.iv (0.570g, 1.51mmo1) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.279 g, 1. 1 eq), the title compound (0.420g. 52% yield) was obtained as a white solid according to the procedure described in Example 1, step l.x.
iH NMR (d6-DMSO) main signals 8: 8.69 (d, J = 4.4 Hz, 1H); 8.27 (d, J = 9.0 Hz, 1H);
7.59 (d, J= 4.5 Hz, 1H); 7.52 (m, 2H); 7.32-7.23 (m, 2H); 7.22-7.10 (m, 1H);
6.62 (overlapped t, J = 16.3 Hz, 1H); 6.53 (overlapped m, 1H); 4.58 (m, 1H);
4.48 (d, J = 6.5 Hz, 1H); 4.26-4.09 (m, 1H); 4.04 (s, 3H); 3.91 (m, 1H); 3.72 (m, 1H);
3.53 (m, 2H);
3.40-3.29 (m, 4H); 2.92 (m, 1H); 2.76 (m, 1H); 1.96 (m, 1H); 1.82-1.68 (m, 4H);
1.62-1.37 (m, 3H).
Rf = 0.38 (DCM-MeOH 9-1 containing 1% aq. NH4OH).
MS (ESI, m/z): 529.8.
6.vi. [(E)-3-(2,5-difluoro phenyl)-allylJ-{(2R,3R,6S)-2-((2RS)-2,3-dihydroxy propyl)-6-[(1S)-1-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4 yl)-ethylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
Starting from intermediate 6.v (0.363 g, 0.69 mmol), and using the procedure of Example 4, step 4.iii, the title N-protected amine (0.279 g, 64% yield) was obtained as a white foam. The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 629.9 [M+H+].
6.vii. {(2R,3R,6S)-3-{tert-butoxycarbonyl-[(E)-3-(2,5-difluoro phenyl)-allylJ-amino}-6-[(IS)-1-hydroxy-2-(6-methoxy-[],5Jnaphthyridin-4 yl)-ethylJ-tetrahydro pyran-2 yl}-acetic acid:
Starting from intermediate 6.vi (0.275 g, 0.43 mmol), the title acid (0.257 g, 99% yield) was obtained as a colourless foam using the procedure described in Example 2, steps 2.v and vi.
MS (ESI, m/z): 614.0 [M+].
6.viii. {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro phenyl)-allylaminoJ-6-[(IS)-1-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4 yl)-ethylJ-tetrahydro pyran-2 yl}-acetic acid dihydrochloride:
Starting from intermediate 6.vii (0.252 g, 0.41 mmol), the title acid (0.24 g, 99% yield) was obtained as a yellowish solid, using the procedure described in Example 4, step 4.vi. The compound was triturated in ether.
iH NMR (d6-DMSO) 8: 8.69 (d, J = 4.4 Hz, 1H); 8.27 (d, J = 9.0 Hz, 1H); 7.59 (d, J = 4.5 Hz, 1H); 7.52 (m, 2H); 7.32-7.23 (m, 2H); 7.22-7.10 (m, 1H); 6.62 (overlapped t, J
= 16.3 Hz, 1H); 6.53 (overlapped m, 1H); 4.5 8(m, 1H); 4.48 (d, J = 6.5 Hz, 1H); 4.26-4.09 (m, 1H);
4.04 (s, 3H); 3.91 (m, 1H); 3.72 (m, 1H); 3.53 (m, 2H); 3.40-3.29 (m, 4H);
2.92 (m, 1H);
2.76 (m, 1H); 1.96 (m, 1H); 1.82-1.68 (m, 4H); 1.62-1.37 (m, 3H).
MS (ESI, m/z): 514.0 [M+H+].
Example 7: (1RS)-2-{(2S,5R,6S)-5-[trans-3-(2,5-ditluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl}-1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol:
7.i. (2R, 3S, 6R)-6-allyl-2-(tert-butyl-diphenyl-silanyloxymethyl)-3, 6-dihydro-2H-pyran-3-ol:
To an ice-chilled solution of (2R,3S,6R)-6-allyl-2-hydroxymethyl-3,6-dihydro-2H-pyran-3-ol (obtained as described in Eur. J. Org. Chem. (2003), 2418-2427; 31.55 g, 185.4 mmol) in DCM (650 ml) was added imidazole (24.96 g, 2 eq.). A solution of tert-butylchlorodiphenylsilane (50.45 g, 210.7 mmol) in DCM (130 ml) was added dropwise over 90 min. After 2 h, aq. sat. NaHCO3 (250 ml) was added. The two layers were separated and the org. layer was washed twice with brine, dried over MgS04, filtered and concentrated to dryness. The residue was chromatographed over Si0z (Hex-EA 5-1) to afford the title compound as a yellow oil (51.52 g, 68% yield).
iH NMR (CDC13) 8: 7.74-7.68 (m, 4H); 7.47-7.38 (6H); 5.87-5.76 (m, 3H); 5.10-5.04 (m, 2H); 4.19-4.15 (m, 2H); 3.89 (dd, J = 5.3, 10.0 Hz, 1H); 3.79 (dd, J = 7.3, 10.0 Hz, 1H);
3.68 (m, 1H); 2.70 (br s, 1H); 2.38 (m, 1H); 2.28 (m, 1H); 1.09 (s, 9H).
7.ii. (2RS)-3-[(2R, 5S, 6R)-6-(tert-butyl-diphenyl-silanyloxymethyl)-5-hydroxy-5, 6-dihydro-2H pyran-2 ylJ propane-1,2-diol:
To a solution of intermediate 7.i (51.52 g, 126.1 mmol) in 2-methyl-2-propanol (560 ml), EA
(15 ml) and water (560 ml), were added potassium ferricyanide (189.48 g, 3 eq.), K2C03 (67.10 g, 3 eq.), (DHQD)2PHAL (1.5121 g, 0.015 eq.) and potassium osmate dihydrate (0.1907 g, 0.004 eq.). The reaction mixture was stirred two days and sodium bisulfite (150.92 g) was added. The two layers were decanted and the aq. layer was extracted twice with EA (2 x 350 ml). The combined org. layers were washed with brine (500 ml), dried over MgSO4, filtered and concentrated to dryness. The residue was filtered over Si02 (Hex-EA
1-1, then EA) to afford the title product as a yellow oil (36.33 g, 65%
yield). The compound was obtained as a 2-1 mixture of epimers.
iH NMR (d6-DMSO) 8: 7.71-7.65 (m, 4H); 7.47-7.40 (m, 6H); 5.80-5.65 (m, 2H);
4.95 (m, 1H); 4.50-4.35 (m, 3H); 3.92- 3.28 (m, 7H); 1.80-1.65 (m, 1.33H);
1.17 (m, 0.67H);
0.99 (s, 9H).
7.iii. (2R,3S,6R)-2-(tert-butyl-diphenyl-silanyloxymethyl)-6-((4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-3,6-dihydro-2H-pyran-3-ol:
To a solution of intermediate 7.ii (34.83 g, 78.7 mmol) in DCM (575 ml) were added at rt PTSA (0.90 g, 4.7 mmol) and 2,2-dimethoxypropane (24 ml, 195.2 mmol). After 2h., water (100 mL) and saturated NaHCO3 (200 ml) were added and the two phases were separated.
The aq. layer was extracted with DCM (260 ml). The combined org. layers were washed with brine, dried over MgSO4, filtered and concentrated to dryness. The residue was chromatographed over Si02 (Hex-EA 1-1) to afford the title compound as a yellow oil (36.19 g, 74.9 mmol). The compound was obtained as a 2-1 mixture of epimers.
'H NMR (CDC13) 8: 7.72-7.67 (m, 4H); 7.50-7.39 (m, 6H); 5.85-5.77 (m, 2H);
4.23-3.41 (m, 8H); 2.80 (br s, 1H); 2.06 (m, 0.33H); 1.80-1.65 (1.67H); 1.40 (s, 3H); 1.33 (s, 3H);
1.09 (s, 9H).
7.iv. (2R,3S,6R)-2-(tert-butyl-diphenyl-silanyloxymethyl)-6-((4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-tetrahydro pyran-3-ol:
To a solution of intermediate 7.iii (36.16 g, 74.9 mmol) in EA (600 ml) was added platinum oxide hydrate (1.l g, 4.8 mmol). The reaction mixture was stirred under hydrogen for 2 h. The catalyst was removed by filtration and the filtrate was concentrated to dryness to yield the title alcohol (36.18 g, 99% yield) as a thick oil. The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 485.2 [M+H+].
Starting from intermediate 6.vii (0.252 g, 0.41 mmol), the title acid (0.24 g, 99% yield) was obtained as a yellowish solid, using the procedure described in Example 4, step 4.vi. The compound was triturated in ether.
iH NMR (d6-DMSO) 8: 8.69 (d, J = 4.4 Hz, 1H); 8.27 (d, J = 9.0 Hz, 1H); 7.59 (d, J = 4.5 Hz, 1H); 7.52 (m, 2H); 7.32-7.23 (m, 2H); 7.22-7.10 (m, 1H); 6.62 (overlapped t, J
= 16.3 Hz, 1H); 6.53 (overlapped m, 1H); 4.5 8(m, 1H); 4.48 (d, J = 6.5 Hz, 1H); 4.26-4.09 (m, 1H);
4.04 (s, 3H); 3.91 (m, 1H); 3.72 (m, 1H); 3.53 (m, 2H); 3.40-3.29 (m, 4H);
2.92 (m, 1H);
2.76 (m, 1H); 1.96 (m, 1H); 1.82-1.68 (m, 4H); 1.62-1.37 (m, 3H).
MS (ESI, m/z): 514.0 [M+H+].
Example 7: (1RS)-2-{(2S,5R,6S)-5-[trans-3-(2,5-ditluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl}-1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol:
7.i. (2R, 3S, 6R)-6-allyl-2-(tert-butyl-diphenyl-silanyloxymethyl)-3, 6-dihydro-2H-pyran-3-ol:
To an ice-chilled solution of (2R,3S,6R)-6-allyl-2-hydroxymethyl-3,6-dihydro-2H-pyran-3-ol (obtained as described in Eur. J. Org. Chem. (2003), 2418-2427; 31.55 g, 185.4 mmol) in DCM (650 ml) was added imidazole (24.96 g, 2 eq.). A solution of tert-butylchlorodiphenylsilane (50.45 g, 210.7 mmol) in DCM (130 ml) was added dropwise over 90 min. After 2 h, aq. sat. NaHCO3 (250 ml) was added. The two layers were separated and the org. layer was washed twice with brine, dried over MgS04, filtered and concentrated to dryness. The residue was chromatographed over Si0z (Hex-EA 5-1) to afford the title compound as a yellow oil (51.52 g, 68% yield).
iH NMR (CDC13) 8: 7.74-7.68 (m, 4H); 7.47-7.38 (6H); 5.87-5.76 (m, 3H); 5.10-5.04 (m, 2H); 4.19-4.15 (m, 2H); 3.89 (dd, J = 5.3, 10.0 Hz, 1H); 3.79 (dd, J = 7.3, 10.0 Hz, 1H);
3.68 (m, 1H); 2.70 (br s, 1H); 2.38 (m, 1H); 2.28 (m, 1H); 1.09 (s, 9H).
7.ii. (2RS)-3-[(2R, 5S, 6R)-6-(tert-butyl-diphenyl-silanyloxymethyl)-5-hydroxy-5, 6-dihydro-2H pyran-2 ylJ propane-1,2-diol:
To a solution of intermediate 7.i (51.52 g, 126.1 mmol) in 2-methyl-2-propanol (560 ml), EA
(15 ml) and water (560 ml), were added potassium ferricyanide (189.48 g, 3 eq.), K2C03 (67.10 g, 3 eq.), (DHQD)2PHAL (1.5121 g, 0.015 eq.) and potassium osmate dihydrate (0.1907 g, 0.004 eq.). The reaction mixture was stirred two days and sodium bisulfite (150.92 g) was added. The two layers were decanted and the aq. layer was extracted twice with EA (2 x 350 ml). The combined org. layers were washed with brine (500 ml), dried over MgSO4, filtered and concentrated to dryness. The residue was filtered over Si02 (Hex-EA
1-1, then EA) to afford the title product as a yellow oil (36.33 g, 65%
yield). The compound was obtained as a 2-1 mixture of epimers.
iH NMR (d6-DMSO) 8: 7.71-7.65 (m, 4H); 7.47-7.40 (m, 6H); 5.80-5.65 (m, 2H);
4.95 (m, 1H); 4.50-4.35 (m, 3H); 3.92- 3.28 (m, 7H); 1.80-1.65 (m, 1.33H);
1.17 (m, 0.67H);
0.99 (s, 9H).
7.iii. (2R,3S,6R)-2-(tert-butyl-diphenyl-silanyloxymethyl)-6-((4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-3,6-dihydro-2H-pyran-3-ol:
To a solution of intermediate 7.ii (34.83 g, 78.7 mmol) in DCM (575 ml) were added at rt PTSA (0.90 g, 4.7 mmol) and 2,2-dimethoxypropane (24 ml, 195.2 mmol). After 2h., water (100 mL) and saturated NaHCO3 (200 ml) were added and the two phases were separated.
The aq. layer was extracted with DCM (260 ml). The combined org. layers were washed with brine, dried over MgSO4, filtered and concentrated to dryness. The residue was chromatographed over Si02 (Hex-EA 1-1) to afford the title compound as a yellow oil (36.19 g, 74.9 mmol). The compound was obtained as a 2-1 mixture of epimers.
'H NMR (CDC13) 8: 7.72-7.67 (m, 4H); 7.50-7.39 (m, 6H); 5.85-5.77 (m, 2H);
4.23-3.41 (m, 8H); 2.80 (br s, 1H); 2.06 (m, 0.33H); 1.80-1.65 (1.67H); 1.40 (s, 3H); 1.33 (s, 3H);
1.09 (s, 9H).
7.iv. (2R,3S,6R)-2-(tert-butyl-diphenyl-silanyloxymethyl)-6-((4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-tetrahydro pyran-3-ol:
To a solution of intermediate 7.iii (36.16 g, 74.9 mmol) in EA (600 ml) was added platinum oxide hydrate (1.l g, 4.8 mmol). The reaction mixture was stirred under hydrogen for 2 h. The catalyst was removed by filtration and the filtrate was concentrated to dryness to yield the title alcohol (36.18 g, 99% yield) as a thick oil. The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 485.2 [M+H+].
7.v. (2R,6S)-2-(tert-butyl-diphenyl-silanyloxymethyl)-6-((4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-dihydro pyran-3-one:
To a solution of intermediate 7.iv (12 g, 24.75 mmol) in DCM (100 ml) was added a solution of Dess-Martin periodinane (15 wt% in DCM, 50 ml). The mixture was stirred at rt for 4 h.
The reaction mixture was diluted with DCM (30 ml) and washed with sat. NaHCO3 (30 ml).
The org. layer was dried over Na2SO4, filtered and concentrated to dryness.
The residue was chromatographed (Hex-EA 3-1) to afford the title compound (10.9 g, 91% yield) as a colourless oil. The compound was obtained as a 2-1 mixture of epimers.
iH NMR (CDC13) 8: 7.72-7.61 (m, 4H); 7.46-7.38 (m, 6H); 4.55 (m, 1H); 4.32 (m, 1H);
4.13-3.90 (m, 7H); 3.59 (m, 1H); 2.65-2.59 (m, 2H); 2.2-2.05 (m, 1.33H); 1.91-1.71 (m, 2.66H); 1.42 (s, 3H); 1.38 (s, 2H); 1.36 (s, 1H); 1.05 (s, 9H).
7.vi. (2S, 3RS, 6S)-benzyl-[2-(tert-butyl-diphenyl-silanyloxymethyl)-6-((4RS)2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-tetrahydro pyran-3 ylJ-amine:
To a solution of intermediate 7.v (10.9 g, 22.58 mmol) in 1,2-DCE (60 ml) were added benzylamine (2.5 ml, 1 eq.) and sodium triacetoxyborohydride (6.7 g, 1.4 eq.).
The mixture was stirred overnight at rt. Saturated NaHCO3 (200 ml) was added. The two layers were decanted and the org. layer was dried over NazSO4, filtered and concentrated to dryness. The residue was chromatographed over Si0z (Hex-EA 3-1) to afford the title compound (9.7 g, 74% yield) as a yellowish oil. The compound was obtained as a mixture of four isomers.
MS (ESI, m/z): 574.8 [M+H+].
7.vii. (2S, 3RS, 6S)-2-(tert-butyl-diphenyl-silanyloxymethyl)-6-((4RS)2, 2-dimethyl-[1,3]dioxolan-4 ylmethyl)-tetrahydro pyran-3 ylamine:
To a solution of intermediate 7.vi (9.7 g, 16.9 mmol) in EtOH (190 ml) was added AcOH
(l.l ml) and 10% Pd/C (4 g). The reaction mixture was then stirred under hydrogen atmosphere for 8 h. The reaction mixture was filtered and the catalyst was washed with EtOH
and water. After concentration, the residue was diluted with sat. NaHCO3 (100 ml) and then extracted with EA (2 x 250 mL). The combined org. extracts were washed with brine, dried over NazSO4, filtered and concentrated to dryness. The residue was chromatographed over Si0z (DCM-MeOH 97-3 containing 1% aq. NH4OH) to afford the title amine (5.5 g, 67%
yield) as a colourless oil.
MS (ESI, m/z): 484.1 [M+H+].
To a solution of intermediate 7.iv (12 g, 24.75 mmol) in DCM (100 ml) was added a solution of Dess-Martin periodinane (15 wt% in DCM, 50 ml). The mixture was stirred at rt for 4 h.
The reaction mixture was diluted with DCM (30 ml) and washed with sat. NaHCO3 (30 ml).
The org. layer was dried over Na2SO4, filtered and concentrated to dryness.
The residue was chromatographed (Hex-EA 3-1) to afford the title compound (10.9 g, 91% yield) as a colourless oil. The compound was obtained as a 2-1 mixture of epimers.
iH NMR (CDC13) 8: 7.72-7.61 (m, 4H); 7.46-7.38 (m, 6H); 4.55 (m, 1H); 4.32 (m, 1H);
4.13-3.90 (m, 7H); 3.59 (m, 1H); 2.65-2.59 (m, 2H); 2.2-2.05 (m, 1.33H); 1.91-1.71 (m, 2.66H); 1.42 (s, 3H); 1.38 (s, 2H); 1.36 (s, 1H); 1.05 (s, 9H).
7.vi. (2S, 3RS, 6S)-benzyl-[2-(tert-butyl-diphenyl-silanyloxymethyl)-6-((4RS)2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-tetrahydro pyran-3 ylJ-amine:
To a solution of intermediate 7.v (10.9 g, 22.58 mmol) in 1,2-DCE (60 ml) were added benzylamine (2.5 ml, 1 eq.) and sodium triacetoxyborohydride (6.7 g, 1.4 eq.).
The mixture was stirred overnight at rt. Saturated NaHCO3 (200 ml) was added. The two layers were decanted and the org. layer was dried over NazSO4, filtered and concentrated to dryness. The residue was chromatographed over Si0z (Hex-EA 3-1) to afford the title compound (9.7 g, 74% yield) as a yellowish oil. The compound was obtained as a mixture of four isomers.
MS (ESI, m/z): 574.8 [M+H+].
7.vii. (2S, 3RS, 6S)-2-(tert-butyl-diphenyl-silanyloxymethyl)-6-((4RS)2, 2-dimethyl-[1,3]dioxolan-4 ylmethyl)-tetrahydro pyran-3 ylamine:
To a solution of intermediate 7.vi (9.7 g, 16.9 mmol) in EtOH (190 ml) was added AcOH
(l.l ml) and 10% Pd/C (4 g). The reaction mixture was then stirred under hydrogen atmosphere for 8 h. The reaction mixture was filtered and the catalyst was washed with EtOH
and water. After concentration, the residue was diluted with sat. NaHCO3 (100 ml) and then extracted with EA (2 x 250 mL). The combined org. extracts were washed with brine, dried over NazSO4, filtered and concentrated to dryness. The residue was chromatographed over Si0z (DCM-MeOH 97-3 containing 1% aq. NH4OH) to afford the title amine (5.5 g, 67%
yield) as a colourless oil.
MS (ESI, m/z): 484.1 [M+H+].
7.viii. (2S,3R,6S)-[2-(tert-butyl-diphenyl-silanyloxymethyl)-6-((4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-tetrahydro pyran-3 ylJ-carbamic acid tert-butyl ester:
To a solution of intermediate 7.vii (5.5 g, 11.37 mmol) in DCM (65 ml) were added Boc2O
(3.0 g, 1.2 eq.) and TEA (3.2 mL, 2.0 eq.). The reaction mixture was stirred overnight at rt.
After concentration to dryness, the residue was chromatographed over Si02 (Hex-Toluene-DCM-EA 13-3-1-3) to afford first the (2S,3S,6S)-isomer (1.98 g, 29% yield) as a 2-1 mixture of epimers, and then the desired isomer (4.0 g, 60% yield) as a 2-1 mixture of epimers.
iH NMR (CDC13) 8: 7.71-7.67 (m, 4H); 7.48-7.38 (m, 6H); 5.39 (d, J = 7.5 Hz, 1H);
4.18-3.43 (m, 8H); 2.12 (m, 0.33H); 1.89-1.49 (m, 5.67H); 1.43 (s, 9H); 1.37 (s, 3H); 1.31 (s, 1H); 1.28 (s, 2H); 1.07 (s, 9H).
7.ix. [(2S, 3R, 6S)-2-(tert-butyl-diphenyl-silanyloxymethyl)-6-((2RS)-2, 3-dihydroxy propyl)-tetrahydro pyran-3 ylJ-carbamic acid tert-butyl ester:
A solution of intermediate 7.viii (4.0 g, 6.85 mmol) in AcOH (30 ml), water (10 ml) and THF
(10 ml) was heated at 50 C for 3 h. The reaction mixture was concentrated to dryness and the residue was partitioned between sat. NaHCO3 (40 ml) and EA (100 ml). The org.
layer was dried over Na2SO4, filtered and concentrated to dryness. The residue was chromatographed over Si02 (Hex-EA 1-3) to afford the title diol (3.38 g, 90% yield) as a colourless oil.
MS (ESI, m/z): 544.2 [M+H+].
7.x. [(2S,3R,6S)-2-(tert-butyl-diphenyl-silanyloxymethyl)-6-(2-oxo-ethyl)-tetrahydro pyran-3 ylJ-carbamic acid tert-butyl ester:
To a solution of intermediate 7.ix (1.5 g, 2.75 mmol) in acetone (30 ml) was added at rt a solution of Na104 (1.5 g, 2.5 eq.) in water (10 ml). The reaction was stirred 40 min, the solids were filtered off and the filtrate was concentrated in vacuo. The residue was partitioned between water (50 ml) and EA (100 ml). The aq. layer was extracted once with EA (100 ml) and the combined extracts were washed with brine, dried over NazSO4, filtered and concentrated to dryness. The residue was chromatographed over Si0z (Hex-EA 2-1) to afford the title aldehyde (1.3 g) as a colourless foam.
iH NMR (CDC13) 8: 9.74 (t, J = 1.9 Hz, 1H); 7.69-7.66 (m, 4H); 7.49-7.39 (m, 6H); 5.45 (d, J = 6.75 Hz, 1H); 4.26 (m, 1H); 3.96-3.61 (m, 4H); 2.68 (m, 1H); 2.44 (ddd, J
= 1.8, 5.4, 16.3 Hz, 1H); 1.92-1.78 (m, 3H); 1.44 (s, 9H); 1.43 (m, 1H); 1.07 (s, 9H).
To a solution of intermediate 7.vii (5.5 g, 11.37 mmol) in DCM (65 ml) were added Boc2O
(3.0 g, 1.2 eq.) and TEA (3.2 mL, 2.0 eq.). The reaction mixture was stirred overnight at rt.
After concentration to dryness, the residue was chromatographed over Si02 (Hex-Toluene-DCM-EA 13-3-1-3) to afford first the (2S,3S,6S)-isomer (1.98 g, 29% yield) as a 2-1 mixture of epimers, and then the desired isomer (4.0 g, 60% yield) as a 2-1 mixture of epimers.
iH NMR (CDC13) 8: 7.71-7.67 (m, 4H); 7.48-7.38 (m, 6H); 5.39 (d, J = 7.5 Hz, 1H);
4.18-3.43 (m, 8H); 2.12 (m, 0.33H); 1.89-1.49 (m, 5.67H); 1.43 (s, 9H); 1.37 (s, 3H); 1.31 (s, 1H); 1.28 (s, 2H); 1.07 (s, 9H).
7.ix. [(2S, 3R, 6S)-2-(tert-butyl-diphenyl-silanyloxymethyl)-6-((2RS)-2, 3-dihydroxy propyl)-tetrahydro pyran-3 ylJ-carbamic acid tert-butyl ester:
A solution of intermediate 7.viii (4.0 g, 6.85 mmol) in AcOH (30 ml), water (10 ml) and THF
(10 ml) was heated at 50 C for 3 h. The reaction mixture was concentrated to dryness and the residue was partitioned between sat. NaHCO3 (40 ml) and EA (100 ml). The org.
layer was dried over Na2SO4, filtered and concentrated to dryness. The residue was chromatographed over Si02 (Hex-EA 1-3) to afford the title diol (3.38 g, 90% yield) as a colourless oil.
MS (ESI, m/z): 544.2 [M+H+].
7.x. [(2S,3R,6S)-2-(tert-butyl-diphenyl-silanyloxymethyl)-6-(2-oxo-ethyl)-tetrahydro pyran-3 ylJ-carbamic acid tert-butyl ester:
To a solution of intermediate 7.ix (1.5 g, 2.75 mmol) in acetone (30 ml) was added at rt a solution of Na104 (1.5 g, 2.5 eq.) in water (10 ml). The reaction was stirred 40 min, the solids were filtered off and the filtrate was concentrated in vacuo. The residue was partitioned between water (50 ml) and EA (100 ml). The aq. layer was extracted once with EA (100 ml) and the combined extracts were washed with brine, dried over NazSO4, filtered and concentrated to dryness. The residue was chromatographed over Si0z (Hex-EA 2-1) to afford the title aldehyde (1.3 g) as a colourless foam.
iH NMR (CDC13) 8: 9.74 (t, J = 1.9 Hz, 1H); 7.69-7.66 (m, 4H); 7.49-7.39 (m, 6H); 5.45 (d, J = 6.75 Hz, 1H); 4.26 (m, 1H); 3.96-3.61 (m, 4H); 2.68 (m, 1H); 2.44 (ddd, J
= 1.8, 5.4, 16.3 Hz, 1H); 1.92-1.78 (m, 3H); 1.44 (s, 9H); 1.43 (m, 1H); 1.07 (s, 9H).
7.xi. {(2S, 3R, 6S)-2-(tert-butyl-diphenyl-silanyloxymethyl)-6-[(2RS)-2-(3 fluoro-6-methoxy-quinolin-4 yl)-2-hydroxy-ethylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
To a solution of DIPA (0.9 ml, 2.5 eq.) in THF (17 ml) was added at -78 C, n-BuLi (2.5N in hexanes, 2.5 ml). The mixture was stirred 5 min at this temperature before warming to 0 C.
After 15 min, the solution was cooled to -78 C and a solution of 3-fluoro-6-methoxy-quinoline (prepared as described in WO 2005/049575; 1.12 g, 2.5 eq.) in THF (5 ml) was added. The reaction proceeded for 4 h. A solution of intermediate 7.x (1.3 g, 2.54 mmol) in THF (5 ml) was added dropwise and the reaction proceeded for 10 min before quick warming to rt. The reaction was further stirred for 20 min and was quenched with 10%
aq. NaHSO4 (30 ml). The org. layer was diluted with EA (100 ml). The two layers were decanted and the aq. layer was extracted twice with EA. The combined org. layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was chromatographed over Si02 (Hex-EA 2- then 1-1) to afford the title compound (0.98 g, 56%
yield) as a colourless foam. The compound was obtained as a 1-1 mixture of epimers.
MS (ESI, m/z): 689.0 [M+H+].
7.xii. {(2S, 3R, 6S)-6-[(2RS)-2-(3 fluoro-6-methoxy-quinolin-4 yl)-2-hydroxy-ethylJ-2-hydroxymethyl-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
To a solution of intermediate 7.xi (0.98 g, 1.42 mmol) in THF (5 ml) was added TBAF (1M in THF, 2.2 ml). The reaction proceeded at rt for 1 h. After concentration to dryness, the residue was chromatographed on Si0z (EA-Hex 3-1) to afford the title compound (0.57 g, 89% yield) as a colourless foam. The compound was obtained as a 1-1 mixture of isomers.
MS (ESI, m/z): 451.0 [M+H+].
7.xiii. (IRS)-2-((2S,5R,6S)-5-amino-6-hydroxymethyl-tetrahydro pyran-2 yl)-1-(3 fluoro-6-methoxy-quinolin-4 yl)-ethanol:
To a solution of intermediate 7.xii (0.57 g, 1.26 mmol) in dioxane (3 ml) was added HC1 in dioxane (5N, 3 ml). The mixture was stirred at rt for 3 h. The solvent was removed in vacuo and the residue was dissolved in water (5 ml). The pH was adjusted to 7 adding K2C03. Water was evaporated and the residue chromatographed on Si0z (DCM-MeOH 6-1 1% aq.
NH4OH) to afford the title amine (0.4 g, 90% yield) as a colourless foam. The compound was obtained as a 1-1 mixture of isomers.
MS (ESI, m/z): 351.0 [M+H+].
To a solution of DIPA (0.9 ml, 2.5 eq.) in THF (17 ml) was added at -78 C, n-BuLi (2.5N in hexanes, 2.5 ml). The mixture was stirred 5 min at this temperature before warming to 0 C.
After 15 min, the solution was cooled to -78 C and a solution of 3-fluoro-6-methoxy-quinoline (prepared as described in WO 2005/049575; 1.12 g, 2.5 eq.) in THF (5 ml) was added. The reaction proceeded for 4 h. A solution of intermediate 7.x (1.3 g, 2.54 mmol) in THF (5 ml) was added dropwise and the reaction proceeded for 10 min before quick warming to rt. The reaction was further stirred for 20 min and was quenched with 10%
aq. NaHSO4 (30 ml). The org. layer was diluted with EA (100 ml). The two layers were decanted and the aq. layer was extracted twice with EA. The combined org. layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was chromatographed over Si02 (Hex-EA 2- then 1-1) to afford the title compound (0.98 g, 56%
yield) as a colourless foam. The compound was obtained as a 1-1 mixture of epimers.
MS (ESI, m/z): 689.0 [M+H+].
7.xii. {(2S, 3R, 6S)-6-[(2RS)-2-(3 fluoro-6-methoxy-quinolin-4 yl)-2-hydroxy-ethylJ-2-hydroxymethyl-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
To a solution of intermediate 7.xi (0.98 g, 1.42 mmol) in THF (5 ml) was added TBAF (1M in THF, 2.2 ml). The reaction proceeded at rt for 1 h. After concentration to dryness, the residue was chromatographed on Si0z (EA-Hex 3-1) to afford the title compound (0.57 g, 89% yield) as a colourless foam. The compound was obtained as a 1-1 mixture of isomers.
MS (ESI, m/z): 451.0 [M+H+].
7.xiii. (IRS)-2-((2S,5R,6S)-5-amino-6-hydroxymethyl-tetrahydro pyran-2 yl)-1-(3 fluoro-6-methoxy-quinolin-4 yl)-ethanol:
To a solution of intermediate 7.xii (0.57 g, 1.26 mmol) in dioxane (3 ml) was added HC1 in dioxane (5N, 3 ml). The mixture was stirred at rt for 3 h. The solvent was removed in vacuo and the residue was dissolved in water (5 ml). The pH was adjusted to 7 adding K2C03. Water was evaporated and the residue chromatographed on Si0z (DCM-MeOH 6-1 1% aq.
NH4OH) to afford the title amine (0.4 g, 90% yield) as a colourless foam. The compound was obtained as a 1-1 mixture of isomers.
MS (ESI, m/z): 351.0 [M+H+].
7.xiv. (IRS)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro phenyl)-allylamino]-6-hydroxymethyl-tetrahydro pyran-2 yl}-1-(3 fluoro-6-methoxy-quinolin-4 yl)-ethanol:
Starting from intermediate 7.xiii (0.1 g, 0.285 mmol) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.053 g, l.l eq), the title compound (0.135 g, 94% yield) was obtained as a colourless foam using the procedure of Example 1, step l.x. The compound was purified by chromatography over Si0z (DCM-MeOH 93-7 containing 1% aq. NH4OH). The compound was obtained as a 1-1 mixture of isomers.
MS (ESI, m/z): 503.2 [M+H+].
Example 8: 2-{(2R,3R,6R)-3-[(E)-3-(2,5-ditluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide dihydrochloride:
8.i. [(E)-3-(2,5-difluoro phenyl)-allylJ-{(2R,3R,6R)-2-hydroxycarbamoylmethyl-6-[2-(6-methoxy-[1,5]naphthyridin-4 yl)-ethylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester and {(2R,3R,6R)-2-carbamoylmethyl-6-[2-(6-methoxy-[1,5]naphthyridin-4 yl)-ethylJ-tetrahydro pyran-3 yl}-[(E)-3-(2,5-difluoro phenyl)-allylJ-carbamic acid tert-butyl ester:
To a solution of intermediate 5.v (0.11 g, 0.19 mmol) in DMF (2.3 ml) were added DIPEA
(0.16 ml, 0.93 mmol) and HATU (0.11 g, 0.28 mmol). The resulting solution was stirred at rt for 30 min. Hydroxylamine hydrochloride (0.019 g, 0.28 mmol) was added. After stirring at rt overnight, hydroxylamine hydrochloride (0.019 g, 0.28 mmol) was added and the reaction was further stirred at rt for 24 h. The reaction mixture was concentrated to dryness. The residue was partitioned between water and DCM-MeOH 9-1 and the phases were separated.
The aq. layer was extracted five times with DCM-MeOH. The combined org. layers were dried over NazSO4, filtered and the filtrate was evaporated under reduced pressure. The residue was purified by column chromatography over Si0z (DCM-MeOH 9-1 containing 1%
aq. NH4OH) to afford the title amide as a yellow oil (0.032 g, 29% yield) and then the title hydroxamic acid (0.045 g, 40% yield).
Amide : MS (ESI, m/z): 597.0 [M+H+].
Hydroxamic acid: MS (ESI, m/z): 613.0 [M+H+].
Starting from intermediate 7.xiii (0.1 g, 0.285 mmol) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.053 g, l.l eq), the title compound (0.135 g, 94% yield) was obtained as a colourless foam using the procedure of Example 1, step l.x. The compound was purified by chromatography over Si0z (DCM-MeOH 93-7 containing 1% aq. NH4OH). The compound was obtained as a 1-1 mixture of isomers.
MS (ESI, m/z): 503.2 [M+H+].
Example 8: 2-{(2R,3R,6R)-3-[(E)-3-(2,5-ditluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide dihydrochloride:
8.i. [(E)-3-(2,5-difluoro phenyl)-allylJ-{(2R,3R,6R)-2-hydroxycarbamoylmethyl-6-[2-(6-methoxy-[1,5]naphthyridin-4 yl)-ethylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester and {(2R,3R,6R)-2-carbamoylmethyl-6-[2-(6-methoxy-[1,5]naphthyridin-4 yl)-ethylJ-tetrahydro pyran-3 yl}-[(E)-3-(2,5-difluoro phenyl)-allylJ-carbamic acid tert-butyl ester:
To a solution of intermediate 5.v (0.11 g, 0.19 mmol) in DMF (2.3 ml) were added DIPEA
(0.16 ml, 0.93 mmol) and HATU (0.11 g, 0.28 mmol). The resulting solution was stirred at rt for 30 min. Hydroxylamine hydrochloride (0.019 g, 0.28 mmol) was added. After stirring at rt overnight, hydroxylamine hydrochloride (0.019 g, 0.28 mmol) was added and the reaction was further stirred at rt for 24 h. The reaction mixture was concentrated to dryness. The residue was partitioned between water and DCM-MeOH 9-1 and the phases were separated.
The aq. layer was extracted five times with DCM-MeOH. The combined org. layers were dried over NazSO4, filtered and the filtrate was evaporated under reduced pressure. The residue was purified by column chromatography over Si0z (DCM-MeOH 9-1 containing 1%
aq. NH4OH) to afford the title amide as a yellow oil (0.032 g, 29% yield) and then the title hydroxamic acid (0.045 g, 40% yield).
Amide : MS (ESI, m/z): 597.0 [M+H+].
Hydroxamic acid: MS (ESI, m/z): 613.0 [M+H+].
8.ii. 2-{(2R, 3R, 6R)-3-[(E)-3-(2, 5-d fluoro phenyl)-allylaminoJ-6-[2-(6-methoxy-[1,5]naphthyridin-4 yl)-ethylJ-tetrahydro pyran-2 yl}-acetamide dihydrochloride:
Starting from {(2R,3R,6R)-2-carbamoylmethyl-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-[(E)-3-(2,5-difluoro-phenyl)-allyl]-carbamic acid tert-butyl ester (0.030 g, 0.049 mmol), the title compound (0.017 g, 60% yield) was obtained as a yellow solid using the procedure of Example 4, step 4.vi. The compound was purified by trituration in ether.
MS (ESI, m/z): 497.0 [M+H+].
Example 9: 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(IR,2R)-1,2-dihydroxy-2-(3-methoxy-quinoxalin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide:
9.i. {(2R, 3R, 6S)-2-((4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-6-[2-(3-methoxy-quinoxalin-S yl)-vinyl]-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
The Julia coupling was performed as in Example 1, step l.vi, starting from intermediate l.v (9.67 g, 18 mmol) and 3-methoxy-quinoxaline-5-carbaldehyde (see Preparation D;
3.38 g), affording the title compound as a yellowish foam (3.72 g, 41% yield). The compound was purified by column chromatography over Si0z (EA-Hex 1-1). The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 500.1 [M+H+].
9.ii. {(2R,3R,6S)-2-((2RS)-2,3-dihydroxy propyl)-6-[(E)-2-(3-methoxy-quinoxalin-S yl)-vinylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
A solution of intermediate 9.i (3.72 g) in AcOH (60 ml), water (20 ml) and THF
(20 ml) was heated at 60 C for 5 h. The reaction mixture was concentrated to dryness and the residue partitioned between EA (200 ml) and saturated NaHCO3 (200 ml). The pH of the aq. layer was adjusted to 8 by adding 1M aq. NaOH. The precipitate was then extracted twice with EA
(2 x 150 ml). The combined extracts were washed with brine, dried over NazSO4, filtered and concentrated to dryness. The residue was chromatographed over Si0z (EA-Hept 4-1) to afford the title compound (2.45 g) as a colourless foam. The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 460.1.1 [M+H+].
Starting from {(2R,3R,6R)-2-carbamoylmethyl-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-[(E)-3-(2,5-difluoro-phenyl)-allyl]-carbamic acid tert-butyl ester (0.030 g, 0.049 mmol), the title compound (0.017 g, 60% yield) was obtained as a yellow solid using the procedure of Example 4, step 4.vi. The compound was purified by trituration in ether.
MS (ESI, m/z): 497.0 [M+H+].
Example 9: 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(IR,2R)-1,2-dihydroxy-2-(3-methoxy-quinoxalin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide:
9.i. {(2R, 3R, 6S)-2-((4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-6-[2-(3-methoxy-quinoxalin-S yl)-vinyl]-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
The Julia coupling was performed as in Example 1, step l.vi, starting from intermediate l.v (9.67 g, 18 mmol) and 3-methoxy-quinoxaline-5-carbaldehyde (see Preparation D;
3.38 g), affording the title compound as a yellowish foam (3.72 g, 41% yield). The compound was purified by column chromatography over Si0z (EA-Hex 1-1). The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 500.1 [M+H+].
9.ii. {(2R,3R,6S)-2-((2RS)-2,3-dihydroxy propyl)-6-[(E)-2-(3-methoxy-quinoxalin-S yl)-vinylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
A solution of intermediate 9.i (3.72 g) in AcOH (60 ml), water (20 ml) and THF
(20 ml) was heated at 60 C for 5 h. The reaction mixture was concentrated to dryness and the residue partitioned between EA (200 ml) and saturated NaHCO3 (200 ml). The pH of the aq. layer was adjusted to 8 by adding 1M aq. NaOH. The precipitate was then extracted twice with EA
(2 x 150 ml). The combined extracts were washed with brine, dried over NazSO4, filtered and concentrated to dryness. The residue was chromatographed over Si0z (EA-Hept 4-1) to afford the title compound (2.45 g) as a colourless foam. The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 460.1.1 [M+H+].
9.iii. {(2R,3R,6S)-3-tert-butoxycarbonylamino-6-[(E)-2-(3-methoxy-quinoxalin-S
yl)-vinylJ-tetrahydro pyran-2 yl}-acetic acid:
Starting from intermediate 9.ii (2.45 g, 5.3 mmol), the title acid (0.65 g, 1.46 mmol) was obtained as a colourless foam using the procedure of Example 2, steps 2.v and 2.vi. The compound was purified by chromatography over Si0z using EA-Hex 1-2 as an eluent.
MS (ESI, m/z): 443.8 [M+H +].
9.iv. {(2R,3R,6S)-2-carbamoylmethyl-6-[(E)-2-(3-methoxy-quinoxalin-S yl)-vinylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
To a solution of intermediate 9.iii (0.65 g, 1.46 mmol) in THF (10 ml) were added at 0 C, TEA (0.265 ml) and i-butylchloroformate (0.24 g). The reaction was stirred 1 h at this temperature then aq. NH4OH (3 ml) was added. The reaction was vigorously stirred for 30 min. EA (50 ml) was added. The two layers were decanted and the aq. layer was extracted once with EA (50 ml). The combined org. layers were washed with brine, dried over NazSO4, filtered and concentrated to dryness. The residue was triturated (Hex) to afford the title amide (0.47 g) as a light beige solid of 75% purity.
MS (ESI, m/z): 442.8 [M+H +].
9.v. {2R,3R,6S)-2-carbamoylmethyl-6-[(IR2R)-1,2-dihydroxy-2-(3-methoxy-quinoxalin-S yl)-ethylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
The asymmetric dihydroxylation of intermediate 9.iv (0.47 g, 1.05 mmol) was performed using the procedure of Example 6, step 6.i to give the title diol (0.19 g, 38%
yield) as a colourless foam. The compound was purified by chromatography over Si0z using DCM-MeOH 9-1 as an eluent.
iH NMR (d6-DMSO) 8: 8.60 (s, 1H); 7.91-7.87 (m, 2H); 7.63 (dd, J = 7.3, 8.2 Hz, 1H);
7.39 (br s, 1H); 6.89 (br s, 1H); 6.82 (d, J = 8.8 Hz, 1H); 5.62 (d, J = 7.2 Hz, 1H); 5.11 (d, J = 7.2 Hz, 1H); 4.35 (d, J = 3.7 Hz, 1H); 4.06 (m, 1H); 4.03 (overlapped s, 3H);
4.02-3.92 (m, 2H); 3.57 (m, 1H); 2.39 (dd, J = 10.4, 15.9 Hz, 1H); 2.10-2.04 (m, 2H);
1.85 (m, 1H); 1.68-1.57 (m, 2H); 1.40 (s, 9H).
MS (ESI, m/z): 477.0 [M+H+].
yl)-vinylJ-tetrahydro pyran-2 yl}-acetic acid:
Starting from intermediate 9.ii (2.45 g, 5.3 mmol), the title acid (0.65 g, 1.46 mmol) was obtained as a colourless foam using the procedure of Example 2, steps 2.v and 2.vi. The compound was purified by chromatography over Si0z using EA-Hex 1-2 as an eluent.
MS (ESI, m/z): 443.8 [M+H +].
9.iv. {(2R,3R,6S)-2-carbamoylmethyl-6-[(E)-2-(3-methoxy-quinoxalin-S yl)-vinylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
To a solution of intermediate 9.iii (0.65 g, 1.46 mmol) in THF (10 ml) were added at 0 C, TEA (0.265 ml) and i-butylchloroformate (0.24 g). The reaction was stirred 1 h at this temperature then aq. NH4OH (3 ml) was added. The reaction was vigorously stirred for 30 min. EA (50 ml) was added. The two layers were decanted and the aq. layer was extracted once with EA (50 ml). The combined org. layers were washed with brine, dried over NazSO4, filtered and concentrated to dryness. The residue was triturated (Hex) to afford the title amide (0.47 g) as a light beige solid of 75% purity.
MS (ESI, m/z): 442.8 [M+H +].
9.v. {2R,3R,6S)-2-carbamoylmethyl-6-[(IR2R)-1,2-dihydroxy-2-(3-methoxy-quinoxalin-S yl)-ethylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
The asymmetric dihydroxylation of intermediate 9.iv (0.47 g, 1.05 mmol) was performed using the procedure of Example 6, step 6.i to give the title diol (0.19 g, 38%
yield) as a colourless foam. The compound was purified by chromatography over Si0z using DCM-MeOH 9-1 as an eluent.
iH NMR (d6-DMSO) 8: 8.60 (s, 1H); 7.91-7.87 (m, 2H); 7.63 (dd, J = 7.3, 8.2 Hz, 1H);
7.39 (br s, 1H); 6.89 (br s, 1H); 6.82 (d, J = 8.8 Hz, 1H); 5.62 (d, J = 7.2 Hz, 1H); 5.11 (d, J = 7.2 Hz, 1H); 4.35 (d, J = 3.7 Hz, 1H); 4.06 (m, 1H); 4.03 (overlapped s, 3H);
4.02-3.92 (m, 2H); 3.57 (m, 1H); 2.39 (dd, J = 10.4, 15.9 Hz, 1H); 2.10-2.04 (m, 2H);
1.85 (m, 1H); 1.68-1.57 (m, 2H); 1.40 (s, 9H).
MS (ESI, m/z): 477.0 [M+H+].
9.vi. 2-{2R,3R,6S)-3-amino-6-[(IR,2R)-1,2-dihydroxy-2-(3-methoxy-quinoxalin-S
yl)-ethylJtetrahydro pyran-2 yl}-acetamide:
The title amine (0.071 g, 47% yield) was obtained as a colourless foam starting from intermediate 9.v (0.19 g, 0.4 mmol) and using the procedure of Example 1, step l.ix.
MS (ESI, m/z): 377.2 [M+H+].
9.vii. 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro phenyl)-allylaminoJ-6-[(IR,2R)-1,2-dihydroxy-2-(3-methoxy-quinoxalin-S yl)-ethylJ-tetrahydro pyran-2 yl}-acetamide:
Starting from intermediate 9.vi (0.071 g, 0.285 mmol) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.031 g, 1.1 eq), the title compound (0.020 g, 20% yield and 75%
purity) was obtained as as a colorless foam according to the procedure described in Example 1, step l.x.
The compound was purified by chromatography over Si0z (DCM-MeOH 9-1 containing 1%
aq. NH4OH).
MS (ESI, m/z): 528.7 [M+H+].
Example 10: {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid dihydrochloride:
10.i. {(2R,3R,6R)-3-{tert-butoxycarbonyl-[(E)-3-(2,5-difluoro phenyl)-allylJ-amino}-6-[2-(6-methoxy-quinolin-4 yl)-ethyl]-tetrahydro pyran-2 yl}-acetic acid:
Starting from intermediate 1.v (5.68 g, 10.57 mmol) and 6-methoxy-quinoline-4-carbaldehyde (1.8 g, 9.6 mmol), the title compound (1.48 g, 2.41 mmol) was obtained as a colourless foam using successively the procedures of Example 1, step l.vi (Julia coupling, 46%
yield), Example 2, steps 2.ii (hydrogenation, 96% yield) and 2.iii (acetonide and Boc deprotection, 99% yield), Example 1, step l.x (reductive amination, 78% yield), Example 4, step 4.iii (Boc formation, 68% yield), and Example 2, steps 2.v (periodic cleavage, 95% yield) and 2.vi (acid formation, 99% yield).
MS (ESI, m/z): 581.1 [M+H+].
yl)-ethylJtetrahydro pyran-2 yl}-acetamide:
The title amine (0.071 g, 47% yield) was obtained as a colourless foam starting from intermediate 9.v (0.19 g, 0.4 mmol) and using the procedure of Example 1, step l.ix.
MS (ESI, m/z): 377.2 [M+H+].
9.vii. 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro phenyl)-allylaminoJ-6-[(IR,2R)-1,2-dihydroxy-2-(3-methoxy-quinoxalin-S yl)-ethylJ-tetrahydro pyran-2 yl}-acetamide:
Starting from intermediate 9.vi (0.071 g, 0.285 mmol) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.031 g, 1.1 eq), the title compound (0.020 g, 20% yield and 75%
purity) was obtained as as a colorless foam according to the procedure described in Example 1, step l.x.
The compound was purified by chromatography over Si0z (DCM-MeOH 9-1 containing 1%
aq. NH4OH).
MS (ESI, m/z): 528.7 [M+H+].
Example 10: {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid dihydrochloride:
10.i. {(2R,3R,6R)-3-{tert-butoxycarbonyl-[(E)-3-(2,5-difluoro phenyl)-allylJ-amino}-6-[2-(6-methoxy-quinolin-4 yl)-ethyl]-tetrahydro pyran-2 yl}-acetic acid:
Starting from intermediate 1.v (5.68 g, 10.57 mmol) and 6-methoxy-quinoline-4-carbaldehyde (1.8 g, 9.6 mmol), the title compound (1.48 g, 2.41 mmol) was obtained as a colourless foam using successively the procedures of Example 1, step l.vi (Julia coupling, 46%
yield), Example 2, steps 2.ii (hydrogenation, 96% yield) and 2.iii (acetonide and Boc deprotection, 99% yield), Example 1, step l.x (reductive amination, 78% yield), Example 4, step 4.iii (Boc formation, 68% yield), and Example 2, steps 2.v (periodic cleavage, 95% yield) and 2.vi (acid formation, 99% yield).
MS (ESI, m/z): 581.1 [M+H+].
10.ii. {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro phenyl)-allylaminoJ-6-[2-(6-methoxy-quinolin-4 yl)-ethylJ-tetrahydro pyran-2 yl}-acetic acid dihydrochloride:
Starting from intermediate 10.i (0.283 g, 0.475 mmol), the title acid (0.267 g, 96% yield) was obtained as a beige solid using the procedure of Example 4, step 4.vi. The compound was purified by trituration in ether.
MS (ESI, m/z): 497.0 [M+H +].
Example 11: 2-{(2R,3R,6R)-3-[(E)-3-(2,5-ditluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide dihydrochloride:
ll.i. {(2R,3R,6R)-2-carbamoylmethyl-6-[2-(6-methoxy-quinolin-4 yl)-ethyl]-tetrahydro-pyran-3 yl}-[(E)-3-(2,5-difluoro phenyl)-allylJ-carbamic acid tert-butyl ester:
Starting from intermediate 10.i (1.15 g, 1.93 mmol), the title acetamide (0.506 g, 44% yield) was obtained as an off-white foam using the procedure of Example 9, step 9.iv.
The compound was purified by chromatography over Si0z, using DCM-MeOH 19-1 containing 0.5% aq. NH4OH as an eluent.
MS (ESI, m/z): 596.0 [M+H +].
11.ii. 2-{(2R, 3R, 6R)-3-[(E)-3-(2, 5-difluoro phenyl)-allylaminoJ-6-[2-(6-methoxy-quinolin-4 yl)-ethylJ-tetrahydro pyran-2 yl}-acetamide:
Starting from intermediate 11.i (0.045 g, 0.076 mmol), the title compound (0.034 g, 80%
yield) was obtained as a yellowish solid, using the procedure of Example 4, step 4.vi. The compound was purified by trituration in ether.
MS (ESI, m/z): 496.0 [M+H +].
Example 12: 2-{(2R,3R,6S)-3-[(E)-3-(2,5-ditluoro-phenyl)-allylamino]-6-[(S)-1-hydroxy-2-(6-methoxy-[1,5] naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide:
12.i. {(2R,3R,6S)-2-carbamoylmethyl-6-[(S)-1-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4 yl)-ethylJ-tetrahydro pyran-3 yl}-[(E)-3-(2,5-difluoro phenyl)-allylJ-carbamic acid tert-butyl ester:
To a solution of intermediate 6.vii (0.724 g) in THF (8 ml) were added at 0 C, TEA
(0.427 ml) and i-butylchloroformate (0.367 ml). The reaction was stirred 1 h at this temperature then aq. ammonia (2.5 ml) was added. The reaction was vigorously stirred for 45 min. EA (20 ml) was added. The two layers were decanted and the aq. layer was extracted once with EA (10 ml). The combined org. layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by column chromatography over Si02 (DCM-MeOH 19-1 containing 0.5% aq. NH4OH then 9-1 containing 1% aq.
NH4OH) to give the title amide as an off-white foam (0.485 g).
MS (ESI, m/z): 613.0 [M+H+].
12.ii. 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro phenyl)-allylaminoJ-6-[(S)-1-hydroxy-2-(6-methoxy-[],5Jnaphthyridin-4 yl)-ethylJ-tetrahydro pyran-2 yl}-acetamide:
5N HC1 in dioxane (0.346 ml) was added to a solution of intermediate 12.i (0.1 g) in dioxane (0.311 ml). After evaporation to dryness, the residue was finally purified by column chromatography over Si0z (DCM-MeOH 19-1 containing 1% aq. NH4OH, then 9-1 containing 1% aq. NH4OH) to afford the title compound as a off-white foam (0.032 g).
Rf = 0.33 in DCM-MeOH 9-1 containing 1% aq. NH4OH.
MS (ESI, m/z): 513.0 [M+H+].
Example 13: 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6- [(2RS)2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl] -2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide:
Starting from intermediate 7.xiii (0.100 g, 0.29 mmol) and (E)-3-(2,5-difluoro-phenyl)-acrylic acid (0.058 g, 0.31 mmol), and using the procedure of Example 2, step 2.iv, the title amide (0.123 g, 83% yield) was obtained as a yellow foam. The compound was purified by chromatography over Si0z (DCM-MeOH 19-1 containing 1% aq. NH4OH) and obtained as a 1-1 mixture of epimers.
Rf = 0.41 (DCM-MeOH 9-1 containing 1% aq. NH4OH).
MS (ESI, m/z): 517.2 [M+H+].
Example 14: 3-oxo-3,4-dihydro-2H-pyrido[3,2-b] [1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6- [(2RS)2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl] -2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide:
Starting from intermediate 7.xiii (0.100 g, 0.29 mmol) and 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid (0.06 g, 1 eq.) and using the procedure of Example 2, step 2.iv, the title amide (0.072 g, 46% yield) was obtained as a beige solid. The compound was purified by chromatography over Si02 (DCM-MeOH 19-1 containing 1%
aq.
NH4OH) and obtained as a 1-1 mixture of epimers.
Rf = 0.41 (DCM-MeOH 9-1 containing 1% aq. NH4OH).
iH NMR (d6-DMSO) 8: 11.24 (s, 0.5H); 11.16 (s, 0.5H); 8.69 (d, J= 1.8 Hz, 0.5H); 8.68 (d, J= 1.8 Hz, 0.5H); 8.32 (d, J= 8.9 Hz, 0.5H); 8.27 (d, J= 8.9 Hz, 0.5H); 7.98-7.90 (m, 3H);
7.62 (d, J = 4.4 Hz, 0.5H); 7.59 (d, J = 4.4 Hz, 0.5H); 7.40 (d, J = 2.2 Hz, 0.5H); 7.37 (d, J = 2.2 Hz, 0.5H); 5.79 (m, 1H); 5.62-5.50 (two overlapped m, 2 x 0.5H); 4.66 (t, J = 5.0 Hz, 0.5H); 4.61 (t, J = 5.5 Hz, 0.5H); 4.27 (m, 0.5H); 4.12-4.02 (m, 1H); 3.91 (s, 3H);
3.91 (overlapped m, 0.5H); 3.80 (m, 0.5H); 3.70-3.60 (m, 2.5H); 3.45-3.34 (m, 2H);
2.61 (m, 0.5H); 2.27 (m, 0.5H); 2.11 (m, 1H); 2.15-2.06 (m, 0.5H); 1.99-1.64 (m, 2.5H);
1.45-1.33 (m, 1H).
MS (ESI, m/z): 542.8 [M+].
Example 15: 3-oxo-3,4-dihydro-2H-pyrido[3,2-b] [1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2RS)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide:
15.i. 2-(tert-butyl-diphenyl-silanyloxymethyl)-6-[(2RS)-2-hydroxy-2-(3-methoxy-quinolin-S yl)-ethylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
To a solution of 5-bromo-3-methoxyquinoline (3.12 g) in THF (70 ml), cooled to -78 C, was added n-BuLi (2.5N, 5.2 ml). The mixture was stirred at the same temperature for 15 min and a solution of intermediate 7.x (1.6 g, 3.12 mmol) in THF (5 ml) was quickly added. The reaction proceeded for 5 min before warming to rt. After 15 min, 10% aq.
NaHSO4 (100 ml) was added. The two layers were decanted and the aq. layer was extracted with EA (100 ml).
The combined org. layers were washed with brine, dried over NazSO4, filtered and concentrated to dryness. The residue was chromatographed on Si0z (Hept-EA 3-1 then 1-1 ) to afford the title compound (0.46 g) as a colourless foam. The compound was obtained as a 2-1 mixture of isomers.
MS (ESI, m/z): 671.0 [M+H+].
Starting from intermediate 10.i (0.283 g, 0.475 mmol), the title acid (0.267 g, 96% yield) was obtained as a beige solid using the procedure of Example 4, step 4.vi. The compound was purified by trituration in ether.
MS (ESI, m/z): 497.0 [M+H +].
Example 11: 2-{(2R,3R,6R)-3-[(E)-3-(2,5-ditluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide dihydrochloride:
ll.i. {(2R,3R,6R)-2-carbamoylmethyl-6-[2-(6-methoxy-quinolin-4 yl)-ethyl]-tetrahydro-pyran-3 yl}-[(E)-3-(2,5-difluoro phenyl)-allylJ-carbamic acid tert-butyl ester:
Starting from intermediate 10.i (1.15 g, 1.93 mmol), the title acetamide (0.506 g, 44% yield) was obtained as an off-white foam using the procedure of Example 9, step 9.iv.
The compound was purified by chromatography over Si0z, using DCM-MeOH 19-1 containing 0.5% aq. NH4OH as an eluent.
MS (ESI, m/z): 596.0 [M+H +].
11.ii. 2-{(2R, 3R, 6R)-3-[(E)-3-(2, 5-difluoro phenyl)-allylaminoJ-6-[2-(6-methoxy-quinolin-4 yl)-ethylJ-tetrahydro pyran-2 yl}-acetamide:
Starting from intermediate 11.i (0.045 g, 0.076 mmol), the title compound (0.034 g, 80%
yield) was obtained as a yellowish solid, using the procedure of Example 4, step 4.vi. The compound was purified by trituration in ether.
MS (ESI, m/z): 496.0 [M+H +].
Example 12: 2-{(2R,3R,6S)-3-[(E)-3-(2,5-ditluoro-phenyl)-allylamino]-6-[(S)-1-hydroxy-2-(6-methoxy-[1,5] naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide:
12.i. {(2R,3R,6S)-2-carbamoylmethyl-6-[(S)-1-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4 yl)-ethylJ-tetrahydro pyran-3 yl}-[(E)-3-(2,5-difluoro phenyl)-allylJ-carbamic acid tert-butyl ester:
To a solution of intermediate 6.vii (0.724 g) in THF (8 ml) were added at 0 C, TEA
(0.427 ml) and i-butylchloroformate (0.367 ml). The reaction was stirred 1 h at this temperature then aq. ammonia (2.5 ml) was added. The reaction was vigorously stirred for 45 min. EA (20 ml) was added. The two layers were decanted and the aq. layer was extracted once with EA (10 ml). The combined org. layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by column chromatography over Si02 (DCM-MeOH 19-1 containing 0.5% aq. NH4OH then 9-1 containing 1% aq.
NH4OH) to give the title amide as an off-white foam (0.485 g).
MS (ESI, m/z): 613.0 [M+H+].
12.ii. 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro phenyl)-allylaminoJ-6-[(S)-1-hydroxy-2-(6-methoxy-[],5Jnaphthyridin-4 yl)-ethylJ-tetrahydro pyran-2 yl}-acetamide:
5N HC1 in dioxane (0.346 ml) was added to a solution of intermediate 12.i (0.1 g) in dioxane (0.311 ml). After evaporation to dryness, the residue was finally purified by column chromatography over Si0z (DCM-MeOH 19-1 containing 1% aq. NH4OH, then 9-1 containing 1% aq. NH4OH) to afford the title compound as a off-white foam (0.032 g).
Rf = 0.33 in DCM-MeOH 9-1 containing 1% aq. NH4OH.
MS (ESI, m/z): 513.0 [M+H+].
Example 13: 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6- [(2RS)2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl] -2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide:
Starting from intermediate 7.xiii (0.100 g, 0.29 mmol) and (E)-3-(2,5-difluoro-phenyl)-acrylic acid (0.058 g, 0.31 mmol), and using the procedure of Example 2, step 2.iv, the title amide (0.123 g, 83% yield) was obtained as a yellow foam. The compound was purified by chromatography over Si0z (DCM-MeOH 19-1 containing 1% aq. NH4OH) and obtained as a 1-1 mixture of epimers.
Rf = 0.41 (DCM-MeOH 9-1 containing 1% aq. NH4OH).
MS (ESI, m/z): 517.2 [M+H+].
Example 14: 3-oxo-3,4-dihydro-2H-pyrido[3,2-b] [1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6- [(2RS)2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl] -2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide:
Starting from intermediate 7.xiii (0.100 g, 0.29 mmol) and 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid (0.06 g, 1 eq.) and using the procedure of Example 2, step 2.iv, the title amide (0.072 g, 46% yield) was obtained as a beige solid. The compound was purified by chromatography over Si02 (DCM-MeOH 19-1 containing 1%
aq.
NH4OH) and obtained as a 1-1 mixture of epimers.
Rf = 0.41 (DCM-MeOH 9-1 containing 1% aq. NH4OH).
iH NMR (d6-DMSO) 8: 11.24 (s, 0.5H); 11.16 (s, 0.5H); 8.69 (d, J= 1.8 Hz, 0.5H); 8.68 (d, J= 1.8 Hz, 0.5H); 8.32 (d, J= 8.9 Hz, 0.5H); 8.27 (d, J= 8.9 Hz, 0.5H); 7.98-7.90 (m, 3H);
7.62 (d, J = 4.4 Hz, 0.5H); 7.59 (d, J = 4.4 Hz, 0.5H); 7.40 (d, J = 2.2 Hz, 0.5H); 7.37 (d, J = 2.2 Hz, 0.5H); 5.79 (m, 1H); 5.62-5.50 (two overlapped m, 2 x 0.5H); 4.66 (t, J = 5.0 Hz, 0.5H); 4.61 (t, J = 5.5 Hz, 0.5H); 4.27 (m, 0.5H); 4.12-4.02 (m, 1H); 3.91 (s, 3H);
3.91 (overlapped m, 0.5H); 3.80 (m, 0.5H); 3.70-3.60 (m, 2.5H); 3.45-3.34 (m, 2H);
2.61 (m, 0.5H); 2.27 (m, 0.5H); 2.11 (m, 1H); 2.15-2.06 (m, 0.5H); 1.99-1.64 (m, 2.5H);
1.45-1.33 (m, 1H).
MS (ESI, m/z): 542.8 [M+].
Example 15: 3-oxo-3,4-dihydro-2H-pyrido[3,2-b] [1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2RS)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide:
15.i. 2-(tert-butyl-diphenyl-silanyloxymethyl)-6-[(2RS)-2-hydroxy-2-(3-methoxy-quinolin-S yl)-ethylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
To a solution of 5-bromo-3-methoxyquinoline (3.12 g) in THF (70 ml), cooled to -78 C, was added n-BuLi (2.5N, 5.2 ml). The mixture was stirred at the same temperature for 15 min and a solution of intermediate 7.x (1.6 g, 3.12 mmol) in THF (5 ml) was quickly added. The reaction proceeded for 5 min before warming to rt. After 15 min, 10% aq.
NaHSO4 (100 ml) was added. The two layers were decanted and the aq. layer was extracted with EA (100 ml).
The combined org. layers were washed with brine, dried over NazSO4, filtered and concentrated to dryness. The residue was chromatographed on Si0z (Hept-EA 3-1 then 1-1 ) to afford the title compound (0.46 g) as a colourless foam. The compound was obtained as a 2-1 mixture of isomers.
MS (ESI, m/z): 671.0 [M+H+].
15.ii. {(2S, 3R, 6S)-6-[(2RS)-2-hydroxy-2-(3-methoxy-quinolin-S yl)-ethylJ-2-hydroxymethyl-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
This alcohol (0.26 g, 86% yield) was obtained as a colourless foam, starting from intermediate 15.i (0.46 g, 0.68 mmol) and using the procedure of Example 7, step 7.xii. The compound was purified by chromatography over Si02 using EA as eluent. The compound was obtained as a 2-1 mixture of isomers.
MS (ESI, m/z): 432.9 [M+].
15.iii. (2RS)-2-[(2S,5R,6S)-5-amino-6-hydroxymethyl-tetrahydro pyran-2 yl]-1-(3-methoxy-quinolin-S yl)-ethanol:
This amine (0.15 g, 84% yield) was obtained as a colourless foam, starting from intermediate 15.ii (0.23 g, 0.53 mmol) and using the procedure of Example 1, step l.ix.
MS (ESI, m/z): 333.1 [M+H+].
15.iv. 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S, 3R, 6S)-6-[(2RS)-2-hydroxy-2-(3-methoxy-quinolin-5 yl)-ethylJ-2-hydroxymethyl-tetrahydro pyran-3 yl}-amide:
Starting from intermediate 15.iii (0.05 g, 0.15 mmol) and 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid (0.032 g, 1 eq.) and using the procedure of Example 2, step 2.iv, the title amide (0.030 g, 38% yield) was obtained as an off-white solid.
The compound was purified by chromatography over Si0z (DCM-MeOH 9-1 containing 1%
aq. NH4OH) and obtained as a 2-1 mixture of epimers.
iH NMR (d6-DMSO) 8: 11.24 (s, 0.34H); 11.18 (s, 0.66H); 8.66 (m, 1H); 8.34 (d, J= 9.0 Hz, 0.34H); 8.26 (d, J= 9.0 Hz, 0.66H); 7.99-7.94 (m, 1.66H); 7.74-7.69 (m, 1.34H); 7.71 (m, 1H); 7.63-7.55 (m, 2H); 5.48-5.35 (m, 2H); 4.75 (t, J = 5.5 Hz, 0.34H); 4.67 (t, J = 5.1 Hz, 0.66H); 4.33 (m, 0.34H); 4.09 (m, 0.66H); 3.97 (s, 3 x 0.34H); 3.95 (s, 3 x 0.66H);
3.96 (overlapped m, 1H); 3.80 (m, 0.66H); 3.66-3.60 (m, 2H); 3.52 (m, 0.34H);
3.41 (t, J= 5.6Hz, 1H); 2.43-2.27 (two overlapped m, 1H); 2.03-1.83 (m, 3H); 1.69-1.59 (m, 2H);
1.51-1.41 (m, 1H).
MS (ESI, m/z): 525.6 [M+H+].
This alcohol (0.26 g, 86% yield) was obtained as a colourless foam, starting from intermediate 15.i (0.46 g, 0.68 mmol) and using the procedure of Example 7, step 7.xii. The compound was purified by chromatography over Si02 using EA as eluent. The compound was obtained as a 2-1 mixture of isomers.
MS (ESI, m/z): 432.9 [M+].
15.iii. (2RS)-2-[(2S,5R,6S)-5-amino-6-hydroxymethyl-tetrahydro pyran-2 yl]-1-(3-methoxy-quinolin-S yl)-ethanol:
This amine (0.15 g, 84% yield) was obtained as a colourless foam, starting from intermediate 15.ii (0.23 g, 0.53 mmol) and using the procedure of Example 1, step l.ix.
MS (ESI, m/z): 333.1 [M+H+].
15.iv. 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S, 3R, 6S)-6-[(2RS)-2-hydroxy-2-(3-methoxy-quinolin-5 yl)-ethylJ-2-hydroxymethyl-tetrahydro pyran-3 yl}-amide:
Starting from intermediate 15.iii (0.05 g, 0.15 mmol) and 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid (0.032 g, 1 eq.) and using the procedure of Example 2, step 2.iv, the title amide (0.030 g, 38% yield) was obtained as an off-white solid.
The compound was purified by chromatography over Si0z (DCM-MeOH 9-1 containing 1%
aq. NH4OH) and obtained as a 2-1 mixture of epimers.
iH NMR (d6-DMSO) 8: 11.24 (s, 0.34H); 11.18 (s, 0.66H); 8.66 (m, 1H); 8.34 (d, J= 9.0 Hz, 0.34H); 8.26 (d, J= 9.0 Hz, 0.66H); 7.99-7.94 (m, 1.66H); 7.74-7.69 (m, 1.34H); 7.71 (m, 1H); 7.63-7.55 (m, 2H); 5.48-5.35 (m, 2H); 4.75 (t, J = 5.5 Hz, 0.34H); 4.67 (t, J = 5.1 Hz, 0.66H); 4.33 (m, 0.34H); 4.09 (m, 0.66H); 3.97 (s, 3 x 0.34H); 3.95 (s, 3 x 0.66H);
3.96 (overlapped m, 1H); 3.80 (m, 0.66H); 3.66-3.60 (m, 2H); 3.52 (m, 0.34H);
3.41 (t, J= 5.6Hz, 1H); 2.43-2.27 (two overlapped m, 1H); 2.03-1.83 (m, 3H); 1.69-1.59 (m, 2H);
1.51-1.41 (m, 1H).
MS (ESI, m/z): 525.6 [M+H+].
Example 16: 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2RS)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl] -2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide:
Starting from intermediate 15.iii (0.1 g, 0.3 mmol) and (E)-3-(2,5-difluoro-phenyl)-acrylic acid (0.055 g, 1 eq.) and using the procedure of Example 2, step 2.iv, the title amide (0.095 g, 63% yield) was obtained as a colourless oil. The compound was purified by chromatography over Si0z (DCM-MeOH 9-1 containing 1% aq. NH4OH) and obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 498.9 [M+H+].
Example 17: 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-[1,5] naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide:
17.i. {(2R,3R,6S)-2-((4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-6-[(E)-2-(3 fluoro-6-methoxy-[1,5]naphthyridin-4 yl)-vinylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
Starting from 3-fluoro-6-methoxy-[1,5]naphthyridine-4-carbaldehyde (see Preparation E;
3.17 g, 15.37 mmol) and intermediate l.v (8.98 g, 16.71 mmol), the title alkene (4.02 g, 50%
yield) was obtained as a pale yellow foam using the procedure of Example 1, step l.vi. The compound was purified by chromatography over Si0z using Hept-EA 1-2 as an eluent. The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 500.4 [M+H+].
17.ii. {2-carbamoylmethyl-6-[2-(3 fluoro-6-methoxy-[1,5]naphthyridin-4 yl)-vinylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
Starting from intermediate 17.i (3.85 g, 7.44 mmol), this amide (0.759 g, 1.65 mmol) was obtained as an off-white solid, using the procedures of Example 9, steps 9.ii (deprotection, 80% yield), 9.iii (aldehyde formation then oxidation, respectively 93% and 62%
yield) and 9.iv (amide formation, 51 % yield).
iH NMR (d6-DMSO) 8: 8.81 (d, J = 3.8 Hz, 1H); 8.29 (d, J = 9.0 Hz, 1H); 7.35 (br s, 1H);
7.28-7.20 (m, 3H); 6.88 (br d, J = 8.4 Hz, 1H); 6.82 (br s, 1H); 4.52 (m, 1H);
4.33 (m, 1H);
Starting from intermediate 15.iii (0.1 g, 0.3 mmol) and (E)-3-(2,5-difluoro-phenyl)-acrylic acid (0.055 g, 1 eq.) and using the procedure of Example 2, step 2.iv, the title amide (0.095 g, 63% yield) was obtained as a colourless oil. The compound was purified by chromatography over Si0z (DCM-MeOH 9-1 containing 1% aq. NH4OH) and obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 498.9 [M+H+].
Example 17: 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-[1,5] naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide:
17.i. {(2R,3R,6S)-2-((4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-6-[(E)-2-(3 fluoro-6-methoxy-[1,5]naphthyridin-4 yl)-vinylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
Starting from 3-fluoro-6-methoxy-[1,5]naphthyridine-4-carbaldehyde (see Preparation E;
3.17 g, 15.37 mmol) and intermediate l.v (8.98 g, 16.71 mmol), the title alkene (4.02 g, 50%
yield) was obtained as a pale yellow foam using the procedure of Example 1, step l.vi. The compound was purified by chromatography over Si0z using Hept-EA 1-2 as an eluent. The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 500.4 [M+H+].
17.ii. {2-carbamoylmethyl-6-[2-(3 fluoro-6-methoxy-[1,5]naphthyridin-4 yl)-vinylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
Starting from intermediate 17.i (3.85 g, 7.44 mmol), this amide (0.759 g, 1.65 mmol) was obtained as an off-white solid, using the procedures of Example 9, steps 9.ii (deprotection, 80% yield), 9.iii (aldehyde formation then oxidation, respectively 93% and 62%
yield) and 9.iv (amide formation, 51 % yield).
iH NMR (d6-DMSO) 8: 8.81 (d, J = 3.8 Hz, 1H); 8.29 (d, J = 9.0 Hz, 1H); 7.35 (br s, 1H);
7.28-7.20 (m, 3H); 6.88 (br d, J = 8.4 Hz, 1H); 6.82 (br s, 1H); 4.52 (m, 1H);
4.33 (m, 1H);
4.05 (s, 3H); 3.66 (m, 1H); 2.58 (dd, J = 10.3, 14.8 Hz, 1H); 2.13-1.98 (m, 2H); 1.72-1.53 (m, 3H); 1.40 (s, 9H).
MS (ESI, m/z): 460.7 [M+H+].
17.iii. 2-{(2R,3R,6S)-3-amino-6-[2-(3 fluoro-6-methoxy-[1,5]naphthyridin-4 yl)-vinylJ-tetrahydro pyran-2 yl}-acetamide:
This amine (0.132 g, 65% yield) was obtained as a beige solid, starting from intermediate 17.ii (0.258 g, 0.56 mmol) and using the procedure of Example 1, step l.ix.
MS (ESI, m/z): 361.0 [M+H+].
17.iv. 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro phenyl)-allylaminoJ-6-[(E)2-(3 fluoro-6-methoxy-[1,5]naphthyridin-4 yl)-vinylJ-tetrahydro pyran-2 yl}-acetamide:
Starting from intermediate 17.iii (0.126 g, 0.35 mmol) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.065 g, 1.1 eq.), the title compound (0.060 g, 33% yield) was obtained as a white solid using the procedure of Example 1, step 1.x.
iH NMR (d6-DMSO) 8: 8.82 (d, J = 2.1 Hz, 1H); 8.28 (d, J = 9.0 Hz, 1H); 7.49 (m, 1H);
7.35 (br s, 1H); 7.31-7.20 (m, 4H); 7.13 (m, 1H); 6.81 (br s, 1H); 6.62 (d, J
= 16.0 Hz, 1H);
6.51 (td, J = 5.3, 16.0 Hz, 1H); 4.51-4.41 (m, 2H); 4.05 (s, 3H); 3.42-3.34 (m, 2H); 2.80 (m, 1H); 2.62 (dd, J= 9.7, 14.4 Hz, 1H); 2.35 (dd, J= 3.8, 14.4 Hz, 1H); 1.95-1.74 (m, 3H);
1.61-1.43 (m, 2H).
MS (ESI, m/z): 512.9 [M+H+].
Example 18: (2S,5R,6R)-(5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-(2-hydroxy-ethyl))-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide:
18.i. (2S, 5R, 6R)-5-tert-butoxycarbonylamino-6-[(4RS)2,2-dimethyl-[1, 3]dioxolan-4 ylmethylJ-tetrahydro pyran-2-carboxylic acid:
To an ice-chilled solution of intermediate l.ii (5 g, 14.48 mmol) in DCM (32 ml), MeCN
(32 ml) and water (46 ml) was added Na104 (14.6 g, 68.17 mmol) and RuC13 (0.030 g, 0.15 mmol). The reaction mixture was stirred at the same temperature for 5 h.
The reaction mixture was diluted with EA (150 ml) and the solids were removed by filtration. MeOH
(30 ml) was added and the resulting suspension was filtered. The filtrate was treated with aqueous 10% NaHSO3 (60 ml). The phases were separated and the aq. layer was extracted three times with EA. The combined org. layers were washed with brine, dried over Na2SO4, filtered and evaporated under reduced pressure to give a brown foam (quant.).
The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 360.1 [M+H+].
18.ii. {(2S,5R,6R)-6-carbamoyl-2-[(4RS)-2,2-dimethyl-[],3Jdioxolan-4 ylmethylJ-tetrahydro-pyran-3 yl}-carbamic acid tert-butyl ester:
Starting from intermediate 18.i (5.27 g, 14.6 mmol), the title amide (3.16 g, 60% yield) was obtained as a colourless foam using the procedure of Example 12, step 12.i.
The compound was purified by chromatography over Si0z using EA-cyclohexane 4-1 as an eluent. The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 359.1 [M+H+].
18.iii. {(2S,5R,6R)-2-[(4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-6-(6-methoxy-[1,5]naphthyridin-4 ylcarbamoyl)-tetrahydro pyran-3 ylJ-carbamic acid tert-butyl ester:
To a mixture of intermediate 18.ii (2.3 g, 6.42 mmol), rac-BINAP (0.288 g, 0.46 mmol), (dba)3Pd2.CHC13 (0.120 g, 0.12 mmol) and cesium carbonate (2.56 g, 7.86 mmol) was added dioxane (82 ml). The mixture was sonicated for 10 min, whereupon trifluoro-methanesulfonic acid 6-methoxy- [ 1,5 ]naphthyridin-4-yl ester (prepared as described in WO
03/064431; 2.10 g, 6.81 mmol) was added in one portion. The resulting mixture was heated at 100 C
for 4 h. The reaction mixture was filtrated through a pad of Celite and the filtrate was concentrated in vacuo. The residue was purified over Si0z (DCM-MeOH 19-1) to afford the title amide (3.27 g, 6.32 mmol) as a reddish foam.. The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 477.0 [M+H+].
18.iv. (2S, 5R, 6S)-5-amino-6-[(2RS)-2, 3-dihydroxy propylJ-tetrahydro pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4 yl)-amide:
Starting from intermediate 18.iii (2.72 g, 2.06 mmol), the title amine (1.27 g, 64% yield) was obtained as a reddish solid using the procedure of Example 1, step l.ix. The compound was purified by chromatography over Si0z using DCM-MeOH 6-1 containing 1% aq.
NH4OH as an eluent. The compound was obtained as a 2-1 mixture of epimers.
iH NMR (d6-DMSO) 8: 10.59 (s, 0.66H); 10.51 (s, 0.34H); 8.70 (d, J = 5.0 Hz, 1H); 8.45 (d, J = 5.0 Hz, 0.34H); 8.39 (d, J = 5.0Hz, 0.66H); 8.28 (d, J = 9.0 Hz, 1H); 7.33 (d, J = 9.0 Hz, 1H); 4.50 (br s, 1H); 4.47 (dd, J = 4.3, 7.0 Hz, 0.34H); 4.31 (dd, J = 3.5, 9.0 Hz, 0.66H);
MS (ESI, m/z): 460.7 [M+H+].
17.iii. 2-{(2R,3R,6S)-3-amino-6-[2-(3 fluoro-6-methoxy-[1,5]naphthyridin-4 yl)-vinylJ-tetrahydro pyran-2 yl}-acetamide:
This amine (0.132 g, 65% yield) was obtained as a beige solid, starting from intermediate 17.ii (0.258 g, 0.56 mmol) and using the procedure of Example 1, step l.ix.
MS (ESI, m/z): 361.0 [M+H+].
17.iv. 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro phenyl)-allylaminoJ-6-[(E)2-(3 fluoro-6-methoxy-[1,5]naphthyridin-4 yl)-vinylJ-tetrahydro pyran-2 yl}-acetamide:
Starting from intermediate 17.iii (0.126 g, 0.35 mmol) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.065 g, 1.1 eq.), the title compound (0.060 g, 33% yield) was obtained as a white solid using the procedure of Example 1, step 1.x.
iH NMR (d6-DMSO) 8: 8.82 (d, J = 2.1 Hz, 1H); 8.28 (d, J = 9.0 Hz, 1H); 7.49 (m, 1H);
7.35 (br s, 1H); 7.31-7.20 (m, 4H); 7.13 (m, 1H); 6.81 (br s, 1H); 6.62 (d, J
= 16.0 Hz, 1H);
6.51 (td, J = 5.3, 16.0 Hz, 1H); 4.51-4.41 (m, 2H); 4.05 (s, 3H); 3.42-3.34 (m, 2H); 2.80 (m, 1H); 2.62 (dd, J= 9.7, 14.4 Hz, 1H); 2.35 (dd, J= 3.8, 14.4 Hz, 1H); 1.95-1.74 (m, 3H);
1.61-1.43 (m, 2H).
MS (ESI, m/z): 512.9 [M+H+].
Example 18: (2S,5R,6R)-(5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-(2-hydroxy-ethyl))-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide:
18.i. (2S, 5R, 6R)-5-tert-butoxycarbonylamino-6-[(4RS)2,2-dimethyl-[1, 3]dioxolan-4 ylmethylJ-tetrahydro pyran-2-carboxylic acid:
To an ice-chilled solution of intermediate l.ii (5 g, 14.48 mmol) in DCM (32 ml), MeCN
(32 ml) and water (46 ml) was added Na104 (14.6 g, 68.17 mmol) and RuC13 (0.030 g, 0.15 mmol). The reaction mixture was stirred at the same temperature for 5 h.
The reaction mixture was diluted with EA (150 ml) and the solids were removed by filtration. MeOH
(30 ml) was added and the resulting suspension was filtered. The filtrate was treated with aqueous 10% NaHSO3 (60 ml). The phases were separated and the aq. layer was extracted three times with EA. The combined org. layers were washed with brine, dried over Na2SO4, filtered and evaporated under reduced pressure to give a brown foam (quant.).
The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 360.1 [M+H+].
18.ii. {(2S,5R,6R)-6-carbamoyl-2-[(4RS)-2,2-dimethyl-[],3Jdioxolan-4 ylmethylJ-tetrahydro-pyran-3 yl}-carbamic acid tert-butyl ester:
Starting from intermediate 18.i (5.27 g, 14.6 mmol), the title amide (3.16 g, 60% yield) was obtained as a colourless foam using the procedure of Example 12, step 12.i.
The compound was purified by chromatography over Si0z using EA-cyclohexane 4-1 as an eluent. The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 359.1 [M+H+].
18.iii. {(2S,5R,6R)-2-[(4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-6-(6-methoxy-[1,5]naphthyridin-4 ylcarbamoyl)-tetrahydro pyran-3 ylJ-carbamic acid tert-butyl ester:
To a mixture of intermediate 18.ii (2.3 g, 6.42 mmol), rac-BINAP (0.288 g, 0.46 mmol), (dba)3Pd2.CHC13 (0.120 g, 0.12 mmol) and cesium carbonate (2.56 g, 7.86 mmol) was added dioxane (82 ml). The mixture was sonicated for 10 min, whereupon trifluoro-methanesulfonic acid 6-methoxy- [ 1,5 ]naphthyridin-4-yl ester (prepared as described in WO
03/064431; 2.10 g, 6.81 mmol) was added in one portion. The resulting mixture was heated at 100 C
for 4 h. The reaction mixture was filtrated through a pad of Celite and the filtrate was concentrated in vacuo. The residue was purified over Si0z (DCM-MeOH 19-1) to afford the title amide (3.27 g, 6.32 mmol) as a reddish foam.. The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 477.0 [M+H+].
18.iv. (2S, 5R, 6S)-5-amino-6-[(2RS)-2, 3-dihydroxy propylJ-tetrahydro pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4 yl)-amide:
Starting from intermediate 18.iii (2.72 g, 2.06 mmol), the title amine (1.27 g, 64% yield) was obtained as a reddish solid using the procedure of Example 1, step l.ix. The compound was purified by chromatography over Si0z using DCM-MeOH 6-1 containing 1% aq.
NH4OH as an eluent. The compound was obtained as a 2-1 mixture of epimers.
iH NMR (d6-DMSO) 8: 10.59 (s, 0.66H); 10.51 (s, 0.34H); 8.70 (d, J = 5.0 Hz, 1H); 8.45 (d, J = 5.0 Hz, 0.34H); 8.39 (d, J = 5.0Hz, 0.66H); 8.28 (d, J = 9.0 Hz, 1H); 7.33 (d, J = 9.0 Hz, 1H); 4.50 (br s, 1H); 4.47 (dd, J = 4.3, 7.0 Hz, 0.34H); 4.31 (dd, J = 3.5, 9.0 Hz, 0.66H);
4.11 (m, 0.66H); 4.09 (s, 3 x 0.34H); 4.08 (s, 3 x 0.66H); 3.96 (m, 0.34H);
3.63 (m, 1H);
3.37-3.21 (m, 5H), 2.97 (m, 0.66H); 2.91 (m, 0.34H); 2.08 (m, 1H); 1.96 (m, 0.66H);
1.82-1.42 (m, 4.34H).
MS (ESI, m/z): 377.0 [M+H+].
18.v. (2S, 5R, 6R)-5-[(E)-3-(2, 5-difluoro phenyl)-allylaminoJ-6-[(2RS)-2, 3-dihydroxy propyl]-tetrahydro pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4 yl)-amide:
Starting from intermediate 18.iv (0.58 g, 1.55 mmol) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.286 g, 1.1 eq.), the title compound (0.393 g, 48% yield) was obtained as a white solid using the procedure of Example 1, step l.x. The compound was purified by chromatography over Si0z using DCM-MeOH 9-1 containing 1% aq. NH4OH as an eluent.
The compound was obtained as a 2-1 mixture of epimers.
iH NMR (d6-DMSO) 8: 10.64 (s, 0.66H); 10.56 (s, 0.34H); 8.69 (d. J = 5.0 Hz, 1H); 8.42 (d, J = 5.0 Hz, 0.34H); 8.37 (d, J = 5.0 Hz, 0.66H); 8.28 (d, J = 9.0 Hz, 1H);
7.49 (m, 1H);
7.32 (d, J = 9.0 Hz, 1H); 7.27 (m, 1H); 7.12 (m, 1H); 6.63 (d, J = 16.2 Hz, 1H); 6.49 (m, 1H);
4.52-4.42 (m, 3H); 4.26 (m, 1H); 4.06 (s, 3 x 0.34H); 4.04 (s, 3 x 0.66H);
3.65 (m, 1H);
3.44-3.24 (m, 4H); 2.81 (m, 1H); 2.12-1.41 (m, 7H).
MS (ESI, m/z): 529.0 [M+H+].
18.vi. [(E)-3-(2, 5-dif luoro phenyl)-allylJ-{(2R, 3R, 6S)-2-[(2RS)-2, 3-dihydroxy propylJ-6-(6-methoxy-[1,5]naphthyridin-4 ylcarbamoyl)-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
Starting from the intermediate 18.v (0.351 g, 0.66 mmol), this diol (0.307 g, 73% yield) was obtained as a colourless foam, using the procedure of Example 4, step 4.iii.
The compound was purified by chromatography over Si0z using DCM containing 7.5% MeOH, and was recovered as a 2-1 mixture of epimers.
MS (ESI, m/z): 629.0 [M+H+].
18.vii. [(E)-3-(2,5-difluoro phenyl)-allylJ-[(2R,3R,6S)-2-(2-hydroxy-ethyl)-6-(6-methoxy-[1,5]naphthyridin-4 ylcarbamoyl)-tetrahydro pyran-3 ylJ-carbamic acid tert-butyl ester:
To a solution of intermediate 18.vi (0.294 g, 0.47 mmol) in acetone (4 ml) was added a solution of Na104 (0.25 g, 1.17 mmol) in water (0.9 ml). The reaction proceeded 1 h. The solids were filtered off and the filtrate concentrated to dryness. The white residual foam was taken up in MeOH (3 ml) and NaBH4 (0.042 g, 1.12 mmol) was added portionwise.
The reaction was stirred for 1 h at rt. Water was added and the volatiles were evaporated under reduced pressure. DCM-MeOH was added and the phases were separated. The aq.
layer was extracted twice with DCM-MeOH 9-1 and the combined org. layers were dried over Na2SO4 and evaporated under reduced pressure. After drying under HV, the title compound (0.272 g, 97% yield) was obtained as yellow foam.
Rf = 0.30 in DCM-MeOH 19-1.
MS (ESI, m/z): 599.1 [M+H+].
18.viii. (2S,5R,6R)-(5-[(E)-3-(2,5-difluoro phenyl)-allylaminoJ-6-(2-hydroxy-ethyl)-tetrahydro pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4 yl)-amide:
The title compound (0.271 g, 96% yield) was obtained as a off-white foam, starting from intermediate 18.vii. (0.268 g, 0.45 mmol) and using the procedure of Example 2, step 2.iii.
iH NMR (d6-DMSO) 8: 10.56 (s, 1H); 8.70 (d, J = 5.0 Hz, 1H); 8.39 (d, J = 5.0 Hz, 1H);
8.28 (d, J = 9.0 Hz, 1H); 7.48 (m, 1H); 7.32 (d, J = 9.0 Hz, 1H); 7.24 (m, 1H); 7.13 (m 1H);
6.65 (d, J = 16.1 Hz, 1H); 6.51 (td, J = 5.6, 16.1 Hz, 1H); 4.40 (br s, 1H);
4.36 (m, 1H);
4.26 (m, 1H); 4.04 (s, 3H); 3.65-3.54 (m, 2H); 3.51-3.35 (m, 2H); 2.85 (m, 1H); 2.14 (m, 1H);
1.97 (m, 1H); 1.80-1.70 (m, 2H); 1.68-1.54 (m, 3H).
Example 19: (2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide:
19.i. (3R,6S)-(6-carbamoyl-tetrahydro pyran-3 yl)-carbamic acid tert-butyl ester:
To a solution of (2S,5R)-5-tert-butoxycarbonylamino-tetrahydro-pyran-2-carboxylic acid (obtained as described in Eur. J. Org. Chem. (2003), 2418-2427; 3 g) in EA (50 ml) was added NHS (1.5 g) and DCC (2.7 g). The reaction was stirred overnight at rt.
The solids were removed by filtration. The filtrate was concentrated in vacuo and the residue was taken up in THF (180 ml). NH3 was bubbled through the solution for 10 min, and the resulting turbid mixture was stirred at rt for 1 h. Si0z (20 g) was added in the mixture, and the volatiles were removed by rotatory evaporation. The material was chromatographed over Si0z (DCM-MeOH 19-1) to afford the title compound (1.3 g) as a white solid.
MS (ESI, m/z) : 245.3 [M+H+].
3.63 (m, 1H);
3.37-3.21 (m, 5H), 2.97 (m, 0.66H); 2.91 (m, 0.34H); 2.08 (m, 1H); 1.96 (m, 0.66H);
1.82-1.42 (m, 4.34H).
MS (ESI, m/z): 377.0 [M+H+].
18.v. (2S, 5R, 6R)-5-[(E)-3-(2, 5-difluoro phenyl)-allylaminoJ-6-[(2RS)-2, 3-dihydroxy propyl]-tetrahydro pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4 yl)-amide:
Starting from intermediate 18.iv (0.58 g, 1.55 mmol) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.286 g, 1.1 eq.), the title compound (0.393 g, 48% yield) was obtained as a white solid using the procedure of Example 1, step l.x. The compound was purified by chromatography over Si0z using DCM-MeOH 9-1 containing 1% aq. NH4OH as an eluent.
The compound was obtained as a 2-1 mixture of epimers.
iH NMR (d6-DMSO) 8: 10.64 (s, 0.66H); 10.56 (s, 0.34H); 8.69 (d. J = 5.0 Hz, 1H); 8.42 (d, J = 5.0 Hz, 0.34H); 8.37 (d, J = 5.0 Hz, 0.66H); 8.28 (d, J = 9.0 Hz, 1H);
7.49 (m, 1H);
7.32 (d, J = 9.0 Hz, 1H); 7.27 (m, 1H); 7.12 (m, 1H); 6.63 (d, J = 16.2 Hz, 1H); 6.49 (m, 1H);
4.52-4.42 (m, 3H); 4.26 (m, 1H); 4.06 (s, 3 x 0.34H); 4.04 (s, 3 x 0.66H);
3.65 (m, 1H);
3.44-3.24 (m, 4H); 2.81 (m, 1H); 2.12-1.41 (m, 7H).
MS (ESI, m/z): 529.0 [M+H+].
18.vi. [(E)-3-(2, 5-dif luoro phenyl)-allylJ-{(2R, 3R, 6S)-2-[(2RS)-2, 3-dihydroxy propylJ-6-(6-methoxy-[1,5]naphthyridin-4 ylcarbamoyl)-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
Starting from the intermediate 18.v (0.351 g, 0.66 mmol), this diol (0.307 g, 73% yield) was obtained as a colourless foam, using the procedure of Example 4, step 4.iii.
The compound was purified by chromatography over Si0z using DCM containing 7.5% MeOH, and was recovered as a 2-1 mixture of epimers.
MS (ESI, m/z): 629.0 [M+H+].
18.vii. [(E)-3-(2,5-difluoro phenyl)-allylJ-[(2R,3R,6S)-2-(2-hydroxy-ethyl)-6-(6-methoxy-[1,5]naphthyridin-4 ylcarbamoyl)-tetrahydro pyran-3 ylJ-carbamic acid tert-butyl ester:
To a solution of intermediate 18.vi (0.294 g, 0.47 mmol) in acetone (4 ml) was added a solution of Na104 (0.25 g, 1.17 mmol) in water (0.9 ml). The reaction proceeded 1 h. The solids were filtered off and the filtrate concentrated to dryness. The white residual foam was taken up in MeOH (3 ml) and NaBH4 (0.042 g, 1.12 mmol) was added portionwise.
The reaction was stirred for 1 h at rt. Water was added and the volatiles were evaporated under reduced pressure. DCM-MeOH was added and the phases were separated. The aq.
layer was extracted twice with DCM-MeOH 9-1 and the combined org. layers were dried over Na2SO4 and evaporated under reduced pressure. After drying under HV, the title compound (0.272 g, 97% yield) was obtained as yellow foam.
Rf = 0.30 in DCM-MeOH 19-1.
MS (ESI, m/z): 599.1 [M+H+].
18.viii. (2S,5R,6R)-(5-[(E)-3-(2,5-difluoro phenyl)-allylaminoJ-6-(2-hydroxy-ethyl)-tetrahydro pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4 yl)-amide:
The title compound (0.271 g, 96% yield) was obtained as a off-white foam, starting from intermediate 18.vii. (0.268 g, 0.45 mmol) and using the procedure of Example 2, step 2.iii.
iH NMR (d6-DMSO) 8: 10.56 (s, 1H); 8.70 (d, J = 5.0 Hz, 1H); 8.39 (d, J = 5.0 Hz, 1H);
8.28 (d, J = 9.0 Hz, 1H); 7.48 (m, 1H); 7.32 (d, J = 9.0 Hz, 1H); 7.24 (m, 1H); 7.13 (m 1H);
6.65 (d, J = 16.1 Hz, 1H); 6.51 (td, J = 5.6, 16.1 Hz, 1H); 4.40 (br s, 1H);
4.36 (m, 1H);
4.26 (m, 1H); 4.04 (s, 3H); 3.65-3.54 (m, 2H); 3.51-3.35 (m, 2H); 2.85 (m, 1H); 2.14 (m, 1H);
1.97 (m, 1H); 1.80-1.70 (m, 2H); 1.68-1.54 (m, 3H).
Example 19: (2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide:
19.i. (3R,6S)-(6-carbamoyl-tetrahydro pyran-3 yl)-carbamic acid tert-butyl ester:
To a solution of (2S,5R)-5-tert-butoxycarbonylamino-tetrahydro-pyran-2-carboxylic acid (obtained as described in Eur. J. Org. Chem. (2003), 2418-2427; 3 g) in EA (50 ml) was added NHS (1.5 g) and DCC (2.7 g). The reaction was stirred overnight at rt.
The solids were removed by filtration. The filtrate was concentrated in vacuo and the residue was taken up in THF (180 ml). NH3 was bubbled through the solution for 10 min, and the resulting turbid mixture was stirred at rt for 1 h. Si0z (20 g) was added in the mixture, and the volatiles were removed by rotatory evaporation. The material was chromatographed over Si0z (DCM-MeOH 19-1) to afford the title compound (1.3 g) as a white solid.
MS (ESI, m/z) : 245.3 [M+H+].
19.ii. [(3R,6S)-6-(6-methoxy-[1,5]naphthyridin-4 ylcarbamoyl)-tetrahydro pyran-3 ylJ-carbamic acid tert-butyl ester:
To a mixture of intermediate 19.i (0.8 g), cesium carbonate (1.3g), rac-BINAP
(0.145 g) and (dba)3Pd2.CHC13 (0.057 g) was added dioxane (41 ml). The mixture was sonicated 15 min and trifluoro-methanesulfonic acid 6-methoxy-[1,5]naphthyridin-4-yl ester (1.0 g) was added. The mixture was heated at 100 C overnight. After filtration, the filtrate was concentrated to dryness and the residue was purified over Si02 (DCM-MeOH 19-1) to afford the title amide (1.3 g) as a foam.
iH NMR (CDC13) 8: 10.57 (s, 1H); 8.70 (d, J = 5.2 Hz, 1H); 8.51 (d, J = 5.2 Hz, 1H); 8.22 (d, J= 9.0 Hz, 1H); 7.16 (d, J= 9.0 Hz, 1H); 4.32 (m, 2H); 4.12 (s, 3H); 4.01 (dd, J= 2.5, 11.4 Hz, 1H); 3.72 (m, 1H); 3.23 (t, J= 10.6 Hz, 1H); 2.3 9(qd, J= 2.8, 10.2 Hz, 1H);
2.22 (m. 1H); 1.76 (m, 1H); 1.47 (overlapped m, 1H); 1.47 (s, 9H).
MS (ESI, m/z) : 403.6 [M+H+].
19.iii. (2S, 5R)-5-amino-tetrahydro pyran-2-carboxylic acid (6-methoxy-[1, 5]naphthyridin-4-yl)-amide:
The title amine (0.5 g) was obtained as a white solid, starting from intermediate 19.ii (1.3 g) and using the procedure of Example 1, step l.ix. The compound was purified by chromatography over Si0z (DCM-MeOH 19-1 containing 1% concentrated aq. NH4OH).
MS (ESI, m/z): 303.2 [M+H+].
19.iv. (2S, 5R)-5-[(E)-3-(2, 5-difluoro phenyl)-allylaminoJ-tetrahydro pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4 yl)-amide:
Starting from intermediate 19.iii (0.254 g, 0.84 mmol) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.141 g, 1.0 eq.), the title compound (0.12 g, 31 % yield) was obtained as a white solid using the procedure of Example 1, step l.x. The compound was purified by chromatography over Si0z using DCM-MeOH 97-3 containing 0.5% aq. NH4OH as an eluent.
iH NMR (d6-DMSO) 8: 10.52 (s, 1H); 8.71 (d, J = 5.0 Hz, 1H); 8.38 (d, J = 5.0 Hz, 1H);
8.27 (d, J 9.0 Hz, 1H); 7.48 (m, 1H); 7.32 (d, J = 9.0 Hz, 1H); 7.25 (m, 1H);
7.11 (m, 1H);
6.63 (d, J 16.2 Hz, 1 H); 6.50 (td, J = 5.3, 16.2 Hz, 1 H); 4.21 (dd, J = 3.2, 10.7 Hz, 1 H);
4.08 (dd, J = 2.1, 10.7 Hz, 1H); 4.02 (s, 3H); 3.48-3.35 (m, 2H); 3.25 (t, J =
10.5 Hz, 1H);
2.69 (m, 1H); 2.18-2.14 (m, 2H); 1.99 (br s, 1H); 1.55 (m, 1H); 1.35 (m, 1 H).
To a mixture of intermediate 19.i (0.8 g), cesium carbonate (1.3g), rac-BINAP
(0.145 g) and (dba)3Pd2.CHC13 (0.057 g) was added dioxane (41 ml). The mixture was sonicated 15 min and trifluoro-methanesulfonic acid 6-methoxy-[1,5]naphthyridin-4-yl ester (1.0 g) was added. The mixture was heated at 100 C overnight. After filtration, the filtrate was concentrated to dryness and the residue was purified over Si02 (DCM-MeOH 19-1) to afford the title amide (1.3 g) as a foam.
iH NMR (CDC13) 8: 10.57 (s, 1H); 8.70 (d, J = 5.2 Hz, 1H); 8.51 (d, J = 5.2 Hz, 1H); 8.22 (d, J= 9.0 Hz, 1H); 7.16 (d, J= 9.0 Hz, 1H); 4.32 (m, 2H); 4.12 (s, 3H); 4.01 (dd, J= 2.5, 11.4 Hz, 1H); 3.72 (m, 1H); 3.23 (t, J= 10.6 Hz, 1H); 2.3 9(qd, J= 2.8, 10.2 Hz, 1H);
2.22 (m. 1H); 1.76 (m, 1H); 1.47 (overlapped m, 1H); 1.47 (s, 9H).
MS (ESI, m/z) : 403.6 [M+H+].
19.iii. (2S, 5R)-5-amino-tetrahydro pyran-2-carboxylic acid (6-methoxy-[1, 5]naphthyridin-4-yl)-amide:
The title amine (0.5 g) was obtained as a white solid, starting from intermediate 19.ii (1.3 g) and using the procedure of Example 1, step l.ix. The compound was purified by chromatography over Si0z (DCM-MeOH 19-1 containing 1% concentrated aq. NH4OH).
MS (ESI, m/z): 303.2 [M+H+].
19.iv. (2S, 5R)-5-[(E)-3-(2, 5-difluoro phenyl)-allylaminoJ-tetrahydro pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4 yl)-amide:
Starting from intermediate 19.iii (0.254 g, 0.84 mmol) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.141 g, 1.0 eq.), the title compound (0.12 g, 31 % yield) was obtained as a white solid using the procedure of Example 1, step l.x. The compound was purified by chromatography over Si0z using DCM-MeOH 97-3 containing 0.5% aq. NH4OH as an eluent.
iH NMR (d6-DMSO) 8: 10.52 (s, 1H); 8.71 (d, J = 5.0 Hz, 1H); 8.38 (d, J = 5.0 Hz, 1H);
8.27 (d, J 9.0 Hz, 1H); 7.48 (m, 1H); 7.32 (d, J = 9.0 Hz, 1H); 7.25 (m, 1H);
7.11 (m, 1H);
6.63 (d, J 16.2 Hz, 1 H); 6.50 (td, J = 5.3, 16.2 Hz, 1 H); 4.21 (dd, J = 3.2, 10.7 Hz, 1 H);
4.08 (dd, J = 2.1, 10.7 Hz, 1H); 4.02 (s, 3H); 3.48-3.35 (m, 2H); 3.25 (t, J =
10.5 Hz, 1H);
2.69 (m, 1H); 2.18-2.14 (m, 2H); 1.99 (br s, 1H); 1.55 (m, 1H); 1.35 (m, 1 H).
MS (ESI, m/z): 454.9 [M+H+].
Example 20: (1S)-1-{(2S,5R)-5-[(E)-3-(3-Fluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-methoxy-quinolin-4-yl)-ethanol:
20.i. {(3R,6S)-6-[2-(3-methoxy-quinolin-S yl)-vinyl]-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
Starting from (3R,6S)-[6-(1-phenyl-lH-tetrazole-5-sulfonylmethyl)-tetrahydro-pyran-3-yl]-carbamic acid tert-butyl ester (see Preparation G; 15 g, 35.4 mmol) and 3-methoxy-quinoline-5-carbaldehyde (see Preparation F; 6.3 g, 33.7 mmol), the title alkene (9.9 g, 76% yield) was obtained as a colourless solid, using the procedure of Example 1, step 1. vi.
The compound was purified by trituraton in a Hex-ether mixture.
iH NMR (CDC13) 8: 8.72 (d, J = 4.5 Hz, 1H); 8.02 (d, J = 9.2 Hz, 1H); 7.36-7.25 (m, 3H);
7.26 (d, J = 15.8 Hz, 1H); 6.42 (dd, J = 5.2, 15.8 Hz, 1H); 4.27 (m, 1H); 4.08 (m, 1H); 3.98 (s, 3H); 3.74 (br s, 1H); 3.18 (t, J = 10.6 Hz, 1H); 2.22 (m, 1H); 1.98 (m, 1H);
1.75-1.60 (m, 2H);
1.48 (s, 9H), 1.47 (overlapped m, 1H).
MS (ESI, m/z): 385.3 [M+H+].
20.ii. {(3R,6S)-6-[(IS,2S)-1,2-dihydroxy-2-(6-methoxy-quinolin-4 yl)-ethylJ-tetrahydro-pyran-3 yl}-carbamic acid tert-butyl ester:
Starting from intermediate 20.i (9.9 g, 25.7 mmol), the title diol (10.5 g, 97% yield) was obtained as a colourless foam using the procedure of Example 6, step 6.i. The compound was purified by chromatography over Si0z using DCM-MeOH 9-1 as eluent.
iH NMR (d6-DMSO) 8: 8.71 (d, J = 4.5 Hz, 1H); 7.93 (d, J = 9.0 Hz, 1H); 7.54 (d, J = 4.5 Hz, 1H); 7.44-7.3 8(m, 2H); 6.851 (br s, 1H); 6.65 (d, J = 8.2 Hz, 1H); 5.43 (d, J
= 5.4 Hz, 1H);
5.36 (m, 1H); 4.83 (d, J = 6.3 Hz, 1H); 3.89 (s, 3H); 3.79 (m, 1H); 3.56 (m, 1H); 3.37 (br s, 1H); 2.72 (t, J = 10.6 Hz, 1H); 1.85 (m, 1H); 1.71-1.65 (m, 2H); 1.36 (s, 9H);
1.21 (m, 1H).
20.iii. (3R,6S)-{6-[(4R,5R)-5-(6-methoxy-quinolin-4 yl)-2-oxo-[1,3]dioxolan-4 ylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
To an ice-chilled solution of intermediate 20.ii (10.2 g) in DCM (130 ml) were added pyridine (12 ml) and triphosgene (3.62 g). The reaction was stirred 30 min at this temperature and then 90 min at rt. The reaction mixture was diluted with aq. NaHCO3 and the two layers were decanted. The org. layer was dried over NazSO4, filtered, and concentrated to dryness. The residue was chromatographed over Si02 (DCM-MeOH 19-1) to afford the title cyclic carbonate (10.5 g) as a a colourless foam.
iH NMR (CDC13) 8: 8.82 (d, J = 4.5 Hz, 1H); 8.10 (d, J = 9.3 Hz, 1H); 7.49-7.43(m, 2H);
7.21 (br. s, 1 H); 6.27 (d, J = 4.2 Hz, 1 H); 4.61 (m, 1 H); 4.28 (ddd, J =
2.0, 4.7, 10.6 Hz, 2H);
3.95 (s, 3H); 3.70 (m, 2H); 3.18 (t, J = 10.7 Hz, 1H); 2.27 (m, 1H); 1.84 (m, 2H); 1.46 (s, 9H);
1.45 (m overlapped, 1H).
MS (ESI, m/z): 445.0 [M+H+].
20.iv. (3R, 6S)-{6-[(1 S)-1-hydroxy-2-(6-methoxy-quinolin-4 yl)-ethylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
To a solution of intermediate 20.iii (2.75 g) in EA (250 ml) under argon was added Pd/C
(1.32 g). The resulting suspension was stirred under hydrogen atmosphere.
After 2.5 h, more Pd/C (0.66 g) was added and the reaction was stirred overnight under hydrogen atmosphere.
The catalyst was filtered off and the filtrate concentrated in vacuo. The residue was purified by column chromatography over Si0z (DCM-MeOH 19-1 containing 1% aq. NH4OH) to afford the title compound as a white foam (1.23 g).
iH NMR (d6-DMSO) 8: 8.62 (d, J = 4.4 Hz, 1H); 7.92 (d, J = 9.0 Hz, 1H); 7.42 (d, J = 2.5 Hz, 1H); 7.40 (dd, J = 2.7, 9.0 Hz, 1H); 7.33 (d, J = 4.4 Hz, 1H); 6.76 (br d, J =
8.0 Hz, 1H);
4.83 (d, J = 6.4 Hz, 1H); 3.91 (s, 3H); 3.90 (overlapped m, 1H); 3.74 (m, 1H);
3.38 (br. s, 1H); 3.29 (overlapped dd, visible J = 3.8 Hz, 1H); 3.12 (d, J = 10.4 Hz, 1H);
2.98 (t, J = 10.3 Hz, 1H); 2.97 (m overlapped, 1H); 1.90 (d, J = 9.2 Hz, 1H); 1.60 (m, 2H); 1.39 (s, 9H); 1.38 (m overlapped, 1H).
MS (ESI, m/z): 403.0 [M+H+].
20.v. (1 S)-1-((2S, 5R)-(5-amino-tetrahydro pyran-2 yl)-2-(6-methoxy-quinolin-4 yl)-ethanol:
A solution of intermediate 20.iv (1.23 g) in TFA (15 ml) was stirred for 10 min. The solution was concentrated to dryness, basified with a 2M aq. NaOH solution, diluted with DCM-MeOH 9-1 and the phases separated. The aq. layer was extracted 6 times with DCM-MeOH 9-1. The combined org. layers were dried over NazSO4, filtered and concentrated to dryness to afford a white solid (0.768 g).
iH NMR (DMSO) 8: 8.62 (d, J = 4.4 Hz, 1H); 7.92 (d, J = 9.1 Hz, 1H); 7.44 (d, J = 2.7 Hz, 1H); 7.39 (dd, J = 2.8, 9.1 Hz, 1H); 7.32 (d, J = 4.4 Hz, 1H); 4.79 (d, J =
6.3 Hz, 1H); 3.91 (s, 3H); 3.88 (ddd, J = 1.8, 4.4, 10.5 Hz, 1H); 3.73 (m, 1H); 3.31 (dd, J = 4.0, 13.6 Hz, 1H);
Example 20: (1S)-1-{(2S,5R)-5-[(E)-3-(3-Fluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-methoxy-quinolin-4-yl)-ethanol:
20.i. {(3R,6S)-6-[2-(3-methoxy-quinolin-S yl)-vinyl]-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
Starting from (3R,6S)-[6-(1-phenyl-lH-tetrazole-5-sulfonylmethyl)-tetrahydro-pyran-3-yl]-carbamic acid tert-butyl ester (see Preparation G; 15 g, 35.4 mmol) and 3-methoxy-quinoline-5-carbaldehyde (see Preparation F; 6.3 g, 33.7 mmol), the title alkene (9.9 g, 76% yield) was obtained as a colourless solid, using the procedure of Example 1, step 1. vi.
The compound was purified by trituraton in a Hex-ether mixture.
iH NMR (CDC13) 8: 8.72 (d, J = 4.5 Hz, 1H); 8.02 (d, J = 9.2 Hz, 1H); 7.36-7.25 (m, 3H);
7.26 (d, J = 15.8 Hz, 1H); 6.42 (dd, J = 5.2, 15.8 Hz, 1H); 4.27 (m, 1H); 4.08 (m, 1H); 3.98 (s, 3H); 3.74 (br s, 1H); 3.18 (t, J = 10.6 Hz, 1H); 2.22 (m, 1H); 1.98 (m, 1H);
1.75-1.60 (m, 2H);
1.48 (s, 9H), 1.47 (overlapped m, 1H).
MS (ESI, m/z): 385.3 [M+H+].
20.ii. {(3R,6S)-6-[(IS,2S)-1,2-dihydroxy-2-(6-methoxy-quinolin-4 yl)-ethylJ-tetrahydro-pyran-3 yl}-carbamic acid tert-butyl ester:
Starting from intermediate 20.i (9.9 g, 25.7 mmol), the title diol (10.5 g, 97% yield) was obtained as a colourless foam using the procedure of Example 6, step 6.i. The compound was purified by chromatography over Si0z using DCM-MeOH 9-1 as eluent.
iH NMR (d6-DMSO) 8: 8.71 (d, J = 4.5 Hz, 1H); 7.93 (d, J = 9.0 Hz, 1H); 7.54 (d, J = 4.5 Hz, 1H); 7.44-7.3 8(m, 2H); 6.851 (br s, 1H); 6.65 (d, J = 8.2 Hz, 1H); 5.43 (d, J
= 5.4 Hz, 1H);
5.36 (m, 1H); 4.83 (d, J = 6.3 Hz, 1H); 3.89 (s, 3H); 3.79 (m, 1H); 3.56 (m, 1H); 3.37 (br s, 1H); 2.72 (t, J = 10.6 Hz, 1H); 1.85 (m, 1H); 1.71-1.65 (m, 2H); 1.36 (s, 9H);
1.21 (m, 1H).
20.iii. (3R,6S)-{6-[(4R,5R)-5-(6-methoxy-quinolin-4 yl)-2-oxo-[1,3]dioxolan-4 ylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
To an ice-chilled solution of intermediate 20.ii (10.2 g) in DCM (130 ml) were added pyridine (12 ml) and triphosgene (3.62 g). The reaction was stirred 30 min at this temperature and then 90 min at rt. The reaction mixture was diluted with aq. NaHCO3 and the two layers were decanted. The org. layer was dried over NazSO4, filtered, and concentrated to dryness. The residue was chromatographed over Si02 (DCM-MeOH 19-1) to afford the title cyclic carbonate (10.5 g) as a a colourless foam.
iH NMR (CDC13) 8: 8.82 (d, J = 4.5 Hz, 1H); 8.10 (d, J = 9.3 Hz, 1H); 7.49-7.43(m, 2H);
7.21 (br. s, 1 H); 6.27 (d, J = 4.2 Hz, 1 H); 4.61 (m, 1 H); 4.28 (ddd, J =
2.0, 4.7, 10.6 Hz, 2H);
3.95 (s, 3H); 3.70 (m, 2H); 3.18 (t, J = 10.7 Hz, 1H); 2.27 (m, 1H); 1.84 (m, 2H); 1.46 (s, 9H);
1.45 (m overlapped, 1H).
MS (ESI, m/z): 445.0 [M+H+].
20.iv. (3R, 6S)-{6-[(1 S)-1-hydroxy-2-(6-methoxy-quinolin-4 yl)-ethylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
To a solution of intermediate 20.iii (2.75 g) in EA (250 ml) under argon was added Pd/C
(1.32 g). The resulting suspension was stirred under hydrogen atmosphere.
After 2.5 h, more Pd/C (0.66 g) was added and the reaction was stirred overnight under hydrogen atmosphere.
The catalyst was filtered off and the filtrate concentrated in vacuo. The residue was purified by column chromatography over Si0z (DCM-MeOH 19-1 containing 1% aq. NH4OH) to afford the title compound as a white foam (1.23 g).
iH NMR (d6-DMSO) 8: 8.62 (d, J = 4.4 Hz, 1H); 7.92 (d, J = 9.0 Hz, 1H); 7.42 (d, J = 2.5 Hz, 1H); 7.40 (dd, J = 2.7, 9.0 Hz, 1H); 7.33 (d, J = 4.4 Hz, 1H); 6.76 (br d, J =
8.0 Hz, 1H);
4.83 (d, J = 6.4 Hz, 1H); 3.91 (s, 3H); 3.90 (overlapped m, 1H); 3.74 (m, 1H);
3.38 (br. s, 1H); 3.29 (overlapped dd, visible J = 3.8 Hz, 1H); 3.12 (d, J = 10.4 Hz, 1H);
2.98 (t, J = 10.3 Hz, 1H); 2.97 (m overlapped, 1H); 1.90 (d, J = 9.2 Hz, 1H); 1.60 (m, 2H); 1.39 (s, 9H); 1.38 (m overlapped, 1H).
MS (ESI, m/z): 403.0 [M+H+].
20.v. (1 S)-1-((2S, 5R)-(5-amino-tetrahydro pyran-2 yl)-2-(6-methoxy-quinolin-4 yl)-ethanol:
A solution of intermediate 20.iv (1.23 g) in TFA (15 ml) was stirred for 10 min. The solution was concentrated to dryness, basified with a 2M aq. NaOH solution, diluted with DCM-MeOH 9-1 and the phases separated. The aq. layer was extracted 6 times with DCM-MeOH 9-1. The combined org. layers were dried over NazSO4, filtered and concentrated to dryness to afford a white solid (0.768 g).
iH NMR (DMSO) 8: 8.62 (d, J = 4.4 Hz, 1H); 7.92 (d, J = 9.1 Hz, 1H); 7.44 (d, J = 2.7 Hz, 1H); 7.39 (dd, J = 2.8, 9.1 Hz, 1H); 7.32 (d, J = 4.4 Hz, 1H); 4.79 (d, J =
6.3 Hz, 1H); 3.91 (s, 3H); 3.88 (ddd, J = 1.8, 4.4, 10.5 Hz, 1H); 3.73 (m, 1H); 3.31 (dd, J = 4.0, 13.6 Hz, 1H);
3.10 (dt, J = 3.4, 10.4 Hz, 1H); 2.93 (m overlapped, 1H); 2.87 (t overlapped, J = 10.5 Hz, 1H);
2.61 (m, 1 H); 1.92 (m, 1 H); 1.56 (m, 2H); 1.39 (br s, 2H)1.13 (m, 1 H).
MS (ESI, m/z): 303.2 [M+H+].
20.vi. (IS)-1-{(2S,5R)-5-[(E)-3-(3 fluoro phenyl)-allylaminoJ-tetrahydro pyran-2 yl}-2-(6-methoxy-quinolin-4 yl)-ethanol:
Starting from intermediate 20.v (0.1 g, 0.33 mmol) and and (E)-3-(3-fluoro-phenyl)-propenal (0.050 g, 1.0 eq.), the title compound (0.063 g, 43% yield) was obtained as a white solid using the procedure of Example 1, step l.x. The compound was purified by chromatography over Si02 using DCM-MeOH 97-3 containing 0.5% aq. NH4OH as an eluent.
MS (ESI, m/z): 437.0 [M+H+].
Example 21: 7-fluoro-6-({(3R,6S)-6-[(1S)-1-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl] -tetrahydro-pyran-3-ylamino}-methyl)-4H-benzo [1,4] thiazin-3-one:
Starting from intermediate 20.v (0.051 g, 0.17 mmol) and 7-fluoro-3-oxo-3,4-dihydro-2H-benzo[1,4]thiazine-6-carbaldehyde (obtained as described in WO 02/056882, 0.036 g, 1.0 eq.), the title compound (0.020 g, 23% yield) was obtained as a white solid using the procedure of Example 1, step l.x. The compound was purified by chromatography over Si02 using DCM-MeOH 19-1 containing 0.5% aq. NH4OH as an eluent.
iH NMR (d6-DMSO) 8: 10.55 (s, 1H); 8.62 (d, J = 4.4 Hz, 1H); 7.91 (d, J 9.0 Hz, 1H);
7.42-7.40 (m, 2H); 7.32 (d, J = 4.4 Hz, 1H); 7.20 (d, J = 9.0 Hz, 1H); 7.09 (d, J 6.8 Hz, 1H);
4.79 (d, J = 6.3 Hz, 1H); 4.04 (m, 1H); 3.90 (s, 3H); 3.77-3.71 (m, 3H); 3.46 (s, 2H); 3.30 (dd, J= 3.8, 13.1 Hz, 1H); 3.15 (m, 1H); 3.00-2.90 (m, 2H); 2.50 (overlapped m, 1H);
2.09-1.99 (m, 2H); 1.66-1.51 (m, 2H); 1.18 (m, 1H).
MS (ESI, m/z): 498.1 [M+H+].
Example 22: 3-(2-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-1-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide:
Starting from intermediate 20.v (0.1 g, 0.33 mmol) and (E)- 3-(2-fluoro-phenyl)-acrylic acid (0.055 g, 1.0 eq.), the title compound (0.085 g, 57% yield) was obtained as a white solid using the procedure of Example 2, step 2.iv. The compound was purified by chromatography over Si0z using DCM-MeOH 97-3 containing 0.5% aq. NH4OH as an eluent.
2.61 (m, 1 H); 1.92 (m, 1 H); 1.56 (m, 2H); 1.39 (br s, 2H)1.13 (m, 1 H).
MS (ESI, m/z): 303.2 [M+H+].
20.vi. (IS)-1-{(2S,5R)-5-[(E)-3-(3 fluoro phenyl)-allylaminoJ-tetrahydro pyran-2 yl}-2-(6-methoxy-quinolin-4 yl)-ethanol:
Starting from intermediate 20.v (0.1 g, 0.33 mmol) and and (E)-3-(3-fluoro-phenyl)-propenal (0.050 g, 1.0 eq.), the title compound (0.063 g, 43% yield) was obtained as a white solid using the procedure of Example 1, step l.x. The compound was purified by chromatography over Si02 using DCM-MeOH 97-3 containing 0.5% aq. NH4OH as an eluent.
MS (ESI, m/z): 437.0 [M+H+].
Example 21: 7-fluoro-6-({(3R,6S)-6-[(1S)-1-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl] -tetrahydro-pyran-3-ylamino}-methyl)-4H-benzo [1,4] thiazin-3-one:
Starting from intermediate 20.v (0.051 g, 0.17 mmol) and 7-fluoro-3-oxo-3,4-dihydro-2H-benzo[1,4]thiazine-6-carbaldehyde (obtained as described in WO 02/056882, 0.036 g, 1.0 eq.), the title compound (0.020 g, 23% yield) was obtained as a white solid using the procedure of Example 1, step l.x. The compound was purified by chromatography over Si02 using DCM-MeOH 19-1 containing 0.5% aq. NH4OH as an eluent.
iH NMR (d6-DMSO) 8: 10.55 (s, 1H); 8.62 (d, J = 4.4 Hz, 1H); 7.91 (d, J 9.0 Hz, 1H);
7.42-7.40 (m, 2H); 7.32 (d, J = 4.4 Hz, 1H); 7.20 (d, J = 9.0 Hz, 1H); 7.09 (d, J 6.8 Hz, 1H);
4.79 (d, J = 6.3 Hz, 1H); 4.04 (m, 1H); 3.90 (s, 3H); 3.77-3.71 (m, 3H); 3.46 (s, 2H); 3.30 (dd, J= 3.8, 13.1 Hz, 1H); 3.15 (m, 1H); 3.00-2.90 (m, 2H); 2.50 (overlapped m, 1H);
2.09-1.99 (m, 2H); 1.66-1.51 (m, 2H); 1.18 (m, 1H).
MS (ESI, m/z): 498.1 [M+H+].
Example 22: 3-(2-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-1-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide:
Starting from intermediate 20.v (0.1 g, 0.33 mmol) and (E)- 3-(2-fluoro-phenyl)-acrylic acid (0.055 g, 1.0 eq.), the title compound (0.085 g, 57% yield) was obtained as a white solid using the procedure of Example 2, step 2.iv. The compound was purified by chromatography over Si0z using DCM-MeOH 97-3 containing 0.5% aq. NH4OH as an eluent.
iH NMR (d6-DMSO) 8: 8.63 (d, J = 4.2 Hz, 1H); 8.13 (d, J = 7.2 Hz, 1H); 7.95 (d, J = 9.0 Hz, 1H); 7.64 (t, J = 7.2 Hz, 1H); 7.62-7.19 (m, 7H); 6.70 (d, J = 15.8 Hz, 1H);
4.87 (d, J = 6.4 Hz, 1H); 4.02 (m, 1H); 3.92 (s, 3H); 3.92-3.78 (m, 2H); 3.35 (m, 1H);
3.21 (m, 1H);
3.08-2.93 (m, 2H); 1.98 (m, 1H); 1.80-1.60 (m, 2H); 1.43 (m, 1H).
Example 23: 3-(3-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-1-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl] -tetrahydro-pyran-3-yl}-(E)-acrylamide:
Starting from intermediate 20.v (0.1 g, 0.33 mmol) and (E)- 3-(3-fluoro-phenyl)-acrylic acid (0.055 g, 1.0 eq.), the title compound (0.030 g, 20% yield) was obtained as a white solid using the procedure of Example 2, step 2.iv. The compound was purified by chromatography over Si0z using DCM-MeOH 97-3 containing 0.5% aq. NH4OH as an eluent.
iH NMR (d6-DMSO) 8: 8.63 (d, J = 4.2 Hz, 1H); 8.05 (d, J = 7.8 Hz, 1H); 7.92 (d, J = 9.0 Hz, 1H); 7.56-7.25 (m, 7H); 7.19 (m, 1H); 6.62 (d, J = 15.8 Hz, 1H); 4.87 (d, J =
6.5 Hz, 1H);
4.02 (m, 1H); 3.92 (s, 3H); 3.92-3.78 (m, 2H); 3.35 (m, 1H); 3.21 (m, 1H);
3.08-2.93 (m, 2H);
2.01 (m, 1H); 1.80-1.60 (m, 2H); 1.43 (m, 1H).
Example 24: 8-((1R,2R)-2-{(2S,5R)-5-[(E)-3-(2,5-ditluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-1,2-dihydroxy-ethyl)-quinoline-2-carbonitrile:
24.i. (3R,6S)-(6 formyl-tetrahydro pyran-3 yl)-carbamic acid tert-butyl ester:
To a solution of oxalyl chloride (3.5 ml) in DCM (25 ml) cooled to -78 C, was added dropwise a solution of DMSO (3.5 ml) in DCM (25 ml). After 15 min stirring, a solution of (3R,6S)-(6-hydroxymethyl-tetrahydro-pyran-3-yl)-carbamic acid tert-butyl ester (prepared as described in Eur. J. Org. Chem. (2003), 2418-2427) in DCM (25 ml) was added dropwise.
The reaction mixture was stirred 1 h and a solution of TEA (15 ml) in DCM (15 ml) was added dropwise. The reaction proceeded for 1 h, with warming to 0 C. Saturated NaHCO3 (50 ml) was added. The org. layer was separated, dried over NazSO4, filtered and concentrated in vacuo. The residue was chromatographed over Si0z (Hex-EA 1-2) to afford the title aldehyde (2.5 g) as a colourless solid.
24.ii. (3R, 6S)-(6-ethynyl-tetrahydro pyran-3 yl)-carbamic acid tert-butyl ester:
To a solution of p-toluenesulfonyl azide (3.08 g) in MeCN (200 ml) were added (5.38 g) and dimethyl-2-oxophosphonate (2.13 ml). The mixture was stirred 2 h at rt and a solution of intermediate 24.i (2.5 g) in MeOH (30 ml) was added. The mixture was stirred overnight at rt. After concentration to dryness, the residue was partitioned between water (50 ml) and EA (100 ml). The aq. layer was extracted with EA (2 x 100 ml). The combined org. layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness.
The residue was filtered through Si02 (EA-Hex 1-3) to afford the title alkyne (1.9 g) as a white solid.
iH NMR (CDC13) 8: 4.78 (m, 1H); 4.39 (m, 1H); 4.14 (dd, J= 3.0, 11.4 Hz, 1H);
3.71 (m, 1H); 3.34 (m, 1H); 2.5 0(d, J= 2.2 Hz, 1H); 2.11-1.99 (m, 2H); 1.73 (m, 1H);
1.60 (m, 1H);
1.46 (s, 9H).
MS (ESI, m/z): 226.2 [M+H+].
24.iii. cis, trans-[(3R, 6S)-6-(2-tributylstannanyl-vinyl)-tetrahydropyran-3 ylJ-carbamic acid tert-butyl ester:
To a solution of intermediate 24.ii (1.95 g, 8.65 mmol) in THF (26 ml) was added bis(triphenylphosphine) palladium dichloride (0.12 g, 0.17 mmol) and then tributyltin hydride (2.75 ml, 10.38 mmol). The mixture was stirred at rt for 20 min. The reaction mixture was concentrated to dryness and the residue was chromatographed over Si0z (Hex then Hex-EA
9-1) to afford the title stannane (3.4 g) as an equimolar mixture of cis and trans isomers.
24.iv. trans-{(3R, 6S)-6-[2-(6-methoxy-[], 5Jnaphthyridin-4 yl)-vinylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
To a solution of intermediate 24.iii (5 g) in dioxane (freshly distilled, 50 ml) were added trifluoromethanesulfonic acid 2-cyano-quinolin-8-yl ester (2.0 g, 6.6 mmol), LiC1 (0.936 g), 2,6-di-tert-butyl-4-methylphenol (few seeds), (PPh3)4Pd (0.153 g). The mixture was heated at 100 C overnight. After cooling, the solids were filtered off and the filtrate was concentrated to dryness. The residue was chromatographed over Si0z (Hex-EA 1-1) to afford the title alkene (1.80 g, 71% yield) as a white solid.
iH NMR (d6-DMSO) 8: 8.72 (d, J = 4.7 Hz, 1H); 8.25 (d, J = 9.0 Hz, 1H); 7.84 (d, J = 4.7 Hz, 1H); 7.55 (d, J = 16.5 Hz, 1H); 7.28 (d, J = 9.0 Hz, 1H); 6.93 (dd, J = 5.3 Hz, 16.5 Hz, 1H);
6.85 (d, J = 7.7 Hz, 1H); 4.04 (s, 3H); 4.01 (partially overlapped m, 1H);
3.90 (m, 1H);
3.39 (br s, 1H); 3.10 (t, J = 10.6 Hz, 1H); 1.89 (m, 2H); 1.50 (m, 2H); 1.39 (s, 9H).
MS (ESI, m/z): 386.1 [M+H+].
4.87 (d, J = 6.4 Hz, 1H); 4.02 (m, 1H); 3.92 (s, 3H); 3.92-3.78 (m, 2H); 3.35 (m, 1H);
3.21 (m, 1H);
3.08-2.93 (m, 2H); 1.98 (m, 1H); 1.80-1.60 (m, 2H); 1.43 (m, 1H).
Example 23: 3-(3-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-1-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl] -tetrahydro-pyran-3-yl}-(E)-acrylamide:
Starting from intermediate 20.v (0.1 g, 0.33 mmol) and (E)- 3-(3-fluoro-phenyl)-acrylic acid (0.055 g, 1.0 eq.), the title compound (0.030 g, 20% yield) was obtained as a white solid using the procedure of Example 2, step 2.iv. The compound was purified by chromatography over Si0z using DCM-MeOH 97-3 containing 0.5% aq. NH4OH as an eluent.
iH NMR (d6-DMSO) 8: 8.63 (d, J = 4.2 Hz, 1H); 8.05 (d, J = 7.8 Hz, 1H); 7.92 (d, J = 9.0 Hz, 1H); 7.56-7.25 (m, 7H); 7.19 (m, 1H); 6.62 (d, J = 15.8 Hz, 1H); 4.87 (d, J =
6.5 Hz, 1H);
4.02 (m, 1H); 3.92 (s, 3H); 3.92-3.78 (m, 2H); 3.35 (m, 1H); 3.21 (m, 1H);
3.08-2.93 (m, 2H);
2.01 (m, 1H); 1.80-1.60 (m, 2H); 1.43 (m, 1H).
Example 24: 8-((1R,2R)-2-{(2S,5R)-5-[(E)-3-(2,5-ditluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-1,2-dihydroxy-ethyl)-quinoline-2-carbonitrile:
24.i. (3R,6S)-(6 formyl-tetrahydro pyran-3 yl)-carbamic acid tert-butyl ester:
To a solution of oxalyl chloride (3.5 ml) in DCM (25 ml) cooled to -78 C, was added dropwise a solution of DMSO (3.5 ml) in DCM (25 ml). After 15 min stirring, a solution of (3R,6S)-(6-hydroxymethyl-tetrahydro-pyran-3-yl)-carbamic acid tert-butyl ester (prepared as described in Eur. J. Org. Chem. (2003), 2418-2427) in DCM (25 ml) was added dropwise.
The reaction mixture was stirred 1 h and a solution of TEA (15 ml) in DCM (15 ml) was added dropwise. The reaction proceeded for 1 h, with warming to 0 C. Saturated NaHCO3 (50 ml) was added. The org. layer was separated, dried over NazSO4, filtered and concentrated in vacuo. The residue was chromatographed over Si0z (Hex-EA 1-2) to afford the title aldehyde (2.5 g) as a colourless solid.
24.ii. (3R, 6S)-(6-ethynyl-tetrahydro pyran-3 yl)-carbamic acid tert-butyl ester:
To a solution of p-toluenesulfonyl azide (3.08 g) in MeCN (200 ml) were added (5.38 g) and dimethyl-2-oxophosphonate (2.13 ml). The mixture was stirred 2 h at rt and a solution of intermediate 24.i (2.5 g) in MeOH (30 ml) was added. The mixture was stirred overnight at rt. After concentration to dryness, the residue was partitioned between water (50 ml) and EA (100 ml). The aq. layer was extracted with EA (2 x 100 ml). The combined org. layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness.
The residue was filtered through Si02 (EA-Hex 1-3) to afford the title alkyne (1.9 g) as a white solid.
iH NMR (CDC13) 8: 4.78 (m, 1H); 4.39 (m, 1H); 4.14 (dd, J= 3.0, 11.4 Hz, 1H);
3.71 (m, 1H); 3.34 (m, 1H); 2.5 0(d, J= 2.2 Hz, 1H); 2.11-1.99 (m, 2H); 1.73 (m, 1H);
1.60 (m, 1H);
1.46 (s, 9H).
MS (ESI, m/z): 226.2 [M+H+].
24.iii. cis, trans-[(3R, 6S)-6-(2-tributylstannanyl-vinyl)-tetrahydropyran-3 ylJ-carbamic acid tert-butyl ester:
To a solution of intermediate 24.ii (1.95 g, 8.65 mmol) in THF (26 ml) was added bis(triphenylphosphine) palladium dichloride (0.12 g, 0.17 mmol) and then tributyltin hydride (2.75 ml, 10.38 mmol). The mixture was stirred at rt for 20 min. The reaction mixture was concentrated to dryness and the residue was chromatographed over Si0z (Hex then Hex-EA
9-1) to afford the title stannane (3.4 g) as an equimolar mixture of cis and trans isomers.
24.iv. trans-{(3R, 6S)-6-[2-(6-methoxy-[], 5Jnaphthyridin-4 yl)-vinylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
To a solution of intermediate 24.iii (5 g) in dioxane (freshly distilled, 50 ml) were added trifluoromethanesulfonic acid 2-cyano-quinolin-8-yl ester (2.0 g, 6.6 mmol), LiC1 (0.936 g), 2,6-di-tert-butyl-4-methylphenol (few seeds), (PPh3)4Pd (0.153 g). The mixture was heated at 100 C overnight. After cooling, the solids were filtered off and the filtrate was concentrated to dryness. The residue was chromatographed over Si0z (Hex-EA 1-1) to afford the title alkene (1.80 g, 71% yield) as a white solid.
iH NMR (d6-DMSO) 8: 8.72 (d, J = 4.7 Hz, 1H); 8.25 (d, J = 9.0 Hz, 1H); 7.84 (d, J = 4.7 Hz, 1H); 7.55 (d, J = 16.5 Hz, 1H); 7.28 (d, J = 9.0 Hz, 1H); 6.93 (dd, J = 5.3 Hz, 16.5 Hz, 1H);
6.85 (d, J = 7.7 Hz, 1H); 4.04 (s, 3H); 4.01 (partially overlapped m, 1H);
3.90 (m, 1H);
3.39 (br s, 1H); 3.10 (t, J = 10.6 Hz, 1H); 1.89 (m, 2H); 1.50 (m, 2H); 1.39 (s, 9H).
MS (ESI, m/z): 386.1 [M+H+].
24.v. (3R,6S)-{6-[(IR,2R)-2-(cyano-quinolin-8 yl)-1,2-dihydroxy-ethylJ-tetrahydro pyran-3-yl}-carbamic acid tert-butyl ester:
The title diol (1.60 g, 81% yield) was obtained as a white solid starting from intermediate 24.iv (1.80 g, 4.74 mmol) and using the procedure of Example 6, step 6.i.
MS (ESI, m/z): 419.2 [M+H+].
24.vi. 8-[(IR,2R)-2-((2S,5R)-5-amino-tetrahydro pyran-2 yl)-1,2-dihydroxy-ethylJ-quinoline-2-carbonitrile:
The title amine (0.62 g, 74% yield) was obtained as a colourless solid starting from intermediate 24.v (l.l g, 2.61 mmol) and using the procedure of Example 1, step l.ix.
MS (ESI, m/z): 314.2 [M+H+].
24.vii. 8-((IR,2R)-2-{(2S,5R)-5-[(E)-3-(2,5-difluoro phenyl)-allylaminoJ-tetrahydro pyran-2 yl}-1,2-dihydroxy-ethyl)-quinoline-2-carbonitrile:
Starting from intermediate 24.vi (0.158 g, 0.5 mmol) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.084 g, 1.0 eq.), the title compound (0.04 g, 17% yield) was obtained as a white solid according to the procedure of Example 1, step l.x. The compound was purified by chromatography over Si0z using DCM-MeOH 19-1 containing 0.5% aq. NH4OH as an eluent.
iH NMR (d6-DMSO) 8: 8.65 (d, J = 8.5 Hz, 1H); 8.07-7.99 (m, 3H); 7.80 (dd, J =
7.2, 8.3 Hz, 1H); 7.49 (m, 1H); 7.25 (m, 1H); 7.13 (m, 1H); 6.61 (d, J = 16.4 Hz, 1H); 6.48 (td, J = 5.4, 16.4 Hz, 1H); 5.77 (dd, J = 2.9, 6.3 Hz, 1H); 5.16 (d, J = 7.6 Hz, 1H); 4.3 5(d, J = 6.3 Hz, 1H); 3.91 (m, 1H); 3.60 (m, 1H); 3.42-3.32 (m, 2H), 3.24 (m, 1H); 2.81 (t, J =
10.3 Hz, 1H);
2.56 (overlapped m, 1H); 2.11 (m, 1H); 1.90 (m, 1H); 1.76 (br s, 1H); 1.56 (m, 1H); 1.24 (m, 1 H).
MS (ESI, m/z): 465.6 [M+H+].
Example 25: [(E)-3-(2,5-difluoro-phenyl)-allyl]-{3R,6S)-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-5-yl)-vinyl] -tetrahydro-pyran-3-yl}-amine:
25.i. {(3R, 6S)-6-[(E)-2-(3 fluoro-6-methoxy-quinolin-S yl)-vinylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
Starting from (3R,6S)-[6-(1-phenyl-lH-tetrazole-5-sulfonylmethyl)-tetrahydro-pyran-3-yl]-carbamic acid tert-butyl ester (described in Preparation G; 1.43 g, 3.4 mmol) and 3-fluoro-6-methoxy-quinoline-5-carbaldehyde (0.462 g, 2.25 mmol), the title alkene (0.85 g, 62%
yield) was obtained as a white solid, using the procedure of Example 1, step 1. vi. The compound was purified by chromatography over Si02 using EA-Hex 1-las eluent.
iH NMR (d6-DMSO) 8: 8.90 (d, J = 2.7 Hz, 1H); 8.32 (dd, J = 3.0, 11.4 Hz, 1H);
8.12 (d, J = 9.3 Hz, 1H); 7.78 (d, J = 9.3 Hz, 1H); 7.99 (d, J = 16.2 Hz, 1H); 6.93 (d, J = 8.1 Hz, 1H);
6.35 (dd, J = 5.7, 16.2 Hz, 1H); 4.12-3.99 (m, 2H); 4.10 (s, 3H); 3.50 (br s, 1H); 3.21 (t, J= 10.5 Hz, 1H); 2.03-2.00 (m, 2H); 1.62 (m, 1H); 1.49 (m, 1H); 1.49 (s, 9H).
25.ii. 6-[(3R,6S)-(E)-2-(3 fluoro-6-methoxy-quinolin-S yl)-vinylJ-tetrahydro pyran-3 ylamine:
The title amine (0.16 g, 71% yield) was obtained as a white solid starting from intermediate 25.i (0.3 g, 0.745 mmol) and using the procedure of Example 1, step l.ix. The compound was purified by chromatography over Si02 using DCM-MeOH 9-1 containing 1%
aq. NH4OH as eluent.
MS (ESI, m/z): 465.6 [M+H+].
25.iii. [(E)-3-(2, 5-difluoro phenyl)-allylJ-{3R, 6S)-6-[(E)-2-(3 fluoro-6-methoxy-quinolin-S yl)-vinylJ-tetrahydro pyran-3 yl}-amine:
Starting from intermediate 25.ii (0.1 g, 0.33 mmol) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.055 g, 1.0 eq.), the title compound (0.034 g, 22% yield) was obtained as a colourless oil using the procedure of Example 1, step l.x. The compound was purified by chromatography over Si0z using DCM-MeOH 19-1 containing 0.5% aq. NH4OH as an eluent.
MS (ESI, m/z): 455.0 [M+H+].
Example 26: [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3R,6S)-6-[2-(6-fluoro-3-methoxy-quinolin-4-yl)-ethyl] -tetrahydro-pyran-3-yl}-amine:
26.i. {(3R,6S)-6-[2-(6 fluoro-3-methoxy-quinolin-4 yl)-ethylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
To a solution of intermediate 25.i (0.55 g, 1.36 mmol) in EA (6 ml) and MeOH
(20 ml) was added 10% Pd/C (0.25 g). The reaction was stirred under hydrogen atmosphere for 2 h. The catalyst was removed by filtration and the filtrate was concentrated to dryness to afford the title compound (0.55 g) as a white solid.
MS (ESI, m/z): 405.0 [M+H+].
The title diol (1.60 g, 81% yield) was obtained as a white solid starting from intermediate 24.iv (1.80 g, 4.74 mmol) and using the procedure of Example 6, step 6.i.
MS (ESI, m/z): 419.2 [M+H+].
24.vi. 8-[(IR,2R)-2-((2S,5R)-5-amino-tetrahydro pyran-2 yl)-1,2-dihydroxy-ethylJ-quinoline-2-carbonitrile:
The title amine (0.62 g, 74% yield) was obtained as a colourless solid starting from intermediate 24.v (l.l g, 2.61 mmol) and using the procedure of Example 1, step l.ix.
MS (ESI, m/z): 314.2 [M+H+].
24.vii. 8-((IR,2R)-2-{(2S,5R)-5-[(E)-3-(2,5-difluoro phenyl)-allylaminoJ-tetrahydro pyran-2 yl}-1,2-dihydroxy-ethyl)-quinoline-2-carbonitrile:
Starting from intermediate 24.vi (0.158 g, 0.5 mmol) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.084 g, 1.0 eq.), the title compound (0.04 g, 17% yield) was obtained as a white solid according to the procedure of Example 1, step l.x. The compound was purified by chromatography over Si0z using DCM-MeOH 19-1 containing 0.5% aq. NH4OH as an eluent.
iH NMR (d6-DMSO) 8: 8.65 (d, J = 8.5 Hz, 1H); 8.07-7.99 (m, 3H); 7.80 (dd, J =
7.2, 8.3 Hz, 1H); 7.49 (m, 1H); 7.25 (m, 1H); 7.13 (m, 1H); 6.61 (d, J = 16.4 Hz, 1H); 6.48 (td, J = 5.4, 16.4 Hz, 1H); 5.77 (dd, J = 2.9, 6.3 Hz, 1H); 5.16 (d, J = 7.6 Hz, 1H); 4.3 5(d, J = 6.3 Hz, 1H); 3.91 (m, 1H); 3.60 (m, 1H); 3.42-3.32 (m, 2H), 3.24 (m, 1H); 2.81 (t, J =
10.3 Hz, 1H);
2.56 (overlapped m, 1H); 2.11 (m, 1H); 1.90 (m, 1H); 1.76 (br s, 1H); 1.56 (m, 1H); 1.24 (m, 1 H).
MS (ESI, m/z): 465.6 [M+H+].
Example 25: [(E)-3-(2,5-difluoro-phenyl)-allyl]-{3R,6S)-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-5-yl)-vinyl] -tetrahydro-pyran-3-yl}-amine:
25.i. {(3R, 6S)-6-[(E)-2-(3 fluoro-6-methoxy-quinolin-S yl)-vinylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
Starting from (3R,6S)-[6-(1-phenyl-lH-tetrazole-5-sulfonylmethyl)-tetrahydro-pyran-3-yl]-carbamic acid tert-butyl ester (described in Preparation G; 1.43 g, 3.4 mmol) and 3-fluoro-6-methoxy-quinoline-5-carbaldehyde (0.462 g, 2.25 mmol), the title alkene (0.85 g, 62%
yield) was obtained as a white solid, using the procedure of Example 1, step 1. vi. The compound was purified by chromatography over Si02 using EA-Hex 1-las eluent.
iH NMR (d6-DMSO) 8: 8.90 (d, J = 2.7 Hz, 1H); 8.32 (dd, J = 3.0, 11.4 Hz, 1H);
8.12 (d, J = 9.3 Hz, 1H); 7.78 (d, J = 9.3 Hz, 1H); 7.99 (d, J = 16.2 Hz, 1H); 6.93 (d, J = 8.1 Hz, 1H);
6.35 (dd, J = 5.7, 16.2 Hz, 1H); 4.12-3.99 (m, 2H); 4.10 (s, 3H); 3.50 (br s, 1H); 3.21 (t, J= 10.5 Hz, 1H); 2.03-2.00 (m, 2H); 1.62 (m, 1H); 1.49 (m, 1H); 1.49 (s, 9H).
25.ii. 6-[(3R,6S)-(E)-2-(3 fluoro-6-methoxy-quinolin-S yl)-vinylJ-tetrahydro pyran-3 ylamine:
The title amine (0.16 g, 71% yield) was obtained as a white solid starting from intermediate 25.i (0.3 g, 0.745 mmol) and using the procedure of Example 1, step l.ix. The compound was purified by chromatography over Si02 using DCM-MeOH 9-1 containing 1%
aq. NH4OH as eluent.
MS (ESI, m/z): 465.6 [M+H+].
25.iii. [(E)-3-(2, 5-difluoro phenyl)-allylJ-{3R, 6S)-6-[(E)-2-(3 fluoro-6-methoxy-quinolin-S yl)-vinylJ-tetrahydro pyran-3 yl}-amine:
Starting from intermediate 25.ii (0.1 g, 0.33 mmol) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.055 g, 1.0 eq.), the title compound (0.034 g, 22% yield) was obtained as a colourless oil using the procedure of Example 1, step l.x. The compound was purified by chromatography over Si0z using DCM-MeOH 19-1 containing 0.5% aq. NH4OH as an eluent.
MS (ESI, m/z): 455.0 [M+H+].
Example 26: [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3R,6S)-6-[2-(6-fluoro-3-methoxy-quinolin-4-yl)-ethyl] -tetrahydro-pyran-3-yl}-amine:
26.i. {(3R,6S)-6-[2-(6 fluoro-3-methoxy-quinolin-4 yl)-ethylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
To a solution of intermediate 25.i (0.55 g, 1.36 mmol) in EA (6 ml) and MeOH
(20 ml) was added 10% Pd/C (0.25 g). The reaction was stirred under hydrogen atmosphere for 2 h. The catalyst was removed by filtration and the filtrate was concentrated to dryness to afford the title compound (0.55 g) as a white solid.
MS (ESI, m/z): 405.0 [M+H+].
26.ii. (3R,6S)-6-[2-(6 fluoro-3-methoxy-quinolin-4 yl)-ethylJ-tetrahydro pyran-3 ylamine:
The title amine (0.3 g, 72% yield) was obtained as a colourless oil, starting from intermediate 26.i (0.55 g, 1.36 mmol) and using the procedure of Example 1, step l.ix. The compound was purified by chromatography over Si02 using DCM-MeOH 9-1 containing 1% aq.
NH4OH as eluent.
MS (ESI, m/z): 305.1 [M+H+].
26.iii. [(E)-3-(2,5-dfluoro phenyl)-allylJ-{(3R,6S)-6-[2-(6 fluoro-3-methoxy-quinolin-4 yl)-ethylJ-tetrahydro pyran-3 yl}-amine:
Starting from intermediate 26.ii (0.15 g, 0.49 mmol) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.082 g, 1.0 eq.), the title compound (0.17 g, 75% yield) was obtained as a colourless oil using the procedure of Example 1, step l.x. The compound was purified by chromatography over Si0z using DCM-MeOH 19-1 containing 0.5% aq. NH4OH as an eluent.
iH NMR (d6-DMSO) 8: 8.77 (d, J= 2.7 Hz, 1H); 8.12 (dd, J= 3.2, 11.2 Hz, 1H);
7.97 (d, J = 9.2 Hz, 1 H), 7.63 (d, J = 9.2 Hz, 1H); 7.48 (m, 1H); 7.24 (m, 1H); 7.11 (m, 1 H) 6.59 (d, J = 16.1 Hz, 1H); 6.48 (td, J 5.2, 16.2 Hz, 1H); 4.02 (m 1H); 3.95 (s, 3H);
3.37 (m, 2H), 3.13-2.92 (m, 3H); 2.88 (t, J= 10.5 Hz, 1H); 2.55 (m, 1H); 1.96 (m, 1H); 1.75 (br s, 1H);
1.66-1.55 (m, 3H); 1.26-1.10 (m, 2H).
MS (ESI, m/z): 456.9 [M+H+].
Example 27: 6-({(3R,6S)-6-[2-(6-fluoro-3-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-pyrido [3,2-b] [ 1,4] thiazin-3-one:
Starting from intermediate 26.ii (0.15 g, 0.49 mmol) and 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carbaldehyde (0.095 g, 1.0 eq.), the title compound (0.035 g, 17% yield) was obtained as an off-white solid using the procedure of Example 1, step 1.x. The compound was purified by chromatography over Si0z using DCM-MeOH 9-1 containing 1%
aq. NH4OH as an eluent.
MS (ESI, m/z): 482.8 [M+H+].
The title amine (0.3 g, 72% yield) was obtained as a colourless oil, starting from intermediate 26.i (0.55 g, 1.36 mmol) and using the procedure of Example 1, step l.ix. The compound was purified by chromatography over Si02 using DCM-MeOH 9-1 containing 1% aq.
NH4OH as eluent.
MS (ESI, m/z): 305.1 [M+H+].
26.iii. [(E)-3-(2,5-dfluoro phenyl)-allylJ-{(3R,6S)-6-[2-(6 fluoro-3-methoxy-quinolin-4 yl)-ethylJ-tetrahydro pyran-3 yl}-amine:
Starting from intermediate 26.ii (0.15 g, 0.49 mmol) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.082 g, 1.0 eq.), the title compound (0.17 g, 75% yield) was obtained as a colourless oil using the procedure of Example 1, step l.x. The compound was purified by chromatography over Si0z using DCM-MeOH 19-1 containing 0.5% aq. NH4OH as an eluent.
iH NMR (d6-DMSO) 8: 8.77 (d, J= 2.7 Hz, 1H); 8.12 (dd, J= 3.2, 11.2 Hz, 1H);
7.97 (d, J = 9.2 Hz, 1 H), 7.63 (d, J = 9.2 Hz, 1H); 7.48 (m, 1H); 7.24 (m, 1H); 7.11 (m, 1 H) 6.59 (d, J = 16.1 Hz, 1H); 6.48 (td, J 5.2, 16.2 Hz, 1H); 4.02 (m 1H); 3.95 (s, 3H);
3.37 (m, 2H), 3.13-2.92 (m, 3H); 2.88 (t, J= 10.5 Hz, 1H); 2.55 (m, 1H); 1.96 (m, 1H); 1.75 (br s, 1H);
1.66-1.55 (m, 3H); 1.26-1.10 (m, 2H).
MS (ESI, m/z): 456.9 [M+H+].
Example 27: 6-({(3R,6S)-6-[2-(6-fluoro-3-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-pyrido [3,2-b] [ 1,4] thiazin-3-one:
Starting from intermediate 26.ii (0.15 g, 0.49 mmol) and 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carbaldehyde (0.095 g, 1.0 eq.), the title compound (0.035 g, 17% yield) was obtained as an off-white solid using the procedure of Example 1, step 1.x. The compound was purified by chromatography over Si0z using DCM-MeOH 9-1 containing 1%
aq. NH4OH as an eluent.
MS (ESI, m/z): 482.8 [M+H+].
Example 28: (1R,2R)-1-{(2R,5S)-5-[(E)-3-(2,5-ditluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-fluoro-quinolin-4-yl)-ethane-1,2-diol:
28.i. {(3S, 6R)-6-[(E)-2-(6 fluoro-quinolin-4 yl)-vinylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
Starting from (3S,6R)-[6-(1-phenyl-lH-tetrazole-5-sulfonylmethyl)-tetrahydro-pyran-3-yl]-carbamic acid tert-butyl ester (see preparation I, 1.69 g, 4 mmol) and 3-methoxy-quinoline-5-carbaldehyde (see preparation D, 0.7 g, 4 mmol), the title alkene (1.03 g, 69% yield) was obtained as a white solid, using the procedure of Example 1, step 1. vi. The compound was purified by chromatography over Si0z using Hept-EA 1-1 then 1-4 as eluent.
MS (ESI, m/z): 373.1 [M+H+].
28.ii. {(3S,6R)-6-[(IR,2R)-2-(6 fluoro-quinolin-4 yl)-1,2-dihydroxy-ethylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
Starting from intermediate 28.i (0.497 g, 1.33 mmol), the title diol (0.54 g, 99% yield) was obtained as a white solid using the procedure of Example 6, step 6.i.The compound was purified by chromatography over Si0z using DCM-MeOH 9-1 as eluent.
MS (ESI, m/z): 407.0 [M+H+].
28.iii. (IR,2R)-1-[(2R,5S)-5-amino-tetrahydro pyran-2 ylJ-2-(6 fluoro-quinolin-4 yl)-ethane-1,2-diol:
The title amine (0.21 g, 51% yield) was obtained as a colourless foam, starting from intermediate 28.ii (0.54 g, 1.32mmol) and using the procedure of Example 1, step l.ix.
MS (ESI, m/z): 307.1 [M+H+].
28.iv. (IR,2R)-1-{(2R,5S)-5-[(E)-3-(2,5-difluoro phenyl)-allylaminoJ-tetrahydro pyran-2 yl}-2-(6 fluoro-quinolin-4 yl)-ethane-1,2-diol:
Starting from intermediate 28.iii (0.21 g, 0.68 mmol) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.115 g, 1.0 eq.), the title compound (0.095 g, 31 % yield) was obtained as a white foam using the procedure of Example 1, step l.x. The compound was purified by chromatography over Si0z using DCM-MeOH 9-1 containing 1% aq. NH4OH as an eluent.
MS (ESI, m/z): 458.9 [M+H+].
28.i. {(3S, 6R)-6-[(E)-2-(6 fluoro-quinolin-4 yl)-vinylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
Starting from (3S,6R)-[6-(1-phenyl-lH-tetrazole-5-sulfonylmethyl)-tetrahydro-pyran-3-yl]-carbamic acid tert-butyl ester (see preparation I, 1.69 g, 4 mmol) and 3-methoxy-quinoline-5-carbaldehyde (see preparation D, 0.7 g, 4 mmol), the title alkene (1.03 g, 69% yield) was obtained as a white solid, using the procedure of Example 1, step 1. vi. The compound was purified by chromatography over Si0z using Hept-EA 1-1 then 1-4 as eluent.
MS (ESI, m/z): 373.1 [M+H+].
28.ii. {(3S,6R)-6-[(IR,2R)-2-(6 fluoro-quinolin-4 yl)-1,2-dihydroxy-ethylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
Starting from intermediate 28.i (0.497 g, 1.33 mmol), the title diol (0.54 g, 99% yield) was obtained as a white solid using the procedure of Example 6, step 6.i.The compound was purified by chromatography over Si0z using DCM-MeOH 9-1 as eluent.
MS (ESI, m/z): 407.0 [M+H+].
28.iii. (IR,2R)-1-[(2R,5S)-5-amino-tetrahydro pyran-2 ylJ-2-(6 fluoro-quinolin-4 yl)-ethane-1,2-diol:
The title amine (0.21 g, 51% yield) was obtained as a colourless foam, starting from intermediate 28.ii (0.54 g, 1.32mmol) and using the procedure of Example 1, step l.ix.
MS (ESI, m/z): 307.1 [M+H+].
28.iv. (IR,2R)-1-{(2R,5S)-5-[(E)-3-(2,5-difluoro phenyl)-allylaminoJ-tetrahydro pyran-2 yl}-2-(6 fluoro-quinolin-4 yl)-ethane-1,2-diol:
Starting from intermediate 28.iii (0.21 g, 0.68 mmol) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.115 g, 1.0 eq.), the title compound (0.095 g, 31 % yield) was obtained as a white foam using the procedure of Example 1, step l.x. The compound was purified by chromatography over Si0z using DCM-MeOH 9-1 containing 1% aq. NH4OH as an eluent.
MS (ESI, m/z): 458.9 [M+H+].
Example 29: [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-(E)-6-[2-(6-fluoro-quinolin-4-yl)-vinyl] -tetrahydro-pyran-3-yl}-amine:
29.i. (3S, 6R)-6-[(E)-2-(6 fluoro-quinolin-4 yl)-vinylJ-tetrahydro pyran-3 ylamine:
The title amine (0.135 g, 82% yield) was obtained as a colourless foam, starting from intermediate 28.i (0.226 g, 0.6 mmol) and using the procedure of Example 1, step l.ix. The compound was purified by chromatography over Si02 using DCM-MeOH 9-1 containing 1%
aq. NH4OH as an eluent.
MS (ESI, m/z): 273.2 [M+H+].
29.ii. [(E)-3-(2,5-difluoro phenyl)-allylJ-{(3S,6R)-(E)-6-[2-(6 fluoro-quinolin-4 yl)-vinyl]-tetrahydro pyran-3 yl}-amine:
Starting from intermediate 29.i (0.131 g, 0.48 mmol) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.089 g, 1. 1 eq.), the title compound (0.112 g, 54% yield) was obtained as a colourless oil according to the procedure of Example 1, step l.x. The compound was purified by chromatography over Si0z using DCM-MeOH 97-3 containing 0.3% aq. NH4OH as an eluent.
iH NMR (d6-DMSO) 8: 8.82 (d, J = 4.6 Hz, 1H); 8.09 (dd, J = 5.7, 9.2 Hz, 1H);
7.97 (dd, J = 2.7, 10.6 Hz, 1H); 7.72-7.65 (M, 2H); 7.48 (m, 1H); 7.31 (d, J = 15.8 Hz, 1H); 7.24 (m, 1H); 7.11 (m, 1H); 6.63 (d, J= 15.8 Hz, 1H); 6.62 (d, J= 15.8 Hz, 1H); 6.51 (td, J = 5.5, 15.8 Hz, 1H); 4.11-4.03 (m, 2H); 3.48-3.35 (m, 2H); 3.10 (t, J = 10.5 Hz, 1H);
2.60 (m, 1H); 2.10 (m, 1H); 1.90-1.88 (m, 2H); 1.54-1.23 (m, 2H).
MS (ESI, m/z): 425.0 [M+H+].
Example 30: [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl] -tetrahydro-pyran-3-yl}-amine:
30.i. {(3S, 6R)-6-[2-(6 fluoro-quinolin-4 yl)-ethyl]-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
This alkane (0.267 g, 95% yield) was obtained as a colourless foam starting from intermediate 28.i (0.277 g, 0.74 mmol) and using the procedure of Example 2, step 2.ii. The compound was purified by chromatography over Si0z using DCM-MeOH 9-1 containing 1%
aq. NH4OH as an eluent.
MS (ESI, m/z): 375.1 [M+H+].
29.i. (3S, 6R)-6-[(E)-2-(6 fluoro-quinolin-4 yl)-vinylJ-tetrahydro pyran-3 ylamine:
The title amine (0.135 g, 82% yield) was obtained as a colourless foam, starting from intermediate 28.i (0.226 g, 0.6 mmol) and using the procedure of Example 1, step l.ix. The compound was purified by chromatography over Si02 using DCM-MeOH 9-1 containing 1%
aq. NH4OH as an eluent.
MS (ESI, m/z): 273.2 [M+H+].
29.ii. [(E)-3-(2,5-difluoro phenyl)-allylJ-{(3S,6R)-(E)-6-[2-(6 fluoro-quinolin-4 yl)-vinyl]-tetrahydro pyran-3 yl}-amine:
Starting from intermediate 29.i (0.131 g, 0.48 mmol) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.089 g, 1. 1 eq.), the title compound (0.112 g, 54% yield) was obtained as a colourless oil according to the procedure of Example 1, step l.x. The compound was purified by chromatography over Si0z using DCM-MeOH 97-3 containing 0.3% aq. NH4OH as an eluent.
iH NMR (d6-DMSO) 8: 8.82 (d, J = 4.6 Hz, 1H); 8.09 (dd, J = 5.7, 9.2 Hz, 1H);
7.97 (dd, J = 2.7, 10.6 Hz, 1H); 7.72-7.65 (M, 2H); 7.48 (m, 1H); 7.31 (d, J = 15.8 Hz, 1H); 7.24 (m, 1H); 7.11 (m, 1H); 6.63 (d, J= 15.8 Hz, 1H); 6.62 (d, J= 15.8 Hz, 1H); 6.51 (td, J = 5.5, 15.8 Hz, 1H); 4.11-4.03 (m, 2H); 3.48-3.35 (m, 2H); 3.10 (t, J = 10.5 Hz, 1H);
2.60 (m, 1H); 2.10 (m, 1H); 1.90-1.88 (m, 2H); 1.54-1.23 (m, 2H).
MS (ESI, m/z): 425.0 [M+H+].
Example 30: [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl] -tetrahydro-pyran-3-yl}-amine:
30.i. {(3S, 6R)-6-[2-(6 fluoro-quinolin-4 yl)-ethyl]-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
This alkane (0.267 g, 95% yield) was obtained as a colourless foam starting from intermediate 28.i (0.277 g, 0.74 mmol) and using the procedure of Example 2, step 2.ii. The compound was purified by chromatography over Si0z using DCM-MeOH 9-1 containing 1%
aq. NH4OH as an eluent.
MS (ESI, m/z): 375.1 [M+H+].
30.ii. (3S, 6R)-6-[2-(6 fluoro-quinolin-4 yl)-ethyl]-tetrahydro pyran-3 ylamine:
The title amine (0.155 g, 81% yield) was obtained as a yellowish oil, starting from intermediate 30.i (0.261 g, 0.7 mmol) and using the procedure of Example 1, step l.ix. The compound was purified by chromatography over Si02 using DCM-MeOH 9-1 containing 1%
aq. NH4OH as an eluent.
MS (ESI, m/z): 275.1 [M+H+].
30.iii. [(E)-3-(2,5-d fluoro phenyl)-allylJ-{(3S,6R)-6-[2-(6 fluoro-quinolin-4 yl)-ethyl]-tetrahydro pyran-3 yl}-amine:
Starting from intermediate 30.ii (0.08 g, 0.29 mmol) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.054 g, 1. 1 eq.), the title compound (0.106 g, 85% yield) was obtained as a colourless oil according to the procedure of Example 1, step l.x. The compound was purified by chromatography over Si0z using DCM-MeOH 19-1 containing 0.5% aq. NH4OH as an eluent.
MS (ESI, m/z): 426.7 [M+H+].
Example 31: 6-({3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-pyrido [3,2-b] [ 1,4] thiazin-3-one:
Starting from intermediate 30.ii (0.064 g, 0.24 mmol) and 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carbaldehyde (0.050 g, 1.0 eq.), the title compound (0.063 g, 60% yield) was obtained as a white foam using the procedure of Example 1, step l.x. The compound was purified by chromatography over Si0z using DCM-MeOH 9-1 containing 1%
aq. NH4OH as an eluent.
iH NMR (d6-DMSO) 8: 10.87 (s, 1H); 8.77 (d, J = 4.4 Hz, 1H); 8.08 (dd, J =
5.7, 9.2 Hz, 1H); 7.85 (dd, J = 2.8, 10.7 Hz, 1H); 7.73 (d, J = 7.8 Hz, 1H); 7.66 (m, 1H);
7.39 (d, J = 4.4 Hz, 1H); 7.09 (d, J = 7.8 Hz, 1H); 4.00 (m, 1H); 3.78-3.68 (m, 2H);
3.53 (s, 2H);
3.17 (m, 1H); 3.10-3.00 (m, 2H); 2.94 (t, J= 10.5 Hz, 1H); 2.50 (m, 1H); 2.11 (m, 1H);
1.99 (m, 1H); 1.79-1.65 (m, 3H); 1.32-1.11 (m, 2H).
MS (ESI, m/z): 452.8 [M+H+].
The title amine (0.155 g, 81% yield) was obtained as a yellowish oil, starting from intermediate 30.i (0.261 g, 0.7 mmol) and using the procedure of Example 1, step l.ix. The compound was purified by chromatography over Si02 using DCM-MeOH 9-1 containing 1%
aq. NH4OH as an eluent.
MS (ESI, m/z): 275.1 [M+H+].
30.iii. [(E)-3-(2,5-d fluoro phenyl)-allylJ-{(3S,6R)-6-[2-(6 fluoro-quinolin-4 yl)-ethyl]-tetrahydro pyran-3 yl}-amine:
Starting from intermediate 30.ii (0.08 g, 0.29 mmol) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.054 g, 1. 1 eq.), the title compound (0.106 g, 85% yield) was obtained as a colourless oil according to the procedure of Example 1, step l.x. The compound was purified by chromatography over Si0z using DCM-MeOH 19-1 containing 0.5% aq. NH4OH as an eluent.
MS (ESI, m/z): 426.7 [M+H+].
Example 31: 6-({3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-pyrido [3,2-b] [ 1,4] thiazin-3-one:
Starting from intermediate 30.ii (0.064 g, 0.24 mmol) and 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carbaldehyde (0.050 g, 1.0 eq.), the title compound (0.063 g, 60% yield) was obtained as a white foam using the procedure of Example 1, step l.x. The compound was purified by chromatography over Si0z using DCM-MeOH 9-1 containing 1%
aq. NH4OH as an eluent.
iH NMR (d6-DMSO) 8: 10.87 (s, 1H); 8.77 (d, J = 4.4 Hz, 1H); 8.08 (dd, J =
5.7, 9.2 Hz, 1H); 7.85 (dd, J = 2.8, 10.7 Hz, 1H); 7.73 (d, J = 7.8 Hz, 1H); 7.66 (m, 1H);
7.39 (d, J = 4.4 Hz, 1H); 7.09 (d, J = 7.8 Hz, 1H); 4.00 (m, 1H); 3.78-3.68 (m, 2H);
3.53 (s, 2H);
3.17 (m, 1H); 3.10-3.00 (m, 2H); 2.94 (t, J= 10.5 Hz, 1H); 2.50 (m, 1H); 2.11 (m, 1H);
1.99 (m, 1H); 1.79-1.65 (m, 3H); 1.32-1.11 (m, 2H).
MS (ESI, m/z): 452.8 [M+H+].
Example 32: 3-oxo-3,4-dihydro-2H-pyrido[3,2-b] [1,4]thiazine-6-carboxylic acid {(2R,3R, 6S)-2-(2-hydroxy-ethyl)-6- [(E)-2-(6-methoxy-[1,5] naphthyridin-4-yl)-vinyl] -tetrahydro-pyran-3-yl}-amide:
32.i. 3-{3-amino-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4 yl)-vinylJ-tetrahydro pyran-2 yl}-propane-l,2-diol:
Starting from intermediate l.vi (2.19 g, 4.39 mmol), the title compound (1.35 g, 85% yield) was obtained as an off-white solid using the procedure of Example 2, step 2.iii. The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 360.3 [M+H+].
32.ii. 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2R,3R,6S)-2-((2R)-2,3-dihydroxy propyl)-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4 yl)-vinylJ-tetrahydro pyran-3 yl}-amide and 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2R,3R,6S)-2-((2S)-2,3-dihydroxy propyl)-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4 yl)-vinylJ-tetrahydro pyran-3 yl}-amide:
Starting from intermediate 32.i (0.2 g, 0.55 mmol) and 3-oxo-3,4-dihydro-2H-pyrido [3,2-b] [ 1,4]thiazine-6-carboxylic acid (0.116 g, 1. 1 eq.) and using the procedure described in Example 1, step l.x., the title compounds were obtained as white solids. The isomers were partially separated by chromatography over Si0z (DCM-MeOH 93-7 containing 0.7% aq.NH4OH) to afford a first eluting isomer (0.019 g, 6% yield), a fraction containing both isomers (0.12 g, 39% yield) and the second eluting isomer (0.055 g, 18%
yield).
MS (ESI, m/z): 551.9 [M+H+] (mixture of isomers).
32.iii. 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid [6-[2-(6-methoxy-[1,5]naphthyridin-4 yl)-vinylJ-2-(2-oxo-ethyl)-tetrahydro pyran-3 ylJ-amide:
Starting from intermediate 32.ii (0.12 g, 0.21 mmol), the title aldehyde (0.09 g, 72% yield) was obtained as a white solid using the procedure of Example 2, step 2.v.
iH NMR (d6-DMSO) 8: 11.24 (s, 1H); 9.72 (s, 1H); 8.77 (d, J = 4.5 Hz, 1H);
8.34 (d, J = 9.0 Hz, 1H); 8.28 (d, J 9.0 Hz, 1H); 8.02-7.94 (m, 2H); 7.68-7.57 (m, 2H);
7.30 (d, J= 9.0 Hz, 1 H); 7.11 (dd, J 4.0, 16.8 Hz, 1 H); 4.76 (m, 1 H); 4.65 (m, 1 H);
4.05 (m, 1 H);
4.03 (s, 3H); 3.72 (s, 2H); 2.57 (m, 2H); 2.18-1.90 (m, 2H); 1.94-1.89 (m, 2H).
MS (ESI, m/z): 520.1 [M+H+].
32.i. 3-{3-amino-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4 yl)-vinylJ-tetrahydro pyran-2 yl}-propane-l,2-diol:
Starting from intermediate l.vi (2.19 g, 4.39 mmol), the title compound (1.35 g, 85% yield) was obtained as an off-white solid using the procedure of Example 2, step 2.iii. The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 360.3 [M+H+].
32.ii. 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2R,3R,6S)-2-((2R)-2,3-dihydroxy propyl)-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4 yl)-vinylJ-tetrahydro pyran-3 yl}-amide and 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2R,3R,6S)-2-((2S)-2,3-dihydroxy propyl)-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4 yl)-vinylJ-tetrahydro pyran-3 yl}-amide:
Starting from intermediate 32.i (0.2 g, 0.55 mmol) and 3-oxo-3,4-dihydro-2H-pyrido [3,2-b] [ 1,4]thiazine-6-carboxylic acid (0.116 g, 1. 1 eq.) and using the procedure described in Example 1, step l.x., the title compounds were obtained as white solids. The isomers were partially separated by chromatography over Si0z (DCM-MeOH 93-7 containing 0.7% aq.NH4OH) to afford a first eluting isomer (0.019 g, 6% yield), a fraction containing both isomers (0.12 g, 39% yield) and the second eluting isomer (0.055 g, 18%
yield).
MS (ESI, m/z): 551.9 [M+H+] (mixture of isomers).
32.iii. 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid [6-[2-(6-methoxy-[1,5]naphthyridin-4 yl)-vinylJ-2-(2-oxo-ethyl)-tetrahydro pyran-3 ylJ-amide:
Starting from intermediate 32.ii (0.12 g, 0.21 mmol), the title aldehyde (0.09 g, 72% yield) was obtained as a white solid using the procedure of Example 2, step 2.v.
iH NMR (d6-DMSO) 8: 11.24 (s, 1H); 9.72 (s, 1H); 8.77 (d, J = 4.5 Hz, 1H);
8.34 (d, J = 9.0 Hz, 1H); 8.28 (d, J 9.0 Hz, 1H); 8.02-7.94 (m, 2H); 7.68-7.57 (m, 2H);
7.30 (d, J= 9.0 Hz, 1 H); 7.11 (dd, J 4.0, 16.8 Hz, 1 H); 4.76 (m, 1 H); 4.65 (m, 1 H);
4.05 (m, 1 H);
4.03 (s, 3H); 3.72 (s, 2H); 2.57 (m, 2H); 2.18-1.90 (m, 2H); 1.94-1.89 (m, 2H).
MS (ESI, m/z): 520.1 [M+H+].
32.iv. 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2R,3R,6S)-2-(2-hydroxy-ethyl)-6-[(E)-2-(6-methoxy-[I,5]naphthyridin-4 yl)-vinylJ-tetrahydro pyran-3 yl}-amide:
To a solution of intermediate 32.iii. (0.07 g, 0.13 mmol) in MeOH (3 ml) and THF (1 ml) was added, at 0 C, NaBH4 (0.02 g). The reaction was stirred 1 h at this temperature. Water (2 ml) was added. The volatiles were removed in vacuo and the residue was chromatographed (DCM-MeOH 19-1 containing 0.5% aq. NH4OH) to afford a solid that was further triturated in ether, filtered and dried under HV. The title alcohol (0.025 g, 35% yield) was obtained as a white solid.
MS (ESI, m/z): 521.8 [M+H+].
Example 33: 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6- [(E)-2-(6-methoxy- [ 1,5] naphthyridin-4-yl)-vinyl] -tetrahydro-pyran-2-yl}-acetamide:
33.i. {(2R,3R,6S)-2-carbamoylmethyl-6-[(E)-2-(6-methoxy-[I,5]naphthyridin-4 yl)-vinylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
Starting from intermediate l.vi (5.5 g, 11 mmol), the title amide (0.602 g, 1.36 mmol) was obtained as a yellowish solid, using the procedures described respectively in Example 9, step 9.ii. (deprotection, 89% yield), Example 2, steps 2.v (aldehyde formation, 99% yield) and 2.vi (acid formation, 76% yield) and Example 9, step 9.iv (30% yield).
MS (ESI, m/z): 521.8 [M+H+].
33.ii. 2-{3-amino-6-[(E)-2-(6-methoxy-[I,5]naphthyridin-4 yl)-vinylJ-tetrahydro pyran-2 yl}-acetamide:
Starting from intermediate 33.i (0.6 g, 1.36 mmol), the title amine (0.33 g, 71% yield) was obtained as a brown solid using the procedure of Example 1, step 1.ix.
MS (ESI, m/z): 343.0 [M+H+].
33.iii. 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro phenyl)-allylaminoJ-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4 yl)-vinylJ-tetrahydro pyran-2 yl}-acetamide:
Starting from intermediate 33.ii (0.110 g, 0.32 mmol) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.059 g, 1.1 eq), the title compound (0.054 g, 34% yield) was obtained as as a white solid according to the procedure of Example 1, step l.x. The compound was purified by chromatography over Si0z (DCM-MeOH 19-1 containing 0.5% aq. NH4OH).
To a solution of intermediate 32.iii. (0.07 g, 0.13 mmol) in MeOH (3 ml) and THF (1 ml) was added, at 0 C, NaBH4 (0.02 g). The reaction was stirred 1 h at this temperature. Water (2 ml) was added. The volatiles were removed in vacuo and the residue was chromatographed (DCM-MeOH 19-1 containing 0.5% aq. NH4OH) to afford a solid that was further triturated in ether, filtered and dried under HV. The title alcohol (0.025 g, 35% yield) was obtained as a white solid.
MS (ESI, m/z): 521.8 [M+H+].
Example 33: 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6- [(E)-2-(6-methoxy- [ 1,5] naphthyridin-4-yl)-vinyl] -tetrahydro-pyran-2-yl}-acetamide:
33.i. {(2R,3R,6S)-2-carbamoylmethyl-6-[(E)-2-(6-methoxy-[I,5]naphthyridin-4 yl)-vinylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
Starting from intermediate l.vi (5.5 g, 11 mmol), the title amide (0.602 g, 1.36 mmol) was obtained as a yellowish solid, using the procedures described respectively in Example 9, step 9.ii. (deprotection, 89% yield), Example 2, steps 2.v (aldehyde formation, 99% yield) and 2.vi (acid formation, 76% yield) and Example 9, step 9.iv (30% yield).
MS (ESI, m/z): 521.8 [M+H+].
33.ii. 2-{3-amino-6-[(E)-2-(6-methoxy-[I,5]naphthyridin-4 yl)-vinylJ-tetrahydro pyran-2 yl}-acetamide:
Starting from intermediate 33.i (0.6 g, 1.36 mmol), the title amine (0.33 g, 71% yield) was obtained as a brown solid using the procedure of Example 1, step 1.ix.
MS (ESI, m/z): 343.0 [M+H+].
33.iii. 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro phenyl)-allylaminoJ-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4 yl)-vinylJ-tetrahydro pyran-2 yl}-acetamide:
Starting from intermediate 33.ii (0.110 g, 0.32 mmol) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.059 g, 1.1 eq), the title compound (0.054 g, 34% yield) was obtained as as a white solid according to the procedure of Example 1, step l.x. The compound was purified by chromatography over Si0z (DCM-MeOH 19-1 containing 0.5% aq. NH4OH).
MS (ESI, m/z): 495.0 [M+H+].
Example 34: (2R,3R,6S)-{3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-vinyl] -tetrahydro-pyran-2-yl}-acetic acid:
34.i. 3 fluoro-6-methoxy-quinoline-4-carbaldehyde:
To a solution of DIPA (3.5 ml) in THF (100 ml), cooled to -78 C, was added n-BuLi (2.5N in hexanes, 10 ml). The reaction mixture was stirred 5 min at this temperature before warming to 0 C. The reaction mixture was stirred 15 min before cooling to -78 C. 3-fluoro-6-methoxy-quinoline (4.38 g, 24.7 mmol) in THF (20 ml + 5 ml rinse) was added and the mixture was stirred 3 h at -78 C. DMF (3 ml) was added dropwise. After 15 min, the reaction mixture was warmed up to rt. 10% aq. NaHSO4 (10 ml) was added. The volatiles were removed in vacuo and the residue was made basic with sat. sodium bicarbonate. The aq. layer was extracted twice with EA (2 x 200 ml). The combined org. layers were washed with brine, dried over NazSO4, filtered and concentrated to dryness. The residue was chromatographed (Hex-EA
1-1) to afford the title aldehyde (3.05 g, 60% yield) as a yellowish solid.
The compound was contaminated by 20% of the remaining starting material.
iH NMR (CDC13) 8: 10.86 (s, 1H); 8.81 (d, J = 1.8 Hz, 1H); 8.50 (d, J = 2.8 Hz, 1H); 8.03 (d, J = 9.2 Hz, 1H); 7.40 (dd, J = 2.8, 9.2 Hz, 1H); 4.01 (s, 3H).
34.ii. {(2R,3R,6S)-2-[(4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethylJ-6-[(E)-2-(3 fluoro-6-methoxy-quinolin-4 yl)-vinylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
Starting from intermediate 34.i (3.05 g, 11.9 mmol) and intermediate 1.v (6.95 g, 12.9 mmol), the title alkene (5.38 g, 80% yield) was obtained as a pale yellow foam using the procedure of Example 1, step l.vi. The compound was purified by chromatography using Hept-EA 1-2 as an eluent. The compound was obtained as a 2-1 mixture of epimers and a 3-1 E-Z
mixture.
MS (ESI, m/z): 517.1 [M+H+].
34.iii. (2RS)-3-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro phenyl)-allylaminoJ-6-[(E)-2-(3 fluoro-6-methoxy-quinolin-4 yl)-vinylJ-tetrahydro pyran-2 yl} propane-l,2-diol:
Starting from intermediate 34.ii (2.63 g, 5.1 mmol), the title compound (1.62 g) was obtained as a yellowish foam, using the procedures described in Example 2, step 2.iii (deprotection, 67% yield) and in Example 1, step l.x (reductive amination, 91% yield). After each step, the crude reaction mixture was purified by chromatography over Si0z using respectively DCM-MeOH 6-1 containing 1% aq. NH4OH and DCM-MeOH 9-1 containing 1% aq.
NH4OH as eluents. The compound was obtained as a 2-1 mixture of epimers and a mixture.
MS (ESI, m/z): 567.7 [M+H+].
34.iv. (2R,3R,6S)-{3-[(E)-3-(2,5-difluoro phenyl)-allylaminoJ-6-[(E)-2-(3 fluoro-6-methoxy-quinolin-4 yl)-vinylJ-tetrahydro pyran-2 yl}-acetic acid:
Starting from intermediate 34.iii (1.58 g, 3 mmol), the title compound (0.037 g) was obtained as an off-white solid using the procedures described in Example 4, step 4.iii (Boc formation, 74% yield), Example 2, steps 2.v (aldehyde formation, 82% yield) and 2.vi (acid formation, 98% yield), and Example 4, step 4.vi (52% yield). The compound was purified by chromatography over Si0z using DCM-MeOH 6-1 containing 1% aq. NH4OH) after the last step. The compound was obtained as a 2-1 E-Z mixture.
MS (ESI, m/z): 513.0 [M+H+].
Example 35: {(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid:
35.i. (2RS)-3-{(2R,3R,6S)-3-[(E)-3-(2,5-dfluoro phenyl)-allylaminoJ-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4 yl)-vinylJ-tetrahydro pyran-2 yl} propane-l,2-diol:
Starting from intermediate 32.i (1.43 g, 4 mmol) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.672 g, 1.0 eq), the title compound (1.34 g, 65% yield) was obtained as as a colourless foam using the procedure of Example 1, step l.x. After purification by chromatography over Si0z (DCM-MeOH 9-1 containing 1% aq. NH4OH), the compound was obtained as a 2-1 mixture of epimers.
iH NMR (d6-DMSO) 8: 8.71 (d, J = 4.6 Hz, 1H); 8.24 (d, J = 9.0 Hz, 1H); 7.84 (d, J = 4.5 Hz, 0.33H); 7.82 (d, J = 4.5 Hz, 0.67H); 7.58-7.45 (m, 2H); 7.27 (d, J = 9.0 Hz, 1H); 7.25 (m, 1H); 7.12 (m, 1H); 7.01-6.92 (m, 1 H), 6.63 (d, J = 16.1 Hz, 1H); 6.51 (td, J
= 5.1, 16.1 Hz, 1H); 4.68 (br s, 0.67H); 4.51-4.35 (m, 2.33H); 4.21 (m, 0.67H); 4.11 (m, 0.33H); 4.04 (s, 3 x 0.33H); 4.02 (s, 3 x 0.67H); 3.62 (m, 1H); 3.39-3.25 (m, 4H); 2.75 (m, 1H);
2.05-1.37 (m, 7H).
MS (ESI, m/z): 512.0 [M+H+].
Example 34: (2R,3R,6S)-{3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-vinyl] -tetrahydro-pyran-2-yl}-acetic acid:
34.i. 3 fluoro-6-methoxy-quinoline-4-carbaldehyde:
To a solution of DIPA (3.5 ml) in THF (100 ml), cooled to -78 C, was added n-BuLi (2.5N in hexanes, 10 ml). The reaction mixture was stirred 5 min at this temperature before warming to 0 C. The reaction mixture was stirred 15 min before cooling to -78 C. 3-fluoro-6-methoxy-quinoline (4.38 g, 24.7 mmol) in THF (20 ml + 5 ml rinse) was added and the mixture was stirred 3 h at -78 C. DMF (3 ml) was added dropwise. After 15 min, the reaction mixture was warmed up to rt. 10% aq. NaHSO4 (10 ml) was added. The volatiles were removed in vacuo and the residue was made basic with sat. sodium bicarbonate. The aq. layer was extracted twice with EA (2 x 200 ml). The combined org. layers were washed with brine, dried over NazSO4, filtered and concentrated to dryness. The residue was chromatographed (Hex-EA
1-1) to afford the title aldehyde (3.05 g, 60% yield) as a yellowish solid.
The compound was contaminated by 20% of the remaining starting material.
iH NMR (CDC13) 8: 10.86 (s, 1H); 8.81 (d, J = 1.8 Hz, 1H); 8.50 (d, J = 2.8 Hz, 1H); 8.03 (d, J = 9.2 Hz, 1H); 7.40 (dd, J = 2.8, 9.2 Hz, 1H); 4.01 (s, 3H).
34.ii. {(2R,3R,6S)-2-[(4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethylJ-6-[(E)-2-(3 fluoro-6-methoxy-quinolin-4 yl)-vinylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
Starting from intermediate 34.i (3.05 g, 11.9 mmol) and intermediate 1.v (6.95 g, 12.9 mmol), the title alkene (5.38 g, 80% yield) was obtained as a pale yellow foam using the procedure of Example 1, step l.vi. The compound was purified by chromatography using Hept-EA 1-2 as an eluent. The compound was obtained as a 2-1 mixture of epimers and a 3-1 E-Z
mixture.
MS (ESI, m/z): 517.1 [M+H+].
34.iii. (2RS)-3-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro phenyl)-allylaminoJ-6-[(E)-2-(3 fluoro-6-methoxy-quinolin-4 yl)-vinylJ-tetrahydro pyran-2 yl} propane-l,2-diol:
Starting from intermediate 34.ii (2.63 g, 5.1 mmol), the title compound (1.62 g) was obtained as a yellowish foam, using the procedures described in Example 2, step 2.iii (deprotection, 67% yield) and in Example 1, step l.x (reductive amination, 91% yield). After each step, the crude reaction mixture was purified by chromatography over Si0z using respectively DCM-MeOH 6-1 containing 1% aq. NH4OH and DCM-MeOH 9-1 containing 1% aq.
NH4OH as eluents. The compound was obtained as a 2-1 mixture of epimers and a mixture.
MS (ESI, m/z): 567.7 [M+H+].
34.iv. (2R,3R,6S)-{3-[(E)-3-(2,5-difluoro phenyl)-allylaminoJ-6-[(E)-2-(3 fluoro-6-methoxy-quinolin-4 yl)-vinylJ-tetrahydro pyran-2 yl}-acetic acid:
Starting from intermediate 34.iii (1.58 g, 3 mmol), the title compound (0.037 g) was obtained as an off-white solid using the procedures described in Example 4, step 4.iii (Boc formation, 74% yield), Example 2, steps 2.v (aldehyde formation, 82% yield) and 2.vi (acid formation, 98% yield), and Example 4, step 4.vi (52% yield). The compound was purified by chromatography over Si0z using DCM-MeOH 6-1 containing 1% aq. NH4OH) after the last step. The compound was obtained as a 2-1 E-Z mixture.
MS (ESI, m/z): 513.0 [M+H+].
Example 35: {(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid:
35.i. (2RS)-3-{(2R,3R,6S)-3-[(E)-3-(2,5-dfluoro phenyl)-allylaminoJ-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4 yl)-vinylJ-tetrahydro pyran-2 yl} propane-l,2-diol:
Starting from intermediate 32.i (1.43 g, 4 mmol) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.672 g, 1.0 eq), the title compound (1.34 g, 65% yield) was obtained as as a colourless foam using the procedure of Example 1, step l.x. After purification by chromatography over Si0z (DCM-MeOH 9-1 containing 1% aq. NH4OH), the compound was obtained as a 2-1 mixture of epimers.
iH NMR (d6-DMSO) 8: 8.71 (d, J = 4.6 Hz, 1H); 8.24 (d, J = 9.0 Hz, 1H); 7.84 (d, J = 4.5 Hz, 0.33H); 7.82 (d, J = 4.5 Hz, 0.67H); 7.58-7.45 (m, 2H); 7.27 (d, J = 9.0 Hz, 1H); 7.25 (m, 1H); 7.12 (m, 1H); 7.01-6.92 (m, 1 H), 6.63 (d, J = 16.1 Hz, 1H); 6.51 (td, J
= 5.1, 16.1 Hz, 1H); 4.68 (br s, 0.67H); 4.51-4.35 (m, 2.33H); 4.21 (m, 0.67H); 4.11 (m, 0.33H); 4.04 (s, 3 x 0.33H); 4.02 (s, 3 x 0.67H); 3.62 (m, 1H); 3.39-3.25 (m, 4H); 2.75 (m, 1H);
2.05-1.37 (m, 7H).
MS (ESI, m/z): 512.0 [M+H+].
35.ii. [(E)-3-(2, 5-difluoro phenyl)-allylJ-{(2R, 3R, 6S)-2-[(2RS)-2, 3-dihydroxy propylJ-6-[2-(6-methoxy-[1,5]naphthyridin-4 yl)-vinylJ-tetrahydro pyran-3 yl}-carbamic acid tert-butyl ester:
To a solution of intermediate 35.i (1.34 g, 2.62 mmol) in DCM (13 ml) was added di-tert-butyl dicarbonate (0.9 g) and TEA (0.75 ml). The mixture was stirred at rt for 24 h.
Di-tert-butyl dicarbonate (0.5 g) was added and the reaction proceeded further 24 h. The reaction mixture was concentrated to dryness and the residue was chromatographed over Si02 (DCM-MeOH 19-1 then 9-1) to afford the title compound (0.77 g, 48% yield) as a colourless foam.
'H NMR (CDC13) 8: 8.71 (d, J = 4.7 Hz, 1H); 8.23 (d, J = 9.0 Hz, 0.67H); 8.22 (d, J = 9.0 Hz, 0.33H); 7.68-7.61 (m, 2H); 7.14 (d, J= 9.0 Hz, 1H); 7.13 (m, 1H); 7.01 (m, 1H); 6.94 (m, 1H); 6.77 (dd, J = 5.6, 16.5 Hz, 1 H), 6.5 7(d, J = 16.1 Hz, 1H); 6.29 (td, J
= 5.1, 16.1 Hz, 1H);
4.64 (m, 0.33H); 4.48-4.24 (m, 3.67H); 4.12 (s, 3 x 0.33H); 4.11 (s, 3 x 0.67H); 4.10-3.92 (m, 2H); 3.71 (app td, J = 3.4, 11.0 Hz, 1H); 3.58 (m, 1H); 2.31-1.71 (m, 8H);
1.50 (s, 9H).
35.iii. {(2R,3R,6S)-3-{tert-butoxycarbonyl-[(E)-3-(2,5-difluoro phenyl)-allylJ-amino}-6-[(E)-2-(6-methoxy-[],5Jnaphthyridin-4 yl)-vinylJ-tetrahydro pyran-2 yl}-acetic acid:
Starting from intermediate 35.ii (0.77 g, 1.25mmo1), the title acid (0.48 g) was prepared as a colourless foam using the procedures described in Example 2, steps 2.v (aldehyde formation, 82% yield) and 2.vi (acid formation, 98% yield). The compound was purified by chromatography over Si0z using DCM-MeOH 93-7) after the last step.
iH NMR (d6-DMSO) 8: 12.19 (br s, 1H); 8.72 (d, J = 4.8 Hz, 1H); 8.25 (d, J =
9.0 Hz, 1H);
7.85 (d, J = 4.8 Hz, 1H); 7.57-7.47 (m, 2H); 7.27 (d, J = 9.0 Hz, 1H); 7,24 (m, 1H); 7.13 (m, 1H); 6.91 (dd, J = 16.1, 5.3 Hz, 1 H); 6.52 (d, J = 16.1 Hz, 1H); 6.43 (td, J
= 5.0, 16.1 Hz, 1H); 4.55-4.45 (m, 2 H); 4.27-4.04 (m, 2H); 4.04 (s, 3H); 3.85 (dd, J = 4.8, 16.9 Hz, 1H);
2.88 (dd, J = 9.8, 14.7 Hz, 1H); 2.38 (dd, J = 4.6, 14.7 Hz, 1H); 2.17 (m, 1 H); 2.02-1.85 (m, 2H); 1.61 (m, 1 H); 1.40 (s, 9 H).
35.iv. {(2R,3R,6S)-3-[(E)-3-(2,5-difluoro phenyl)-allylaminoJ-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4 yl)-vinylJ-tetrahydro pyran-2 yl}-acetic acid:
A solution of intermediate 35.iii. (0.1 g, 0.17 mmol) in TFA (2 ml) was stirred at rt for 15 min. The solvent was removed in vacuo and the residue was taken up in water (10 ml) and DCM-MeOH (9-1, 30 ml). The pH of the aq. layer was adjusted to 7 and the org.
layer was separated. The aq. layer was extracted once more with DCM-MeOH (9-1, 30 ml) and the combined org. layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was triturated in ether and the solid was filtered off, dried under HV to afford the title compound (0.045 g, 54% yield) as a colourless solid.
MS (ESI, m/z): 496.4 [M+H+].
Example 36: [(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-(6-methoxy-[1,5]naphthyridin-4-ylcarbamoyl)-tetrahydro-pyran-2-yl]-acetic acid:
36.i. (2S,5R,6R)-5-tert-butoxycarbonylamino-6-[(4RS)2,2-dimethyl-[1,3]dioxolan-4 ylmethylJ-tetrahydro pyran-2-carboxylic acid:
To an ice-chilled solution of intermediate l.ii (5 g, 14.48 mmol) in DCM (32 ml), MeCN
(32 ml) and water (46 ml) was added Na104 (14.6 g, 68.17 mmol) and RuC13 (0.030 g, 0.15 mmol). The reaction mixture was stirred at the same temperature for 5 h.
The reaction mixture was diluted with EA (150 ml) and the solids were removed by filtration. MeOH
(30 ml) was added and the resulting suspension was filtered. The filtrate was treated with aq.
10% NaHSO3 (60 ml). The phases were separated and the aq. layer was extracted three times with EA. The combined org. layers were washed with brine, dried over NazSO4, filtered and evaporated under reduced pressure to give a brown foam (quant.). The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 360.1 [M+H+].
36.ii. {(2S,5R,6R)-6-carbamoyl-2-[(4RS)-2,2-dimethyl-[],3Jdioxolan-4 ylmethylJ-tetrahydro-pyran-3 yl}-carbamic acid tert-butyl ester:
Starting from intermediate 36.i (5.27 g, 14.6 mmol), the title amide (3.16 g, 60% yield) was obtained as a colourless foam using the procedure of Example 10, step 10.ii.
The compound was purified by chromatography using EA-cyclohexane 4-1 as an eluent. The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 359.1 [M+H+].
36.iii. {(2S,5R,6R)-2-[(4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-6-(6-methoxy-[1,5]naphthyridin-4 ylcarbamoyl)-tetrahydro pyran-3 ylJ-carbamic acid tert-butyl ester:
To a mixture of intermediate 36.ii (2.3 g, 6.42 mmol), rac-BINAP (0.288 g, 0.46 mmol), (dba)3Pd2.CHC13 (0.120 g, 0.12 mmol) and cesium carbonate (2.56 g, 7.86 mmol) was added dioxane (82 ml). The mixture was sonicated for 10 min, whereupon trifluoro-methanesulfonic acid 6-methoxy-[1,5]naphthyridin-4-yl ester (prepared as described in WO
03/064431, 2.10 g, 6.81 mmol) was added in one portion. The resulting mixture was heated at 100 C
for 4 h. The reaction mixture was filtrated through a pad of celite and the filtrate was concentrated in vacuo. The residue was purified over Si02 (DCM-MeOH 19-1) to afford the title amide (reddish foam; 3.27 g, 6.32 mmol) as a 2-1 mixture of epimers.
MS (ESI, m/z): 477.0 [M+H+].
36.iv. (2S, 5R, 6S)-5-amino-6-[(2RS)-2, 3-dihydroxy propylJ-tetrahydro pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4 yl)-amide:
Starting from intermediate 36.iii (2.72 g, 2.06 mmol), the title amine (1.27 g, 64% yield) was obtained as a reddish solid using the procedure of Example 1, step l.viii. The compound was purified by chromatography using DCM-MeOH 6-1 containing 1% aq. NH4OH as an eluent.
The compound was obtained as a 2-1 mixture of epimers.
iH NMR (d6-DMSO) 8: 10.59 (s, 0.66H); 10.51 (s, 0.34H); 8.70 (d, J = 5.0 Hz, 1H); 8.45 (d, J = 5.0 Hz, 0.34H); 8.39 (d, J = 5.0 Hz, 0.66H); 8.28 (d, J = 9.0 Hz, 1H);
7.33 (d, J = 9.0 Hz, 1H); 4.50 (br s, 1H); 4.47 (dd, J = 4.3, 7.0 Hz, 0.34H); 4.31 (dd, J = 3.5, 9.0 Hz, 0.66H);
4.11 (m, 0.66H); 4.09 (s, 3 x 0.34H); 4.08 (s, 3 x 0.66H); 3.96 (m, 0.34H);
3.63 (m, 1H);
3.37-3.21 (m, 5H), 2.97 (m, 0.66H); 2.91 (m, 0.34H); 2.08 (m, 1H); 1.96 (m, 0.66H);
1.82-1.42 (m, 4.34H).
MS (ESI, m/z): 377.0 [M+H+].
36.v. (2S,5R,6R)-5-[(E)-3-(2,5-difluoro phenyl)-allylaminoJ-6-[(2RS)-2,3-dihydroxy propyl]-tetrahydro pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4 yl)-amide:
To a solution of intermediate 36.iv (1.0 g, 2.65 mmol) in 1,2-DCE (30 ml) and MeOH (10 ml) were added 3A molecular sieves (10 g) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.49 g, 1.1 eq). The mixture was heated at 50 C for 18 h. After cooling to 0 C, NaBH4 (1 g) was added, and the reaction proceeded for 45 min. The reaction mixture was filtered and the solids were washed with DCM-MeOH (9-1, 200 ml). The filtrate was washed with brine (50 ml), dried over NazSO4, filtered and concentrated to dryness. The residue was chromatographed (DCM-MeOH 93-7 containing 0.7% aq. NH4OH) to afford the title diol (1.1 g, 78%
yield) as a colourless foam. The compound was obtained as a 2-1 mixture of epimers.
iH NMR (d6-DMSO) 8: 10.64 (s, 0.66H); 10.56 (s, 0.34H); 8.69 (d. J = 5.0 Hz, 1H); 8.42 (d, J = 5.0 Hz, 0.34H); 8.37 (d, J = 5.0 Hz, 0.66H); 8.28 (d, J = 9.0 Hz, 1H);
7.49 (m, 1H);
To a solution of intermediate 35.i (1.34 g, 2.62 mmol) in DCM (13 ml) was added di-tert-butyl dicarbonate (0.9 g) and TEA (0.75 ml). The mixture was stirred at rt for 24 h.
Di-tert-butyl dicarbonate (0.5 g) was added and the reaction proceeded further 24 h. The reaction mixture was concentrated to dryness and the residue was chromatographed over Si02 (DCM-MeOH 19-1 then 9-1) to afford the title compound (0.77 g, 48% yield) as a colourless foam.
'H NMR (CDC13) 8: 8.71 (d, J = 4.7 Hz, 1H); 8.23 (d, J = 9.0 Hz, 0.67H); 8.22 (d, J = 9.0 Hz, 0.33H); 7.68-7.61 (m, 2H); 7.14 (d, J= 9.0 Hz, 1H); 7.13 (m, 1H); 7.01 (m, 1H); 6.94 (m, 1H); 6.77 (dd, J = 5.6, 16.5 Hz, 1 H), 6.5 7(d, J = 16.1 Hz, 1H); 6.29 (td, J
= 5.1, 16.1 Hz, 1H);
4.64 (m, 0.33H); 4.48-4.24 (m, 3.67H); 4.12 (s, 3 x 0.33H); 4.11 (s, 3 x 0.67H); 4.10-3.92 (m, 2H); 3.71 (app td, J = 3.4, 11.0 Hz, 1H); 3.58 (m, 1H); 2.31-1.71 (m, 8H);
1.50 (s, 9H).
35.iii. {(2R,3R,6S)-3-{tert-butoxycarbonyl-[(E)-3-(2,5-difluoro phenyl)-allylJ-amino}-6-[(E)-2-(6-methoxy-[],5Jnaphthyridin-4 yl)-vinylJ-tetrahydro pyran-2 yl}-acetic acid:
Starting from intermediate 35.ii (0.77 g, 1.25mmo1), the title acid (0.48 g) was prepared as a colourless foam using the procedures described in Example 2, steps 2.v (aldehyde formation, 82% yield) and 2.vi (acid formation, 98% yield). The compound was purified by chromatography over Si0z using DCM-MeOH 93-7) after the last step.
iH NMR (d6-DMSO) 8: 12.19 (br s, 1H); 8.72 (d, J = 4.8 Hz, 1H); 8.25 (d, J =
9.0 Hz, 1H);
7.85 (d, J = 4.8 Hz, 1H); 7.57-7.47 (m, 2H); 7.27 (d, J = 9.0 Hz, 1H); 7,24 (m, 1H); 7.13 (m, 1H); 6.91 (dd, J = 16.1, 5.3 Hz, 1 H); 6.52 (d, J = 16.1 Hz, 1H); 6.43 (td, J
= 5.0, 16.1 Hz, 1H); 4.55-4.45 (m, 2 H); 4.27-4.04 (m, 2H); 4.04 (s, 3H); 3.85 (dd, J = 4.8, 16.9 Hz, 1H);
2.88 (dd, J = 9.8, 14.7 Hz, 1H); 2.38 (dd, J = 4.6, 14.7 Hz, 1H); 2.17 (m, 1 H); 2.02-1.85 (m, 2H); 1.61 (m, 1 H); 1.40 (s, 9 H).
35.iv. {(2R,3R,6S)-3-[(E)-3-(2,5-difluoro phenyl)-allylaminoJ-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4 yl)-vinylJ-tetrahydro pyran-2 yl}-acetic acid:
A solution of intermediate 35.iii. (0.1 g, 0.17 mmol) in TFA (2 ml) was stirred at rt for 15 min. The solvent was removed in vacuo and the residue was taken up in water (10 ml) and DCM-MeOH (9-1, 30 ml). The pH of the aq. layer was adjusted to 7 and the org.
layer was separated. The aq. layer was extracted once more with DCM-MeOH (9-1, 30 ml) and the combined org. layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was triturated in ether and the solid was filtered off, dried under HV to afford the title compound (0.045 g, 54% yield) as a colourless solid.
MS (ESI, m/z): 496.4 [M+H+].
Example 36: [(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-(6-methoxy-[1,5]naphthyridin-4-ylcarbamoyl)-tetrahydro-pyran-2-yl]-acetic acid:
36.i. (2S,5R,6R)-5-tert-butoxycarbonylamino-6-[(4RS)2,2-dimethyl-[1,3]dioxolan-4 ylmethylJ-tetrahydro pyran-2-carboxylic acid:
To an ice-chilled solution of intermediate l.ii (5 g, 14.48 mmol) in DCM (32 ml), MeCN
(32 ml) and water (46 ml) was added Na104 (14.6 g, 68.17 mmol) and RuC13 (0.030 g, 0.15 mmol). The reaction mixture was stirred at the same temperature for 5 h.
The reaction mixture was diluted with EA (150 ml) and the solids were removed by filtration. MeOH
(30 ml) was added and the resulting suspension was filtered. The filtrate was treated with aq.
10% NaHSO3 (60 ml). The phases were separated and the aq. layer was extracted three times with EA. The combined org. layers were washed with brine, dried over NazSO4, filtered and evaporated under reduced pressure to give a brown foam (quant.). The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 360.1 [M+H+].
36.ii. {(2S,5R,6R)-6-carbamoyl-2-[(4RS)-2,2-dimethyl-[],3Jdioxolan-4 ylmethylJ-tetrahydro-pyran-3 yl}-carbamic acid tert-butyl ester:
Starting from intermediate 36.i (5.27 g, 14.6 mmol), the title amide (3.16 g, 60% yield) was obtained as a colourless foam using the procedure of Example 10, step 10.ii.
The compound was purified by chromatography using EA-cyclohexane 4-1 as an eluent. The compound was obtained as a 2-1 mixture of epimers.
MS (ESI, m/z): 359.1 [M+H+].
36.iii. {(2S,5R,6R)-2-[(4RS)-2,2-dimethyl-[1,3]dioxolan-4 ylmethyl)-6-(6-methoxy-[1,5]naphthyridin-4 ylcarbamoyl)-tetrahydro pyran-3 ylJ-carbamic acid tert-butyl ester:
To a mixture of intermediate 36.ii (2.3 g, 6.42 mmol), rac-BINAP (0.288 g, 0.46 mmol), (dba)3Pd2.CHC13 (0.120 g, 0.12 mmol) and cesium carbonate (2.56 g, 7.86 mmol) was added dioxane (82 ml). The mixture was sonicated for 10 min, whereupon trifluoro-methanesulfonic acid 6-methoxy-[1,5]naphthyridin-4-yl ester (prepared as described in WO
03/064431, 2.10 g, 6.81 mmol) was added in one portion. The resulting mixture was heated at 100 C
for 4 h. The reaction mixture was filtrated through a pad of celite and the filtrate was concentrated in vacuo. The residue was purified over Si02 (DCM-MeOH 19-1) to afford the title amide (reddish foam; 3.27 g, 6.32 mmol) as a 2-1 mixture of epimers.
MS (ESI, m/z): 477.0 [M+H+].
36.iv. (2S, 5R, 6S)-5-amino-6-[(2RS)-2, 3-dihydroxy propylJ-tetrahydro pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4 yl)-amide:
Starting from intermediate 36.iii (2.72 g, 2.06 mmol), the title amine (1.27 g, 64% yield) was obtained as a reddish solid using the procedure of Example 1, step l.viii. The compound was purified by chromatography using DCM-MeOH 6-1 containing 1% aq. NH4OH as an eluent.
The compound was obtained as a 2-1 mixture of epimers.
iH NMR (d6-DMSO) 8: 10.59 (s, 0.66H); 10.51 (s, 0.34H); 8.70 (d, J = 5.0 Hz, 1H); 8.45 (d, J = 5.0 Hz, 0.34H); 8.39 (d, J = 5.0 Hz, 0.66H); 8.28 (d, J = 9.0 Hz, 1H);
7.33 (d, J = 9.0 Hz, 1H); 4.50 (br s, 1H); 4.47 (dd, J = 4.3, 7.0 Hz, 0.34H); 4.31 (dd, J = 3.5, 9.0 Hz, 0.66H);
4.11 (m, 0.66H); 4.09 (s, 3 x 0.34H); 4.08 (s, 3 x 0.66H); 3.96 (m, 0.34H);
3.63 (m, 1H);
3.37-3.21 (m, 5H), 2.97 (m, 0.66H); 2.91 (m, 0.34H); 2.08 (m, 1H); 1.96 (m, 0.66H);
1.82-1.42 (m, 4.34H).
MS (ESI, m/z): 377.0 [M+H+].
36.v. (2S,5R,6R)-5-[(E)-3-(2,5-difluoro phenyl)-allylaminoJ-6-[(2RS)-2,3-dihydroxy propyl]-tetrahydro pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4 yl)-amide:
To a solution of intermediate 36.iv (1.0 g, 2.65 mmol) in 1,2-DCE (30 ml) and MeOH (10 ml) were added 3A molecular sieves (10 g) and (E)-3-(2,5-difluoro-phenyl)-propenal (0.49 g, 1.1 eq). The mixture was heated at 50 C for 18 h. After cooling to 0 C, NaBH4 (1 g) was added, and the reaction proceeded for 45 min. The reaction mixture was filtered and the solids were washed with DCM-MeOH (9-1, 200 ml). The filtrate was washed with brine (50 ml), dried over NazSO4, filtered and concentrated to dryness. The residue was chromatographed (DCM-MeOH 93-7 containing 0.7% aq. NH4OH) to afford the title diol (1.1 g, 78%
yield) as a colourless foam. The compound was obtained as a 2-1 mixture of epimers.
iH NMR (d6-DMSO) 8: 10.64 (s, 0.66H); 10.56 (s, 0.34H); 8.69 (d. J = 5.0 Hz, 1H); 8.42 (d, J = 5.0 Hz, 0.34H); 8.37 (d, J = 5.0 Hz, 0.66H); 8.28 (d, J = 9.0 Hz, 1H);
7.49 (m, 1H);
7.32 (d, J = 9.0 Hz, 1 H); 7.27 (m, 1 H); 7.12 (m, 1 H); 6.63 (d, J = 16.2 Hz, 1 H); 6.49 (m, 1 H);
4.52-4.42 (m, 3H); 4.26 (m, 1H); 4.06 (s, 3 x 0.34H); 4.04 (s, 3 x 0.66H);
3.65 (m, 1H);
3.44-3.24 (m, 4H); 2.81 (m, 1H); 2.12-1.41 (m, 7H).
MS (ESI, m/z): 529.0 [M+H+].
36.vi. [(2R,3R,6S)-3-[(E)-3-(2,5-dfluoro phenyl)-allylaminoJ-6-(6-methoxy-[1,5]naphthyridin-4 ylcarbamoyl)-tetrahydro pyran-2 ylJ-acetic acid:
Starting from intermediate 36.v (l.l g, 2.1 mmol), the title compound (0.080 g) was obtained as a white solid using the procedures described in Example 4, step 4.iii (Boc formation, 68%
yield), Example 2, steps 2.v (aldehyde formation) and 2.vi (acid formation, 30% yield, two steps), and Example 35, step 35.vi (deprotection, 54% yield). The compound was purified by chromatography over Si0z using DCM-MeOH 6-1 containing 1% aq. NH4OH after the last step.
MS (ESI, m/z): 513.4 [M+H+].
Pharmacological properties of the invention compounds In vitro assay Exp erimental_ metho d:
These assays have been performed following the description given in "Methods for dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 4th ed.; Approved standard: NCCLS Document M7-A4; National Committee for Clinical Laboratory Standards:
Villanova, PA, USA, 1997". Minimal inhibitory concentrations (MICs; mg/1) were determined in cation-adjusted Mueller-Hinton Broth (BBL) by a microdilution method following NCCLS guidelines (National Committee for Clinical Laboratory Standards.
Methods for Dilution Antimicrobial Susceptibility). The pH of the test medium was 7.2-7.3.
4.52-4.42 (m, 3H); 4.26 (m, 1H); 4.06 (s, 3 x 0.34H); 4.04 (s, 3 x 0.66H);
3.65 (m, 1H);
3.44-3.24 (m, 4H); 2.81 (m, 1H); 2.12-1.41 (m, 7H).
MS (ESI, m/z): 529.0 [M+H+].
36.vi. [(2R,3R,6S)-3-[(E)-3-(2,5-dfluoro phenyl)-allylaminoJ-6-(6-methoxy-[1,5]naphthyridin-4 ylcarbamoyl)-tetrahydro pyran-2 ylJ-acetic acid:
Starting from intermediate 36.v (l.l g, 2.1 mmol), the title compound (0.080 g) was obtained as a white solid using the procedures described in Example 4, step 4.iii (Boc formation, 68%
yield), Example 2, steps 2.v (aldehyde formation) and 2.vi (acid formation, 30% yield, two steps), and Example 35, step 35.vi (deprotection, 54% yield). The compound was purified by chromatography over Si0z using DCM-MeOH 6-1 containing 1% aq. NH4OH after the last step.
MS (ESI, m/z): 513.4 [M+H+].
Pharmacological properties of the invention compounds In vitro assay Exp erimental_ metho d:
These assays have been performed following the description given in "Methods for dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 4th ed.; Approved standard: NCCLS Document M7-A4; National Committee for Clinical Laboratory Standards:
Villanova, PA, USA, 1997". Minimal inhibitory concentrations (MICs; mg/1) were determined in cation-adjusted Mueller-Hinton Broth (BBL) by a microdilution method following NCCLS guidelines (National Committee for Clinical Laboratory Standards.
Methods for Dilution Antimicrobial Susceptibility). The pH of the test medium was 7.2-7.3.
Results:
All Examples were tested against several Gram positive and Gram negative bacteria.
Typical antibacterial test results are given in the table hereafter (MIC in mg/1).
Example S. aureus A798 S. Pneumoniae 49619 M. catarrhalis A894 No.
1 <=.031 <=.031 <=.031 9 <=.031 <=.031 <=.031 16 0.063 1 0.25 21 0.125 0.5 <=.031
All Examples were tested against several Gram positive and Gram negative bacteria.
Typical antibacterial test results are given in the table hereafter (MIC in mg/1).
Example S. aureus A798 S. Pneumoniae 49619 M. catarrhalis A894 No.
1 <=.031 <=.031 <=.031 9 <=.031 <=.031 <=.031 16 0.063 1 0.25 21 0.125 0.5 <=.031
Claims (9)
1. A compound selected from the group consisting of:
- (E)-2-{(2R,3R,6R)-(3-[3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-ethanol;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-acryloylamino]-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-3-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carbonyl)-amino]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-3-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-ylmethyl)-amino]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1S)-1-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- (1R)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl}-1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- (1S)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl}-1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- 2-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1R,2R)-1,2-dihydroxy-
- (E)-2-{(2R,3R,6R)-(3-[3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-ethanol;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-acryloylamino]-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-3-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carbonyl)-amino]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-3-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-ylmethyl)-amino]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1S)-1-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- (1R)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl}-1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- (1S)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl}-1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- 2-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1R,2R)-1,2-dihydroxy-
2-(3-methoxy-quinoxalin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- 2-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(S)-1-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2R)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2S)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2R)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2S)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2S,SR,6R)-(5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-(2-hydroxy-ethyl))-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide;
- (2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide;
- (1S)-1-{(2S,5R)-5-[(E)-3-(3-fluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-methoxy-quinolin-4-yl)-ethanol;
- 7-fluoro-6-({(3R,6S)-6-[(1S)-1-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-benzo[1,4]thiazin-3-one;
- 3-(2-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-1-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(3-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-1-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 8-((1R,2R)-2-{(2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-1,2-dihydroxy-ethyl)-quinoline-2-carbonitrile;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{3R,6S)-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-5-yl)-vinyl]-tetrahydro-pyran-3-yl}-amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3R,6S)-6-[2-(6-fluoro-3-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-amine;
- 6-({(3R,6S)-6-[2-(6-fluoro-3-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- 2-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(S)-1-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2R)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2S)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2R)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2S)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2S,SR,6R)-(5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-(2-hydroxy-ethyl))-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide;
- (2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide;
- (1S)-1-{(2S,5R)-5-[(E)-3-(3-fluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-methoxy-quinolin-4-yl)-ethanol;
- 7-fluoro-6-({(3R,6S)-6-[(1S)-1-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-benzo[1,4]thiazin-3-one;
- 3-(2-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-1-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(3-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-1-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 8-((1R,2R)-2-{(2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-1,2-dihydroxy-ethyl)-quinoline-2-carbonitrile;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{3R,6S)-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-5-yl)-vinyl]-tetrahydro-pyran-3-yl}-amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3R,6S)-6-[2-(6-fluoro-3-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-amine;
- 6-({(3R,6S)-6-[2-(6-fluoro-3-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-
3-ylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
- (1R,2R)-1-{(2R,5S)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-fluoro-quinolin-4-yl)-ethane-1,2-diol;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-(E)-6-[2-(6-fluoro-quinolin-4-yl)-vinyl]-tetrahydro-pyran-3-yl}-amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-amine; and - 6-({3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2R,3R,6S)-2-(2-hydroxy-ethyl)-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-3-yl}-amide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2R,3R,6S)-{3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
- [(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-(6-methoxy-[1,5]naphthyridin-
- (1R,2R)-1-{(2R,5S)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-fluoro-quinolin-4-yl)-ethane-1,2-diol;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-(E)-6-[2-(6-fluoro-quinolin-4-yl)-vinyl]-tetrahydro-pyran-3-yl}-amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-amine; and - 6-({3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2R,3R,6S)-2-(2-hydroxy-ethyl)-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-3-yl}-amide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2R,3R,6S)-{3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
- [(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-(6-methoxy-[1,5]naphthyridin-
4-ylcarbamoyl)-tetrahydro-pyran-2-yl]-acetic acid;
or a salt of one of these compounds.
2. A compound according to claim 1, which is selected from the group consisting of:
- (E)-2-{(2R,3R,6R)-(3-[3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-ethanol;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-acryloylamino]-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-3-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carbonyl)-amino]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-3-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-ylmethyl)-amino]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1S)-1-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- (1R)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl}-1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- (1S)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl}-1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- 2-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1R,2R)-1,2-dihydroxy-2-(3-methoxy-quinoxalin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- 2-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(S)-1-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2R)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2S)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2R)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2S)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2S,SR,6R)-(5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-(2-hydroxy-ethyl))-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide;
- (2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide;
- (1S)-1-{(2S,5R)-5-[(E)-3-(3-fluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-methoxy-quinolin-4-yl)-ethanol;
- 7-fluoro-6-({(3R,6S)-6-[(1S)-1-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-benzo[1,4]thiazin-3-one;
- 3-(2-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-1-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(3-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-1-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 8-((1R,2R)-2-{(2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-1,2-dihydroxy-ethyl)-quinoline-2-carbonitrile;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{3R,6S)-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-5-yl)-vinyl]-tetrahydro-pyran-3-yl}-amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3R,6S)-6-[2-(6-fluoro-3-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-amine;
- 6-({(3R,6S)-6-[2-(6-fluoro-3-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
- (1R,2R)-1-{(2R,5S)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-fluoro-quinolin-4-yl)-ethane-1,2-diol;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-(E)-6-[2-(6-fluoro-quinolin-4-yl)-vinyl]-tetrahydro-pyran-3-yl}-amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-amine; and - 6-({3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
or a salt of one of these compounds.
3. A compound according to claim 1, which is selected from the group consisting of:
- (E)-2-{(2R,3R,6R)-(3-[3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-ethanol;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-acryloylamino]-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1S)-1-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- (1R)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl}-1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- (1S)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl}-1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- 2-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1R,2R)-1,2-dihydroxy-2-(3-methoxy-quinoxalin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- 2-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(S)-1-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2S,5R,6R)-(5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-(2-hydroxy-ethyl))-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide;
- (2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide;
- (1S)-1-{(2S,5R)-5-[(E)-3-(3-fluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-methoxy-quinolin-4-yl)-ethanol;
- 3-(2-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-1-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(3-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-1-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 8-((1R,2R)-2-{(2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-1,2-dihydroxy-ethyl)-quinoline-2-carbonitrile;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{3R,6S)-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-5-yl)-vinyl]-tetrahydro-pyran-3-yl}-amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3R,6S)-6-[2-(6-fluoro-3-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-amine;
- (1R,2R)-1-{(2R,5S)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-fluoro-quinolin-4-yl)-ethane-1,2-diol;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-(E)-6-[2-(6-fluoro-quinolin-4-yl)-vinyl]-tetrahydro-pyran-3-yl}-amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-amine;
- 6-({3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2R,3R,6S)-{3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
or a salt of one of these compounds.
4. A compound according to claim 3, which is selected from the group consisting of:
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{3R,6S)-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-5-yl)-vinyl]-tetrahydro-pyran-3-yl}-amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-(E)-6-[2-(6-fluoro-quinolin-4-yl)-vinyl]-tetrahydro-pyran-3-yl}-amine;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2R,3R,6S)-{3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
or a salt of one of these compounds.
or a salt of one of these compounds.
2. A compound according to claim 1, which is selected from the group consisting of:
- (E)-2-{(2R,3R,6R)-(3-[3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-ethanol;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-acryloylamino]-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-3-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carbonyl)-amino]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-3-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-ylmethyl)-amino]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1S)-1-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- (1R)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl}-1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- (1S)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl}-1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- 2-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1R,2R)-1,2-dihydroxy-2-(3-methoxy-quinoxalin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- 2-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(S)-1-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2R)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2S)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2R)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2S)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2S,SR,6R)-(5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-(2-hydroxy-ethyl))-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide;
- (2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide;
- (1S)-1-{(2S,5R)-5-[(E)-3-(3-fluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-methoxy-quinolin-4-yl)-ethanol;
- 7-fluoro-6-({(3R,6S)-6-[(1S)-1-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-benzo[1,4]thiazin-3-one;
- 3-(2-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-1-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(3-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-1-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 8-((1R,2R)-2-{(2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-1,2-dihydroxy-ethyl)-quinoline-2-carbonitrile;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{3R,6S)-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-5-yl)-vinyl]-tetrahydro-pyran-3-yl}-amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3R,6S)-6-[2-(6-fluoro-3-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-amine;
- 6-({(3R,6S)-6-[2-(6-fluoro-3-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
- (1R,2R)-1-{(2R,5S)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-fluoro-quinolin-4-yl)-ethane-1,2-diol;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-(E)-6-[2-(6-fluoro-quinolin-4-yl)-vinyl]-tetrahydro-pyran-3-yl}-amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-amine; and - 6-({3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
or a salt of one of these compounds.
3. A compound according to claim 1, which is selected from the group consisting of:
- (E)-2-{(2R,3R,6R)-(3-[3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-ethanol;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-acryloylamino]-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1S)-1-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- (1R)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl}-1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- (1S)-2-{(2S,5R,6S)-5-[trans-3-(2,5-difluoro-phenyl)-allylamino]-6-hydroxymethyl-tetrahydro-pyran-2-yl}-1-(3-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- 2-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(1R,2R)-1,2-dihydroxy-2-(3-methoxy-quinoxalin-5-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- {(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetic acid;
- 2-{(2R,3R,6R)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(S)-1-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-tetrahydro-pyran-2-yl}-acetamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2R)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(2,5-difluoro-phenyl)-N-{(2S,3R,6S)-6-[(2S)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2S,5R,6R)-(5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-(2-hydroxy-ethyl))-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide;
- (2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide;
- (1S)-1-{(2S,5R)-5-[(E)-3-(3-fluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-methoxy-quinolin-4-yl)-ethanol;
- 3-(2-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-1-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 3-(3-fluoro-phenyl)-N-{(3R,6S)-6-[(1S)-1-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-(E)-acrylamide;
- 8-((1R,2R)-2-{(2S,5R)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-1,2-dihydroxy-ethyl)-quinoline-2-carbonitrile;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{3R,6S)-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-5-yl)-vinyl]-tetrahydro-pyran-3-yl}-amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3R,6S)-6-[2-(6-fluoro-3-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-amine;
- (1R,2R)-1-{(2R,5S)-5-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-tetrahydro-pyran-2-yl}-2-(6-fluoro-quinolin-4-yl)-ethane-1,2-diol;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-(E)-6-[2-(6-fluoro-quinolin-4-yl)-vinyl]-tetrahydro-pyran-3-yl}-amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-yl}-amine;
- 6-({3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2R,3R,6S)-{3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
or a salt of one of these compounds.
4. A compound according to claim 3, which is selected from the group consisting of:
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{3R,6S)-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-5-yl)-vinyl]-tetrahydro-pyran-3-yl}-amine;
- [(E)-3-(2,5-difluoro-phenyl)-allyl]-{(3S,6R)-(E)-6-[2-(6-fluoro-quinolin-4-yl)-vinyl]-tetrahydro-pyran-3-yl}-amine;
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2R,3R,6S)-{3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
or a salt of one of these compounds.
5. A compound according to claim 4, which is selected from the group consisting of:
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2R,3R,6S)-{3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
or a salt of one of these compounds.
- 2-{(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetamide;
- (2R,3R,6S)-{3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6S)-3-[(E)-3-(2,5-difluoro-phenyl)-allylamino]-6-[(E)-2-(6-methoxy-[1,5]naphthyridin-4-yl)-vinyl]-tetrahydro-pyran-2-yl}-acetic acid;
or a salt of one of these compounds.
6. A compound according to claim 1, which is selected from the group consisting of:
- {(2R,3R,6R)-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-3-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carbonyl)-amino]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-3-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-ylmethyl)-amino]-tetrahydro-pyran-2-yl}-acetic acid;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2R)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2S)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2R)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2S)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 7-fluoro-6-({(3R,6S)-6-[(1S)-1-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-benzo[1,4]thiazin-3-one;
- 6-({(3R,6S)-6-[2-(6-fluoro-3-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
- 6-({3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
or a salt of one of these compounds.
- {(2R,3R,6R)-6-[2-(3-methoxy-quinolin-5-yl)-ethyl]-3-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carbonyl)-amino]-tetrahydro-pyran-2-yl}-acetic acid;
- {(2R,3R,6R)-6-[2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-3-[(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-ylmethyl)-amino]-tetrahydro-pyran-2-yl}-acetic acid;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2R)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2S)-2-(3-fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2R)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {(2S,3R,6S)-6-[(2S)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-2-hydroxymethyl-tetrahydro-pyran-3-yl}-amide;
- 7-fluoro-6-({(3R,6S)-6-[(1S)-1-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-benzo[1,4]thiazin-3-one;
- 6-({(3R,6S)-6-[2-(6-fluoro-3-methoxy-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
- 6-({3S,6R)-6-[2-(6-fluoro-quinolin-4-yl)-ethyl]-tetrahydro-pyran-3-ylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
or a salt of one of these compounds.
7. As a medicament, a compound as defined in one of claims 1 to 6 or a pharmaceutically acceptable salt thereof.
8. A pharmaceutical composition containing, as active principle, a compound as defined in one of claims 1 to 6 or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.
9. Use of a compound according to one of claims 1 to 6, or of a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention or treatment of infection(s).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IBPCT/IB2006/050762 | 2006-03-10 | ||
| IB2006050762 | 2006-03-10 | ||
| PCT/IB2007/050784 WO2007105154A2 (en) | 2006-03-10 | 2007-03-09 | Antibiotic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2643962A1 true CA2643962A1 (en) | 2007-09-20 |
Family
ID=38267680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002643962A Abandoned CA2643962A1 (en) | 2006-03-10 | 2007-03-09 | Antibiotic compounds |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1996579A2 (en) |
| JP (1) | JP2009529525A (en) |
| CN (1) | CN101400674A (en) |
| CA (1) | CA2643962A1 (en) |
| WO (1) | WO2007105154A2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2370123T3 (en) * | 2007-06-15 | 2011-12-12 | Actelion Pharmaceuticals Ltd. | DERIVATIVES OF 3-AMINO-6- (1-AMINOETIL) -TETRAHYDROPIRANE. |
| CA2706837C (en) | 2007-12-18 | 2016-05-03 | Actelion Pharmaceuticals Ltd | 5-aminocyclylmethyl-oxazolidin-2-one derivatives |
| RU2525541C2 (en) | 2008-12-12 | 2014-08-20 | Актелион Фармасьютиклз Лтд | 5-amino-2-(1-hydroxyethyl)tetrahydropyran derivatives |
| CN116574105B (en) * | 2018-09-27 | 2025-10-10 | 深圳微芯生物科技股份有限公司 | Quinoline derivatives with indoleamine-2,3-dioxygenase inhibitory activity |
| CN115677708B (en) * | 2022-10-19 | 2024-11-29 | 深圳万知达企业管理有限公司 | A preparation method of pyrroloquinoxaline |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4602903B2 (en) * | 2002-10-10 | 2010-12-22 | モルフォケム アクチェンゲゼルシャフト フュア コンビナトリシェ ヘミー | New compounds with antibacterial activity |
| DE10316081A1 (en) * | 2003-04-08 | 2004-10-21 | Morphochem AG Aktiengesellschaft für kombinatorische Chemie | New compounds with antibacterial activity |
| CA2580621A1 (en) * | 2004-09-24 | 2006-03-30 | Actelion Pharmaceuticals Ltd | New bicyclic antibiotics |
| RU2007147413A (en) * | 2005-05-24 | 2009-06-27 | Астразенека Аб (Se) | AMINOPIPERIDINCHINOLINS AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY |
| CN101374831B (en) * | 2006-01-26 | 2011-04-27 | 埃科特莱茵药品有限公司 | tetrahydropyran antibiotics |
-
2007
- 2007-03-09 CA CA002643962A patent/CA2643962A1/en not_active Abandoned
- 2007-03-09 JP JP2008557888A patent/JP2009529525A/en not_active Ceased
- 2007-03-09 WO PCT/IB2007/050784 patent/WO2007105154A2/en not_active Ceased
- 2007-03-09 EP EP07713226A patent/EP1996579A2/en not_active Withdrawn
- 2007-03-09 CN CNA2007800084306A patent/CN101400674A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN101400674A (en) | 2009-04-01 |
| JP2009529525A (en) | 2009-08-20 |
| EP1996579A2 (en) | 2008-12-03 |
| WO2007105154A2 (en) | 2007-09-20 |
| WO2007105154A3 (en) | 2007-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2876879C (en) | Oxazolidinone antibiotics | |
| CA2689102C (en) | 3-amino-6-(1-amino-ethyl)-tetrahydropyran derivatives | |
| US20070173532A1 (en) | New Piperidine Antibiotics | |
| CA2580621A1 (en) | New bicyclic antibiotics | |
| EP2066678B1 (en) | Spiro antibiotic derivatives | |
| CN102232078B (en) | 5-amino-2-(1-hydroxy-ethyl)-tetrahydropyran derivatives | |
| CA2643962A1 (en) | Antibiotic compounds | |
| EP1981881B1 (en) | Tetrahydropyrane antibiotics | |
| WO2009034546A2 (en) | Trans-decahydroisoquinoline derivatives | |
| EP1799674A1 (en) | New piperidine antibiotics | |
| EP1799676A2 (en) | New bicyclic antibiotics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |
Effective date: 20130311 |